0000950170-24-09404410-Q UNIVERSAL HEALTH REALTY INCOME TRUST 20240808202408081620241620251620250 0000950170-24-094044 10-Q 59 20240630 20240808 20240808 UNIVERSAL HEALTH REALTY INCOME TRUST 0000798783 6798 236858580 MD 1231 10-Q 34 001-09321 241188718 UNIVERSAL CORPORATE CTR 367 S GULPH RD KING OF PRUSSIA PA 19406 610-265-0688 UNIVERSAL CORPORATE CTR 367 S GULPH ROAD KING OF PRUSSIA PA 19406 10-Q 1 uht-20240630.htm 10-Q 10-Q Q2--12-31false00007987830.511110000798783uht:UniversalHealthServicesOfDelawareIncMember2024-01-012024-06-300000798783us-gaap:NonrelatedPartyMemberuht:BaseRentsMember2023-01-012023-06-300000798783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberuht:InterestRateSwapAgreementOneMemberus-gaap:CashFlowHedgingMember2023-05-150000798783uht:FTXMobPhaseTwoLPMember2023-01-012023-03-3100007987832022-12-310000798783uht:UniversalHealthServicesIncMember2023-01-012023-06-300000798783us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300000798783uht:UniversalHealthServicesIncMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember2024-01-012024-06-300000798783us-gaap:FairValueInputsLevel2Member2024-06-300000798783us-gaap:EquityMethodInvestmentsMemberuht:GraysonPropertiesTwoLPMember2023-12-310000798783uht:FTXMobPhaseTwoLPMember2021-03-310000798783uht:CumulativeDividendsMember2024-01-012024-06-300000798783us-gaap:BaseRateMemberuht:RevolvingBFacilityMember2024-01-012024-06-300000798783uht:RevolvingCreditAgreementMember2024-04-012024-06-300000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000798783us-gaap:AdditionalPaidInCapitalMember2023-03-310000798783uht:UniversalHealthServicesIncMemberuht:AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember2024-01-012024-06-300000798783uht:InterestRateSwapAgreementThreeMemberus-gaap:CashFlowHedgingMember2019-09-300000798783uht:UniversalHealthServicesIncMemberuht:CliveBehavioralHealthHospitalMember2024-06-300000798783uht:McAllenMedicalCenterMemberuht:UniversalHealthServicesHospitalIncMember2023-04-012023-06-300000798783uht:LimitedLiabilityCompanyOrLimitedPartnerMember2024-06-300000798783uht:CumulativeDividendsMember2024-06-300000798783uht:UniversalHealthServicesIncMembersrt:SubsidiariesMember2022-01-012022-03-310000798783uht:McAllenMedicalCenterMember2023-09-3000007987832023-03-310000798783us-gaap:InterestRateSwapMember2023-01-012023-06-300000798783us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-12-012023-12-310000798783us-gaap:EquityMethodInvestmentsMemberuht:GraysonPropertiesTwoLPMember2024-06-3000007987832024-06-300000798783uht:EquityMethodInvestmentGroupOfInvesteesNameMember2023-12-310000798783uht:UniversalHealthServicesIncMemberuht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMembersrt:MaximumMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMembersrt:MinimumMemberuht:GroundLeaseAndMasterFlexLeaseAgreementMember2023-01-012023-06-300000798783us-gaap:NonrelatedPartyMemberuht:BaseRentsMember2023-04-012023-06-300000798783us-gaap:CommonStockMember2023-01-012023-06-300000798783uht:RevolvingCreditAgreementMember2024-06-300000798783uht:RevolvingCreditAgreementMember2018-03-270000798783uht:UniversalHealthServicesIncMembersrt:MinimumMemberuht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember2024-01-012024-06-300000798783us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-12-310000798783us-gaap:NonrelatedPartyMember2023-04-012023-06-300000798783us-gaap:NonrecourseMemberuht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember2024-01-012024-06-300000798783uht:McAllenMedicalCenterMember2023-07-012023-09-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMemberuht:GroundLeaseAndMasterFlexLeaseAgreementMember2022-01-3100007987832024-01-012024-03-310000798783us-gaap:RetainedEarningsMember2023-04-012023-06-300000798783us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000798783us-gaap:AdditionalPaidInCapitalMember2024-03-310000798783us-gaap:NonrecourseMemberuht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember2024-06-300000798783uht:InterestRateSwapAgreementOneMemberus-gaap:CashFlowHedgingMember2020-03-012020-03-310000798783uht:InterestRateSwapAgreementTwoMemberus-gaap:CashFlowHedgingMember2020-01-310000798783uht:TempleTexasMemberuht:UniversalHealthServicesIncMemberuht:AssetPurchaseAndSaleAgreementMemberuht:CanyonCreekBehavioralHealthMembersrt:SubsidiariesMember2022-01-012022-03-310000798783uht:UniversalHealthServicesIncMemberuht:BaseRentsMember2023-01-012023-06-300000798783uht:AikenRegionalMedicalCenterMember2022-03-310000798783uht:RevolvingCreditAgreementMember2023-01-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:AssetPurchaseAndSaleAgreementMemberuht:InlandValleyCampusOfSouthwestHealthcareSystemMemberuht:WildomarCaliforniaMemberuht:UniversalHealthServicesIncMemberuht:InterestRateSwapAgreementThreeMemberus-gaap:CashFlowHedgingMember2019-07-012019-09-300000798783uht:UniversalHealthServicesIncMemberuht:CliveIowaMemberuht:CliveBehavioralHealthMembersrt:MaximumMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:WellingtonRegionalMedicalCenterMember2024-06-300000798783us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-01-012023-06-300000798783us-gaap:ProductAndServiceOtherMemberus-gaap:NonrelatedPartyMember2024-04-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:TenantsMemberus-gaap:CustomerConcentrationRiskMemberuht:RevenueMember2023-01-012023-06-3000007987832023-04-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:CliveIowaMemberuht:CliveBehavioralHealthMember2024-01-012024-06-300000798783srt:MinimumMemberuht:RevolvingAFacilityMember2018-03-272018-03-270000798783uht:DenisonTexasMemberuht:GraysonPropertiesTwoLPMember2024-06-300000798783us-gaap:EquityMethodInvestmentsMemberuht:GraysonPropertiesTwoLPMember2024-01-012024-06-300000798783us-gaap:InterestRateSwapMember2023-01-012023-03-3100007987832024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:TenantsMemberuht:RevenueMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300000798783srt:MaximumMember2024-06-300000798783uht:UniversalHealthServicesIncMemberuht:WellingtonRegionalMedicalCenterMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberus-gaap:CustomerConcentrationRiskMemberuht:RevenueMember2024-01-012024-06-300000798783srt:MinimumMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:McAllenMedicalCenterMember2024-06-300000798783uht:RevolvingAFacilityMembersrt:MaximumMember2018-03-272018-03-270000798783us-gaap:RetainedEarningsMember2023-03-310000798783uht:UniversalHealthServicesIncMemberus-gaap:ProductAndServiceOtherMember2024-04-012024-06-3000007987832023-12-310000798783us-gaap:ManagementServiceMember2024-01-012024-06-300000798783uht:UniversalHealthServicesOfDelawareIncMember2023-04-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:TenantReimbursementsMember2024-04-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember2024-06-300000798783uht:RevolvingCreditAgreementMemberus-gaap:LetterOfCreditMember2018-03-270000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMemberuht:MasterFlexLeaseAgreementMember2023-03-310000798783uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember2022-03-310000798783uht:UniversalHealthServicesIncMemberuht:BaseRentsMember2024-04-012024-06-300000798783uht:UniversalHealthServicesIncMemberus-gaap:ProductAndServiceOtherMember2023-01-012023-06-300000798783uht:EquityMethodInvestmentGroupOfInvesteesNameMember2024-06-300000798783uht:PalmBeachFloridaMemberuht:UniversalHealthServicesIncMemberuht:WellingtonRegionalMedicalCenterMember2021-12-310000798783uht:UniversalHealthServicesIncMemberuht:AcuteCareHospitalsMember2024-01-012024-06-300000798783uht:UniversalHealthServicesOfDelawareIncMember2024-04-012024-06-300000798783uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMembersrt:MaximumMember2024-06-300000798783uht:FTXMobPhaseTwoLPMember2023-03-310000798783us-gaap:NonrecourseMemberuht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember2024-01-012024-06-300000798783us-gaap:InterestRateSwapMember2024-01-012024-06-300000798783uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember2024-04-102024-04-100000798783uht:PalmBeachFloridaMemberuht:UniversalHealthServicesIncMemberuht:WellingtonRegionalMedicalCenterMember2021-01-012021-12-310000798783uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember2024-04-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:McAllenMedicalCenterMember2023-09-300000798783us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:AssetPurchaseAndSaleAgreementMemberuht:AikenSouthCarolinaMemberuht:AikenRegionalMedicalCenterMembersrt:SubsidiariesMember2022-01-012022-03-310000798783uht:PalmBeachFloridaMemberuht:UniversalHealthServicesIncMemberuht:WellingtonRegionalMedicalCenterMember2024-06-300000798783us-gaap:NonrelatedPartyMember2023-01-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMemberuht:MasterFlexLeaseAgreementMember2023-01-012023-06-3000007987832024-07-310000798783us-gaap:RetainedEarningsMember2023-12-310000798783uht:LimitedLiabilityCompanyOrLimitedPartnerMember2023-12-310000798783uht:EquityMethodInvestmentGroupOfInvesteesNameMember2024-04-012024-06-300000798783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMemberuht:RevolvingAFacilityMember2018-03-272018-03-270000798783uht:UniversalHealthServicesIncMemberuht:TenantsMemberuht:RevenueMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberus-gaap:ProductAndServiceOtherMember2023-04-012023-06-300000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000798783us-gaap:EquityMethodInvestmentsMemberuht:BrunswickAssociatesMember2023-12-310000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:BaseRentsMember2024-01-012024-06-300000798783uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMembersrt:MinimumMember2024-06-300000798783us-gaap:FairValueInputsLevel2Member2023-12-310000798783uht:FinancingArrangementsMember2024-01-012024-06-300000798783uht:EquityMethodInvestmentGroupOfInvesteesNameMember2023-04-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:TenantReimbursementsMember2023-01-012023-06-300000798783uht:RevolvingCreditAgreementMember2023-04-012023-06-300000798783us-gaap:AdditionalPaidInCapitalMember2024-06-300000798783us-gaap:BaseRateMemberuht:RevolvingAFacilityMembersrt:MaximumMember2018-03-272018-03-270000798783uht:CumulativeDividendsMember2024-03-310000798783uht:RevolvingCreditAgreementMember2024-01-012024-06-300000798783uht:FTXMobPhaseTwoLPMember2021-01-012021-03-310000798783us-gaap:InterestRateSwapMember2024-04-012024-06-300000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000798783uht:EquityMethodInvestmentGroupOfInvesteesNameMember2023-01-012023-06-300000798783uht:RevolvingBFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2024-01-012024-06-300000798783us-gaap:NonrecourseMemberuht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember2024-01-012024-06-300000798783uht:InterestRateSwapAgreementOneMemberus-gaap:CashFlowHedgingMember2020-03-310000798783uht:RevolvingCreditAgreementMember2018-03-272018-03-270000798783uht:UniversalHealthServicesIncMemberuht:SpecialtyHospitalInChicagoIllinoisMemberuht:ChicagoIllinoisMember2022-10-012022-12-310000798783us-gaap:NonrelatedPartyMember2024-04-012024-06-300000798783uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember2023-04-012023-06-300000798783uht:GraysonPropertiesTwoLPMember2024-03-310000798783us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300000798783srt:MaximumMember2024-01-012024-06-300000798783us-gaap:CommonStockMember2022-12-310000798783us-gaap:EquityMethodInvestmentsMemberuht:BrunswickAssociatesMember2024-06-300000798783uht:UniversalHealthServicesIncMember2023-12-310000798783uht:UniversalHealthServicesIncMemberuht:CliveIowaMemberuht:CliveBehavioralHealthMember2024-06-300000798783uht:TenantReimbursementsMemberus-gaap:NonrelatedPartyMember2024-04-012024-06-300000798783us-gaap:NonrelatedPartyMemberuht:BaseRentsMember2024-01-012024-06-300000798783us-gaap:CommonStockMember2024-03-310000798783uht:CumulativeDividendsMember2024-04-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:BonusRentsMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMembersrt:MinimumMemberuht:GroundLeaseAndMasterFlexLeaseAgreementMember2023-01-012023-03-310000798783uht:UniversalHealthServicesIncMemberus-gaap:ProductAndServiceOtherMember2024-01-012024-06-300000798783us-gaap:RetainedEarningsMember2024-04-012024-06-300000798783us-gaap:RetainedEarningsMember2023-01-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:CanyonCreekBehavioralHealthMember2024-06-300000798783uht:InterestRateSwapAgreementTwoMemberus-gaap:CashFlowHedgingMember2020-01-012020-01-310000798783us-gaap:ManagementServiceMember2024-04-012024-06-3000007987832023-01-012023-06-300000798783uht:AccountingStandardsUpdate202206Member2024-06-300000798783uht:CanyonCreekBehavioralHealthMember2022-03-310000798783uht:UniversalHealthServicesIncMemberuht:CliveIowaMembersrt:MinimumMemberuht:CliveBehavioralHealthMember2024-01-012024-06-300000798783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberuht:RevolvingAFacilityMembersrt:MaximumMember2018-03-272018-03-270000798783us-gaap:AdditionalPaidInCapitalMember2023-06-300000798783uht:TenantReimbursementsMemberus-gaap:NonrelatedPartyMember2023-04-012023-06-300000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000798783uht:SpecialtyHospitalInChicagoIllinoisMemberuht:ChicagoIllinoisMember2023-01-012023-06-300000798783uht:CumulativeDividendsMember2022-12-310000798783us-gaap:EquityMethodInvestmentsMember2023-12-310000798783us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:CliveBehavioralHealthHospitalMember2024-01-012024-06-300000798783us-gaap:CommonStockMember2024-04-012024-06-300000798783us-gaap:NonrelatedPartyMemberuht:BaseRentsMember2024-04-012024-06-300000798783us-gaap:OtherExpenseMember2024-01-012024-06-300000798783us-gaap:InterestRateSwapMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMember2023-12-310000798783uht:LimitedLiabilityCompanyOrLimitedPartnerMemberuht:MedicalOfficeBuildingsMember2024-06-300000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000798783us-gaap:CommonStockMember2023-04-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:MasterFlexLeaseAgreementMemberuht:SierraMedicalPlazaIMember2023-06-300000798783uht:UniversalHealthServicesIncMembersrt:MaximumMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:AssetPurchaseAndSaleAgreementMembersrt:SubsidiariesMember2022-01-012022-03-310000798783uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMemberuht:BonusRentsMember2024-01-012024-06-300000798783uht:FederalFundsEffectiveRateMembersrt:MinimumMemberuht:RevolvingAFacilityMember2018-03-272018-03-270000798783uht:GraysonPropertiesTwoLPMember2024-06-300000798783uht:GraysonPropertiesTwoLPMember2024-01-012024-06-300000798783uht:FederalFundsEffectiveRateMemberuht:RevolvingBFacilityMember2024-01-012024-06-300000798783uht:CumulativeDividendsMember2023-04-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:McAllenMedicalCenterMember2023-07-012023-09-300000798783uht:McAllenMedicalCenterMemberuht:UniversalHealthServicesHospitalIncMember2024-04-012024-06-300000798783uht:FTXMobPhaseTwoLPMember2024-01-012024-06-

300000798783us-gaap:ManagementServiceMember2023-01-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMemberuht:GroundLeaseAndMasterFlexLeaseAgreementMember2023-01-012023-06-30000079878322024-04-302024-06-300000798783uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember2021-01-012021-12-310000798783uht:UniversalHealthServicesIncMemberuht:TenantsMemberus-gaap:CustomerConcentrationRiskMemberuht:RevenueMember2023-04-012023-06-300000798783us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-04-012023-06-300000798783us-gaap:EquityMethodInvestmentsMemberuht:BrunswickAssociatesMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:RevenueMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:BonusRentsMember2023-04-012023-06-300000798783us-gaap:EquityMethodInvestmentsMember2024-06-300000798783uht:CumulativeDividendsMember2023-01-012023-06-300000798783us-gaap:NonrelatedPartyMember2024-01-012024-06-300000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000798783us-gaap:BaseRateMembersrt:MinimumMemberuht:RevolvingAFacilityMember2018-03-272018-03-270000798783uht:InterestRateSwapAgreementTwoMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:CashFlowHedgingMember2023-05-150000798783uht:BrunswickAssociatesMember2024-01-012024-06-300000798783uht:DenisonTexasMemberuht:GraysonPropertiesTwoLPMembersrt:MaximumMember2024-06-300000798783uht:CumulativeDividendsMember2023-06-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMemberuht:GroundLeaseAndMasterFlexLeaseAgreementMember2023-01-012023-03-310000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000798783uht:BrunswickAssociatesMember2024-06-300000798783uht:UniversalHealthServicesIncMemberuht:BonusRentsMember2023-01-012023-06-300000798783uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember2021-12-310000798783us-gaap:CommonStockMember2024-01-012024-06-300000798783uht:RevolvingCreditAgreementMember2021-07-020000798783us-gaap:RetainedEarningsMember2022-12-3100007987832024-04-012024-06-300000798783uht:RevolvingCreditAgreementMember2021-07-022021-07-020000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300000798783us-gaap:NonrecourseMemberuht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember2024-06-300000798783uht:UniversalHealthServicesIncMemberus-gaap:CustomerConcentrationRiskMemberuht:RevenueMember2024-04-012024-06-300000798783us-gaap:CommonStockMember2023-03-310000798783uht:UniversalHealthServicesIncMember2023-04-012023-06-300000798783uht:CumulativeDividendsMember2023-03-310000798783uht:TenantReimbursementsMemberus-gaap:NonrelatedPartyMember2023-01-012023-06-300000798783uht:RevolvingCreditAgreementMemberus-gaap:ShortTermDebtMember2018-03-270000798783us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-06-300000798783us-gaap:ProductAndServiceOtherMemberus-gaap:NonrelatedPartyMember2024-01-012024-06-300000798783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-05-152023-05-150000798783uht:UniversalHealthServicesIncMemberuht:CanyonCreekBehavioralHealthMember2024-01-012024-06-300000798783us-gaap:NonrecourseMember2024-06-300000798783us-gaap:ManagementServiceMember2023-04-012023-06-300000798783uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMembersrt:ScenarioForecastMember2024-01-012024-12-310000798783uht:UniversalHealthServicesIncMemberuht:TenantReimbursementsMember2023-04-012023-06-300000798783uht:UniversalHealthServicesIncMemberuht:TenantReimbursementsMember2024-01-012024-06-300000798783uht:CumulativeDividendsMember2023-12-310000798783us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000798783uht:UniversalHealthServicesIncMember2024-03-310000798783us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-04-012024-06-300000798783uht:SuburbanPropertiesMember2024-01-012024-06-300000798783uht:FTXMobPhaseTwoLPMember2024-06-300000798783us-gaap:InterestRateSwapMember2023-12-310000798783uht:UniversalHealthServicesIncMemberuht:BonusRentsMember2024-04-012024-06-300000798783uht:UniversalHealthServicesIncMembersrt:SubsidiariesMember2023-12-310000798783us-gaap:AdditionalPaidInCapitalMember2022-12-310000798783uht:TenantReimbursementsMemberus-gaap:NonrelatedPartyMember2024-01-012024-06-300000798783uht:SpecialtyHospitalInChicagoIllinoisMemberuht:ChicagoIllinoisMember2023-01-012023-12-310000798783uht:UniversalHealthServicesIncMemberuht:BaseRentsMember2023-04-012023-06-300000798783us-gaap:CommonStockMember2024-06-300000798783uht:UniversalHealthServicesIncMembersrt:SubsidiariesMember2024-06-300000798783uht:UniversalHealthServicesIncMemberus-gaap:CustomerConcentrationRiskMemberuht:RevenueMember2023-01-012023-06-300000798783uht:SuburbanPropertiesMember2024-06-3000007987832024-03-310000798783uht:EquityMethodInvestmentGroupOfInvesteesNameMember2024-01-012024-06-300000798783us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member2024-06-300000798783uht:CatholicHealthInitiativesIowaMember2024-01-012024-06-300000798783uht:LastTwoYearRenewalOptionsMemberuht:UniversalHealthServicesIncMembersrt:MinimumMemberuht:CliveBehavioralHealthHospitalMember2024-01-012024-06-300000798783uht:FirstThreeYearRenewalOptionsMemberuht:UniversalHealthServicesIncMembersrt:MinimumMemberuht:CliveBehavioralHealthHospitalMember2024-01-012024-06-300000798783us-gaap:CommonStockMember2023-06-300000798783uht:UniversalHealthServicesIncMember2024-06-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMemberuht:GroundLeaseAndMasterFlexLeaseAgreementMember2024-01-012024-06-300000798783us-gaap:AdditionalPaidInCapitalMember2023-12-310000798783us-gaap:NonrecourseMemberuht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember2024-06-300000798783uht:UniversalHealthServicesIncMemberuht:McAllenMedicalCenterMember2024-01-012024-06-300000798783us-gaap:CommonStockMember2023-12-310000798783uht:FirstThreeYearRenewalOptionsMemberuht:UniversalHealthServicesIncMemberuht:CliveBehavioralHealthHospitalMember2024-01-012024-06-300000798783uht:UniversalHealthServicesIncMemberuht:RenoNevadaMemberuht:SierraMedicalPlazaIMemberuht:GroundLeaseAndMasterFlexLeaseAgreementMember2023-03-310000798783uht:UniversalHealthServicesIncMembersrt:MinimumMember2024-01-012024-06-300000798783us-gaap:RetainedEarningsMember2024-06-300000798783us-gaap:ProductAndServiceOtherMemberus-gaap:NonrelatedPartyMember2023-04-012023-06-300000798783uht:AikenRegionalMedicalCenterMember2024-06-300000798783us-gaap:RetainedEarningsMember2024-01-012024-06-300000798783uht:McAllenMedicalCenterMemberuht:UniversalHealthServicesHospitalIncMember2024-01-012024-06-300000798783uht:CanyonCreekBehavioralHealthMember2024-06-300000798783uht:UniversalHealthServicesIncMember2024-04-012024-06-300000798783us-gaap:RetainedEarningsMember2023-06-300000798783us-gaap:RetainedEarningsMember2024-03-310000798783uht:UniversalHealthServicesOfDelawareIncMember2023-01-012023-06-300000798783uht:AccountingStandardsUpdate202307Member2024-06-300000798783us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberuht:InterestRateSwapAgreementThreeMemberus-gaap:CashFlowHedgingMember2023-05-150000798783uht:LastTwoYearRenewalOptionsMemberuht:UniversalHealthServicesIncMembersrt:MaximumMemberuht:CliveBehavioralHealthHospitalMember2024-01-012024-06-300000798783us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-12-310000798783uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember2024-06-300000798783us-gaap:ProductAndServiceOtherMemberus-gaap:NonrelatedPartyMember2023-01-012023-06-300000798783uht:McAllenMedicalCenterMemberuht:UniversalHealthServicesHospitalIncMember2023-01-012023-06-300000798783uht:FirstThreeYearRenewalOptionsMemberuht:UniversalHealthServicesIncMembersrt:MaximumMemberuht:CliveBehavioralHealthHospitalMember2024-01-012024-06-30uht:Hospitaliso4217:USDxbrli:sharesuht:Leasexbrli:pureuht:Dispositionutr:sqftuht:Beduht:Acquisitionuht:Derivativeuht:Optionuht:Propertyuht:Landxbrli:sharesuht:Segmentuht:Renewaloption

Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â (MARK ONE) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended June 30, 2024 OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from to Commission file number 1-9321 Â UNIVERSAL HEALTH REALTY INCOME TRUST (Exact name of registrant as specified in its charter) Â Â Maryland Â 23-6858580 (State or other jurisdiction ofincorporation or organization) Â (I. R. S. EmployerIdentification No.) Â Â Â UNIVERSAL CORPORATE CENTER367 SOUTH GULPH ROADKING OF PRUSSIA, Pennsylvania Â 19406-0958 (Address of principal executive offices) Â (Zip Code) (610) 265-0688 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Â Trading Symbol(s) Â Name of each exchange on which registered Shares of beneficial interest, $0.01 par value Â UHT Â New York Stock Exchange Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filerâ€, â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜’ Accelerated Filer â˜ Â Â Â Â Non-accelerated filer â˜ Smaller reporting company â˜ Â Â Emerging growth company â˜ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Number of common shares of beneficial interest outstanding at July 31, 2024â€”13,848,952 Â Â Â Â UNIVERSAL HEALTH REALTY INCOME TRUST INDEX Â Â Â Â PAGE NO. PART I. FINANCIAL INFORMATION (unaudited) Â Â Item 1. Â Financial Statements Â Â Â Â Condensed Consolidated Statements of Incomeâ€”Three and Six Months Ended June 30, 2024 and 2023 Â 3 Â Â Condensed Consolidated Statements of Comprehensive Incomeâ€”Three and Six Months Ended June 30, 2024 and 2023 Â 4 Â Â Condensed Consolidated Balance Sheetsâ€”June 30, 2024 and December 31, 2023 Â 5 Â Â Condensed Consolidated Statements of Changes in Equityâ€”Three and Six Months Ended June 30, 2024 and 2023 Â 6Â through 7 Â Â Condensed Consolidated Statements of Cash Flowsâ€”Six Months Ended June 30, 2024 and 2023 Â 8 Â Â Notes to Condensed Consolidated Financial Statements Â 9Â through 19 Item 2. Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 20Â through 29 Item 3. Â Quantitative and Qualitative Disclosures About Market Risk Â 30Â through 31 Item 4. Â Controls and Procedures Â 31 PART II. OTHER INFORMATION Â 32 Item 1A. Â Risk Factors Â 32 Item 5. Â Other Information Â 32 Item 6. Â Exhibits Â 32 Â Â Â Â Â SIGNATURES Â 33 Â Â Â This Quarterly Report on Form 10-Q is for the quarter ended June 30, 2024. In this Quarterly Report, â€œwe,â€ â€œus,â€ â€œourâ€ and the â€œTrustâ€ refer to Universal Health Realty Income Trust and its subsidiaries. As disclosed in this Quarterly Report, including in Note 2 to the condensed consolidated financial statementsâ€”Relationship with Universal Health Services, Inc. (â€œUHSâ€) and Related Party Transactions, a wholly-owned subsidiary of UHS (UHS of Delaware, Inc.) serves as our Advisor pursuant to the terms of an annually renewable Advisory Agreement dated December 24, 1986, and as amended and restated as of January 1, 2019. The Advisory Agreement expires on December 31 of each year, however, it is renewable by us, subject to a determination by our Trustees who are unaffiliated with UHS, that the Advisorâ€™s performance has been satisfactory. The Advisory Agreement was renewed for 2024 with the same terms as the Advisory Agreement in place during 2023 and 2022. Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, five of our hospital facilities are leased to wholly-owned subsidiaries of UHS, one of our hospital facilities is leased to a joint venture between a wholly-owned subsidiary of UHS and a third party, and subsidiaries of UHS are tenants of twenty-one medical/office buildings or free-standing emergency departments, that are either wholly or jointly-owned by us. Any reference to â€œUHSâ€ or â€œUHS facilitiesâ€ in this report is referring to Universal Health Services, Inc.â€™s subsidiaries, including UHS of Delaware, Inc. In this Quarterly Report, the term â€œrevenuesâ€ does not include the revenues of the unconsolidated limited liability companies (â€œLLCsâ€) in which we have various non-controlling equity interests ranging from 33% to 95%. As of June 30, 2024, we had investments in four jointly-owned LLCs/LPs. We currently account for our share of the income/loss from these investments by the equity method (see Note 5 to the condensed consolidated financial statements included herein). Â Â 2 Â Part I. Financial Information Item I. Financial Statements Universal Health Realty Income Trust Condensed Consolidated Statements of Income For the Three and Six Months Ended June 30, 2024 and 2023 (amounts in thousands, except per share information) (unaudited) Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Lease revenue - UHS facilities (a.) Â $ 8,454 Â Â $ 8,236 Â Â $ 17,118 Â Â $ 16,023 Â Â Â Lease revenue - Non-related parties Â Â 14,359 Â Â Â 13,668 Â Â Â 28,846 Â Â Â 27,029 Â Â Â Other revenue - UHS facilities Â Â 220 Â Â Â 245 Â Â Â 440 Â Â Â 476 Â Â Â Other revenue - Non-related parties Â Â 342 Â Â Â 292 Â Â Â 751 Â Â Â 773 Â Â Â Interest income on financing leases - UHS facilities Â Â 1,359 Â Â Â 1,365 Â Â Â 2,720 Â Â Â 2,731 Â Â Â Â Â 24,734 Â Â Â 23,806 Â Â Â 49,875 Â Â Â 47,032 Â Expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Depreciation and amortization Â Â 6,806 Â Â Â 6,849 Â Â Â 13,615 Â Â Â 13,467 Â Â Â Advisory fees to UHS Â Â 1,369 Â Â Â 1,323 Â Â Â 2,707 Â Â Â 2,625 Â Â Â Other operating expenses Â Â 6,975 Â Â Â 8,250 Â Â Â 14,506 Â Â Â 15,771 Â Â Â Â 15,150 Â Â Â 16,422 Â Â Â 30,828 Â Â Â 31,863 Â Income before equity in income of unconsolidated limited liability companies ("LLCs") and interest expense Â Â 9,584 Â Â Â 7,384 Â Â Â 19,047 Â Â Â 15,169 Â Â Â Equity in income of unconsolidated LLCs Â Â 272 Â Â Â 268 Â Â Â 656 Â Â Â 639 Â Â Â Interest expense, net Â Â (4,580 ) Â Â (4,176 ) Â Â (9,127 ) Â Â (7,873 ) Net income Â $ 5,276 Â Â $ 3,476 Â Â $ 10,576 Â Â $ 7,935 Â Basic earnings per share Â $ 0.38 Â Â $ 0.25 Â Â $ 0.77 Â Â $ 0.58 Â Diluted earnings per share Â $ 0.38 Â Â $ 0.25 Â Â $ 0.76 Â Â $ 0.57 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average number of shares outstanding - Basic Â Â 13,798 Â Â Â 13,784 Â Â Â 13,795 Â Â Â 13,781 Â Weighted average number of shares outstanding - Diluted Â Â 13,832 Â Â Â 13,809 Â Â Â 13,828 Â Â Â 13,806 Â (a.) Includes bonus rental on McAllen Medical Center, a UHS acute care hospital facility of $758 and $730 for the three-month periods ended June 30, 2024 and 2023, respectively, and $1,541 and $1,495 for the six-month periods ended June 30, 2024 and 2023, respectively. See accompanying notes to these condensed consolidated financial statements. Â 3 Â Universal Health Realty Income Trust Condensed Consolidated Statements of Comprehensive Income For the Three and Six Months Ended June 30, 2024 and 2023 (amounts in thousands) (unaudited) Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net income Â $ 5,276 Â Â $ 3,476 Â Â $ 10,576 Â Â $ 7,935 Â Other comprehensive gain/(loss): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unrealized derivative (loss)/gain on cash flow hedges Â Â (1,062 ) Â Â 715 Â Â Â (871 ) Â Â (1,032 ) Total other comprehensive (loss)/gain: Â Â (1,062 ) Â Â 715 Â Â Â (871 ) Â Â (1,032 ) Total comprehensive income Â $ 4,214 Â Â $ 4,191 Â Â $ 9,705 Â Â $ 6,903 Â Â See accompanying notes to these condensed consolidated financial statements. Â 4 Â Universal Health Realty Income Trust Condensed Consolidated Balance Sheets (amounts in thousands, except share information) (unaudited) Â Â June 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Assets: Â Â Â Â Â Â Real Estate Investments: Â Â Â Â Â Â Buildings and improvements and construction in progress Â $ 651,638 Â Â $ 649,374 Â Accumulated depreciation Â Â (274,622 ) Â Â (262,449 ) Â Â Â 377,016 Â Â Â 386,925 Â Land Â Â 56,870 Â Â Â 56,870 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net Real Estate Investments Â Â 433,886 Â Â Â 443,795 Â Financing receivable from UHS Â Â 83,043 Â Â Â 83,279 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net Real Estate Investments and Financing receivable Â Â 516,929 Â Â Â 527,074 Â Investments in limited liability companies ("LLCs") Â Â 14,328 Â Â Â 9,102 Â Other Assets: Â Â Â Â Â Â Cash and cash equivalents Â Â 5,577 Â Â Â 8,212 Â Lease and other receivables from UHS Â Â 6,816 Â Â Â 6,180 Â Lease receivable - other Â Â 7,905 Â Â Â 8,166 Â Intangible assets (net of accumulated amortization of $11.4Â million and Â Â Â $12.5Â million, respectively) Â Â 8,193 Â Â Â 9,110 Â Right-of-use land assets, net Â Â 10,932 Â Â Â 10,946 Â Deferred charges, notes receivable and other assets, net Â Â 15,871 Â Â Â 17,579 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Assets Â $ 586,551 Â Â $ 596,369 Â Liabilities: Â Â Â Â Â Â Line of credit borrowings Â $ 342,900 Â Â $ 326,600 Â Mortgage notes payable, non-recourse to us, net Â Â 19,970 Â Â Â 32,863 Â Accrued interest Â Â 1,024 Â Â Â 490 Â Accrued expenses and other liabilities Â Â 10,145 Â Â Â 13,500 Â Ground lease liabilities, net Â Â 10,932 Â Â Â 10,946 Â Tenant reserves, deposits and deferred and prepaid rents Â Â 10,879 Â Â Â 11,036 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Liabilities Â Â

395,850 Â Â Â 395,435 Â Equity: Â Â Â Â Â Â Preferred shares of beneficial interest, Â Â Â $.01Â par value; 5,000,000Â shares authorized; Â Â Â noneÂ issued and outstanding Â Â - Â Â Â - Â Common shares, $.01Â par value; Â Â Â 95,000,000Â shares authorized; issued and outstanding: 2024 - 13,848,950; Â Â Â 2023 - 13,823,899 Â Â 138 Â Â Â 138 Â Capital in excess of par value Â Â 270,592 Â Â Â 270,398 Â Cumulative net income Â Â 836,637 Â Â Â 826,061 Â Cumulative dividends Â Â (923,107 ) Â Â (902,975 ) Accumulated other comprehensive income Â Â 6,441 Â Â Â 7,312 Â Â Â Â Â Â Total Equity Â Â 190,701 Â Â Â 200,934 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total Liabilities and Equity Â $ 586,551 Â Â $ 596,369 Â Â See accompanying notes to these condensed consolidated financial statements. Â 5 Â Â Universal Health Realty Income Trust Condensed Consolidated Statements of Changes in Equity For the Six Months Ended June 30, 2024 (amounts in thousands) (unaudited) Â Â Â Common Shares Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Capital in Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

of UHS exercised its fair market value renewal option and renewed the lease for a 5-year term scheduled to 10 Â expire on December 31, 2026. Effective January 1, 2024, the annual lease rate for this hospital, which is payable to us monthly, is $6.6 million and on each January 1st thereafter through 2026, the annual rent will increase by 2.50% on a cumulative and compounded basis (there is no bonus rental component of the lease payment).Management cannot predict whether the leases with wholly-owned subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases. During the third quarter of 2023, we acquired the McAllen Doctor's Center, an MOB located in McAllen, Texas for a purchase price of approximately $7.6 million, including transaction costs. The building has approximately 79,500 rentable square feet and is 100% master leased to McAllen Hospitals, L.P, a wholly-owned subsidiary of UHS. The triple-net master lease is for twelve years scheduled to expire on August 31, 2035. McAllen Hospitals, L.P. has the option to renew the lease term for three consecutive ten-year terms. The initial annual base rent is approximately $624,000. During the first quarter of 2023, construction was substantially completed on Sierra Medical Plaza I, a multi-tenant MOB located in Reno, Nevada, consisting of approximately 86,000 rentable square feet. This MOB is located on the campus of the Northern Nevada Sierra Medical Center, a newly constructed acute care hospital that is owned and operated by a wholly-owned subsidiary of UHS, which was completed and opened during April of 2022. The cost of the MOB is estimated to be approximately $35 million, approximately $30 million of which was incurred as of June 30, 2024. In connection with this MOB, we entered into a ground lease and master flex-lease agreement with a wholly-owned subsidiary of UHS. The master flex lease agreement has a ten-year term scheduled to expire on March 31, 2033, and covers approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually plus a pro-rata share of the common area maintenance expenses. The master flex-lease is subject to a reduction during the term based upon the execution of third-party leases. The ground lease and the master flex lease each commenced during March, 2023.We are the lessee on thirteen ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments), including one that commenced in March, 2023. The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 25 years to approximately 74 years. The annual aggregate lease payments on these properties are approximately $571,000 during each of the years ended 2024 through 2028, and an aggregate of $31.3 million thereafter. See Note 7 for additional lease accounting disclosure. Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of June 30, 2024 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.Advisory Agreement: UHS of Delaware, Inc. (the â€œAdvisorâ€), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the â€œAdvisory Agreementâ€). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the â€œIndependent Trusteesâ€). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisorâ€™s performance has been satisfactory. The Advisory Agreement was renewed for 2024 with the same terms as the Advisory Agreement in place during 2023 and 2022. Our advisory fee for the three months ended June 30, 2024 and 2023, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets. Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2024 as compared to 2023 and 2022. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.4 million and $1.3 million for the three-month periods ended June 30, 2024 and 2023, respectively, and were based upon average invested real estate assets of $782 million and $756 million, respectively. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $2.7 million and $2.6 million for the six-month periods ended June 30, 2024 and 2023, respectively, and were based upon average invested real estate assets of $773 million and $750 million, respectively. Share Ownership: As of June 30, 2024 and December 31, 2023, UHS owned 5.7% of our outstanding shares of beneficial interest.11 Â SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised approximately 41% of our consolidated revenues during each of the three and six-month periods ended June 30, 2024 and 2023, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SECâ€™s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein. (3) Dividends and Equity Issuance ProgramDividends and dividend equivalents:We declared and paid dividends of approximately $10.2 million, or $.730 per share, during the second quarter of 2024 and approximately $10.0 million, or $.720 per share, during the second quarter of 2023. We declared and paid dividends of approximately $20.2 million, or $1.455 per share, during the six-month period ended June 30, 224, and approximately $19.8 million, or $1.435 per share, during the comparable period of 2023. Amounts reflected above include accrued dividends that were paid related to the vesting of restricted stock. Dividend equivalents, which are applicable to shares of unvested restricted stock, were accrued during the first six months of 2024 and 2023 and were or will be paid upon vesting of the restricted stock. Equity Issuance Program:During the second quarter of 2024, we filed a shelf registration statement on Form S-3 (File No. 333-278730) (the "Form S-3"), registering the offer and sale, from time-to-time, of an indeterminate amount of the common shares of beneficial interest, preferred shares and debt securities up to an aggregate initial offering price of $100 million to or through one or more underwriters, dealers or agents, or directly to purchasers. The Form S-3 became effective on April 30, 2024.No shares were issued under the Form S-3 since the effective date of April 30, 2024 through June 30, 2024. As of June 30, 2024, we have paid or incurred approximately $287,000 in various fees and expenses related to the Form S-3. The availability of the potential liquidity under this shelf registration statement depends on investor demand, market conditions and other factors. We make no assurance regarding when, or if, we will issue any securities under this registration statement. Â (4) Acquisitions and Divestitures Six Months Ended June 30, 2024:Acquisitions:There were no acquisitions during the first six months of 2024.Divestitures:There were no divestitures during the first six months of 2024. Â Six Months Ended June 30, 2023:New Construction:In January 2022, we entered into a ground lease and master flex-lease agreement with a wholly-owned subsidiary of UHS to develop, construct and own the real property of Sierra Medical Plaza I, an MOB located in Reno, Nevada, consisting of approximately 86,000 rentable square feet. This MOB is located on the campus of the Northern Nevada Sierra Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS, which was completed and opened during April of 2022. Construction of this MOB, for which we engaged a non-related third party to act as construction manager, commenced in January, 2022, and was substantially completed in March, 2023. The master flex lease agreement in connection with this building, which commenced in March, 2023 and has a ten-year term scheduled to expire on March 31, 2033, covers approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually, plus pro-rata share of the common area maintenance expenses. This master flex lease agreement is subject to reduction based upon the execution of third-party leases. Additionally, during March, 2023, the ground lease for this property commenced and a right-of-use asset and lease liability was recorded in connection with this lease. The cost of the MOB is estimated to be approximately $35 million, approximately $30 million of which was incurred as of June 30, 2024.Acquisitions:There were no acquisitions during the first six months of 2023.Divestitures:12 Â There were no divestitures during the first six months of 2023. (5) Summarized Financial Information of Equity AffiliatesIn accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting. The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities. Returns of investments are classified as cash flows from investing activities. At June 30, 2024, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of June 30, 2024 we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties. The following property table represents the four LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of June 30, 2024: Â Â Â Â Â Â Name of LLC/LP Â Ownership Â Â Property Owned by LLC/LP Suburban Properties Â Â 33 % Â St. Matthews Medical Plaza II Brunswick Associates (a.)(b.) Â Â 74 % Â Mid Coast Hospital MOB FTX MOB Phase II (c.) Â Â 95 % Â Forney Medical Plaza II Grayson Properties II (d.)(e.) Â Â 95 % Â Texoma Medical Plaza II (a.)This LLC has a third-party term loan of $8.3 million, which is non-recourse to us, outstanding as of June 30, 2024.(b.)We are the lessee with a third party on a ground lease for land.(c.)During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. During the first quarter of 2023, the LP repaid $175,000 of the member loan and the remaining $3.3 million member loan balance was converted to an equity investment in the LP.(d.)This LP constructed, owns and operates the Texoma Medical Plaza II, on which construction substantially completed in December 2020. The MOB is located in Denison, Texas, on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS. We have committed to invest up to $10.2 million in equity and debt financing, of which $7.5 million, net, has been funded as of June 30, 2024. This LP entered into a third-party construction loan commitment, which is non-recourse to us, which had an outstanding balance of $7.0 million as of June 30, 2024. Monthly principal and interest payments on this loan commenced on January 1, 2023. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro rata equity contributions from the partners. The third-party partner's share of the pro rata equity contributions was partially funded with a six-month, $128,000 partner loan from us, which was repaid during July, 2024 with interest. Our share of the pro rata equity contributions, as well as the third-party partner loan, were funded utilizing borrowings from our revolving credit agreement. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated.(e.)We are the lessee with a UHS-related party for the land related to this property.Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at June 30, 2024 and 2023: 13 Â Â Â Three Months EndedJune 30, Â Â Six Months EndedJune 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (amounts in thousands) (amounts in thousands) Â Revenues Â $ 2,057 Â Â $ 2,043 Â Â $ 4,307 Â Â $ 4,269 Â Operating expenses Â Â 826 Â Â Â 812 Â Â Â 1,724 Â Â Â 1,717 Â Depreciation and amortization Â Â 472 Â Â Â 461 Â Â Â 946 Â Â Â 916 Â Interest, net Â Â 142 Â Â Â 198 Â Â Â 301 Â Â Â 439 Â Net income Â $ 617 Â Â $ 572 Â Â $ 1,336 Â Â $ 1,197 Â Our share of net income Â $ 272 Â Â $ 268 Â Â $ 656 Â Â $ 639 Â Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs/LPs that were accounted for under the equity method as of June 30, 2024 and December 31, 2023: Â Â Â June 30,2024 Â Â December 31,2023 Â Â Â (amounts in thousands) Â Net property, including construction in progress Â $ 27,688 Â Â $ 28,488 Â Other assets (a.) Â Â 4,679 Â Â Â 4,667 Â Total assets Â $ 32,367 Â Â $ 33,155 Â Â Â Â Â Â Â Â Other liabilities (a.) Â $ 2,272 Â Â $ 2,074 Â Mortgage notes payable, non-recourse to us Â Â 15,280 Â Â Â 21,206 Â Equity Â Â 14,815 Â Â Â 9,875 Â Total liabilities and equity Â $ 32,367 Â Â $ 33,155 Â Â Â Â Â Â Â Â Investments in and advances to LLCs before amounts included in Â Â Â Â Â Â Â Â Â accrued expenses and other liabilities Â $ 14,328 Â Â $ 9,102 Â Â Â Â Amounts included in accrued expenses and other liabilities Â Â (1,751 ) Â Â (1,729 ) Our share of equity in LLCs, net Â $ 12,577 Â Â $ 7,373 Â (a.)Other assets and other liabilities as of June 30, 2024 and December 31, 2023 include approximately $650,000 and $651,000, respectively, of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS. As of June 30, 2024, and December 31, 2023, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands): Â Â Mortgage Loan Balance (a.) Â Â Â Name of LLC/LP Â 6/30/2024 Â Â 12/31/2023 Â Â Maturity Date Brunswick Associates (2.80% fixed rate mortgage loan) Â $ 8,314 Â Â $ 8,453 Â Â December, 2030 Grayson Properties II (3.70% fixed rate construction loan) (b.) Â Â 6,966 Â Â Â 12,753 Â Â March, 2026 Â Â $ 15,280 Â Â $ 21,206 Â Â Â (a.)All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. (b.)This construction loan required interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022. On January 1, 2023, monthly principal and interest payments on this loan commenced. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro-rate equity contributions from the partners, as discussed above. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated. Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (â€œOffering Memberâ€) to the other member(s) (â€œNon-Offering Memberâ€) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (â€œOffer to Sellâ€) at a price as determined by the Offering Member (â€œTransfer Priceâ€), or; (ii) purchase the entire ownership interest of the Non-Offering Member (â€œOffer to Purchaseâ€) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member. 14 Â (6) Recent Accounting PronouncementsSegment ReportingIn November, 2023, the FASB issued ASU 2023-07, Segment Reporting, Topic 280, "Improvements to Reportable Segment Disclosures ("ASU 2023-07") which was issued to improve the disclosures about s public entity's reportable segments and address requests from investors for additional, more detailed information about a reportable segment's expenses. The ASU requires existing annual segment disclosures to also be disclosed on an interim basis and also requires disclosures around significant segment expenses and disclosures to identify the title and position of the chief operating decision maker ("CODM"). The standard is effective for the fiscal year ended December 31, 2024 and interim periods thereafter. We do not expect the standard to have a material impact on our consolidated financial statements.Reference Rate ReformIn March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, â€œReference Rate Reform.â€ The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. Beginning in the first quarter of 2020, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. We will continue to evaluate the impact of the guidance

and may apply other elections as applicable as additional changes in the market occur. In December 2022, the FASB issued ASU 2022-06, Deferral of the Sunset Date of Topic 848 (â€œASU 2022-06â€) which was issued to defer the sunset date of Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform to December 31, 2024. ASU 2022-06 is effective immediately for all companies. ASU 2022-06 has no impact on the Companyâ€™s condensed consolidated financial statements for the three and six months ended June 30, 2024. (7) Lease AccountingAs Lessor:We lease most of our operating properties to customers under agreements that are typically classified as operating leases (as noted below, two of our leases are accounted for as financing arrangements effective on December 31, 2021). We recognize the total minimum lease payments provided for under the operating leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease. We have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers (â€œtenant reimbursementsâ€) from the associated rental revenue if certain criteria were met. We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and for the leases that qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three and six months ended June 30, 2024 and 2023. On December 31, 2021, as a result of the asset purchase and sale transaction with UHS, as amended during the first quarter of 2022, the real estate assets of two wholly-owned subsidiaries of UHS were transferred to us (Aiken and Canyon Creek). As discussed in Note 2, these assets are accounted for as financing arrangements and our consolidated balance sheets at June 30, 2024 and December 31, 2023 reflect financing receivables related to this transaction amounting to $83.0 million and $83.3 million, respectively. Pursuant to the leases, as amended during the first quarter of 2022, the aggregate annual rental during 2024 on the acquired properties, which is payable to us on a monthly basis, amounts to approximately $5.9 million ($4.1 million related to Aiken and $1.8 million related to Canyon Creek). The portion of these lease payments that will be included in our consolidated statements of income, and reflected as interest income on financing leases, is expected to be approximately $5.4 million during the full year of 2024. Lease revenue will not be impacted by the lease payments received related to these two properties.The components of the â€œLease revenue â€“ UHS facilitiesâ€ and â€œLease revenue â€“ Non-related partiesâ€ captions for the three and six month periods ended June 30, 2024 and 2023 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the term of the lease. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.Â 15 Â Â Three Months Ended Â Â Six Months Ended Â Â June 30, Â Â June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â UHS facilities: Â Â Â Â Â Â Â Â Â Â Â Â Base rents $ 6,888 Â Â $ 6,506 Â Â $ 13,860 Â Â $ 12,780 Â Bonus rents (a.) Â 758 Â Â Â 730 Â Â Â 1,541 Â Â Â 1,494 Â Tenant reimbursements Â 808 Â Â Â 1,000 Â Â Â 1,717 Â Â Â 1,749 Â Lease revenue - UHS facilities $ 8,454 Â Â $ 8,236 Â Â $ 17,118 Â Â $ 16,023 Â Â Â Â Â Â Â Â Â Â Â Â

We invest in healthcare and human-service related facilities currently including acute care hospitals, behavioral health care hospitals, specialty facilities, free-standing emergency departments, childcare centers and medical/office buildings. As of August 1, 2024, we have seventy-six real estate investments or commitments located in twenty-one states consisting of: â€¢six hospital facilities consisting of three acute care hospitals and three behavioral health care hospitals; â€¢four free-standing emergency departments (â€œFEDsâ€); â€¢sixty medical/office buildings, including four owned by unconsolidated limited liability companies (â€œLLCsâ€)/limited liability partnerships (â€œLPsâ€); â€¢four preschool and childcare centers; â€¢one specialty facility that is currently vacant, and; â€¢one vacant parcel of land located in Chicago, Illinois. Forward Looking Statements and Certain Risk Factors You should carefully review all of the information contained in this Quarterly Report, and should particularly consider any risk factors that we set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, this Quarterly Report and in other reports or documents that we file from time to time with the Securities and Exchange Commission (the â€œSECâ€). In this Quarterly Report, we state our beliefs of future events and of our future financial performance. This Quarterly Report contains â€œforward-looking statementsâ€ that reflect our current estimates, expectations and projections about our future results, performance, prospects and opportunities. Words such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œcould,â€ â€œwould,â€ â€œpredicts,â€ â€œpotential,â€ â€œcontinue,â€ â€œexpects,â€ â€œanticipates,â€ â€œfuture,â€ â€œintends,â€ â€œplans,â€ â€œbelieves,â€ â€œestimates,â€ â€œappears,â€ â€œprojectsâ€ and similar expressions, or the negative of those words and expressions, as well as statements in future tense, identify forward-looking statements. You should be aware that those statements are only our predictions. Actual events or results may differ materially. In evaluating those statements, you should specifically consider various factors, including the risks described elsewhere herein and in our Annual Report on Form 10-K for the year ended December 31, 2023 in Item 1A Risk Factors and in Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Forward Looking Statements and Risk Factors and in Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Forward Looking Statements and Certain Risk Factors, as included herein. Those factors may cause our actual results to differ materially from any of our forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, such performance or results will be achieved. Forward-looking information is based on information available at the time and/or our good faith belief with respect to future events and is subject to risks and uncertainties that are difficult to predict and many of which are outside of our control. Many factors could cause actual performance or results to differ materially from those expressed in the statements. Such factors include, among other things, the following: â€¢The increase in interest rates has significantly increased our interest expense thereby reducing our net income, cash provided by operating activities and funds from operations, as well as unfavorably impacting our ability to access the capital markets on favorable terms. Additionally, as discussed below in Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations, Other Operating Results-Interest Expense, our aggregate interest expense during the three and six-month periods ended June 30, 2024, was favorably impacted by four interest rate swaps with a combined notional amount of $165 million, while our aggregate interest expense during the three and six-month periods ended June 30, 2023, was favorably impacted by three interest rate swaps with a combined notional amount of $140 million. Two of these interest rate swaps, with a combined notional amount of $85 million, are scheduled to expire on September 16, 2024. As discussed herein, although we can provide no assurance we will ultimately do so, at a future date in 2024, we are considering replacing the two interest rate swaps that are scheduled to expire in September, 2024, with either interest rate swaps and/or interest rate cap agreements on a total notional amount of up to $85 million. The increased interest rates on our borrowings and/or the increased costs related to new construction could also affect our ability to make additional attractive investments. Given these factors, increased interest rates, including the unfavorable impact on the terms of future interest rate swap and/or cap agreements, could unfavorably impact our future rental revenue and expenses, including interest expense, and may potentially have a material unfavorable impact on our future net income, cash provided by operating activities, funds from operations, lease renewal terms, the underlying value of our properties, our ability to grow our portfolio, and the value of our common shares. 20 Â  â€¢Our tenants have experienced inflationary pressures, primarily in personnel and certain other costs. The extent of any future impacts from inflation on our tenantsâ€™ businesses and results of operations will be dependent upon how long the elevated inflation levels persist and the extent to which the rate of inflation further increases, if at all, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, expenses of our tenants, and our direct operating expenses that are not passed on to our tenants, could increase faster than anticipated and may require utilization of our and our tenantsâ€™ capital resources sooner than expected. Further, given the complexities of the reimbursement landscape in which our tenants operate, their payers may be unwilling or unable to increase reimbursement rates to compensate for inflationary impacts. This may impact their ability and willingness to make rental payments. â€¢A substantial portion of our revenues are dependent upon one operator, UHS, which comprised approximately 41% of our consolidated revenues for each of the three and six-month periods ended June 30, 2024 and 2023. As previously disclosed, on December 31, 2021, a wholly-owned subsidiary of UHS purchased the real estate assets of Inland Valley Campus of Southwest Healthcare System from us and in exchange, transferred the real estate assets of Aiken Regional Medical Center and Canyon Creek Behavioral Health to us. These transactions were approved by the Independent Trustees of our Board, as well as the UHS Board of Directors. The aggregate annual rental rate during 2024 pursuant to the leases, as amended, for the two facilities transferred to us is approximately $5.9 million; there is no bonus rent component applicable to either of these leases. Please see Note 7 to the condensed consolidated financial statements - Lease Accounting, for additional information related to this asset purchase and sale transaction between us and UHS. â€¢We cannot assure you that subsidiaries of UHS will renew the leases on the hospital facilities and free-standing emergency departments, upon the scheduled expirations of the existing lease terms. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital facilities and FEDs, and do not enter into a substitution arrangement upon expiration of the lease terms or otherwise, our future revenues and results of operations could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases. Please see Note 2 to the condensed consolidated financial statements - Relationship with Universal Health Services, Inc. (â€œUHSâ€) and Related Party Transactions, for additional information related to a lease renewal between us and Wellington Regional Medical Center, a wholly-owned subsidiary of UHS. â€¢In the past, staffing shortages have, at times, required our tenants to hire expensive temporary personnel and/or enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel. Our tenants have also experienced general inflationary cost increases related to certain other operating expenses. Many of these factors, which had a material unfavorable impact on the operating results of certain of our tenants during 2022, moderated to a certain degree during 2023 and 2024. â€¢President Biden signed into law fiscal year 2024 appropriations to federal agencies for continuing projects and activities through September 30, 2024. We cannot predict whether or not there will be future legislation averting a federal government shutdown, however, the operating results and results of operations of certain of our tenants, and therefore potentially ours, could be materially unfavorably impacted by a federal government shutdown. â€¢In certain of our markets, the general real estate market has been unfavorably impacted by increased competition/capacity and decreases in occupancy and rental rates which may adversely impact our operating results and the underlying value of our properties. â€¢A number of legislative initiatives have recently been passed into law that may result in major changes in the health care delivery system on a national or state level to the operators of our facilities, including UHS. No assurances can be given that the implementation of these new laws will not have a material adverse effect on the business, financial condition or results of operations of our operators. â€¢A subsidiary of UHS is our Advisor and our officers are all employees of a wholly-owned subsidiary of UHS, which may create the potential for conflicts of interest. â€¢Lost revenues resulting from the exercise of purchase options, lease expirations and renewals and other transactions (see Note 7 to the condensed consolidated financial statements â€“ Lease Accounting for additional disclosure related to lease expirations and subsequent vacancies that occurred during the second and third quarters of 2019 and the fourth quarter of 2021 on three specialty hospital facilities; one of which was divested in December, 2023, and another on which the demolition was substantially completed during the second quarter of 2023). â€¢Potential unfavorable tax consequences and reduced income resulting from an inability to complete, within the statutory timeframes, anticipated tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code, if, and as, applicable from time-to-time. 21 Â  â€¢The potential unfavorable impact on our business of the deterioration in national, regional and local economic and business conditions, including a worsening of credit and/or capital market conditions, which may adversely affect our ability to obtain capital which may be required to fund the future growth of our business and refinance existing debt with near term maturities. â€¢A deterioration in general economic conditions which may result in increases in the number of people unemployed and/or insured and likely increase the number of individuals without health insurance. Under these circumstances, the operators of our facilities may experience declines in patient volumes which could result in decreased occupancy rates at our medical office buildings. â€¢A worsening of the economic and employment conditions in the United States would likely materially affect the business of our operators, including UHS, which would likely unfavorably impact our future bonus rental revenue (on one UHS hospital facility) and may potentially have a negative impact on the future lease renewal terms and the underlying value of the hospital properties. â€¢There is a heightened risk of future cybersecurity threats, including ransomware attacks targeting healthcare providers. If successful, future cyberattacks could have a material adverse effect on our business. Any costs that we, or our third-party property managers, incur as a result of a data security incident or breach, including costs to update security protocols to mitigate such an incident or breach could be significant. Any breach or failure in our, our third-party property managers', our tenantsâ€™, or our or their respective third-party service providersâ€™ operational security systems, can result in loss of data or an unauthorized disclosure of or access to sensitive or confidential member or protected personal or health information and could result in violations of applicable privacy and other laws, significant penalties or fines, litigation, loss of customers, significant damage to our or their reputation and business, and other liability or losses. We may also incur additional costs related to cybersecurity risk management and remediation. There can be no assurance that we, our third-party property managers, our tenants or our or their service providers, if applicable, will not suffer losses relating to cyber-attacks or other information security breaches in the future or that insurance coverage (if applicable) will be adequate to cover all the costs resulting from such events. â€¢The outcome and effects of known and unknown litigation, government investigations, and liabilities and other claims asserted against us, UHS or the other operators of our facilities. UHS and its subsidiaries are subject to legal actions, purported shareholder class actions and shareholder derivative cases, governmental investigations and regulatory actions and the effects of adverse publicity relating to such matters. Since UHS comprised approximately 41% of our consolidated revenues during each of the three and six months ended June 30, 2024, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain and review the disclosures contained in the Legal Proceedings section of Universal Health Services, Inc.â€™s Forms 10-Q and 10-K, as publicly filed with the Securities and Exchange Commission. Those filings are the sole responsibility of UHS and are not incorporated by reference herein. â€¢Failure of UHS or the other operators of our hospital facilities to comply with governmental regulations related to the Medicare and Medicaid licensing and certification requirements could have a material adverse impact on our future revenues and the underlying value of the property. â€¢Real estate market factors, including without limitation, the supply and demand of office space and market rental rates, changes in interest rates as well as an increase in the development of medical office condominiums in certain markets. â€¢The impact of property values and results of operations of severe weather conditions, including the effects of hurricanes. â€¢Government regulations, including changes in the reimbursement levels under the Medicare and Medicaid programs. â€¢The issues facing the health care industry that affect the operators of our facilities, including UHS, such as: changes in, or the ability to comply with, existing laws and government regulations; unfavorable changes in the levels and terms of reimbursement by third party payers or government programs, including Medicare (including, but not limited to, the potential unfavorable impact of future reductions to Medicare reimbursements resulting from the Budget Control Act of 2011, as discussed in the next bullet point below) and Medicaid (most states have reported significant budget deficits that have, in the past, resulted in the reduction of Medicaid funding to the operators of our facilities, including UHS); demographic changes; the ability to enter into managed care provider agreements on acceptable terms; an increase in uninsured and self-pay patients which unfavorably impacts the collectability of patient accounts; decreasing in-patient admission trends; technological and pharmaceutical improvements that may increase the cost of providing, or reduce the demand for, health care, and; the ability to attract and retain qualified medical personnel, including physicians. â€¢The Budget Control Act of 2011 imposed annual spending limits for most federal agencies and programs aimed at reducing budget deficits including Medicare payment reductions of up to 2% per fiscal year. Current legislation extended those cuts through 2032. We cannot predict whether Congress will restructure the implemented Medicare payment reductions or what other federal budget deficit reduction initiatives may be proposed by Congress going forward. We also cannot predict the effect these enactments will have on the operators of our properties (including UHS), and thus, our business. 22 Â  â€¢An increasing number of legislative initiatives have been passed into law that may result in major changes in the health care delivery system on a national or state level. Legislation has already been enacted that has eliminated the penalty for failing to maintain health coverage that was part of the original Patient Protection and Affordable Care Act (the â€œACAâ€). President Biden has undertaken executive actions that will strengthen the ACA. To date, the Biden administration has issued executive orders implementing a special enrollment period permitting individuals to enroll in health plans outside of the annual open enrollment period and reexamining policies that may undermine the ACA or the Medicaid program. The American Rescue Plan Act of 2021's expansion of subsidies to purchase coverage through an exchange, which the Inflation Reduction Act of 2022, passed on August 16, 2022, continues through 2025, is anticipated to increase exchange enrollment. It is also anticipated that these policies, to the extent that they remain as implemented, may create additional cost and reimbursement pressures on hospitals, including ours. In addition, while attempts to repeal the entirety of the ACA have not been successful to date, a key provision of the ACA was eliminated as part of the Tax Cuts and Jobs Act and on December 14, 2018, a federal U.S. District Court Judge in Texas ruled the entire ACA is unconstitutional. That ruling was ultimately appealed to the United States Supreme Court, which decided in California v. Texas that the plaintiffs in the matter lacked standing to bring their constitutionality claims. On September 7, 2022, the Patient Protection and Affordable Care Act, as amended by the Health and Education Reconciliation Act (collectively, the â€œLegislationâ€) faced its most recent challenge when a Texas Federal District Court judge, in the case of Braidwood Management v. Becerra, ruled that certain Legislation provisions violate the Appointments Clause of the U.S. Constitution and the Religious Freedom Restoration Act. The decision was appealed to the U.S. Court of Appeals for the Fifth Circuit, which on June 21, 2024 affirmed the District Courtâ€™s ruling regarding preventive services recommended by United States Preventive Services Task Force being unconstitutional. However, the Fifth Circuit overturned the nationwide injunction imposed by the District Court, preserving access to the majority of preventive services in dispute for now. The matter is expected to be the subject of additional litigation, having been remanded in part to the District Court. Any future efforts to challenge, replace or replace the Legislation or expand or substantially amend its provision is unknown. â€¢There can be no assurance that if any of the announced or proposed changes described above are implemented there will not be negative financial impact on the operators of our hospitals, which material effects may include a potential decrease in the market for health care services or a decrease in the ability of the operators of our hospitals to receive reimbursement for health care services provided which could result in a material adverse effect on the financial condition or results of operations of the operators of our properties, and, thus, our business. â€¢Competition for properties include, but are not limited to, other REITs, private investors and firms, banks and other companies, including UHS. In addition, we may face competition from other REITs for our tenants. â€¢The operators of our facilities face competition from other health care providers, including physician owned facilities and other competing facilities, including certain facilities operated by UHS but the real property of which is not owned by us. Such competition is experienced in markets including, but not limited to, McAllen, Texas, the site of our McAllen Medical Center, a 370-bed acute care hospital. â€¢Changes in, or inadvertent violations of, tax laws and regulations and other factors that can affect REITs and our status as a REIT, including possible future changes to federal tax laws that could materially impact our ability to defer gains on divestitures through like-kind property exchanges. â€¢The individual and collective impact of the changes made by the CARES Act on REITs and their security holders are uncertain and may not become evident for some period of time; it is also possible additional legislation could be enacted in the future as a result of the COVID-19 pandemic which may affect the holders of our securities. â€¢Should we be unable to comply with the strict income distribution requirements applicable to REITs, utilizing only cash generated by operating activities, we would be required to generate cash from other sources which could adversely affect our financial condition. â€¢We hold non-controlling equity interests in four LLCs/LPs, pursuant to the operating and/or partnership agreements of which, the third-party member and the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (â€œOffering Memberâ€) to the other member(s) (â€œNon-Offering Memberâ€) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (â€œOffer to Sellâ€) at a price as determined by the Offering Member (â€œTransfer Priceâ€), or; (ii) purchase the entire ownership interest of the Non-Offering Member (â€œOffer to Purchaseâ€) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering

Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member. â€¢Fluctuations in the value of our common stock, which, among other things could be affected by the current increasing interest rate environment. 23 Â  â€¢Our business, results of operations, financial condition, or stock price may be adversely affected if we are not able to achieve our environmental, social and governance (â€œESGâ€) goals or comply with emerging ESG regulations, or otherwise meet the expectations of our stakeholders with respect to ESG matters. â€¢Other factors referenced herein or in our other filings with the Securities and Exchange Commission. Given these uncertainties, risks and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Our actual results and financial condition, including the operating results of our lessees and the facilities leased to subsidiaries of UHS, could differ materially from those expressed in, or implied by, the forward-looking statements. Forward-looking statements speak only as of the date the statements are made. We assume no obligation to publicly update any forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as may be required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement. Critical Accounting Policies and Estimates There have been no significant changes to our critical accounting policies or estimates from those disclosed in our 2023 Annual Report on Form 10-K. Results of Operations During the three-month period ended June 30, 2024, net income was $5.3 million, as compared to $3.5 million during the second quarter of 2023. The $1.8 million increase was attributable to: â€¢an increase of $1.5 million resulting from a reduction in the expenses related to our property located in Chicago, Illinois, including $862,000 from demolition expenses incurred during the second quarter of 2023, and $563,000 related to a property tax reduction recorded during the second quarter of 2024 which related primarily to prior periods; â€¢an increase of $706,000 resulting from an aggregate net increase in the income generated at various properties, and; â€¢a decrease of $404,000 resulting from an increase in interest expense due primarily to increases in our average borrowing rate as well as our average outstanding borrowings. During the six-month period ended June 30, 2024, net income was $10.6 million, as compared to $7.9 million during the corresponding six-month period of 2023. The $2.6 million increase was attributable to: â€¢an increase of $2.1 million resulting from an aggregate net increase in the income generated at various properties; â€¢an increase of $1.8 million resulting from a reduction in the expenses related to our property located in Chicago, Illinois, including $1.1 million from demolition expenses incurred during the first six months of 2023, and $563,000 related to a property tax reduction recorded during the first six months of 2024 which related primarily to prior periods, and; â€¢a decrease of $1.3 million resulting from an increase in interest expense due primarily to increases in our average borrowing rate as well as our average outstanding borrowings. Revenues increased $928,000, or 3.9%, to $24.7 million during the three-month period ended June 30, 2024, as compared to $23.8 million during the three-month period ended June 30, 2023. The increase during the second quarter of 2024, as compared to the second quarter of 2023, was primarily due to an aggregate net increase generated at various properties, including the revenues generated at an MOB located in McAllen, Texas, that was acquired during the third quarter of 2023. Revenues increased $2.8 million, or 6.0%, to $49.9 million during the six-month period ended June 30, 2024, as compared to $47.0 million during the six-month period ended June 30, 2023. The increase during the first six months of 2024, as compared to the first six months of 2023, was primarily due to an aggregate net increase generated at various properties, including the increased revenues generated at a newly constructed MOB located in Reno, Nevada, that opened during the first quarter of 2023, and the revenues generated at an MOB located in McAllen, Texas, that was acquired during the third quarter of 2023. A large portion of the expenses associated with our consolidated medical office buildings is passed on directly to the tenants either directly as tenant reimbursements of common area maintenance expenses or included in base rental amounts. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred and are included as lease revenue in our condensed consolidated statements of income. Other operating expenses amounted to $6.1 million during the second quarter of 2024 and $6.5 million during the second quarter of 2023 (excluding $862,000 of demolition expenses incurred during the second quarter of 2023). Included in our other operating expenses (excluding ground lease expenses) are expenses related to the consolidated medical office buildings which included two vacant properties during the second quarter of 2024 and three vacant properties during the second quarter of 2023 (the divestiture of one of 24 Â  these vacant properties was completed during the fourth quarter of 2023 and the demolition of one of these vacant properties was substantially completed during the second quarter of 2023). Other operating expenses amounted to $12.8 million and $12.9 million during the six-month periods ended June 30, 2024 and 2023, respectively, (excluding $1.1 million of demolition expenses incurred during the first six month of 2023). Our operating expenses during the three and six-month periods ended June 30, 2024 include a property tax reduction of approximately $563,000, which related primarily to prior periods, recorded in connection with our property located in Chicago, Illinois. Funds from operations (â€œFFOâ€) is a widely recognized measure of performance for Real Estate Investment Trusts (â€œREITsâ€). We believe that FFO and FFO per diluted share, which are non-GAAP financial measures, are helpful to our investors as measures of our operating performance. We compute FFO in accordance with standards established by the National Association of Real Estate Investment Trusts (â€œNAREITâ€), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. FFO adjusts for the effects of certain items, such as gains on transactions that occurred during the periods presented. To the extent a REIT recognizes a gain or loss with respect to the sale of incidental assets, the REIT has the option to exclude or include such gains and losses in the calculation of FFO. We have opted to exclude gains and losses from sales of incidental assets in our calculation of FFO, if and when applicable. FFO does not represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders. Below is a reconciliation of our reported net income to FFO for the three and six-month periods ended June 30, 2024 and 2023 (in thousands): Â Â  Three Months EndedJune 30, Â Â  Six Months EndedJune 30, Â Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Net income Â  $ 5,276 Â Â  $ 3,476 Â Â  $ 10,576 Â Â  $ 7,935 Â Depreciation and amortization expense on consolidatedÂ Â Â investments Â Â  6,806 Â Â Â  6,849 Â Â Â  13,615 Â Â Â  13,467 Â Depreciation and amortization expense on unconsolidatedÂ Â Â affiliates Â Â  303 Â Â Â  298 Â Â Â  607 Â Â Â  591 Â Funds From Operations Â  $ 12,385 Â Â  $ 10,623 Â Â  $ 24,798 Â Â  $ 21,993 Â Weighted average number of shares outstanding - Diluted Â Â  13,832 Â Â Â  13,809 Â Â Â  13,828 Â Â Â  13,806 Â Funds From Operations per diluted share Â  $ 0.90 Â Â  $ 0.77 Â Â  $ 1.79 Â Â  $ 1.59 Â Our FFO increased $1.8 million to $12.4 million during the second quarter of 2024, as compared to $10.6 million during the second quarter of 2023. The net increase was primarily due to the $1.8 million increase in net income, as discussed above. Our FFO increased $2.8 million to $24.8 million during the first six months of 2024, as compared to $22.0 million during the first six months of 2023. The net increase was primarily due to: (i) an increase in net income of $2.6 million, as discussed above, and; (ii) an increase in depreciation and amortization expense incurred by our consolidated and unconsolidated affiliates. Other Operating Results Interest Expense: As reflected in the schedule below, interest expense was $4.6 million and $4.2 million during the three-month periods ended June 30, 2024 and 2023, respectively, and $9.1 million and $7.9 million during the six-month periods ended June 30, 2024 and 2023, respectively (amounts in thousands): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three MonthsEndedJune 30,2024 Â Â  Three MonthsEndedJune 30,2023 Â Â  Six MonthsEndedJune 30,2024 Â Â  Six MonthsEndedJune 30,2023 Â Revolving credit agreement Â  $ 5,815 Â Â  $ 4,989 Â Â  $ 11,473 Â Â  $ 9,484 Â Mortgage interest Â Â  217 Â Â Â  434 Â Â Â  561 Â Â Â  872 Â Interest rate swaps income, net (a.) Â Â  (1,640 ) Â Â  (1,416 ) Â Â  (3,285 ) Â Â  (2,643 ) Amortization of financing fees Â Â  190 Â Â Â  177 Â Â Â  383 Â Â Â  348 Â Amortization of fair value of debt Â Â  - Â Â Â  (12 ) Â Â  - Â Â Â  (24 ) Capitalized interest on major projects Â Â  - Â Â Â  - Â Â Â  - Â Â Â  (149 ) Other interest Â Â  (2 ) Â Â  4 Â Â Â  (5 ) Â Â  (15 ) Interest expense, net Â  $ 4,580 Â Â  $ 4,176 Â Â  $ 9,127 Â Â  $ 7,873 Â Â  25 Â (a.)As disclosed below in Quantitative and Qualitative Disclosures About Market Risk-Financial Instruments, on December 1, 2023, we entered into a fourth interest rate swap with a notional amount of $25 million. During the three and six-months ended June 30, 2024, net interest was paid to us from the counterparties pursuant to four interest rate swaps with a combined notional amount of $165 million (of which two interest rate swaps with a combined notional amount of $85 million are scheduled to expire on September 16, 2024). During the three and six-months ended June 30, 2023, net interest was paid to us from the counterparties pursuant to three interest rates swaps with a combined notional amount of $140 million. Interest expense increased by $404,000 during the three-month period ended June 30, 2024, as compared to the comparable period of 2023, due primarily to: (i) a $826,000 increase in the interest expense on our revolving credit agreement primarily resulting from increases in our average cost of borrowings (6.92% average effective rate during the second quarter of 2024, as compared to 6.59% average effective rate during the comparable quarter of 2023) and in our average outstanding borrowings ($337.9 million during the three months ended June 30, 2024 as compared to $303.8 million in the comparable quarter of 2023); (ii) a $19,000 net increase in other combined interest expenses, partially offset by; (iii) a $224,000 favorable change in interest rate swap income, and; (iv) a $217,000 decrease in mortgage interest expense (due primarily to repayment, utilizing borrowings under our credit agreement, of a $12.2 million fixed rate mortgage loan that matured during the second quarter of 2024). Interest expense increased by $1.3 million during the six-month period ended June 30, 2024, as compared to the comparable period of 2023, due primarily to: (i) a $2.0 million increase in the interest expense on our revolving credit agreement primarily resulting from increases in our average cost of borrowings (6.94% average effective rate during the first six months of 2024, as compared to 6.33% average effective rate during the comparable six months of 2023) and in our average outstanding borrowings ($332.5 million during the six months ended June 30, 2024 as compared to $302.4 million in the comparable six-month period of 2023); (ii) a $149,000 increase due to a decrease in capitalized interest on a major project that was substantially completed during the first quarter of 2023; (iii) a $69,000 net increase in other combined interest expenses, partially offset by; (iv) a $642,000 favorable change in interest rate swap income, and; (v) a $311,000 decrease in mortgage interest expense. Liquidity and Capital Resources Net cash provided by operating activities Net cash provided by operating activities was $23.9 million during the six-month period ended June 30, 2024 as compared to $22.3 million during the comparable period of 2023. The $1.5 million net increase was attributable to: â€¢a favorable change of $2.9 million due to an increase in net income plus/minus the adjustments to reconcile net income to net cash provided by operating activities (depreciation and amortization, amortization related to above/below market leases, amortization of debt premium, as applicable, amortization of deferred financing costs and stock-based compensation), as discussed above; â€¢an unfavorable change of $691,000 in accrued expenses and other liabilities; â€¢a favorable change of $572,000 in accrued interest; â€¢an unfavorable change of $160,000 in leasing costs paid; â€¢a favorable change of $115,000 in lease receivable, and; â€¢other combined net unfavorable changes of $1.2 million. Net cash used in investing activities Net cash used in investing activities was $9.7 million during the first six months of 2024 as compared to $8.9 million during the first six months of 2023. During the six-month period ended June 30, 2024 we funded: (i) $5.9 million in equity investments in unconsolidated LLCs; (ii) $4.3 million in additions to real estate investments including construction costs related to the Sierra Medical Plaza I medical office building located in Reno, Nevada, that was substantially completed during the first quarter of 2023, as well as tenant improvements at various MOBs, and; (iii) $128,000 in an advance made to a third-party partner of an unconsolidated LLC, which was repaid in July, 2024, with interest. In addition, during the six months ended June 30, 2024, we received $688,000 of cash in excess of income from LLCs. During the six-month period ended June 30, 2023 we funded: (i) $8.8 million in additions to real estate investments including construction costs related to the Sierra Medical Plaza I medical office building located in Reno, Nevada, that was substantially completed during the first quarter of 2023, as well as tenant improvements at various MOBs; (ii) $3.9 million in equity investments in unconsolidated LLCs, and; (iii) $100,000 in deposits on real estate assets. In addition, during the six months ended June 30, 2023, we received: (i) $369,000 of cash in excess of income from LLCs, and; (ii) $3.5 million of repayments of an advance we provided to an unconsolidated LLC during 2021. 26 Â  Net cash used in financing activities Net cash used in financing activities was $16.8 million during the six months ended June 30, 2024, as compared to $11.6 million during the six months ended June 30, 2023. During the six-month period ended June 30, 2024, we paid: (i) $12.9 million on mortgage notes payable that are non-recourse to us, including a $12.2 million repayment of a fixed rate mortgage loan that matured during the second quarter of 2024; (ii) $49,000 of financing costs related to the revolving credit agreement; (iii) $20.2 million of dividends, including $78,000 of previously accrued dividends, and; (iv) $10,000, of net cash paid related to the issuance of shares of beneficial interest. Additionally, during the six months ended June 30, 2024, we received $16.3 million of net borrowings on our revolving credit agreement. During the six-month period ended June 30, 2023, we paid: (i) $5.0 million on mortgage notes payable that are non-recourse to us, including a $4.2 million repayment of a fixed rate mortgage loan that matured during the first quarter of 2023; (ii) $132,000 of financing costs related to the amendment to our revolving credit agreement, and; (iii) $19.8 million of dividends, including $58,000 of previously accrued dividends. Additionally, during the six months ended June 30, 2023, we received: (i) $13.3 million of net borrowings on our revolving credit agreement, and; (ii) $76,000 of net cash from the issuance of shares of beneficial interest. During the second quarter of 2024, we commenced an at-the-market ("ATM") equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective on April 30, 2024. No shares were issued pursuant to this ATM equity program since the effective date of April 30, 2024 through June 30, 2024. Pursuant to this ATM program, as of June 30, 2024, we have paid or incurred approximately $287,000 in various fees and expenses related to our ATM program. Additional cash flow and dividends paid information for the six-month periods ended June 30, 2024 and 2023: As indicated on our condensed consolidated statement of cash flows, we generated net cash provided by operating activities of $23.9 million and $22.3 million during the six-month periods ended June 30, 2024 and 2023, respectively. As also indicated on our statement of cash flows, non-cash expenses including depreciation and amortization expense, amortization related to above/below market leases, amortization of debt premium, as applicable, amortization of deferred financing costs and stock-based compensation expense, as well as changes in certain assets and liabilities, are the primary differences between our net income and net cash provided by operating activities during each period. We declared and paid dividends of $20.2 million and $19.8 million during the six-month periods ended June 30, 2024 and 2023, respectively. During the first six months of 2024, the $23.9 million of net cash provided by operating activities was approximately $3.7 million greater than the $20.2 million of dividends paid during the first six months of 2024. During the first six months of 2023, the $22.3 million of net cash provided by operating activities was approximately $2.5 million greater than the $19.8 million of dividends paid during the first six months of 2023. As indicated in the cash flows from investing activities and cash flows from financing activities sections of the statements of cash flows, there were various other sources and uses of cash during the six months ended June 30, 2024 and 2023. From time to time, various other sources and uses of cash may include items such as investments and advances made to/from LLCs, additions to real estate investments, acquisitions/divestiture of properties, net borrowings/repayments of debt, and proceeds generated from the issuance of equity. Therefore, in any given period, the funding source for our dividend payments is not wholly dependent on the operating cash flow generated by our properties. Rather, our dividends as well as our capital reinvestments into our existing properties, acquisitions of real property and other investments are funded based upon the aggregate net cash inflows or outflows from all sources and uses of cash from the properties we own either in whole or through LLCs, as outlined above. In determining and monitoring our dividend level on a quarterly basis, our management and Board of Trustees consider many factors in determining the amount of dividends to be paid each period. These considerations primarily include: (i) the minimum required amount of dividends to be paid in order to maintain our REIT status; (ii) the current and projected operating results of our properties, including those owned in LLCs, and; (iii) our future capital commitments and debt repayments, including those of our LLCs. Based upon the information discussed above, as well as consideration of projections and forecasts of our future operating cash flows, management and the Board of Trustees have determined that our operating cash flows have been sufficient to fund our dividend payments. Future dividend levels will be determined based upon the factors outlined above with consideration given to our projected future results of operations. We expect to finance all capital expenditures and acquisitions and pay dividends utilizing internally generated and additional funds. Additional funds may be obtained through: (i) borrowings under our $375 million revolving credit agreement (which had $32.1 million of available borrowing capacity, net of outstanding borrowings as of June 30, 2024); (ii) borrowings under or refinancing of existing third-party debt pursuant to mortgage loan agreements entered into by our consolidated and unconsolidated LLCs/LPs; (iii) the issuance of other long-term debt, and/or; (iv) the issuance of equity. In April 2024 we filed a shelf registration statement on Form S-3 with the 27 Â  Securities and Exchange Commission pursuant to which we many offer up to $100 million of securities pursuant to supplemental prospectuses which we may file from time to time. We believe that our operating cash flows, cash and cash equivalents, available borrowing capacity under our revolving credit agreement and access to the capital markets provide us with sufficient capital resources to fund our operating, investing and financing requirements for the next twelve months, including providing sufficient capital to allow us to make distributions necessary to enable us to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986. In the event we need to access

the capital markets or other sources of financing, there can be no assurance that we will be able to obtain financing on acceptable terms or within an acceptable time. Our inability to obtain financing on terms acceptable to us could have a material unfavorable impact on our results of operations, financial condition and liquidity. Credit facilities and mortgage debt Management routinely monitors and analyzes the Trustâ€™s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of equity issuances. This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trustâ€™s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trustâ€™s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trustâ€™s growth. On May 15, 2023 we entered into the first amendment to our amended and restated revolving credit agreement ("Credit Agreement") dated as of July 2, 2021 among the Trust as borrower, the lenders party thereto and Wells Fargo Bank, N.A., as administrative agent. The amendment replaced LIBOR with term SOFR plus .10% ("adjusted term SOFR") as an alternative benchmark rate under the Credit Agreement for settings of benchmark rates that occur on or after the closing date in accordance with the benchmark replacement provisions set forth in the Credit Agreement. On July 2, 2021, we entered into an amended and restated Credit Agreement to amend and restate the previously existing $350 million credit agreement, as amended and dated June 5, 2020. Among other things, under the Credit Agreement, our aggregate revolving credit commitment was increased to $375 million from $350 million. The Credit Agreement, which is scheduled to mature on July 2, 2025, provides for a revolving credit facility in an aggregate principal amount of $375 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans. Under the terms of the Credit Agreement, we may request that the revolving line of credit be increased by up to an additional $50 million. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in most of the Trustâ€™s wholly-owned subsidiaries. Borrowings under the Credit Agreement will bear interest at a rate equal to, at our option, at adjusted term SOFR for either one, three, or six months or the Base Rate, plus in either case, a specified margin depending on our total leverage ratio, as determined by the formula set forth in the Credit Agreement. The applicable margin after the first amendment ranges from 1.10% to 1.35% for adjusted term SOFR loans and 0.10% to 0.35% for Base Rate loans. The Credit Agreement, as amended by the first amendment, defines â€œBase Rateâ€ as the greatest of (a) the Administrative Agentâ€™s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month adjusted term SOFR plus 1%. The Trust will also pay a quarterly revolving facility fee ranging from 0.15% to 0.35% (depending on the Trustâ€™s total leverage ratio) on the committed amount of the Credit Agreement. The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods. The margins over adjusted term SOFR, Base Rate and the facility fee are based upon our total leverage ratio. At June 30, 2024, the applicable margin over the adjusted term SOFR rate was 1.20%, the margin over the Base Rate was 0.20% and the facility fee was 0.20%. At June 30, 2024, we had $342.9 million of outstanding borrowings pursuant to the terms of our $375 million Credit Agreement and $32.1 million of available borrowing capacity. There are no compensating balance requirements. At December 31, 2023, we had $326.6 million of outstanding borrowings, $3.1 million of outstanding letters of credit and $45.3 million of available borrowing capacity. In our consolidated statements of cash flows, we report cash flows pursuant to our Credit Agreement on a net basis. Aggregate borrowings under our Credit Agreement were $25.2 million and $14.8 million during the quarters ended June 30, 2024 and 2023, respectively, and aggregate repayments were $15.9 million and $11.8 million during the quarters ended June 30, 2024 and 2023, respectively. Aggregate borrowings under our Credit Agreement were $47.0 million and $34.5 million during the six-months ended June 30, 2024 and 2023, respectively, and aggregate repayments were $30.7 million and $21.2 million during the six-months ended June 30, 2024 and 2023, respectively. 28 Â The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trustâ€™s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts then outstanding under the Credit Agreement. We are in compliance with all of the covenants in the Credit Agreement at June 30, 2024, and were in compliance with all of the covenants of the Credit Agreement at December 31, 2023. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed. The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands): Â Â Covenant Â June 30,2024 Â December 31,2023 Â Tangible net worth Â > $125,000 Â $ 182,508 Â $ 191,824 Â Total leverage Â < =60% Â Â 44.0 % Â 44.5 % Secured leverage Â < 30% Â Â 2.5 % Â 4.1 % Unencumbered leverage Â < 60% Â Â 45.3 % Â 44.2 % Fixed charge coverage Â >1.50x Â 3.2x Â 3.1x Â As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of June 30, 2024 (amounts in thousands): Facility Name Â OutstandingBalance(in thousands) (a.) Â Â InterestRate Â Â MaturityDate Tuscan Professional Building fixed rate mortgage loan (b.) Â $ 717 Â Â Â 5.56 % Â June, 2025 Phoenix Childrenâ€™s East Valley Care Center fixed rate Â Â Â mortgage loan Â Â 7,789 Â Â Â 3.95 % Â January, 2030 Rosenberg Children's Medical Plaza fixed rate mortgage loan Â Â 11,638 Â Â Â 4.42 % Â September, 2033 Total, excluding net debt premium and net financing fees Â Â 20,144 Â Â Â Â Â Â Â Â Â Â Â Â Less net financing fees Â Â (174 ) Â Â Â Â Â Total mortgages notes payable, non-recourse to us, net Â $ 19,970 Â Â Â Â Â Â Â (a.)All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. (b.)This loan is scheduled to mature within the next twelve months, at which time we will either refinance pursuant to a new mortgage loan or repay the mortgage balance in full utilizing borrowings under our Credit Agreement. On April 10, 2024, the $12.2 million fixed rate mortgage loan on Summerlin Hospital Medical Office Building III was fully repaid utilizing borrowings under our Credit Agreement. At June 30, 2024 and December 31, 2023, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of June 30, 2024, had a combined carrying value of approximately $20.1 million and a combined fair value of approximately $18.4 million. The mortgages outstanding as of December 31, 2023, had a combined carrying value of approximately $33.1 million and a combined fair value of approximately $31.2 million. The fair value of our debt was computed based upon quotes received from financial institutions. We consider these to be â€œlevel 2â€ in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow. Off Balance Sheet Arrangements As of June 30, 2024, we had off balance sheet arrangements consisting of certain equity and debt financing commitments. As a result of the first quarter, 2024 partial repayment of the Grayson Properties II construction loan, the associated $3.1 million letter of credit was cancelled. (See Note 5 to the condensed consolidated financial statements). As of December 31, 2023, we had off balance sheet arrangements consisting of standby letters of credit and equity and debt financing commitments. Our outstanding letters of credit at December 31, 2023 totaled $3.1 million related to Grayson Properties II. Acquisition and Divestiture Activity Please see Note 4 to the condensed consolidated financial statements. 29 Â Item 3. Quantitative and Qualitative Disclosures About Market Risk LIBOR Transition In 2017, the U.K. Financial Conduct Authority (â€œFCAâ€) that regulates LIBOR announced it intends to phase out LIBOR and stop compelling banks to submit rates for its calculation. In 2021, the FCA further announced that effective January 1, 2022, the one week and two-month USD LIBOR tenors are no longer being published. Additionally, effective July 1, 2023 all other USD LIBOR tenors are no longer published. The Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee which identified the Secured Overnight Financing Rate ("SOFR") as its preferred alternative to USD-LIBOR in derivatives and other financial contracts. We are not able to predict how the markets will respond to SOFR or any other alternative reference rate as the transition away from LIBOR continues. Any changes adopted by FCA or other governing bodies in the method used for determining LIBOR may result in a sudden or prolonged increase or decrease in reported LIBOR. If that were to occur, our interest payments could change. In addition, uncertainty about the extent and manner of future changes may result in interest rates and/or payments that are higher or lower than if LIBOR were to remain available in its current form. On May 15, 2023 we entered into the first amendment to our amended and restated revolving credit agreement ("Credit Agreement") dated as of July 2, 2021 among the Trust as borrower, the lenders party thereto and Wells Fargo Bank, N.A., as administrative agent. The amendment replaces LIBOR Rate with adjusted term SOFR as an alternative benchmark rate for purposes under the Credit Agreement for settings of benchmark rates the occur on or after the closing date in accordance with the benchmark replacement provisions set forth in the Credit Agreement. Financial Instruments In December 2023, we entered into an interest rate swap agreement on a total notional amount of $25 million with a fixed interest rate of 3.9495% that we designated as a cash flow hedge. The interest rate swap became effective on December 1, 2023 and is scheduled to mature on December 1, 2027. If one-month term SOFR is above 3.9495%, the counterparty pays us, and if one-month term SOFR is less than 3.9495%, we pay the counterparty, the difference between the fixed rate of 3.9495% and one-month term SOFR. In March 2020, we entered into an interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge. The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. On May 15, 2023, this interest rate swap agreement was modified to replace the benchmark rate from LIBOR to term SOFR. If one-month term SOFR is above 0.505%, the counterparty pays us, and if one-month term SOFR is less than 0.505%, we pay the counterparty, the difference between the fixed rate of 0.505% and one-month term SOFR. In January 2020, we entered into an interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge. The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. On May 15, 2023, this interest rate swap agreement was modified to replace the benchmark rate from LIBOR to term SOFR. If the one-month term SOFR is above 1.41%, the counterparty pays us, and if the one-month term SOFR is less than 1.41%, we pay the counterparty, the difference between the fixed rate of 1.41% and one-month term SOFR. Although we can provide no assurance we will ultimately do so, at a future date in 2024, we are considering replacing this interest rate swap agreement with either an interest rate swap or interest rate cap agreement on a total notional amount of approximately $35 million. During the third quarter of 2019, we entered into an interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. On May 15, 2023, this interest rate swap agreement was modified to replace the benchmark rate from LIBOR to term SOFR. If one-month term SOFR is above 1.065%, the counterparty pays us, and if one-month term SOFR is less than 1.065%, we pay the counterparty, the difference between the fixed rate of 1.065% and one-month term SOFR. Although we can provide no assurance we will ultimately do so, at a future date in 2024, we are considering replacing this interest rate swap agreement with either an interest rate swap or interest rate cap agreement on a total notional amount of approximately $50 million. We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties. We consider those inputs to be â€œlevel 2â€ in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At June 30, 2024, the fair value of our interest rate swaps was a net asset of $6.4 million which is included in deferred charges and other assets on the accompanying condensed consolidated balance sheet. During the second quarter of 2024, we received approximately $1.6 million from the counterparty, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the first six months of 2024, we received approximately $3.3 million from the counterparty, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the second quarter of 2023, we received approximately $1.4 million from the counterparty, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the first six months of 2023, we received approximately $2.6 million from the counterparty, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other comprehensive income (â€œAOCIâ€) within shareholdersâ€™ equity. Amounts are reclassified from AOCI to the income statement in the period or periods the hedged 30 Â transaction affects earnings. We do not expect any gains or losses on our interest rate swaps to be reclassified to earnings in the next twelve months. The sensitivity analysis related to our fixed and variable rate debt assumes current market rates with all other variables held constant. As of June 30, 2024, the fair value and carrying value of our debt is approximately $361.0 million and $363.0 million, respectively. As of that date, the carrying value exceeds the fair value by approximately $2.0 million. The table below presents information about our financial instruments that are sensitive to changes in interest rates. The interest rate swaps include the $50 million swap agreement entered into during the third quarter of 2019, the $35 million swap agreement entered into in January, 2020, the $55 million swap agreement entered into in March, 2020 and the $25 million swap agreement entered into in December, 2023. For debt obligations, the amounts of which are as of June 30, 2024, the table presents principal cash flows and related weighted average interest rates by contractual maturity dates. Â Â Â Maturity Date, Year Ending December 31 Â (Dollars in thousands) Â 2024 Â Â 2025 Â Â 2026 Â Â 2027 Â Â 2028 Â Â Thereafter Â Â Total Â Long-term debt: Â Â Â Â Â Â Â Â Â Â Â Â

document does not appear in the Interactive Data file because iXBRL tags are embedded within the Inline XBRL document 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents Â Â Â Â Â Â 104 Cover Page Interactive Data file (formatted as Inline XBRL and contained in Exhibit 101) Â 32 Â Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 8, 2024 Â UNIVERSAL HEALTH REALTY INCOME TRUST(Registrant) Â Â Â Â Â /s/ Alan B. Miller Â Â Alan B. Miller, Â Â Chairman of the Board,President and Chief Executive Officer(Principal Executive Officer) Â Â Â Â Â /s/ Charles F. Boyle Â Â Charles F. Boyle, Senior Vice President and Chief Financial Officer(Principal Financial Officer) Â 33 EX-31.1 2 uht-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATIONâ€"Chief Executive Officer I, Alan B. Miller, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: August 8, 2024 /s/ Alan B. Miller President and Chief Executive Officer Â Â EX-31.2 3 uht-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATIONâ€"Chief Financial Officer I, Charles F. Boyle, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: August 8, 2024 /s/ Charles F. Boyle Senior Vice President and Chief Financial Officer Â Â EX-32.1 4 uht-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Universal Health Realty Income Trust (the â€œTrustâ€) on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Alan B. Miller, President and Chief Executive Officer of the Trust, hereby certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report. /s/ Alan B. Miller President and Chief Executive Officer August 8, 2024 Â A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request. Â Â EX-32.2 5 uht-ex32_2.htm EX-32.2 EX-32.2 Â Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Universal Health Realty Income Trust (the â€œTrustâ€) on Form 10-Q for the quarter ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Charles F. Boyle, Senior Vice President and Chief Financial Officer of the Trust, hereby certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report. /s/ Charles F. Boyle Senior Vice President and Chief Financial Officer Â August 8, 2024 A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request. Â Â EX-101.SCH 6 uht-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Dividends and Equity Issuance Program link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Acquisitions and Divestitures link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Summarized Financial Information of Equity Affiliates link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Lease Accounting link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Debt and Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Lease Accounting (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Debt and Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - General - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail 1) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Acquisitions and Divestitures - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Lease Accounting - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Segment Reporting - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink Interest Rate Swap Agreement One [Member] Interest Rate Swap Agreement One [Member] Interest Rate Swap Agreement One Tenant reserves, deposits and deferred and prepaid rents Tenant Reserves Deposits And Deferred And Prepaid Rents Amount at the balance sheet date that has been received by the entity that represents collections of cash or other assets related to real estate operations revenue for which revenue has not yet been recognized and money paid in advance to protect the provider of a product or services, such as a lessor, against damage or non-payment by the tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property and other contractual breaches. Leases Disclosure [Line Items] Leases Disclosure [Line Items] Leases Disclosure [Line Items] Lessee, Operating Lease, Liability, to be Paid, Year One Aggregate lease payments for 2025 Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Document Transition Report Document Transition Report Bonus Rents Bonus Rents [Member] Bonus rents. Geographical Geographical [Axis] Sierra Medical Plaza I Sierra Medical Plaza I [Member] Sierra medical plaza I. Invoices accrued for construction and improvements Construction in Progress Expenditures Incurred but Not yet Paid Business Acquisitions And Dispositions [Line Items] Business Acquisitions And Dispositions [Line Items] Business acquisitions and dispositions. Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan [Member] Phoenix children's east valley care center fixed rate mortgage loan. Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Swingline/Short-Term Loans Short-Term Debt [Member] Lessee, Operating Lease, Liability, to be Paid, Year Four Aggregate lease payments for 2028 Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method Equity Method Investments Summarized Income Statement Information Table [Text Block] Equity Method Investments Summarized Income Statement Information. Major Property Class Major Property Class [Domain] Number of renewal option at existing lease rates Number of renewal options at existing lease rates Operating Leases Number Of Renewal Options At Existing Lease Rates Operating leases, number of renewal options at existing lease rates. Concentration Risk Type Concentration Risk Type [Axis] Equity Method Investments and Joint Ventures [Abstract] Short-Term Debt, Type Short-Term Debt, Type [Axis] Clive Behavioral Health Hospital Clive Behavioral Health Hospital [Member] Clive Behavioral Health Hospital. Interest Income (Expense), Net, Total Interest expense, net Interest Income (Expense), Net Number of hospital facilities leased Number Of Acute Care And Behavioral Health Care Hospital Facilities Number of acute care and behavioral health care hospital facilities. Equity Method Investment, Nonconsolidated Investee Equity Method Investment, Nonconsolidated Investee [Axis] Fire Mesa Office Building [Member] Fire Mesa Office Building [Member] Fire Mesa office building located in Las Vegas. Repurchased (in shares) Stock Repurchased During Period, Shares Common Stock, Dividends, Per Share, Cash Paid Dividends and dividend equivalents, per share Declared and paid dividends, per share Acute Care Hospitals Acute Care Hospitals [Member] Acute Care Hospitals. 2704 North Tenaya Way Fixed Rate Mortgage Loan Two Seven Zero Four North Tenaya Way Fixed Rate Mortgage Loan [Member] Two seven zero four north Tenaya way fixed rate mortgage loan. Number of renewal options at fair market value lease rates Operating Leases Number Of Renewal Options At Fair Market Value Lease Rates Operating leases, number of renewal options at fair market value lease rates. Payments to Fund Long-Term Loans to Related Parties Advances made to third-party partners Related Party Transactions [Abstract] Repayment of loan Repayment Of Loan Repayment of loan. Total Liabilities and Equity Liabilities and Equity Entity Address, State or Province Entity Address, State or Province Issued, net Stock Issued During Period, Value, New Issues Aiken Regional Medical Center Aiken Regional Medical Center [Member] Aiken Regional Medical Center. Total comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Trading Symbol Trading Symbol Major Property Class Major Property Class [Axis] Common shares, issued Common Stock, Shares, Issued Financing receivable Financing Receivable Financing receivable. Number of medical office buildings and free standing emergency departments Number Of Leased Properties For Medical Office Buildings And Free Standing Emergency Departments Number of leased properties for medical office buildings and free standing emergency departments. Consolidated Entities Consolidated Entities [Domain] Repayments of mortgage notes payable Repayments of Secured Debt Number of lease renewal option exercised Number Of Lease Renewal Option Exercised Number of lease renewal option exercised. Lease expiration date Lease Expiration Date Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Balance, Shares Balance, Shares Shares, Outstanding Available borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Lessee, Operating Lease, Liability, to be Paid,

Year Three Aggregate lease payments for 2027 Accumulated other comprehensive income/(loss) AOCI Attributable to Parent [Member] 4 Unconsolidated Limited Liability Companies / Limited Partner Unconsolidated Limited Liabilities Or Limited Partner [Member] Unconsolidated limited liabilities or limited partner. Cost Of Medical Office Building Incurred Cost of medical office building incurred. Cost of medical office building incurred Revolving A Facility Revolving A Facility [Member] Revolving A facility. Limited Liability Companies Accounted for Under Equity Method Equity Method Investments [Table Text Block] Land Land Entity Address, City or Town Entity Address, City or Town Related Party Transaction [Line Items] Related Party Transaction [Line Items] Operating lease renewal term Lessee, Operating Lease, Renewal Term Other operating expenses demolition costs Other Operating Expenses Demolition Costs Other operating expenses demolition costs. Chicago, Illinois Chicago Illinois [Member] Chicago, Illinois. Monthly lease rent receivable Monthly Lease Rent Receivable Monthly lease rent receivable. Capital in excess of par value Additional Paid-in Capital [Member] Derivative instruments, fixed rate Derivative, Fixed Interest Rate Schedule Of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Operating leases, renewal options term at existing lease rates. Operating Leases Renewal Options Term At Existing Lease Rates Renewal option term at existing lease rates Counterparty Name Counterparty Name [Axis] Percentage of rentable square feet Percentage Of Rentable Square Feet Percentage of rentable square feet. Preferred shares of beneficial interest, par value Preferred Stock, Par or Stated Value Per Share Dividends And Equity Issuance [Table] Dividends And Equity Issuance [Table] Dividends and equity issuance. Statement of Stockholders' Equity [Abstract] Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Other revenue Revenue from Contract with Customer, Including Assessed Tax Denison Texas Denison Texas [Member] Denison, Texas. Maturity date Debt Instrument, Maturity Date Derivative Contract Derivative Contract [Domain] Expiration date of interest rate Derivative, Contract End Date Total mortgages notes payable, non-recourse to us, net Mortgage notes payable, non-recourse to us, net Secured Debt Dividends, per share. Dividends and dividend equivalents, per share Dividend Per Share UHS Hospital Facilities Universal Health Services Hospital Inc [Member] Universal health services hospital Inc. Statement of Comprehensive Income [Abstract] Scenario Scenario [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement Schedule Of Financial Covenants Table [Text Block] Schedule of Financial Covenants. Entity Central Index Key Entity Central Index Key Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Related Party [Member] Related Party Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred shares of beneficial interest, outstanding Preferred Stock, Shares Outstanding Lessee in connection with ground leases for land Number Of Ground Leases For Land Number of ground leases for land. Specialty facility evansville indiana. Specialty Facility Evansville Indiana[Member] Specialty Facility Evansville Indiana Last Two Year Renewal Options Last Two Year Renewal Options [Member] Last two year renewal options. Entity Tax Identification Number Entity Tax Identification Number Renewal Term (years) Lessor, Operating Lease, Renewal Term Leasing costs paid Increase Decrease In Leasing Costs Increase decrease in leasing costs. Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Financial Instruments Financial Instruments [Domain] Investment, Name Investment, Name [Axis] Related and Nonrelated Party Status [Axis] Operating Lease, Lease Income, Total Lease revenue Operating Lease, Lease Income Revolving B Facility Revolving B Facility [Member] Revolving B facility. Equity Method Investment, Nonconsolidated Investee Equity Method Investment, Nonconsolidated Investee [Domain] Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan Summerlin Hospital Medical Office Building Three Fixed Rate Mortgage Loan [Member] Summerlin hospital medical office building three fixed rate mortgage loan. Derivative Instrument Derivative Instrument [Axis] Geographical Geographical [Domain] Lessee, Operating Lease, Term of Contract Lease contract term Lease renewal term Total Assets Assets Right-of-use land assets Right-of-use land assets, net Operating Lease, Right-of-Use Asset Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Entity Registrant Name Entity Registrant Name Proceeds from Issuance or Sale of Equity, Total Issuance of shares of beneficial interest, net Proceeds from Issuance or Sale of Equity Cost of medical office building Cost Of Medical Office Building Cost of medical office building. Lessee operating lease, existence of option to extend Lessee, Operating Lease, Existence of Option to Extend [true false] Covenant, Total leverage Debt Instrument Covenant Leverage Ratio Debt instrument covenant leverage ratio. Related Party Related Party, Type [Domain] Retained Earnings (Accumulated Deficit), Total Cumulative net income Retained Earnings (Accumulated Deficit) Accumulated depreciation Real Estate Investment Property, Accumulated Depreciation Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Cumulative net income Retained Earnings [Member] Renewal options term at fair market value lease rates Operating Leases Renewal Options Term At Fair Market Value Lease Rates Operating leases, renewal options term at fair market value lease rates. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total Equity Balance Balance Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Revenues, Total Revenues Revenues End of Lease Term End of Lease Term Lease Expiration Month And Year Lease expiration, month and year. Ground lease liabilities Operating Lease, Liability, Total Right-of-use land liabilities Ground lease liabilities, net Forecast Forecast [Member] Equity Component Equity Component [Domain] Renewal option term Renewal Options Term Renewal options term. Aggregate lease payments for thereafter Lessee Operating Lease Liability Payments Due After Year Four Lessee operating lease liability payments due after year four. Accounting Standards Update 2022-06. Accounting Standards Update 2022-06 [Member] ASU 2022-06 Repayments of Lines of Credit Aggregate repayments Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Deferred charges, notes receivable and other assets, net. Deferred Charges, Notes Receivable and Other Assets, Net Deferred charges, notes receivable and other assets, net Number of real estate investments Number of Real Estate Properties Debt Disclosure [Abstract] Margin points added to the reference rate Debt Instrument, Basis Spread on Variable Rate Entity Current Reporting Status Entity Current Reporting Status Common shares, shares authorized Common Stock, Shares Authorized BRB Medical Office Building Fixed Rate Mortgage Loan B R B Medical Office Building Fixed Rate Mortgage Loan [Member] BRB medical office building fixed rate mortgage loan. Tenants Tenants [Member] Tenants. Grayson Properties II LP Grayson Properties Two L P Grayson Properties Two L P [Member] Grayson properties two LP. Mortgage loan fair value Long-Term Debt, Fair Value Mortgage notes payable, non-recourse to us Mortgage Loan Balance Equity Method Investment Summarized Financial Information Mortgage Notes Payable Equity Method Investment Summarized Financial Information Mortgage Notes Payable Assets: Assets [Abstract] Frederick, Maryland Frederick Maryland [Member] Frederick, Maryland. Net cash proceeds from stock issued Proceeds from Issuance of Common Stock Hedging Relationship Hedging Relationship [Axis] Base Rate Base Rate [Member] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type [Domain] Real Estate, Type of Property Real Estate, Type of Property [Axis] Derivative interest rate cap, net payment received or accrued from counterparties Derivative Interest Rate Cap Net Payment Received Or Accrued From Counter Parties Derivative interest rate cap, net payment received or accrued from counter parties. Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2024 - 13,848,950; 2023 - 13,823,899 Common Stock, Value, Issued Construction loan outstanding balance Construction Loan Outstanding Balance Construction loan outstanding balance. Other assets Equity Method Investment Summarized Financial Information Other Assets Equity method investment summarized financial information other assets. Canyon Creek Behavioral Health Canyon Creek Behavioral Health [Member] Canyon Creek Behavioral Health. Renewal period of respective leased facilities at same price after lease terms Renewal Option Terms Maximum Additional Period Renewal option terms maximum additional period. Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense, Total Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Covenant, Unencumbered leverage Debt Instrument Covenant Unencumbered Leverage Ratio Debt instrument covenant unencumbered leverage ratio. Income before equity in income of unconsolidated limited liability companies ("LLCs") and interest expense Operating Income (Loss) Repayment of mortgage loan Repayments of Debt Interest, net Equity Method Investment Summarized Financial Information Interest Expense Equity method investment summarized financial information interest expense. Mortgage debt Mortgage Debt Mortgage debt. Operating expenses demolition costs. Operating Expenses Demolition Costs Operating expenses demolition costs Net cash paid as part of asset exchange transaction Payments To Asset Exchange Transaction Payments to asset exchange transaction. Contractual Obligation, Fiscal Year Maturity [Table Text Block] Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method Percentage of revenues generated from leases and tenants Concentration Risk, Percentage Evansville Rehabilitation Hospital Evansville Indiana and Corpus Christi Facility Corpus Christi Texas. Evansville Rehabilitation Hospital Evansville Indiana And Corpus Christi Facility Corpus Christi Texas [Member] Evansville Rehabilitation Hospital Evansville, Indiana and Corpus Christi Facility Corpus Christi, Texas McAllen Doctor's Center McAllen Medical Center Mc Allen Medical Center [Member] McAllen medical center. Recourse Status Recourse Status [Domain] Unencumbered leverage Unencumbered Leverage Ratio Unencumbered leverage ratio. Hedging Relationship Hedging Relationship [Domain] Fair market value of real estate assets received Fair Market Value Of Real Estate Assets Received Fair market value of real estate assets received. Cash distributions from LLCs Cash Distributions In Excess Of Income From Limited Liability Companies Equity investment distribution. Clive Behavioral Health Clive Behavioral Health [Member] Clive behavioral health. Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member Number Of Trading Period Number of trading period. Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive gain/(loss): Dividends and Equity Issuance Program Equity [Text Block] Aiken Regional Medical Center and Canyon Creek Behavioral Health Aiken Regional Medical Center And Canyon Creek Behavioral Health [Member] Aiken Regional Medical Center and Canyon Creek Behavioral Health. Renewal options at fair market value lease rates expiration year Operating Leases Renewal Options At Fair Market Value Lease Rates Expiration Year Operating leases, renewal options at fair market value lease rates, expiration year. Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Aggregate initial offering price of threshold amount Aggregate Initial Offering Price of Threshold Amount Aggregate initial offering price of threshold amount. Liabilities: Liabilities [Abstract] Cumulative dividends Cumulative Dividends [Member] Cumulative dividends. Credit facility, Interest Rate Terms Debt Instrument, Interest Rate Terms Equity: Equity, Attributable to Parent [Abstract] Gain on sale of real estate assets Gain (Loss) on Disposition of Real Estate, Discontinued Operations Investments in limited liability companies ("LLCs") Investment Owned, Fair Value, Beginning Balance Investment Owned, Fair Value, Ending Balance Investment Owned, Fair Value Investments in and advances to LLCs before amounts included in accrued expenses and other liabilities Outstanding borrowing Line of Credit Facility, Maximum Borrowing Capacity Term of lease Lessor, Operating Lease, Term of Contract Advisory fee Cost of Goods and Services Sold, Total Advisory fees to UHS Operating expenses excluding demolition Operating Expenses Excluding Demolition Operating expenses excluding demolition. Lease Contractual Term Lease Contractual Term [Domain] Specialty Hospital In Chicago, Illinois Specialty Hospital In Chicago, Illinois [Member] Specialty hospital in chicago, illinois. Investment, Name Investment, Name [Domain] Accounting Policies [Abstract] Number of wholly-owned subsidiaries Number Of Wholly Owned Subsidiaries Number of wholly-owned subsidiaries. Renewal option at existing lease rates expiration year Operating leases, renewal options at existing lease rates, expiration year. Operating Leases Renewal Options At Existing Lease Rates Expiration Year Number of real estate investments Number Of Real Estate Properties Including Property Under Construction Number of real estate properties including property under construction. Compensating Balance Amount Compensating Balance, Amount Scenario Scenario [Axis] Tenant reserves, deposits and deferred and prepaid rents Increase Decrease In Tenant Reserves Deposits Deferred And Prepaid Rents Increase (decrease) in tenant reserves, deposits, deferred and prepaid rents. Debt Instrument, Unamortized Premium, Total Plus net debt premium Debt Instrument, Unamortized Premium Suburban Properties Suburban Properties [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization consolidation and presentation of financial statements. Maturity Date Debt Instrument Maturity Date Debt Instrument Maturity Month And Year Debt instrument, maturity, month and year. Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. FTX MOB Phase II limited partnership F T X Mob Phase Two L P [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Renewal options at lease rate stipulated in lease expiration year Operating Leases Renewal Options At Lease Rates Stipulated In Lease Expiration Year Operating leases renewal options at lease rates stipulated in lease expiration year. Earnings Per Share, Basic, Total Basic earnings per share Earnings Per Share, Basic Medical office buildings Medical Office Buildings Medical Office Buildings [Member] Medical office buildings. Customer Concentration Risk Customer Concentration Risk [Member] Depreciation and amortization Equity Method Investment Summarized Financial Information Depreciation And Amortization Equity method investment summarized financial information depreciation and amortization. Interest rate swap agreement three. Interest Rate Swap Agreement Three [Member] Interest Rate Swap Agreement Three Derivative, Number of Instruments Held, Total Number of interest rate cap agreements Derivative, Number of Instruments Held Acquisitions and Divestitures Mergers, Acquisitions and Dispositions Disclosures [Text Block] Business Combinations [Abstract] Income Statement [Abstract] Palm Beach, Florida Palm Beach Florida [Member] Palm Beach, Florida. Annual Minimum Rent Operating Leases Annual Future Minimum Payments Receivable Operating leases, annual future minimum payments receivable. Equity Method Investment, Nonconsolidated Investee or Group of Investees Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Restricted stock-based compensation expense APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Net Real Estate Investments and Financing receivable Investments Related Party Related Party, Type [Axis] Lease payments expected Lease payments expected Operating Lease Payments Expected Operating lease payments expected. Lease percentage Lease Percentage Lease percentage. Commitment to investment Investment Commitments Commitments to invest. Statistical Measurement Statistical Measurement [Domain] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Initial rent Initial Rent Initial Rent. Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan Rosenberg Children Medical Plaza Fixed Rate Mortgage Loan [Member] Rosenberg children's medical plaza fixed rate mortgage loan. Number of dispositions Number Of Businesses Disposed Number of businesses disposed. Document Period End Date Document Period End Date Statistical Measurement Statistical Measurement [Axis] Evansville indiana. Evansville Indiana[Member] Evansville, Indiana Other liabilities Equity Method Investment Summarized Financial Information Other Liabilities Equity Method Investment Summarized Financial Information Other Liabilities Interest rate swap agreement two. Interest Rate Swap Agreement Two [Member] Interest Rate Swap Agreement Two Total leverage Leverage Ratio Leverage ratio. Earnings Per Share, Diluted, Total Diluted earnings per share Earnings Per Share, Diluted Product and Service Product and Service [Domain] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Nonrecourse Nonrecourse [Member] Percentage of lease Percentage Of Lease Percentage of lease. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Derivative interest rate cap, payment received or accrued from counterparties Derivative Interest Rate Cap Payment Received Or Accrued From Counter Parties Derivative interest rate cap payment received or accrued from counter parties. Southwest Healthcare System Inland Valley Campus. Southwest Healthcare System Inland Valley Campus [Member] Southwest Healthcare System Inland Valley Campus Master flex lease agreement. Master Flex Lease Agreement [member] Master Flex Lease Agreement Number of reportable segments Number of Reportable Segments Capital in excess of par value Additional Paid in Capital, Common Stock Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions Components Of Lessor Lease Revenue With U H S Facilities And Non Related Parties Table [Text Block] Components of lessor lease revenue with UHS facilities and non-related parties. Financing arrangements. Financing Arrangements [Member] Financing Arrangements Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity Attributable to Noncontrolling Interest, Total Minority ownership interest Equity, Attributable to Noncontrolling Interest Investment, Type [Extensible Enumeration] Lease receivable Increase (Decrease) in Leasing Receivables Tuscan Professional Building Fixed Rate Mortgage Loan Tuscany Professional Building Fixed Rate Mortgage Loan [Member] Debt Instrument 100% consolidated Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Interactive Data Current Entity Interactive Data Current Minority ownership interest held by a third-party Subsidiary, Ownership Percentage, Noncontrolling Owner Related and Nonrelated Party Status [Domain] Credit Facility Credit Facility [Domain] Real Estate Real Estate [Domain] Equity [Abstract] Amortization related to above/below market leases, net Amortization of above and below Market Leases Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Comprehensive income: Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Equity Components Equity Components [Axis] At-The-Market Equity Issuance Program (ATM) At Market A T M Programs [Member] Shelf registration. Payment to acquire business Payments to Acquire Businesses, Gross Other Expenses Other Expense [Member] Schedule Of Equity Method

Investments [Table] Schedule of Equity Method Investments [Table] Fixed charge coverage Fixed Charge Coverage Ratio Fixed charge coverage ratio. Recent Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Local Phone Number Local Phone Number Grayson Properties Grayson Properties [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Number of hospitals operating lease terms of existing and renewal options Number Of Hospitals Operating Lease Terms Of Existing And Renewal Options Number of hospitals operating lease terms of existing and renewal options. Covenant, Secured leverage Debt Instrument Covenant Compliance Secured Leverage Ratio Debt instrument covenant compliance secured leverage ratio. Amounts included in accrued expenses and other liabilities Equity Method Investments Accrued Expenses And Other Liabilities Equity method investments accrued expenses and other liabilities. Schedule Of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Statement of Cash Flows [Abstract] Non rule 10b51 arr modified flag Non Rule 10b5-1 Arr Modified Flag Organization, Consolidation and Presentation of Financial Statements [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Common shares, par value Common Stock, Par or Stated Value Per Share Number of additional six month extension options Number Of Extension Options Number of extension options. Dividends and Equity Issuance [Line Items] Dividends And Equity Issuance [Line Items] Dividends and equity issuance. SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Period Increase (Decrease), Total Additions to real estate investments, net SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Period Increase (Decrease) Interest Rate Debt Instrument Interest Rate Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Maximum Maximum [Member] Deposit on real estate assets Payments For Deposit On Real Estate Assets Payments for deposit on real estate assets. Lease Accounting Disclosures Of Leases [Text Block] Disclosures of leases. Accrued interest Interest Payable Average invested real estate assets Average Invested Real Estate Assets Average invested real estate assets. Dividends and dividend equivalents Dividends, Total Dividends Operating expenses (excluding depreciation and amortization expense. Operating Expenses Excluding Depreciation And Amortization Expense Operating expenses excluding depreciation and amortization expense General Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Payments of Dividends, Total Dividends declared and paid Payments of Dividends Dividends and dividend equivalents Dividends paid Short-Term Debt, Type Short-Term Debt, Type [Domain] Ownership Ownership [Domain] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (Decrease)/increase in cash and cash equivalents Maturity date Unsecured revolving amended credit agreement terminated date Line Of Credit Facility Expiration Year And Month Line of credit facility expiration year and month. Number of acquisitions Number of Businesses Acquired Credit Agreement Revolving Credit Agreement [Member] Revolving credit agreement. Net Real Estate Investments Real Estate Investments, Net Segment Reporting Segment Reporting Disclosure [Text Block] City Area Code City Area Code Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block] Letters of Credit Letter of Credit [Member] Equity Method Investments Equity Method Investments [Member] Nonrelated Party [Member] Non-Related Parties Customer Customer [Domain] Weighted Average Number of Shares Outstanding, Basic, Total Weighted average number of shares outstanding - Basic Weighted Average Number of Shares Outstanding, Basic Debt and Financial Instruments Debt And Financial Instruments Disclosure [Text Block] Debt and financial instruments disclosure. Number of bed facility Number Of Bed Facility Number of bed facility. Real Estate Properties Real Estate Properties [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Statement [Table] Statement [Table] Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Document Fiscal Period Focus Document Fiscal Period Focus Our share of net income Equity in income of unconsolidated LLCs Income (Loss) from Equity Method Investments Number of behavioral health care hospital leased Number Of Behavioral Health Care Hospital Leased Number of behavioral health care hospital leased. Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Related Party Transactions Disclosure [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year Two Aggregate lease payments for 2026 Aiken, South Carolina Aiken South Carolina [Member] Aiken, South Carolina. Statement [Line Items] Statement [Line Items] Other Assets: Other Assets [Abstract] ASU 2023-07 Accounting Standards Update 2023-07 [Member] Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. Payments of Financing Costs, Total Financing costs paid Payments of Financing Costs Percentage of lease guaranteed Percentage Of Lease Guaranteed Percentage Of Lease Guaranteed. Outstanding Mortgages, Excluding Net Debt Premium Schedule of Long-Term Debt Instruments [Table Text Block] Number of lease property Number Of Lease Property Number of lease property. Leases Disclosure [Table] Leases Disclosure [Table] Leases Disclosure [Table] Letters Of Credit Outstanding Amount Letters of Credit Outstanding, Amount Asset Class Asset Class [Domain] Customer Customer [Axis] Common stock Common Stock [Member] Net proceeds from lines of credit. Net Proceeds from Lines of Credit Aggregate borrowings under Credit Agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Repurchased Stock Repurchased During Period, Value Secured leverage Secured Leverage Ratio Secured leverage ratio. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Bonus rental Bonus Rental Income Bonus rental income. Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Cover [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Other Product and Service, Other [Member] Inland Valley Campus of Southwest Healthcare System Inland Valley Campus Of Southwest Healthcare System [Member] Inland Valley Campus of Southwest Healthcare System. Number of term renewal options Number Of Renewal Options Number of renewal options. Segment Reporting [Abstract] Specialty Facility In Corpus Christi Texas [Member] Specialty Facility In Corpus Christi Texas [Member] Specialty Facility In Corpus Christi Texas Security Exchange Name Security Exchange Name Accounting Standards Update and Change in Accounting Principle [Table] Fair market value of real estate asset sold Fair Market Value Of Real Estate Asset Sold Fair market value of real estate asset sold. Total other comprehensive (loss)/gain: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Preferred shares of beneficial interest, issued Preferred Stock, Shares Issued Preferred shares of beneficial interest, shares authorized Preferred Stock, Shares Authorized Liability derivatives, fair value Derivative Liability, Subject to Master Netting Arrangement, before Offset Shares of Beneficial Interest: Shares Of Beneficial Interest [Abstract] Shares of beneficial interest. Corpus Christi, Texas. Corpus Christi, Texas [Member] Corpus Christi, Texas Less net financing fees Financing Fees Net Financing fees net. Financial Instrument Financial Instrument [Axis] Ground Lease and Master Flex-lease Agreement Ground Lease And Master Flex Lease Agreement [Member] Ground lease and master flex-lease agreement. Entity Emerging Growth Company Entity Emerging Growth Company Member loan used to repay mortgage loan Member Loan Used To Repay Mortgage Loan Member loan used to repay mortgage loan. Amendment Flag Amendment Flag Corpus Christi Corpus Christi Texas Corpus Christi Corpus Christi Texas [Member] Corpus Christi Corpus Christi, Texas. Ownership percentage upon completion of the minority ownership purchase Subsidiary, Ownership Percentage, Parent Margin points added to the base rate Margin On Base Rate Margin on base rate. Accounting Standards Update [Domain] Ownership Non-controlling equity interest, ownership percentage Proceeds from Lines of Credit, Total Net borrowings on the line of credit Proceeds from Lines of Credit Interest income on financing leases - UHS facilities Interest income on financing leases Direct Financing Lease, Interest Income Subsidiary Subsidiaries [Member] Leases [Abstract] Variable Rate Variable Rate [Domain] Entity File Number Securities Act File Number The total amount of the contingent obligation under letters of credit terminated as of the reporting date. Letters of Credit Terminated Amount Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Aggregate lease payments for 2024 Recourse Status Recourse Status [Axis] Kindred Chicago Central Hospital Central Chicago, Illinois Kindred Chicago Central Hospital Central Chicago Illinois [Member] Kindred Chicago Central Hospital Central Chicago, Illinois. Clive, Iowa Clive Iowa [Member] Clive, Iowa. Share-Based Payment Arrangement [Abstract] Lease receivable - other Lease Receivable Other Lease receivable, other. Costs and Expenses, Total Costs and Expenses Advances payable to us Equity Method Investment Summarized Financial Information Advance Payment To Loans To Related Party Equity method investment summarized financial information advance payment to loans to related party. Accrued expenses and other liabilities Accrued Liabilities and Other Liabilities Entity Address, Address Line Two Entity Address, Address Line Two Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Entity Small Business Entity Small Business Percentage ownership of outstanding shares Percentage Of Ownership Interest Related Parties Percentage of ownership interest related parties. Entity Shell Company Entity Shell Company Investment Type Investment Type [Axis] Base Rents Base Rents [Member] Base rents. Payments to Acquire Investments, Total Investments in LLCs Payments to Acquire Investments Financing Receivable, before Allowance for Credit Loss, Total Financing receivable from UHS Financing Receivable, before Allowance for Credit Loss Revenues: Revenues [Abstract] Derivative interest rate cap, offset due to counterparties Derivative Interest Rate Cap Payment Offset Due To Counter Parties Derivative interest rate cap payment offset due to counter parties. Entity Address, Address Line One Entity Address, Address Line One Period to purchase respective leased facilities prior to end of lease term or renewal terms Period To Purchase Respective Leased Facilities Prior To End Of Lease Term Or Renewal Terms Period to purchase respective leased facilities prior to end of lease term or renewal terms. Facility fee payable on commitment Line of Credit Facility, Commitment Fee Percentage Real Estate Investment Property, Net, Total Real Estate Investment Property, Net Income Statement Location Income Statement Location [Axis] Amortization of debt premium Amortization of Debt Discount (Premium) Initial lease term on property Triple Net Lease Agreement Period Triple net lease agreement period. Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Remaining lease terms on ground leases Operating Lease Remaining Lease Term Operating lease remaining lease term. Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Our share of equity in LLCs, net Equity Method Investments Revenues Revenue [Member] Revenue. Outstanding Balance Long-Term Debt, Gross Operating Lease Additional Number Of Renewal Options At Fair Market Value Lease Rates Operating Lease Additional Number Of Renewal Options At Fair Market Value Lease Rates Depreciation, Depletion and Amortization, Total Depreciation and amortization Depreciation, Depletion and Amortization Product and Service Product and Service [Axis] Business Acquisitions And Dispositions [Table] Business Acquisitions And Dispositions [Table] Business acquisitions and dispositions. First Three Year Renewal Options First Three Year Renewal Options [Member] First three year renewal options. Title of 12(b) Security Title of 12(b) Security Percentage of annual rental increase Percentage of annual rental increase on cumulative and compound basis. Percentage Of Annual Rental Increase On Cumulative And Compound Basis Percentage of annual rental increase on cumulative and compound basis Intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Lease Contractual Term Lease Contractual Term [Axis] TEXAS Brunswick Associates Brunswick Associates [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Investments Investments [Domain] Accounting Standards Update [Axis] Accounting Changes and Error Corrections [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Amortization of deferred financing costs Amortization of Debt Issuance Costs Interest Rate Swap Interest Rate Swap [Member] Management Service Management Service [Member] Long-Term Line of Credit, Total Outstanding borrowings under revolving credit agreement Line of credit borrowings Long-Term Line of Credit Other operating expenses Other Cost and Expense, Operating Rentable square feet Net Rentable Area Advance received from LLC Advance received from LLC Proceeds from Collection of Long-Term Loans to Related Parties SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type [Axis] Real Estate Property Ownership Real Estate Property Ownership [Axis] Real Estate Investments: Real Estate Investments, Net [Abstract] Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common shares, outstanding Common Stock, Shares, Outstanding Universal Health Services, Inc UHS Facilities Universal Health Services Inc [Member] Related-party principal tenant. Construction loan Construction Loan Annual advisory fee as percentage of average invested real estate assets Annual Advisory Fees As Percentage Of Average Invested Real Estate Assets Annual advisory fees as percentage of average invested real estate assets. Reno, Nevada Reno Nevada [Member] Reno, Nevada. Tenant Reimbursements Tenant Reimbursements [Member] Tenant reimbursements. Concentration Risk Type Concentration Risk Type [Domain] Income Statement Location Income Statement Location [Domain] Percentage of annual rental increase Percentage of annual rental increase on cumulative and compound basis Percentage Of Annual Rental Increase Percentage of annual rental increase. Unrealized derivative (loss)/gain on cash flow hedges Unrealized net gain/(loss) on cash flow hedges Unrealized (loss)/gain on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Total Document Type Document Type Loans Payable, Noncurrent, Total Third-party term loan Loans Payable, Noncurrent Limited Liability Companies Limited Liability Company Or Limited Partner [Member] Limited liability company or limited partner. Ownership Ownership [Axis] Dearborn Michigan Dearborn Michigan [Member] Dearborn michigan. Period to purchase respective leased facilities at same price after lease terms Period To Purchase Respective Leased Facilities After Lease Terms Period to purchase respective leased facilities after lease terms. Real Estate Investment Property, at Cost, Total Buildings and improvements and construction in progress Real Estate Investment Property, at Cost Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Lease Demolition Cost Lease demolition cost. Document Quarterly Report Document Quarterly Report Counterparty Name Counterparty Name [Domain] Increase in borrowing capacity Line Of Credit Increase In Borrowing Capacity Line of credit increase in borrowing capacity. Option to renew lease, notice period prior to termination date of current term Lease Renewal Notice Period Lease renewal, notice period. Notional amount Derivative, Notional Amount Tangible net worth Tangible Net Worth Tangible net worth. Evansville Rehabilitation Hospital Evansville, Indiana Evansville Rehabilitation Hospital Evansville Indiana [Member] Evansville Rehabilitation Hospital Evansville, Indiana. Net property, including construction in progress Equity Method Investment Summarized Financial Information Assets Property Plant And Equipment Net Equity method investment summarized financial information assets property plant and equipment net. Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities 4058 W. Melrose Specialty Facility, Chicago, Illinois Four Zero Five Eight W Melrose Facility Chicago Illinois [Member] Four Zero Five Eight W. Melrose Facility Chicago, Illinois. Entity Filer Category Entity Filer Category Universal Health Services of Delaware Inc Universal Health Services Of Delaware Inc [Member] Wholly-owned subsidiary of Universal Health Services, Inc.; Advisor to UHT Summarized Financial Information of Equity Affiliates Equity Method Investments and Joint Ventures Disclosure [Text Block] Cash received for sale of real estate asset Proceeds from Sale of Real Estate Accrued interest Increase (Decrease) in Accrued Interest Receivable, Net Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Aiken Regional Medical Center Aurora Pavilion Behavioral Health Services [Member] Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services. Variable Rate Variable Rate [Axis] Asset Class Asset Class [Axis] Total Liabilities Liabilities Equity Method Investment, Nonconsolidated Investee or Group of Investees Equity Method Investment Group Of Investees Name [Member] Equity method investment, group of investees name. Number of acute care hospital leased Number Of Acute Care Hospital Leased Number of acute care hospital leased. Base rate description Debt Instrument, Description of Variable Rate Basis Operating expenses Equity Method Investment Summarized Financial Information Operating Expenses Equity method investment, summarized financial information, operating expenses. Stockholders' Equity Attributable to Parent, Ending Balance Stockholders' Equity Attributable to Parent, Beginning Balance Total Equity Equity, Attributable to Parent Temple, Texas Temple Texas [Member] Temple, Texas. Rule 10b51 arr modified flag. Rule 10b5-1 Arr Modified Flag Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Consolidated Entities Consolidated Entities [Axis] Intangible assets (net of accumulated amortization of $11.4 million and $12.5 million, respectively) Intangible Assets, Net (Excluding Goodwill), Total Intangible Assets, Net (Excluding Goodwill) Net income Net income Property Owned by LLC/LP Property Owned By Limited Liability Or Limited Partner Company Property owned by limited liability or limited partner company. Number of ground leases Number Of Ground Leases Number of ground leases. Statement of Financial Position [Abstract] Catholic Health Initiatives Iowa Catholic Health Initiatives Iowa [Member] Catholic Health Initiatives-Iowa. Weighted Average Number of Shares Outstanding, Diluted, Total Weighted average number of shares outstanding - Diluted Weighted Average Number of Shares Outstanding, Diluted Credit Facility Credit Facility [Axis] Lease and other receivables from UHS Lease And Other Receivables Lease and other receivables. Wildomar, California Wildomar California [Member] Wildomar, California. Wellington Regional Medical Center Wellington Regional Medical Center [Member] Wellington regional medical center. Federal Funds Effective Rate Federal Funds Effective Rate [Member] Federal funds effective rate. Desert Valley Medical Center Fixed Rate Mortgage Loan Desert Valley Medical Center Fixed Rate Mortgage Loan [Member] Desert valley medical center fixed rate mortgage loan. Asset Purchase and Sale Agreement Asset Purchase And Sale Agreement [Member] Asset purchase and sale agreement. Expenses: Costs and Expenses [Abstract] Covenant, Fixed charge coverage Debt Instrument Covenant Fixed Charge Coverage Ratio Debt instrument covenant fixed charge coverage ratio. Subtotal - comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Payments to Acquire Property, Plant, and Equipment, Total Cash paid for acquisition of properties Payments to Acquire Property, Plant, and Equipment Cumulative

dividends Cumulative Dividends Covenant, Tangible net worth Debt Instrument Covenant Tangible Net Worth Debt instrument covenant tangible net worth. Issued, net (in shares) Share issued Stock Issued During Period, Shares, New Issues London interbank offered rates libor. London Interbank Offered Rates (LIBOR) [Member] London Interbank Offered Rate (LIBOR) Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash Flow Hedge Cash Flow Hedging [Member] Loan balance converted to equity invesment Conversion of Loan to Equity Method Investment Conversion of loan to equity method investment. Conversion of Loan to Equity Method Investment Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method Equity Method Investments Summarized Combined Balance Sheet Information Table [Text Block] Equity Method Investments Summarized Combined Balance Sheet Information. XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Jul. 31, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Jun. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Entity Registrant Name UNIVERSAL HEALTH REALTY INCOME TRUST Â Entity Central Index Key 0000798783 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Common Stock, Shares Outstanding Â 13,848,952 Entity Current Reporting Status Yes Â Entity Shell Company false Â Entity File Number 1-9321 Â Entity Tax Identification Number 23-6858580 Â Entity Address, Address Line One UNIVERSAL CORPORATE CENTER Â Entity Address, Address Line Two 367 SOUTH GULPH ROAD Â Entity Address, City or Town KING OF PRUSSIA Â Entity Address, State or Province PA Â Entity Address, Postal Zip Code 19406-0958 Â City Area Code 610 Â Local Phone Number 265-0688 Â Entity Interactive Data Current Yes Â Title of 12(b) Security Shares of beneficial interest, $0.01 par value Â Trading Symbol UHT Â Security Exchange Name NYSE Â Entity Incorporation, State or Country Code MD Â Document Quarterly Report true Â Document Transition Report false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenues: Â Â Â Â Revenues, Total $ 24,734 $ 23,806 $ 49,875 $ 47,032 Expenses: Â Â Â Â Depreciation and amortization 6,806 6,849 13,615 13,467 Other operating expenses 6,975 8,250 14,506 15,771 Costs and Expenses, Total 15,150 16,422 30,828 31,863 Income before equity in income of unconsolidated limited liability companies ("LLCs") and interest expense 9,584 7,384 19,047 15,169 Equity in income of unconsolidated LLCs 272 268 656 639 Interest expense, net (4,580) (4,176) (9,127) (7,873) Net income $ 5,276 $ 3,476 $ 10,576 $ 7,935 Basic earnings per share $ 0.38 $ 0.25 $ 0.77 $ 0.58 Diluted earnings per share $ 0.38 $ 0.25 $ 0.76 $ 0.57 Weighted average number of shares outstanding - Basic 13,798 13,784 13,795 13,781 Weighted average number of shares outstanding - Diluted 13,832 13,809 13,828 13,806 Management Service Â Â Â Â Expenses: Â Â Â Â Advisory fees to UHS $ 1,369 $ 1,323 $ 2,707 $ 2,625 UHS Facilities Â Â Â Â Revenues: Â Â Â Â Lease revenue [1] 8,454 8,236 17,118 16,023 Interest income on financing leases - UHS facilities 1,359 1,365 2,720 2,731 UHS Facilities | Other Â Â Â Â Revenues: Â Â Â Â Other revenue 220 245 440 476 Non-Related Parties Â Â Â Â Revenues: Â Â Â Â Lease revenue 14,359 13,668 28,846 27,029 Non-Related Parties | Other Â Â Â Â Revenues: Â Â Â Â Other revenue $ 342 $ 292 $ 751 $ 773 [1] Includes bonus rental on McAllen Medical Center, a UHS acute care hospital facility of $758 and $730 for the three-month periods ended June 30, 2024 and 2023, respectively, and $1,541 and $1,495 for the six-month periods ended June 30, 2024 and 2023, respectively. X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income from net investment in direct financing lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5 + Details Name: us-gaap_DirectFinancingLeaseInterestIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12:

http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net amount of operating interest income (expense). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.10) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_InterestIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479016/842-30-45-3 + Details Name: us-gaap_OperatingLeaseLeaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(7)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherCostAndExpenseOperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance

Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Income (Parenthetical) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 UHS Hospital Facilities | McAllen Medical Center Â Â Â Â Bonus rental $ 758 $ 730 $ 1,541 $ 1,495 X - DefinitionBonus rental income. + ReferencesNo definition available. + Details Name: uht_BonusRentalIncome Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesHospitalIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_McAllenMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net Income (Loss) $ 5,276 $ 3,476 $ 10,576 $ 7,935 Other comprehensive gain/(loss): Â Â Â Â Unrealized derivative (loss)/gain on cash flow hedges (1,062) 715 (871) (1,032) Total other comprehensive (loss)/gain: (1,062) 715 (871) (1,032) Total comprehensive income $ 4,214 $ 4,191 $ 9,705 $ 6,903 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Real Estate Investments: Â Â Buildings and improvements and construction in progress $ 651,638 $ 649,374 Accumulated depreciation (274,622) (262,449) Real Estate Investment Property, Net, Total 377,016 386,925 Land 56,870 56,870 Net Real Estate Investments 433,886 443,795 Financing receivable from UHS 83,043 83,279 Net Real Estate Investments and Financing receivable 516,929 527,074 Investments in limited liability companies ("LLCs") 14,328 9,102 Other Assets: Â Â Cash and cash equivalents 5,577 8,212 Lease and other receivables from UHS 6,816 6,180 Lease receivable - other 7,905 8,166 Intangible assets (net of accumulated amortization of $11.4 million and $12.5 million, respectively) 8,193 9,110 Right-of-use land assets, net 10,932 10,946 Deferred charges, notes receivable and other assets, net 15,871 17,579 Total Assets 586,551 596,369 Liabilities: Â Â Line of credit borrowings 342,900 326,600 Mortgage notes payable, non-recourse to us, net 19,970 32,863 Accrued interest 1,024 490 Accrued expenses and other liabilities 10,145 13,500 Ground lease liabilities, net 10,932 10,946 Tenant reserves, deposits and deferred and prepaid rents 10,879 11,036 Total Liabilities 395,850 395,435 Equity: Â Â Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2024 - 13,848,950; 2023 - 13,823,899 138 138 Capital in excess of par value 270,592 270,398 Cumulative net income 836,637 826,061 Cumulative dividends (923,107) (902,975) Accumulated other comprehensive income 6,441 7,312 Total Equity 190,701 200,934 Total Liabilities and Equity $ 586,551 $ 596,369 X - DefinitionDeferred charges, notes receivable and other assets, net. + ReferencesNo definition available. + Details Name: uht_DeferredChargesNotesReceivableAndOtherAssetsNet Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLease and other receivables. + ReferencesNo definition available. + Details Name: uht_LeaseAndOtherReceivables Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLease receivable, other. + ReferencesNo definition available. + Details Name: uht_LeaseReceivableOther Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount at the balance sheet date that has been received by the entity that represents collections of cash or other assets related to real estate operations revenue for which revenue has not yet been recognized and money paid in advance to protect the provider of a product or services, such as a lessor, against damage or non-payment by the tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property and other contractual breaches. + ReferencesNo definition available. + Details Name: uht_TenantReservesDepositsAndDeferredAndPrepaidRents Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cumulative cash dividends distributed to shareholders. + ReferencesNo definition available. + Details Name: us-gaap_CumulativeDividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of investment in security owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depletion of real estate held for productive use, excluding land held for sale. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_Land Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following

conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 80 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479294/326-20-55-80Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479294/326-20-55-79Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph (a) -Subparagraph (1) -Publisher SECReference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph (a) -Subparagraph (2) -Publisher SECReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-K (SK) -Number 229 -Section 1404 -Paragraph (a) -Publisher SECReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7A -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-7AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5 + Details Name: us-gaap_NotesReceivableGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cumulative amount of depreciation for real estate property held for investment purposes. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 + Details Name: us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 + Details Name: us-gaap_RealEstateInvestmentPropertyAtCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 + Details Name: us-gaap_RealEstateInvestmentPropertyNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of real estate investments, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; (7) other real estate investments; (8) real estate joint ventures; and (9) unconsolidated real estate and other joint ventures not separately presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 + Details Name: us-gaap_RealEstateInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RealEstateInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_SecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Intangible assets, accumulated amortization $ 11.4 $ 12.5 Preferred shares of beneficial interest, par value $ 0.01 $ 0.01 Preferred shares of beneficial interest, shares authorized 5,000,000 5,000,000 Preferred shares of beneficial interest, issued 0 0 Preferred shares of beneficial interest, outstanding 0 0 Common shares, par value $ 0.01 $ 0.01 Common shares, shares authorized 95,000,000 95,000,000 Common shares, issued 13,848,950 13,823,899 Common shares, outstanding 13,848,950 13,823,899 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-

gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands Total Common stock Capital in excess of par value Cumulative net income Cumulative dividends Accumulated other comprehensive income/(loss) Balance at Dec. 31, 2022 $ 229,101 $ 138 $ 269,472 $ 810,661 $ (863,181) $ 12,011 Balance, Shares at Dec. 31, 2022 Â 13,803 Â Â Â Â Shares of Beneficial Interest: Â Â Â Â Â Â Issued, net 75 Â 75 Â Â Â Issued, net (in shares) Â 19 Â Â Â Â Restricted stock-based compensation expense 376 Â 376 Â Â Â Dividends and dividend equivalents (19,820) Â Â Â (19,820) Â Comprehensive income: Â Â Â Â Â Â Net income 7,935 Â Â 7,935 Â Â Unrealized net gain/(loss) on cash flow hedges (1,032) Â Â Â Â (1,032) Subtotal - comprehensive income 6,903 Â Â 7,935 Â (1,032) Balance at Jun. 30, 2023 216,635 $ 138 269,923 818,596 (883,001) 10,979 Balance, Shares at Jun. 30, 2023 Â 13,822 Â Â Â Â Balance at Mar. 31, 2023 222,170 $ 138 269,698 815,120 (873,050) 10,264 Balance, Shares at Mar. 31, 2023 Â 13,804 Â Â Â Â Shares of Beneficial Interest: Â Â Â Â Â Â Issued, net 37 Â 37 Â Â Â Issued, net (in shares) Â 18 Â Â Â Â Restricted stock-based compensation expense 188 Â 188 Â Â Â Dividends and dividend equivalents (9,951) Â Â Â (9,951) Â Comprehensive income: Â Â Â Â Â Â Net income 3,476 Â Â 3,476 Â Â Unrealized net gain/(loss) on cash flow hedges 715 Â Â Â Â 715 Subtotal - comprehensive income 4,191 Â Â 3,476 Â 715 Balance at Jun. 30, 2023 216,635 $ 138 269,923 818,596 (883,001) 10,979 Balance, Shares at Jun. 30, 2023 Â 13,822 Â Â Â Â Balance at Dec. 31, 2023 200,934 $ 138 270,398 826,061 (902,975) 7,312 Balance, Shares at Dec. 31, 2023 Â 13,824 Â Â Â Â Shares of Beneficial Interest: Â Â Â Â Â Â Issued, net (207) Â (207) Â Â Â Issued, net (in shares) Â 26 Â Â Â Â Repurchased (12) Â (12) Â Â Â Repurchased (in shares) Â (1) Â Â Â Â Restricted stock-based compensation expense 413 Â 413 Â Â Â Dividends and dividend equivalents (20,132) Â Â Â (20,132) Â Comprehensive income: Â Â Â Â Â Â Net income 10,576 Â Â 10,576 Â Â Unrealized net gain/(loss) on cash flow hedges (871) Â Â Â Â (871) Subtotal - comprehensive income 9,705 Â Â 10,576 Â (871) Balance at Jun. 30, 2024 190,701 $ 138 270,592 836,637 (923,107) 6,441 Balance, Shares at Jun. 30, 2024 Â 13,849 Â Â Â Â Balance at Mar. 31, 2024 196,458 $ 138 270,454 831,361 (912,998) 7,503 Balance, Shares at Mar. 31, 2024 Â 13,825 Â Â Â Â Shares of Beneficial Interest: Â Â Â Â Â Â Issued, net (61) Â (61) Â Â Â Issued, net (in shares) Â 25 Â Â Â Â Repurchased (12) Â (12) Â Â Â Repurchased (in shares) Â (1) Â Â Â Â Restricted stock-based compensation expense 211 Â 211 Â Â Â Dividends and dividend equivalents (10,109) Â Â Â (10,109) Â Comprehensive income: Â Â Â Â Â Â Net income 5,276 Â Â 5,276 Â Â Unrealized net gain/(loss) on cash flow hedges (1,062) Â Â Â Â (1,062) Subtotal - comprehensive income 4,214 Â Â 5,276 Â (1,062) Balance at Jun. 30, 2024 $ 190,701 $ 138 $ 270,592 $ 836,637 $ (923,107) $ 6,441 Balance, Shares at Jun. 30, 2024 Â 13,849 Â Â Â Â X - DefinitionShares of beneficial interest. + ReferencesNo definition available. + Details Name: uht_SharesOfBeneficialInterestAbstract Namespace Prefix: uht_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2 + Details Name: us-gaap_Dividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher

FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef -Name

Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Changes in Equity (Parenthetical) - $ / shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Stockholders' Equity [Abstract] Â Â Â Â Dividends and dividend equivalents, per share $ 0.73 $ 0.72 $ 1.455 $ 1.435 X - DefinitionDividends, per share. + ReferencesNo definition available. + Details Name: uht_DividendsPerShare Namespace Prefix: uht_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: Â Â Net income $ 10,576 $ 7,935 Adjustments to reconcile net income to net cash provided by operating activities: Â Â Depreciation and amortization 13,615 13,467 Amortization related to above/below market leases, net (89) (73) Amortization of debt premium Â (24) Amortization of deferred financing costs 383 347 Stock-based compensation expense 413 376 Changes in assets and liabilities: Â Â Lease receivable (375) (490) Accrued expenses and other liabilities (1,309) (618) Tenant reserves, deposits and deferred and prepaid rents (157) (241) Accrued interest 534 (38) Leasing costs paid (764) (604) Other, net 1,038 2,285 Net cash provided by operating activities 23,865 22,322 Cash flows from investing activities: Â Â Investments in LLCs (5,892) (3,869) Advances made to third-party partners (128) Â Cash distributions from LLCs 688 369 Advance received from LLC Â 3,500 Additions to real estate investments, net (4,335) (8,789) Deposit on real estate assets Â (100) Net cash used in investing activities (9,667) (8,889) Cash flows from financing activities: Â Â Net borrowings on the line of credit 16,300 13,300 Repayments of mortgage notes payable (12,918) (4,995) Financing costs paid (49) (132) Dividends paid (20,156) (19,837) Issuance of shares of beneficial interest, net (10) 76 Net cash used in financing activities (16,833) (11,588) (Decrease)/increase in cash and cash equivalents (2,635) 1,845 Cash and cash equivalents, beginning of period 8,212 7,614 Cash and cash equivalents, end of period 5,577 9,459 Supplemental disclosures of cash flow information: Â Â Interest paid 8,211 7,736 Invoices accrued for construction and improvements $ 902 $ 1,808 X - DefinitionEquity investment distribution. + ReferencesNo definition available. + Details Name: uht_CashDistributionsInExcessOfIncomeFromLimitedLiabilityCompanies Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease decrease in leasing costs. + ReferencesNo definition available. + Details Name: uht_IncreaseDecreaseInLeasingCosts Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in tenant reserves, deposits, deferred and prepaid rents. + ReferencesNo definition available. + Details Name: uht_IncreaseDecreaseInTenantReservesDepositsDeferredAndPrepaidRents Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayments for deposit on real estate assets. + ReferencesNo definition available. + Details Name: uht_PaymentsForDepositOnRealEstateAssets Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of non-cash amortization of intangible asset (liability) for above and below market leases. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AmortizationOfAboveAndBelowMarketLeases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for construction in progress expenditures that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from borrowers for interest payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInLeasingReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for loan and debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToFundLongtermLoansToRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with collection, whether partial or full, of long-term loans to a related party.

Alternate caption: Proceeds from Advances to Affiliates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4JReference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4KReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) before accumulated depreciation of real estate investments for entities with a substantial portion of business acquiring and holding investment real estate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 970 -SubTopic 360 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-28(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479438/970-360-S99-1 + Details Name: us-gaap_RealEstatePeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfSecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ 5,276 $ 3,476 $ 10,576 $ 7,935 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â  Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false Rule 10b5-1 Arr Modified Flag false Non Rule 10b5-1 Arr Modified Flag false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNon rule 10b51 arr modified flag + ReferencesNo definition available. + Details Name: uht_NonRule10B51ArrModifiedFlag Namespace Prefix: uht_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionRule 10b51 arr modified flag. + ReferencesNo definition available. + Details Name: uht_Rule10B51ArrModifiedFlag Namespace Prefix: uht_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 19 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 General 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â  General (1) GeneralThis Quarterly Report on Form 10-Q is for the quarter ended June 30, 2024. In this Quarterly Report, â€œwe,â€ â€œus,â€ â€œourâ€ and the â€œTrustâ€ refer to Universal Health Realty Income Trust and its subsidiaries.In this Quarterly Report on Form 10-Q, the term â€œrevenuesâ€ does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%. As of June 30, 2024, we had investments in four jointly-owned LLCs/LPs. We currently account for our share of the income/loss from these investments by the equity method (see Note 5). The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2023.The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions 6 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â  Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (2) Relationship with Universal Health Services, Inc. (â€œUHSâ€) and Related Party TransactionsLeases: We commenced operations in 1986 by purchasing certain properties from subsidiaries of UHS and immediately leasing the properties back to the respective subsidiaries. The base rentals and lease and renewal terms for each of the hospitals leased to subsidiaries of UHS as of June 30, 2024, are provided below. The base rents are paid monthly. The lease on McAllen Medical Center also provides for bonus rent which is paid quarterly based upon a computation that compares the hospitalâ€™s current quarter revenue to a corresponding quarter in the base year. The hospital leases with subsidiaries of UHS, with the exception of the lease on Clive Behavioral Health Hospital (which is operated by UHS in a joint venture with an unrelated third party), are unconditionally guaranteed by UHS and are cross-defaulted with one another. The lease for the Clive facility is guaranteed on a several basis by UHS (52%) and Catholic Health Initiatives-Iowa (48%). The combined revenues generated from the leases on the three acute care and three behavioral health care hospital facilities leased to subsidiaries of UHS at June 30, 2024, accounted for approximately 24% and 25% of our consolidated revenues for the three months ended June 30, 2024 and 2023, respectively and approximately 24% and 25% of our consolidated revenues for the six months ended June 30, 2024 and 2023, respectively. In addition to the six UHS hospital facilities, we have twenty-one properties consisting of medical/office buildings, (including one newly constructed medical office building ("MOB") that was substantially completed during the first quarter of 2023 and one MOB that was acquired during the third quarter of 2023), and free-standing emergency departments ("FEDs") that are either wholly or jointly-owned by us that include tenants which are subsidiaries of UHS. The aggregate revenues generated from UHS-related tenants comprised approximately 41% of our consolidated revenues during each of the three and six-month periods ended June 30, 2024 and 2023.On December 31, 2021, we entered into an asset purchase and sale agreement with UHS and certain of its affiliates, which was amended during the first quarter of 2022, pursuant to the terms of which: (i) a wholly-owned subsidiary of UHS purchased from us, the real estate assets of the Inland Valley Campus of Southwest Healthcare System located in Wildomar, California, at its fair market value of $79.6 million; (ii) two wholly-owned subsidiaries of UHS transferred to us, the real estate assets of Aiken Regional Medical Center (â€œAikenâ€), located in Aiken, South Carolina (which includes an acute care hospital and a behavioral health pavilion), at its fair-market value of approximately $57.7 million, and Canyon Creek Behavioral Health (â€œCanyon Creekâ€), located in Temple, Texas, at its fair-market value of approximately $26.0 million, and; (iii) we paid approximately $4.1 million in cash to UHS.As a result of UHSâ€™ purchase option within the lease agreements of Aiken and Canyon Creek, the transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP and the properties acquired by us in connection with the asset purchase and sale agreement with UHS, as amended, were accounted for as financing arrangements. Our consolidated balance sheets as of June 30, 2024 and December 31, 2023 include financing receivables related to this transaction of $83.0 million and $83.3 million, respectively. Also on December 31, 2021, Aiken and Canyon Creek (as lessees), entered into a master lease and individual property leases as amended, (with us as lessor), for initial lease terms on each property of approximately twelve years, ending on December 31, 2033. Subject to the terms of the master lease, Aiken and Canyon Creek have the right to renew their leases, at the then current fair market rent (as defined in the master lease), for seven, five-year optional renewal terms. Pursuant to the leases, as amended during the first quarter of 2022, the aggregate annual rental rate during 2024 on the acquired properties, which is payable to us on a monthly basis, is approximately $5.9 million ($4.1 million related to Aiken and $1.8 million related to Canyon Creek). The portion of the lease payments that is included in our consolidated statements of income, and reflected as interest income on financing leases, was approximately $1.4 million for each of the three months ended June 30, 2024 and 2023, and approximately $2.7 million for each of the six-month periods ended June 30, 2024 and 2023. There is no bonus rental component applicable to either of these leases.Pursuant to the terms of the master leases by and among us and certain subsidiaries of UHS, dated December 24, 1986 and December 31, 2021 (the â€œMaster Leasesâ€), which govern the leases of McAllen Medical Center, Wellington Regional Medical Center (governed by the Master Lease dated December 24, 1986), Aiken Regional Medical Center and Canyon Creek Behavioral Health (governed by the Master Lease dated December 31, 2021, as amended), all of which are hospital properties that are wholly-owned subsidiaries of UHS, UHS has the option, among other things, to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities from us at their appraised fair market value upon any of the following: (i) at the end of the lease terms or any renewal terms; (ii) upon one monthâ€™s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the leases in the event that UHS provides notice to us of their intent to offer a substitution property/properties in exchange for one (or more) of the four wholly-owned UHS hospital facilities leased from us, should we be unable to reach an agreement with UHS on the properties to be substituted. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for a specified period after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for a specified period after, the lease term at the same terms and conditions pursuant to any third-party offer. In addition, a wholly-owned subsidiary of UHS is the managing, majority member in a joint-venture with an unrelated third-party that operates, and leases from us, Clive Behavioral Health. This 100-bed behavioral health care facility is located in Clive, Iowa and was completed and opened in late December, 2020, and the hospital lease commenced on December 31, 2020. The lease on this facility is triple net and has an initial term of 20 years with five 10-year renewal options. On each January 1st through 2040 (and potentially through 2070 if the first three of five, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. The first three of the five 10-year renewal options will provide for annual rental as stipulated in the lease (2041 through 2070) and the two additional 10-year lease renewal options will be at fair market value lease rates (2071 through 2090). Pursuant to the lease on this facility, the joint venture has the option to, among other things, renew the lease at the terms specified in the lease agreement by providing notice to us at least 270 days prior to the termination of the then current term. The joint venture also has the right to purchase the leased facility from us at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 daysâ€™ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the joint venture decline to exercise its purchase right). Additionally, the joint venture has rights of first offer to purchase the facility prior to any third-party sale. The table below details the existing lease terms and renewal options for each of the hospital leases that are related to UHS as of June 30, 2024, consisting of three acute care hospitals and three behavioral health hospitals: Â  Hospital Name Â  AnnualMinimumRent Â  Â  End ofLease Term Â  RenewalTerm(years) Â  Â  McAllen Medical Center Â  $ 5,485,000 Â  Â  December, 2026 Â  Â  5 Â  (a) Wellington Regional Medical Center Â  $ 6,639,000 Â  Â  December, 2026 Â  Â  5 Â  (b) Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Â  $ 4,072,000 Â  Â  December, 2033 Â  Â  35 Â  (c) Canyon Creek Behavioral Health Â  $ 1,841,000 Â  Â  December, 2033 Â  Â  35 Â  (c) Clive Behavioral Health Hospital Â  $ 2,775,000 Â  Â  December, 2040 Â  Â  50 Â  (d) Â (a)UHS has one 5-year renewal option at existing lease rates (through 2031).(b)UHS has one 5-year renewal option at fair market value lease rates (through 2031; see additional disclosure below). The annual rental will increase by 2.5% on an annual compounded basis on each January 1st through 2026.(c)UHS has seven 5-year renewal options at fair market value lease rates (2034 through 2068). The annual rental rate will increase by 2.25% on a cumulative and compounded basis on each January 1st through 2033.(d)The UHS-related joint venture has five 10-year renewal options; the first three of the five 10-year renewal options will be at computed lease rates as stipulated in the lease (2041 through 2070) and the last two 10-year renewal options will be at fair market lease rates (2071 through 2090). On each January 1st through 2040 (and potentially through 2070 if the first three of five, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis.Upon the December 31, 2021 expiration of the lease on Wellington Regional Medical Center located in West Palm Beach, Florida, a wholly-owned subsidiary of UHS exercised its fair market value renewal option and renewed the lease for a 5-year term scheduled to expire on December 31, 2026. Effective January 1, 2024, the annual lease rate for this hospital, which is payable to us monthly, is $6.6 million and on each January 1st thereafter through 2026, the annual rent will increase by 2.50% on a cumulative and compounded basis (there is no bonus rental component of the lease payment).Management cannot predict whether the leases with wholly-owned subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases. During the third quarter of 2023, we acquired the McAllen Doctor's Center, an MOB located in McAllen, Texas for a purchase price of approximately $7.6 million, including transaction costs. The building has approximately 79,500 rentable square feet and is 100% master leased to McAllen Hospitals, L.P, a wholly-owned subsidiary of UHS. The triple-net master lease is for twelve years scheduled to expire on August 31, 2035. McAllen Hospitals, L.P. has the option to renew the lease term for three consecutive ten-year terms. The initial annual base rent is approximately $624,000. During the first quarter of 2023, construction was substantially completed on Sierra Medical Plaza I, a multi-tenant MOB located in Reno, Nevada, consisting of approximately 86,000 rentable square feet. This MOB is located on the campus of the Northern Nevada Sierra Medical Center, a newly constructed acute care hospital that is owned and operated by a wholly-owned subsidiary of UHS, which was completed and opened during April of 2022. The cost of the MOB is estimated to be approximately $35 million, approximately $30 million of which was incurred as of June 30, 2024. In connection with this MOB, we entered into a ground lease and master flex-lease agreement with a wholly-owned subsidiary of UHS. The master flex lease agreement has a ten-year term scheduled to expire on March 31, 2033, and covers approximately 68% of the rentable square feet of the MOB at an

initial minimum rent of $1.3 million annually plus a pro-rata share of the common area maintenance expenses. The master flex-lease is subject to a reduction during the term based upon the execution of third-party leases. The ground lease and the master flex lease each commenced during March, 2023.We are the lessee on thirteen ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments), including one that commenced in March, 2023. The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 25 years to approximately 74 years. The annual aggregate lease payments on these properties are approximately $571,000 during each of the years ended 2024 through 2028, and an aggregate of $31.3 million thereafter. See Note 7 for additional lease accounting disclosure. Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of June 30, 2024 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.Advisory Agreement: UHS of Delaware, Inc. (the â€œAdvisorâ€), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the â€œAdvisory Agreementâ€). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the â€œIndependent Trusteesâ€). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisorâ€™s performance has been satisfactory. The Advisory Agreement was renewed for 2024 with the same terms as the Advisory Agreement in place during 2023 and 2022. Our advisory fee for the three months ended June 30, 2024 and 2023, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets. Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2024 as compared to 2023 and 2022. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.4 million and $1.3 million for the three-month periods ended June 30, 2024 and 2023, respectively, and were based upon average invested real estate assets of $782 million and $756 million, respectively. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $2.7 million and $2.6 million for the six-month periods ended June 30, 2024 and 2023, respectively, and were based upon average invested real estate assets of $773 million and $750 million, respectively. Share Ownership: As of June 30, 2024 and December 31, 2023, UHS owned 5.7% of our outstanding shares of beneficial interest.SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised approximately 41% of our consolidated revenues during each of the three and six-month periods ended June 30, 2024 and 2023, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SECâ€™s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Dividends and Equity Issuance Program 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â  Dividends and Equity Issuance Program (3) Dividends and Equity Issuance ProgramDividends and dividend equivalents:We declared and paid dividends of approximately $10.2 million, or $.730 per share, during the second quarter of 2024 and approximately $10.0 million, or $.720 per share, during the second quarter of 2023. We declared and paid dividends of approximately $20.2 million, or $1.455 per share, during the six-month period ended June 30, 224, and approximately $19.8 million, or $1.435 per share, during the comparable period of 2023. Amounts reflected above include accrued dividends that were paid related to the vesting of restricted stock. Dividend equivalents, which are applicable to shares of unvested restricted stock, were accrued during the first six months of 2024 and 2023 and were or will be paid upon vesting of the restricted stock. Equity Issuance Program:During the second quarter of 2024, we filed a shelf registration statement on Form S-3 (File No. 333-278730) (the "Form S-3"), registering the offer and sale, from time-to-time, of an indeterminate amount of the common shares of beneficial interest, preferred shares and debt securities up to an aggregate initial offering price of $100 million to or through one or more underwriters, dealers or agents, or directly to purchasers. The Form S-3 became effective on April 30, 2024.No shares were issued under the Form S-3 since the effective date of April 30, 2024 through June 30, 2024. As of June 30, 2024, we have paid or incurred approximately $287,000 in various fees and expenses related to the Form S-3. The availability of the potential liquidity under this shelf registration statement depends on investor demand, market conditions and other factors. We make no assurance regarding when, or if, we will issue any securities under this registration statement. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Acquisitions and Divestitures 3 Months Ended Mar. 31, 2024 Business Combinations [Abstract] Â  Acquisitions and Divestitures (4) Acquisitions and Divestitures Six Months Ended June 30, 2024:Acquisitions:There were no acquisitions during the first six months of 2024.Divestitures:There were no divestitures during the first six months of 2024. Â Six Months Ended June 30, 2023:New Construction:In January 2022, we entered into a ground lease and master flex-lease agreement with a wholly-owned subsidiary of UHS to develop, construct and own the real property of Sierra Medical Plaza I, an MOB located in Reno, Nevada, consisting of approximately 86,000 rentable square feet. This MOB is located on the campus of the Northern Nevada Sierra Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS, which was completed and opened during April of 2022. Construction of this MOB, for which we engaged a non-related third party to act as construction manager, commenced in January, 2022, and was substantially completed in March, 2023. The master flex lease agreement in connection with this building, which commenced in March, 2023 and has a ten-year term scheduled to expire on March 31, 2033, covers approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually, plus pro-rata share of the common area maintenance expenses. This master flex lease agreement is subject to reduction based upon the execution of third-party leases. Additionally, during March, 2023, the ground lease for this property commenced and a right-of-use asset and lease liability was recorded in connection with this lease. The cost of the MOB is estimated to be approximately $35 million, approximately $30 million of which was incurred as of June 30, 2024.Acquisitions:There were no acquisitions during the first six months of 2023.Divestitures:There were no divestitures during the first six months of 2023. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//805/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-20/tableOfContent + Details Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summarized Financial Information of Equity Affiliates 6 Months Ended Jun. 30, 2024 Equity Method Investments and Joint Ventures [Abstract] Â Summarized Financial Information of Equity Affiliates (5) Summarized Financial Information of Equity AffiliatesIn accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting. The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities. Returns of investments are classified as cash flows from investing activities. At June 30, 2024, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of June 30, 2024 we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties. The following property table represents the four LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of June 30, 2024: Â Â Â Â Â Â Â Name of LLC/LP Â Ownership Â Â Property Owned by LLC/LP Suburban Properties Â Â 33 % Â St. Matthews Medical Plaza II Brunswick Associates (a.)(b.) Â Â 74 % Â Mid Coast Hospital MOB FTX MOB Phase II (c.) Â Â 95 % Â Forney Medical Plaza II Grayson Properties II (d.)(e.) Â Â 95 % Â Texoma Medical Plaza II (a.)This LLC has a third-party term loan of $8.3

million, which is non-recourse to us, outstanding as of June 30, 2024.(b.)We are the lessee with a third party on a ground lease for land.(c.)During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. During the first quarter of 2023, the LP repaid $175,000 of the member loan and the remaining $3.3 million member loan balance was converted to an equity investment in the LP.(d.)This LP constructed, owns and operates the Texoma Medical Plaza II, on which construction substantially completed in December 2020. The MOB is located in Denison, Texas, on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS. We have committed to invest up to $10.2 million in equity and debt financing, of which $7.5 million, net, has been funded as of June 30, 2024. This LP entered into a third-party construction loan commitment, which is non-recourse to us, which had an outstanding balance of $7.0 million as of June 30, 2024. Monthly principal and interest payments on this loan commenced on January 1, 2023. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro rata equity contributions from the partners. The third-party partner's share of the pro rata equity contributions was partially funded with a six-month, $128,000 partner loan from us, which was repaid during July, 2024 with interest. Our share of the pro rata equity contributions, as well as the third-party partner loan, were funded utilizing borrowings from our revolving credit agreement. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated.(e.)We are the lessee with a UHS-related party for the land related to this property.Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at June 30, 2024 and 2023: Â Â Three Months EndedJune 30, Â Â Six Months EndedJune 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (amounts in thousands) (amounts in thousands) Â Revenues Â $ 2,057 Â Â $ 2,043 Â Â $ 4,307 Â Â $ 4,269 Â Operating expenses Â Â 826 Â Â Â 812 Â Â Â 1,724 Â Â Â 1,717 Â Depreciation and amortization Â Â 472 Â Â Â 461 Â Â Â 946 Â Â Â 916 Â Interest, net Â Â 142 Â Â Â 198 Â Â Â 301 Â Â Â 439 Â Net income Â $ 617 Â Â $ 572 Â Â $ 1,336 Â Â $ 1,197 Â Our share of net income Â $ 272 Â Â $ 268 Â Â $ 656 Â Â $ 639 Â Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs/LPs that were accounted for under the equity method as of June 30, 2024 and December 31, 2023: Â Â Â June 30,2024 Â Â December 31,2023 Â Â Â (amounts in thousands) Â Net property, including construction in progress Â $ 27,688 Â Â $ 28,488 Â Other assets (a.) Â Â 4,679 Â Â Â 4,667 Â Total assets Â $ 32,367 Â Â $ 33,155 Â Â Â Â Â Â Â Â Other liabilities (a.) Â $ 2,272 Â Â $ 2,074 Â Mortgage notes payable, non-recourse to us Â Â 15,280 Â Â Â 21,206 Â Equity Â Â 14,815 Â Â Â 9,875 Â Total liabilities and equity Â $ 32,367 Â Â $ 33,155 Â Â Â Â Â Â Â Â Investments in and advances to LLCs before amounts included in Â Â Â Â Â Â Â Â accrued expenses and other liabilities Â $ 14,328 Â Â $ 9,102 Â Â Â Â Amounts included in accrued expenses and other liabilities Â Â (1,751 ) Â Â (1,729 ) Our share of equity in LLCs, net Â $ 12,577 Â Â $ 7,373 Â (a.)Other assets and other liabilities as of June 30, 2024 and December 31, 2023 include approximately $650,000 and $651,000, respectively, of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS. As of June 30, 2024, and December 31, 2023, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands): Â Â Mortgage Loan Balance (a.) Â Â Â Name of LLC/LP Â 6/30/2024 Â Â 12/31/2023 Â Â Maturity Date Brunswick Associates (2.80% fixed rate mortgage loan) Â $ 8,314 Â Â $ 8,453 Â Â December, 2030 Grayson Properties II (3.70% fixed rate construction loan) (b.) Â Â 6,966 Â Â Â 12,753 Â Â March, 2026 Â Â $ 15,280 Â Â $ 21,206 Â Â Â (a.)All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. (b.)This construction loan required interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022. On January 1, 2023, monthly principal and interest payments on this loan commenced. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro-rate equity contributions from the partners, as discussed above. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated. Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (â€œOffering Memberâ€) to the other member(s) (â€œNon-Offering Memberâ€) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (â€œOffer to Sellâ€) at a price as determined by the Offering Member (â€œTransfer Priceâ€), or; (ii) purchase the entire ownership interest of the Non-Offering Member (â€œOffer to Purchaseâ€) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member. X - ReferencesNo definition available. + Details Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 323 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 323 -Publisher FASB -URI https://asc.fasb.org//323/tableOfContent + Details Name: us-gaap_EquityMethodInvestmentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Recent Accounting Pronouncements 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Recent Accounting Pronouncements (6) Recent Accounting PronouncementsSegment ReportingIn November, 2023, the FASB issued ASU 2023-07, Segment Reporting, Topic 280, "Improvements to Reportable Segment Disclosures ("ASU 2023-07") which was issued to improve the disclosures about s public entity's reportable segments and address requests from investors for additional, more detailed information about a reportable segment's expenses. The ASU requires existing annual segment disclosures to also be disclosed on an interim basis and also requires disclosures around significant segment expenses and disclosures to identify the title and position of the chief operating decision maker ("CODM"). The standard is effective for the fiscal year ended December 31, 2024 and interim periods thereafter. We do not expect the standard to have a material impact on our consolidated financial statements.Reference Rate ReformIn March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, â€œReference Rate Reform.â€ The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. Beginning in the first quarter of 2020, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. We will continue to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur. In December 2022, the FASB issued ASU 2022-06, Deferral of the Sunset Date of Topic 848 (â€œASU 2022-06â€) which was issued to defer the sunset date of Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform to December 31, 2024. ASU 2022-06 is effective immediately for all companies. ASU 2022-06 has no impact on the Companyâ€™s condensed consolidated financial statements for the three and six months ended June 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 250 -Publisher FASB -URI https://asc.fasb.org//250/tableOfContentReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -SubTopic 20 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -SubTopic 20 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2 + Details Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Lease Accounting 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Lease Accounting (7) Lease AccountingAs Lessor:We lease most of our operating properties to customers under agreements that are typically classified as operating leases (as noted below, two of our leases are accounted for as financing arrangements effective on December 31, 2021). We recognize the total minimum lease payments provided for under the operating leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease. We have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers (â€œtenant reimbursementsâ€) from the associated rental revenue if certain criteria were met. We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and for the leases that qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three and six months ended June 30, 2024 and 2023. On December 31, 2021, as a result of the asset purchase and sale transaction with UHS, as amended during the first quarter of 2022, the real estate assets of two wholly-owned subsidiaries of UHS were transferred to us (Aiken and Canyon Creek). As discussed in Note 2, these assets are accounted for as financing arrangements and our consolidated balance sheets at June 30, 2024 and December 31, 2023 reflect financing receivables related to this transaction amounting to $83.0 million and $83.3 million, respectively. Pursuant to the leases, as amended during the first quarter of 2022, the aggregate annual rental during 2024 on the acquired properties, which is payable to us on a monthly basis, amounts to approximately $5.9 million ($4.1 million related to Aiken and $1.8 million related to Canyon Creek). The portion of these lease payments that will be included in our consolidated statements of income, and reflected as interest income on financing leases, is expected to be approximately $5.4 million during the full year of 2024. Lease revenue will not be impacted by the lease payments received related to these two

properties.The components of the â€œLease revenue â€“ UHS facilitiesâ€ and â€œLease revenue â€“ Non-related partiesâ€ captions for the three and six month periods ended June 30, 2024 and 2023 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the term of the lease. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.Â Â Three Months Ended Â Â Six Months Ended Â Â June 30, Â Â June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â UHS facilities: Â Â Â Â Â Â Â Â Â Â Â Â Base rents $ 6,888 Â Â $ 6,506 Â Â $ 13,860 Â Â $ 12,780 Â Bonus rents (a.) Â 758 Â Â Â 730 Â Â Â 1,541 Â Â Â 1,494 Â Tenant reimbursements Â 808 Â Â Â 1,000 Â Â Â 1,717 Â Â Â 1,749 Â Lease revenue - UHS facilities $ 8,454 Â Â $ 8,236 Â Â $ 17,118 Â Â $ 16,023 Â Â Â Â Â Â Â Â Â Â Â Â

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContentReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) 6 Months Ended Jun. 30, 2024 Related Party Transactions [Abstract] Â  Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities The table below details the existing lease terms and renewal options for each of the hospital leases that are related to UHS as of June 30, 2024, consisting of three acute care hospitals and three behavioral health hospitals: Â  Hospital Name Â  AnnualMinimumRent Â  Â  End ofLease Term Â  RenewalTerm(years) Â  Â  McAllen Medical Center Â  $ 5,485,000 Â  Â  December, 2026 Â  Â  5 Â  (a) Wellington Regional Medical Center Â  $ 6,639,000 Â  Â  December, 2026 Â  Â  5 Â  (b) Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Â  $ 4,072,000 Â  Â  December, 2033 Â  Â  35 Â  (c) Canyon Creek Behavioral Health Â  $ 1,841,000 Â  Â  December, 2033 Â  Â  35 Â  (c) Clive Behavioral Health Hospital Â  $ 2,775,000 Â  Â  December, 2040 Â  Â  50 Â  (d) Â (a)UHS has one 5-year renewal option at existing lease rates (through 2031).(b)UHS has one 5-year renewal option at fair market value lease rates (through 2031; see additional disclosure below). The annual rental will increase by 2.5% on an annual compounded basis on each January 1st through 2026.(c)UHS has seven 5-year renewal options at fair market value lease rates (2034 through 2068). The annual rental rate will increase by 2.25% on a cumulative and compounded basis on each January 1st through 2033.(d)The UHS-related joint venture has five 10-year renewal options; the first three of the five 10-year renewal options will be at computed lease rates as stipulated in the lease (2041 through 2070) and the last two 10-year renewal options will be at fair market lease rates (2071 through 2090). On each January 1st through 2040 (and potentially through 2070 if the first three of five, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481501/840-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479773/842-30-50-13Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summarized Financial Information of Equity Affiliates (Tables) 6 Months Ended Jun. 30, 2024 Equity Method Investments and Joint Ventures [Abstract] Â  Limited Liability Companies Accounted for Under Equity Method The following property table represents the four LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of June 30, 2024: Â Â Â Â Â Â Â Name of LLC/LP Â  Ownership Â Â  Property Owned by LLC/LP Suburban Properties Â Â  33 % Â  St. Matthews Medical Plaza II Brunswick Associates (a.)(b.) Â Â  74 % Â  Mid Coast Hospital MOB FTX MOB Phase II (c.) Â Â  95 % Â  Forney Medical Plaza II Grayson Properties II (d.)(e.) Â Â  95 % Â  Texoma Medical Plaza II (a.)This LLC has a third-party term loan of $8.3 million, which is non-recourse to us, outstanding as of June 30, 2024.(b.)We are the lessee with a third party on a ground lease for land.(c.)During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. During the first quarter of 2023, the LP repaid $175,000 of the member loan and the remaining $3.3 million member loan balance was converted to an equity investment in the LP.(d.)This LP constructed, owns and operates the Texoma Medical Plaza II, on which construction substantially completed in December 2020. The MOB is located in Denison, Texas, on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS. We have committed to invest up to $10.2 million in equity and debt financing, of which $7.5 million, net, has been funded as of June 30, 2024. This LP entered into a third-party construction loan commitment, which is non-recourse to us, which had an outstanding balance of $7.0 million as of June 30, 2024. Monthly principal and interest payments on this loan commenced on January 1, 2023. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro rata equity contributions from the partners. The third-party partner's share of the pro rata equity contributions was partially funded with a six-month, $128,000 partner loan from us, which was repaid during July, 2024 with interest. Our share of the pro rata equity contributions, as well as the third-party partner loan, were funded utilizing borrowings from our revolving credit agreement. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated.(e.)We are the lessee with a UHS-related party for the land related to this property. Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at June 30, 2024 and 2023: Â Â Three Months EndedJune 30, Â Â Six Months EndedJune 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (amounts in thousands) (amounts in thousands) Â Revenues Â  $ 2,057 Â Â  $ 2,043 Â Â  $ 4,307 Â Â  $ 4,269 Â Operating expenses Â Â  826 Â Â Â  812 Â Â Â  1,724 Â Â Â  1,717 Â Depreciation and amortization Â Â  472 Â Â Â  461 Â Â Â  946 Â Â Â  916 Â Interest, net Â Â  142 Â Â Â  198 Â Â Â  301 Â Â Â  439 Â Net income Â  $ 617 Â Â  $ 572 Â Â  $ 1,336 Â Â  $ 1,197 Â Our share of net income Â  $ 272 Â Â  $ 268 Â Â  $ 656 Â Â  $ 639 Â Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs/LPs that were accounted for under the equity method as of June 30, 2024 and December 31, 2023: Â Â Â June 30,2024 Â Â December 31,2023 Â Â Â (amounts in thousands) Â Net property, including construction in progress Â  $ 27,688 Â Â  $ 28,488 Â Other assets (a.) Â Â  4,679 Â Â Â  4,667 Â Total assets Â  $ 32,367 Â Â  $ 33,155 Â Â Â Â Â Â Â Â Other liabilities (a.) Â  $ 2,272 Â Â  $ 2,074 Â Mortgage notes payable, non-recourse to us Â Â  15,280 Â Â Â  21,206 Â Equity Â Â  14,815 Â Â Â  9,875 Â Total liabilities and equity Â  $ 32,367 Â Â  $ 33,155 Â Â Â Â Â Â Â Â Investments in and advances to LLCs before amounts included in Â Â Â Â Â Â Â Â accrued expenses and other liabilities Â  $ 14,328 Â Â  $ 9,102 Â Â Â Â Amounts included in accrued expenses and other liabilities Â Â  (1,751 ) Â Â  (1,729 ) Our share of equity in LLCs, net Â  $ 12,577 Â Â  $ 7,373 Â (a.)Other assets and other liabilities as of June 30, 2024 and December 31, 2023 include approximately $650,000 and $651,000, respectively, of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS. Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method As of June 30, 2024, and December 31, 2023, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands): Â Â  Mortgage Loan Balance (a.) Â Â Â  Name of LLC/LP Â  6/30/2024 Â Â  12/31/2023 Â Â  Maturity Date Brunswick Associates (2.80% fixed rate mortgage loan) Â  $ 8,314 Â Â  $ 8,453 Â Â  December, 2030 Grayson Properties II (3.70% fixed rate construction loan) (b.) Â Â  6,966 Â Â Â  12,753 Â Â  March, 2026 Â Â  $ 15,280 Â Â  $ 21,206 Â Â Â  (a.)All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. (b.)This construction loan required interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022. On January 1, 2023, monthly principal and interest payments on this loan commenced. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro-rate equity contributions from the partners, as discussed above. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated. X - DefinitionTabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (S-X 210.12-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details Name: srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock Namespace Prefix: srt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEquity Method Investments Summarized Combined Balance Sheet Information. + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock Namespace Prefix: uht_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionEquity Method Investments Summarized Income Statement Information. + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentsSummarizedIncomeStatementInformationTableTextBlock Namespace Prefix: uht_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Lease Accounting (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â  Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions The components of the â€œLease revenue â€“ UHS facilitiesâ€ and â€œLease revenue â€“ Non-related partiesâ€ captions for the three and six month periods ended June 30, 2024 and 2023 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the term of the lease. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.Â  Â  Three Months Ended Â Â  Six Months Ended Â Â  June 30, Â Â  2024 Â Â  2023 Â Â  2024 Â Â  2023 Â Â  UHS facilities: Â Â Â Â Â Â Â Â Base rents $ 6,888 Â Â  $ 6,506 Â Â  $ 13,860 Â Â  $ 12,780 Â Bonus rents (a.) Â  758 Â Â Â  730 Â Â Â  1,541 Â Â Â  1,494 Â Tenant reimbursements Â  808 Â Â Â  1,000 Â Â  1,717 Â Â Â  1,749 Â Lease revenue - UHS facilities $ 8,454 Â Â  $ 8,236 Â Â  $ 17,118 Â Â  $ 16,023 Â Â Â Â Â Â Â Â

Statements [Line Items] Â  Number of real estate investments 4 4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum Â  Organization Consolidation And Presentation Of Financial Statements [Line Items] Â  Non-controlling equity interest, ownership percentage 33.00% 4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum Â  Organization Consolidation And Presentation Of Financial Statements [Line Items] Â  Non-controlling equity interest, ownership percentage 95.00% X - DefinitionNumber of real estate properties including property under construction. + ReferencesNo definition available. + Details Name: uht_NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionOrganization consolidation and presentation of financial statements. + ReferencesNo definition available. + Details Name: uht_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems Namespace Prefix: uht_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_LimitedLiabilityCompanyOrLimitedPartnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 USD ($) Lease Time Hospital Sep. 30, 2023 USD ($) ftÂ² Jun. 30, 2023 USD ($) Mar. 31, 2023 USD ($) ftÂ² Mar. 31, 2022 USD ($) Subsidiary Jun. 30, 2024 USD ($) Time Lease Bed Hospital Property RenewalOption Jun. 30, 2023 USD ($) Dec. 31, 2024 USD ($) Dec. 31, 2021 USD ($) Mar. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Jan. 31, 2022 ftÂ² Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of bed facility | Bed Â Â Â Â Â Â 100 Â Â Â Â Â Â Â Annual advisory fee as percentage of average invested real estate assets 0.70% Â 0.70% Â Â 0.70% 0.70% Â Â Â Â Â Â McAllen Medical Center Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Initial rent Â $ 624,000 Â Â Â Â Â Â Â Â Â Â Â Â Rentable square feet | ftÂ² Â 79,500 Â Â Â Â Â Â Â Â Â Â Â Â Payment to acquire business Â $ 7,600,000 Â Â Â Â Â Â Â Â Â Â Â Â Percentage of lease guaranteed Â 100.00% Â Â Â Â Â Â Â Â Â Â Â Â Aiken Regional Medical Center Â Â Â Â Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Monthly lease rent receivable $ 4,100,000 Â Â Â $ 4,100,000 $ 4,100,000 Â Â Â Â Â Â Â Canyon Creek Behavioral Health Â Â Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Monthly lease rent receivable $ 1,800,000 Â Â Â 1,800,000 $ 1,800,000 Â Â Â Â Â Â Â Aiken Regional Medical Center and Canyon Creek Behavioral Health Â Â Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Lease expiration date Â Â Â Â Â Â Â Â Â Dec. 31, 2033 Â Â Â Â Lease renewal term 5 years Â Â Â Â 5 years Â Â Â Â Â Â Monthly lease rent receivable $ 5,900,000 Â Â Â $ 5,900,000 $ 5,900,000 Â Â Â Â Â Â Lease payments expected $ 1,400,000 Â $ 1,400,000 Â Â Â Â Â Â Â Â Term of lease Â Â Â Â Â Â Â Â 12 years Â Â Â Number of term renewal options | Time 7 Â Â Â Â 7 Â Â Â Â Â Forecast | Aiken Regional Medical Center and Canyon Creek Behavioral Health Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Â Lease payments expected Â Â Â Â Â Â Â $ 5,400,000 Â Â Â Universal Health Services, Inc Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Â Number of acute care hospital leased | Hospital 3 Â Â Â Â 3 Â Â Â Â Â Number of behavioral health care hospital leased | Hospital 3 Â Â Â 3 Â Â Â Â Â Number of hospital facilities leased | Hospital Â Â Â Â 6 Â Â Â Â Â Number of medical office buildings and free standing emergency departments | Property Â Â Â Â 21 Â Â Â Â Financing receivable $ 83,000,000 Â Â Â $ 83,000,000 Â Â Â $ 83,300,000 Â Lease revenue [1] $ 8,454,000 Â $ 8,236,000 Â Â $ 17,118,000 $ 16,023,000 Â Â Â Â Option to renew lease, notice period prior to termination date of current term Â Â Â Â 90 days Â Â Â Â Number of ground leases | Lease 13 Â Â Â 13 Â Â Â Â Aggregate lease payments for 2024 $ 571,000 Â Â Â $ 571,000 Â Â Â Â Aggregate lease payments for 2025 571,000 Â Â Â 571,000 Â Â Â Â Aggregate lease payments for 2026 571,000 Â Â Â 571,000 Â Â Â Â Aggregate lease payments for 2027 571,000 Â Â Â 571,000 Â Â Â Â Aggregate lease payments for 2028 $ 571,000 Â Â Â $ 571,000 Â Â Â Â Aggregate lease payments for thereafter Â Â Â Â Â Â Â $ 31,300,000 Â Percentage ownership of outstanding shares 5.70% Â Â Â 5.70% Â Â Â 5.70% Â Percentage of lease guaranteed Â Â Â 52.00% Â Â Â Universal Health Services, Inc | Minimum Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Remaining lease terms on ground leases Â Â Â Â 25 years Â Â Â Â Universal Health Services, Inc | Maximum Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Remaining lease terms on ground leases Â Â Â Â 74 years Â Â Â Â Universal Health Services, Inc | Acute Care Hospitals Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Number of hospitals operating lease terms of existing and renewal options | Hospital Â Â Â Â 3 Â Â Â Â Â Universal Health Services, Inc | Wellington Regional Medical Center Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Percentage of annual rental increase on cumulative and compound basis Â Â Â Â Â 2.50% Â Â Â Â Â Renewal options term at fair market value lease rates Â Â Â Â Â 5 years Â Â Â Â Renewal options at fair market value lease rates expiration year Â Â Â Â 2031 Â Â Â Â Universal Health Services, Inc | McAllen Medical Center Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Lease expiration date Â Aug. 31, 2035 Â Â Â Â Â Â Â Â Term of lease Â 12 years Â Â Â Â Â Â Â Â Â Universal Health Services, Inc | Clive, Iowa | Clive Behavioral Health Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Initial lease term on property Â Â Â Â Â 20 years Â Â Â Â Â Lessee operating lease, existence of option to extend Â Â Â Â true Â Â Â Â Â Percentage of annual rental increase on cumulative and compound basis Â Â Â Â 2.75% Â Â Â Â Â Option to renew lease, notice period prior to termination date of current term Â Â Â Â 270 days Â Â Â Â Renewal option term Â Â Â Â 10 years Â Â Â Â Operating Lease Additional Number Of Renewal Options At Fair Market Value Lease Rates | RenewalOption Â Â Â Â 2 Â Â Â Â Renewal options term at fair market value lease rates Â Â Â Â 10 years Â Â Â Â Period to purchase respective leased facilities prior to end of lease term or renewal terms Â Â Â Â 270 days Â Â Â Â Number of term renewal options | Time 5 Â Â Â 5 Â Â Â Â Number of lease renewal option exercised | Time Â Â Â Â 3 Â Â Â Â Universal Health Services, Inc | Clive, Iowa | Clive Behavioral Health | Minimum Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Renewal options at fair market value lease rates expiration year Â Â Â Â 2071 Â Â Â Â Universal Health Services, Inc | Clive, Iowa | Clive Behavioral Health | Maximum Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Renewal options at fair market value lease rates expiration year Â Â Â Â 2090 Â Â Â Â Universal Health Services, Inc | Palm Beach, Florida | Wellington Regional Medical Center Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Monthly lease rent receivable Â Â Â Â Â Â Â $ 6,600,000 Â Â Â Percentage of annual rental increase on cumulative and compound basis Â Â Â Â Â 2.50% Â Â Â Operating lease renewal term 5 years Â Â Â Â 5 years Â Â Â Â Universal Health Services, Inc | Subsidiary Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Number of wholly-owned subsidiaries | Subsidiary Â Â Â 2 Â Â Â Â Â Financing receivable $ 83,000,000 Â Â Â $ 83,000,000 Â Â Â $ 83,300,000 Â Universal Health Services, Inc | Asset Purchase and Sale Agreement | Subsidiary Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Cash received for sale of real estate asset Â Â Â Â $ 4,100,000 Â Â Â Â Â Â Â Universal Health Services, Inc | Asset Purchase and Sale Agreement | Subsidiary | Inland Valley Campus of Southwest Healthcare System | Wildomar, California Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Â Fair market value of real estate asset sold Â Â Â Â 79,600,000 Â Â Â Â Â Â Â Universal Health Services, Inc | Asset Purchase and Sale Agreement | Subsidiary | Aiken Regional Medical Center | Aiken, South Carolina Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Fair market value of real estate assets received Â Â Â 57,700,000 Â Â Â Â Â Â Â Universal Health Services, Inc | Asset Purchase and Sale Agreement | Subsidiary | Canyon Creek Behavioral Health | Temple, Texas Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Fair market value of real estate assets received Â Â Â $ 26,000,000 Â Â Â Â Â Â Universal Health Services, Inc | Ground Lease and Master Flex-lease Agreement | Reno, Nevada | Sierra Medical Plaza I Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Cost of medical office building incurred Â Â Â $ 30,000,000 Â 30,000,000 Â Â Â Â Â Â Rentable square feet | ftÂ² Â Â Â 86,000 Â Â Â Â Â Â 86,000 Cost of medical office building Â Â Â $ 35,000,000 Â 35,000,000 Â Â Â Â Â Percentage of rentable square feet Â Â 68.00% Â 68.00% Â Â Â Â Universal Health Services, Inc | Ground Lease and Master Flex-lease Agreement | Reno, Nevada | Sierra Medical Plaza I | Minimum Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Initial rent Â Â Â $ 1,300,000 Â Â $ 1,300,000 Â Â Â Â Universal Health Services, Inc | Master Flex Lease Agreement | Reno, Nevada | Sierra Medical Plaza I Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Lease expiration date Â Â Â Â Â Mar. 31, 2033 Â Â Â Â Lease renewal term Â Â 10 years Â Â Â 10 years Â Â Â Â Term of lease Â Â Â 10 years Â Â Â Â Â Â Â Universal Health Services of Delaware Inc Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Advisory fee 1,400,000 Â $ 1,300,000 Â Â 2,700,000 $ 2,600,000 Â Â Â Â Average invested real estate assets $ 782,000,000 Â $ 756,000,000 Â Â $ 773,000,000 $ 750,000,000 Â Â Â Â Catholic Health Initiatives Iowa Â Â Â Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Â Â Percentage of lease guaranteed Â Â Â Â 48.00% Â Â Â Â Â [1] Includes bonus rental on McAllen Medical Center, a UHS acute care hospital facility of $758 and $730 for the three-month periods ended June 30, 2024 and 2023, respectively, and $1,541 and $1,495 for the six-month periods ended June 30, 2024 and 2023, respectively. X - DefinitionAnnual advisory fees as percentage of average invested real estate assets. + ReferencesNo definition available. + Details Name: uht_AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAverage invested real estate assets. + ReferencesNo definition available. + Details Name: uht_AverageInvestedRealEstateAssets Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCost of medical office building. + ReferencesNo definition available. + Details Name: uht_CostOfMedicalOfficeBuilding Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCost of medical office building incurred. + ReferencesNo definition available. + Details Name: uht_CostOfMedicalOfficeBuildingIncurred Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair market value of real estate asset sold. + ReferencesNo definition available. + Details Name: uht_FairMarketValueOfRealEstateAssetSold Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair market value of real estate assets received. + ReferencesNo definition available. + Details Name: uht_FairMarketValueOfRealEstateAssetsReceived Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFinancing receivable. + ReferencesNo definition available. + Details Name: uht_FinancingReceivable Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInitial Rent. + ReferencesNo definition available. + Details Name: uht_InitialRent Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLease renewal, notice period. + ReferencesNo definition available. + Details Name: uht_LeaseRenewalNoticePeriod Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLessee operating lease liability payments due after year four. + ReferencesNo definition available. + Details Name: uht_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMonthly lease rent receivable. + ReferencesNo definition available. + Details Name: uht_MonthlyLeaseRentReceivable Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of acute care and behavioral health care hospital facilities. + ReferencesNo definition available. + Details Name: uht_NumberOfAcuteCareAndBehavioralHealthCareHospitalFacilities Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of acute care hospital leased. + ReferencesNo definition available. + Details Name: uht_NumberOfAcuteCareHospitalLeased Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of bed facility. + ReferencesNo definition available. + Details Name: uht_NumberOfBedFacility Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of behavioral health care hospital leased. + ReferencesNo definition available. + Details Name: uht_NumberOfBehavioralHealthCareHospitalLeased Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of ground leases. + ReferencesNo definition available. + Details Name: uht_NumberOfGroundLeases Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of hospitals operating lease terms of existing and renewal options. + ReferencesNo definition available. + Details Name: uht_NumberOfHospitalsOperatingLeaseTermsOfExistingAndRenewalOptions Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of lease renewal option exercised. + ReferencesNo definition available. + Details Name: uht_NumberOfLeaseRenewalOptionExercised Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of leased properties for medical office buildings and free standing emergency departments. + ReferencesNo definition available. + Details Name: uht_NumberOfLeasedPropertiesForMedicalOfficeBuildingsAndFreeStandingEmergencyDepartments Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of renewal options. + ReferencesNo definition available. + Details Name: uht_NumberOfRenewalOptions Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of wholly-owned subsidiaries. + ReferencesNo definition available. + Details Name: uht_NumberOfWhollyOwnedSubsidiaries Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionOperating Lease Additional Number Of Renewal Options At Fair Market Value Lease Rates + ReferencesNo definition available. + Details Name: uht_OperatingLeaseAdditionalNumberOfRenewalOptionsAtFairMarketValueLeaseRates Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionOperating lease payments expected. + ReferencesNo definition available. + Details Name: uht_OperatingLeasePaymentsExpected Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOperating lease remaining lease term. + ReferencesNo definition available. + Details Name: uht_OperatingLeaseRemainingLeaseTerm Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options at fair market value lease rates, expiration year. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear Namespace Prefix: uht_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options term at fair market value lease rates. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual rental increase. + ReferencesNo definition available. + Details Name: uht_PercentageOfAnnualRentalIncrease Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage Of Lease Guaranteed. + ReferencesNo definition available. + Details Name: uht_PercentageOfLeaseGuaranteed Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of ownership interest related parties. + ReferencesNo definition available. + Details Name: uht_PercentageOfOwnershipInterestRelatedParties Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of rentable square feet. + ReferencesNo definition available. + Details Name: uht_PercentageOfRentableSquareFeet Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod to purchase respective leased facilities prior to end of lease term or renewal terms. + ReferencesNo definition available. + Details Name: uht_PeriodToPurchaseRespectiveLeasedFacilitiesPriorToEndOfLeaseTermOrRenewalTerms Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRenewal options term. + ReferencesNo definition available. + Details Name: uht_RenewalOptionsTerm Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTriple net lease agreement period. + ReferencesNo definition available. + Details Name: uht_TripleNetLeaseAgreementPeriod Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate costs related to goods

produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3 + Details Name: us-gaap_LessorOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionNet rentable area for properties owned. + ReferencesNo definition available. + Details Name: us-gaap_NetRentableArea Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479016/842-30-45-3 + Details Name: us-gaap_OperatingLeaseLeaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received for the sale of real estate that is not part of an investing activity during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfRealEstate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_MajorPropertyClassAxis=uht_McAllenMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uht_AikenRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uht_CanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uht_AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_AcuteCareHospitalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_WellingtonRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_CliveIowaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_CliveBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_PalmBeachFloridaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uht_AssetPurchaseAndSaleAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uht_InlandValleyCampusOfSouthwestHealthcareSystemMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_WildomarCaliforniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_AikenSouthCarolinaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_TempleTexasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uht_GroundLeaseAndMasterFlexLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_RenoNevadaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_SierraMedicalPlazaIMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uht_MasterFlexLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesOfDelawareIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_CatholicHealthInitiativesIowaMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail 1) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Bonus Rents | Aiken Regional Medical Center and Canyon Creek Behavioral Health Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Lease revenue Â Â $ 0 Â Universal Health Services, Inc Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Lease revenue [1] $ 8,454,000 $ 8,236,000 17,118,000 $ 16,023,000 Universal Health Services, Inc | Bonus Rents Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Lease revenue [2] $ 758,000 $ 730,000 $ 1,541,000 $ 1,494,000 Universal Health Services, Inc | Revenues | Customer Concentration Risk Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Percentage of revenues generated from leases and tenants 24.00% 25.00% 24.00% 25.00% Universal Health Services, Inc | Revenues | Customer Concentration Risk | Tenants Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Percentage of revenues generated from leases and tenants 41.00% 41.00% 41.00% 41.00% [1] Includes bonus rental on McAllen Medical Center, a UHS acute care hospital facility of $758 and $730 for the three-month periods ended June 30, 2024 and 2023, respectively, and $1,541 and $1,495 for the six-month periods ended June 30, 2024 and 2023, respectively. [2] Consists of bonus rental earned in connection with McAllen Medical Center. X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479016/842-30-45-3 + Details Name: us-gaap_OperatingLeaseLeaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LeaseContractualTermAxis=uht_BonusRentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uht_AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=uht_RevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=uht_TenantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) - Universal Health Services, Inc 6 Months Ended Jun. 30, 2024 USD ($) McAllen Medical Center Â  Operating Leased Assets [Line

Items] Â  Annual Minimum Rent $ 5,485,000 [1] End of Lease Term 2026-12 [1] Renewal Term (years) 5 years [1] Wellington Regional Medical Center Â  Operating Leased Assets [Line Items] Â  Annual Minimum Rent $ 6,639,000 [2] End of Lease Term 2026-12 [2] Renewal Term (years) 5 years [2] Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Â  Operating Leased Assets [Line Items] Â  Annual Minimum Rent $ 4,072,000 [3] End of Lease Term 2033-12 [3] Renewal Term (years) 35 years [3] Canyon Creek Behavioral Health Â  Operating Leased Assets [Line Items] Â  Annual Minimum Rent $ 1,841,000 [3] End of Lease Term 2033-12 [3] Renewal Term (years) 35 years [3] Clive Behavioral Health Hospital Â  Operating Leased Assets [Line Items] Â  Annual Minimum Rent $ 2,775,000 [4] End of Lease Term 2040-12 [4] Renewal Term (years) 50 years [4] [1] UHS has one 5-year renewal option at existing lease rates (through 2031). [2] UHS has one 5-year renewal option at fair market value lease rates (through 2031; see additional disclosure below). The annual rental will increase by 2.5% on an annual compounded basis on each January 1st through 2026. [3] UHS has seven 5-year renewal options at fair market value lease rates (2034 through 2068). The annual rental rate will increase by 2.25% on a cumulative and compounded basis on each January 1st through 2033. [4] The UHS-related joint venture has five 10-year renewal options; the first three of the five 10-year renewal options will be at computed lease rates as stipulated in the lease (2041 through 2070) and the last two 10-year renewal options will be at fair market lease rates (2071 through 2090). On each January 1st through 2040 (and potentially through 2070 if the first three of five, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. X - DefinitionLease expiration, month and year. + ReferencesNo definition available. + Details Name: uht_LeaseExpirationMonthAndYear Namespace Prefix: uht_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, annual future minimum payments receivable. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesAnnualFutureMinimumPaymentsReceivable Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTerm of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3 + Details Name: us-gaap_LessorOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OperatingLeasedAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_McAllenMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_WellingtonRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_CanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_CliveBehavioralHealthHospitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) - Universal Health Services, Inc 6 Months Ended Jun. 30, 2024 Renewaloptions McAllen Medical Center Â  Operating Leased Assets [Line Items] Â  Number of renewal option at existing lease rates 1 Renewal option term at existing lease rates 5 years Renewal option at existing lease rates expiration year 2031 Wellington Regional Medical Center Â  Operating Leased Assets [Line Items] Â  Number of renewal options at fair market value lease rates 1 Renewal options term at fair market value lease rates 5 years Renewal options at fair market value lease rates expiration year 2031 Percentage of annual rental increase 2.50% Aiken Regional Medical Center and Canyon Creek Behavioral Health Â  Operating Leased Assets [Line Items] Â  Number of renewal options at fair market value lease rates 7 Renewal options term at fair market value lease rates 5 years Percentage of annual rental increase on cumulative and compound basis 2.25% Aiken Regional Medical Center and Canyon Creek Behavioral Health | Minimum Â  Operating Leased Assets [Line Items] Â  Renewal options at fair market value lease rates expiration year 2034 Aiken Regional Medical Center and Canyon Creek Behavioral Health | Maximum Â  Operating Leased Assets [Line Items] Â  Renewal options at fair market value lease rates expiration year 2068 Clive Behavioral Health Hospital Â  Operating Leased Assets [Line Items] Â  Number of renewal options at fair market value lease rates 5 Renewal options term at fair market value lease rates 10 years Clive Behavioral Health Hospital | First Three Year Renewal Options Â  Operating Leased Assets [Line Items] Â  Percentage of annual rental increase on cumulative and compound basis 2.75% Clive Behavioral Health Hospital | Minimum | First Three Year Renewal Options Â  Operating Leased Assets [Line Items] Â  Renewal options at lease rate stipulated in lease expiration year 2041 Clive Behavioral Health Hospital | Minimum | Last Two Year Renewal Options Â  Operating Leased Assets [Line Items] Â  Renewal options at fair market value lease rates expiration year 2071 Clive Behavioral Health Hospital | Maximum | First Three Year Renewal Options Â  Operating Leased Assets [Line Items] Â  Renewal options at lease rate stipulated in lease expiration year 2070 Clive Behavioral Health Hospital | Maximum | Last Two Year Renewal Options Â  Operating Leased Assets [Line Items] Â  Renewal options at fair market value lease rates expiration year 2090 X - DefinitionOperating leases, number of renewal options at existing lease rates. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates Namespace Prefix: uht_ Data Type: xbrli:positiveIntegerItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, number of renewal options at fair market value lease rates. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates Namespace Prefix: uht_ Data Type: xbrli:positiveIntegerItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options at existing lease rates, expiration year. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesRenewalOptionsAtExistingLeaseRatesExpirationYear Namespace Prefix: uht_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options at fair market value lease rates, expiration year. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear Namespace Prefix: uht_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating leases renewal options at lease rates stipulated in lease expiration year. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesRenewalOptionsAtLeaseRatesStipulatedInLeaseExpirationYear Namespace Prefix: uht_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options term at existing lease rates. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesRenewalOptionsTermAtExistingLeaseRates Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options term at fair market value lease rates. + ReferencesNo definition available. + Details Name: uht_OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual rental increase. + ReferencesNo definition available. + Details Name: uht_PercentageOfAnnualRentalIncrease Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual rental increase on cumulative and compound basis. + ReferencesNo definition available. + Details Name: uht_PercentageOfAnnualRentalIncreaseOnCumulativeAndCompoundBasis Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OperatingLeasedAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_McAllenMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_WellingtonRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_CliveBehavioralHealthHospitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=uht_FirstThreeYearRenewalOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=uht_LastTwoYearRenewalOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Dividends and Equity Issuance Program - Additional Information (Detail) - USD ($) 2 Months Ended 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dividends and Equity Issuance [Line Items] Â Â Â Â Â  Dividends declared and paid Â  $ 10,200,000 $ 10,000,000 $ 20,156,000 $ 19,837,000 Declared and paid dividends, per share Â  $ 0.73 $ 0.72 $ 1.455 $ 1.435 Aggregate initial offering price of threshold amount $ 100,000,000 $ 100,000,000 Â  $ 100,000,000 Â  Share issued 0 Â Â Â Â Â  Other Expenses Â Â Â Â Â  Dividends and Equity Issuance [Line Items] Â Â Â Â Â  Net cash proceeds from stock issued Â Â Â  $ 287,000 Â  X - DefinitionAggregate initial offering price of threshold amount. + ReferencesNo definition available. + Details Name: uht_AggregateInitialOfferingPriceOfThresholdAmount Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDividends and equity issuance. + ReferencesNo definition available. + Details Name: uht_DividendsAndEquityIssuanceLineItems Namespace Prefix: uht_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate dividends paid during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareCashPaid Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionCash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Acquisitions and Divestitures - Additional Information (Detail) $ in Millions 3 Months Ended 6 Months Ended Mar. 31, 2023 USD ($) ftÂ² Jun. 30, 2024 USD ($) Acquisition Disposition Jun. 30, 2023 USD ($) Disposition Acquisition Jan. 31, 2022 ftÂ² Business Acquisitions And Dispositions [Line Items] Â Â Â Â  Number of acquisitions | Acquisition Â  0 0 Â  Number of dispositions | Disposition Â  0 0 Â  Sierra Medical Plaza I | Reno, Nevada | Ground Lease and Master Flex-lease Agreement | Universal Health Services, Inc Â Â Â Â Â  Business Acquisitions And Dispositions [Line Items] Â Â Â Â Â  Percentage of rentable square feet 68.00% Â  68.00% Â  Rentable square feet | ftÂ² 86,000 Â Â  86,000 Cost of medical office building $ 35.0 $ 35.0 Â Â  Cost of medical office building incurred 30.0 $ 30.0 Â Â  Sierra Medical Plaza I | Reno, Nevada | Ground Lease and Master Flex-lease Agreement | Universal Health Services, Inc | Minimum [Member] Â Â Â Â Â  Business Acquisitions And Dispositions [Line Items] Â Â Â Â Â  Initial rent $ 1.3 Â  $ 1.3 Â  Sierra Medical Plaza I | Reno, Nevada | Master Flex Lease Agreement | Universal Health Services, Inc Â Â Â Â Â  Business Acquisitions And Dispositions [Line Items] Â Â Â Â Â  Lease expiration date Â Â  Mar. 31, 2033 Â  Lease contract term Â Â  10 years Â  X - DefinitionBusiness acquisitions and dispositions. + ReferencesNo definition available. + Details Name: uht_BusinessAcquisitionsAndDispositionsLineItems Namespace Prefix: uht_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCost of medical office building. + ReferencesNo definition available. + Details Name: uht_CostOfMedicalOfficeBuilding Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCost of medical office building incurred. + ReferencesNo definition available. + Details Name: uht_CostOfMedicalOfficeBuildingIncurred Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInitial Rent. + ReferencesNo definition available. + Details Name: uht_InitialRent Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of businesses disposed. + ReferencesNo definition available. + Details Name: uht_NumberOfBusinessesDisposed Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPercentage of rentable square feet. + ReferencesNo definition available. + Details Name: uht_PercentageOfRentableSquareFeet Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionNet rentable area for properties owned. + ReferencesNo definition available. + Details Name: us-gaap_NetRentableArea Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionThe number of businesses acquired by the entity during the period. + ReferencesNo definition available. + Details Name: us-gaap_NumberOfBusinessesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_MajorPropertyClassAxis=uht_SierraMedicalPlazaIMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_RenoNevadaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uht_GroundLeaseAndMasterFlexLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uht_MasterFlexLeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summarized Financial Information of Equity Affiliates - Additional Information (Detail) 6 Months Ended Jun. 30, 2024 Property Limited Liability Companies | Medical office buildings Â  Schedule Of Equity Method Investments [Line Items] Â  Number of real estate investments 4 Minimum Â  Schedule Of Equity Method Investments [Line Items] Â  Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or

from Offering Member 60 days Maximum Â  Schedule Of Equity Method Investments [Line Items] Â  Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 90 days 4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum Â  Schedule Of Equity Method Investments [Line Items] Â  Non-controlling equity interest, ownership percentage 33.00% 4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum Â  Schedule Of Equity Method Investments [Line Items] Â  Non-controlling equity interest, ownership percentage 95.00% X - DefinitionNumber of trading period. + ReferencesNo definition available. + Details Name: uht_NumberOfTradingPeriod Namespace Prefix: uht_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe number of real estate properties owned as of the balance sheet date. + ReferencesNo definition available. + Details Name: us-gaap_NumberOfRealEstateProperties Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_LimitedLiabilityCompanyOrLimitedPartnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RealEstatePropertiesAxis=uht_MedicalOfficeBuildingsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Limited Liability Companies Accounted for Under Equity Method (Detail) 6 Months Ended Jun. 30, 2024 Suburban Properties Â  Schedule Of Equity Method Investments [Line Items] Â  Ownership 33.00% Property Owned by LLC/LP St. Matthews Medical Plaza II Brunswick Associates Â  Schedule Of Equity Method Investments [Line Items] Â  Ownership 74.00% [1],[2] Property Owned by LLC/LP Mid Coast Hospital MOB [1],[2] FTX MOB Phase II limited partnership Â  Schedule Of Equity Method Investments [Line Items] Â  Ownership 95.00% [3] Property Owned by LLC/LP Forney Medical Plaza II [3] Grayson Properties Two L P Â  Schedule Of Equity Method Investments [Line Items] Â  Ownership 95.00% [4],[5] Property Owned by LLC/LP Texoma Medical Plaza II [4],[5] [1] This LLC has a third-party term loan of $8.3 million, which is non-recourse to us, outstanding as of June 30, 2024. [2] We are the lessee with a third party on a ground lease for land. [3] During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. During the first quarter of 2023, the LP repaid $175,000 of the member loan and the remaining $3.3 million member loan balance was converted to an equity investment in the LP. [4] This LP constructed, owns and operates the Texoma Medical Plaza II, on which construction substantially completed in December 2020. The MOB is located in Denison, Texas, on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS. We have committed to invest up to $10.2 million in equity and debt financing, of which $7.5 million, net, has been funded as of June 30, 2024. This LP entered into a third-party construction loan commitment, which is non-recourse to us, which had an outstanding balance of $7.0 million as of June 30, 2024. Monthly principal and interest payments on this loan commenced on January 1, 2023. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro rata equity contributions from the partners. The third-party partner's share of the pro rata equity contributions was partially funded with a six-month, $128,000 partner loan from us, which was repaid during July, 2024 with interest. Our share of the pro rata equity contributions, as well as the third-party partner loan, were funded utilizing borrowings from our revolving credit agreement. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated. [5] We are the lessee with a UHS-related party for the land related to this property. X - DefinitionProperty owned by limited liability or limited partner company. + ReferencesNo definition available. + Details Name: uht_PropertyOwnedByLimitedLiabilityOrLimitedPartnerCompany Namespace Prefix: uht_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_SuburbanPropertiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_BrunswickAssociatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_FTXMobPhaseTwoLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_GraysonPropertiesTwoLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) - USD ($) 3 Months Ended Mar. 31, 2023 Mar. 31, 2021 Jun. 30, 2024 Mar. 31, 2024 Brunswick Associates Â Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Â Third-party term loan Â Â Â $ 8,300,000 Â FTX MOB Phase II limited partnership Â Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Repayment of loan $ 175,000 $ 4,700,000 Â Â Member loan used to repay mortgage loan Â $ 3,500,000 Â Â Conversion of Loan to Equity Method Investment $ 3,300,000 Â Â Â Grayson Properties II LP Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Member loan used to repay mortgage loan Â Â 128,000 Â Construction loan Â Â 5,700,000 $ 5,700,000 Letters of Credit Terminated Amount Â Â 3,100,000 Â Construction loan outstanding balance Â Â 7,000,000 Â Grayson Properties II LP | Denison Texas Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Commitment to investment Â Â 7,500,000 Â Grayson Properties II LP | Maximum | Denison Texas Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Commitment to investment Â Â $ 10,200,000 Â X - DefinitionConstruction loan outstanding balance. + ReferencesNo definition available. + Details Name: uht_ConstructionLoanOutstandingBalance Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionConversion of loan to equity method investment. + ReferencesNo definition available. + Details Name: uht_ConversionOfLoanToEquityMethodInvestment Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCommitments to invest. + ReferencesNo definition available. + Details Name: uht_InvestmentCommitments Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount of the contingent obligation under letters of credit terminated as of the reporting date. + ReferencesNo definition available. + Details Name: uht_LettersOfCreditTerminatedAmount Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMember loan used to repay mortgage loan. + ReferencesNo definition available. + Details Name: uht_MemberLoanUsedToRepayMortgageLoan Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepayment of loan. + ReferencesNo definition available. + Details Name: uht_RepaymentOfLoan Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConstructionLoan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermLoansPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_BrunswickAssociatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_FTXMobPhaseTwoLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_GraysonPropertiesTwoLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_DenisonTexasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Schedule Of Equity Method Investments [Line Items] Â Â Â Â Revenues $ 24,734 $ 23,806 $ 49,875 $ 47,032 Net income Â Â 10,576 7,935 Our share of net income 272 268 656 639 Equity Method Investment, Nonconsolidated Investee or Group of Investees Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Revenues 2,057 2,043 4,307 4,269 Operating expenses 826 812 1,724 1,717 Depreciation and amortization 472 461 946 916 Interest, net 142 198 301 439 Net income 617 572 1,336 1,197 Equity Method Investment, Nonconsolidated Investee or Group of Investees Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Our share of net income $ 272 $ 268 $ 656 $ 639 X - DefinitionEquity method investment summarized financial information depreciation and amortization. + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentSummarizedFinancialInformationDepreciationAndAmortization Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEquity method investment summarized financial information interest expense. + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentSummarizedFinancialInformationInterestExpense Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEquity method investment, summarized financial information, operating expenses. + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic

235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4JReference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4KReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_EquityMethodInvestmentGroupOfInvesteesNameMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail) - USD ($) $ in Thousands Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Jun. 30, 2023 Mar. 31, 2023 Dec. 31, 2022 Schedule Of Equity Method Investments [Line Items] Â Â Â Â Â Â Total Assets $ 586,551 Â $ 596,369 Â Â Â Equity 190,701 $ 196,458 200,934 $ 216,635 $ 222,170 $ 229,101 Total Liabilities and Equity 586,551 Â 596,369 Â Â Â Investments in and advances to LLCs before amounts included in accrued expenses and other liabilities 14,328 Â 9,102 Â Â Â Equity Method Investment, Nonconsolidated Investee or Group of Investees Â Â Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Â Â Net property, including construction in progress 27,688 Â 28,488 Â Â Â Other assets [1] 4,679 Â 4,667 Â Â Â Total Assets 32,367 Â 33,155 Â Â Â Other liabilities [1] 2,272 Â 2,074 Â Â Â Mortgage notes payable, non-recourse to us 15,280 Â 21,206 Â Â Â Equity 14,815 Â 9,875 Â Â Â Total Liabilities and Equity 32,367 Â 33,155 Â Â Â Investments in and advances to LLCs before amounts included in accrued expenses and other liabilities 14,328 Â 9,102 Â Â Â Amounts included in accrued expenses and other liabilities (1,751) Â (1,729) Â Â Â Equity Method Investment, Nonconsolidated Investee or Group of Investees Â Â Â Â Â Â Schedule Of Equity Method Investments [Line Items] Â Â Â Â Â Â Our share of equity in LLCs, net $ 12,577 Â $ 7,373 Â Â Â [1] Other assets and other liabilities as of June 30, 2024 and December 31, 2023 include approximately $650,000 and $651,000, respectively, of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS. X - DefinitionEquity method investment summarized financial information assets property plant and equipment net. + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEquity Method Investment Summarized Financial Information Mortgage Notes Payable + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity method investment summarized financial information other assets. + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEquity Method Investment Summarized Financial Information Other Liabilities + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X -

DefinitionEquity method investments accrued expenses and other liabilities. + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentsAccruedExpensesAndOtherLiabilities Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in security owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic

10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_EquityMethodInvestmentGroupOfInvesteesNameMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Schedule Of Equity Method Investments [Line Items] Â Â Right-of-use land assets $ 10,932,000 $ 10,946,000 Right-of-use land liabilities 10,932,000 10,946,000 Limited Liability Companies Â Â Schedule Of Equity Method Investments [Line Items] Â Â Right-of-use land assets 650,000 651,000 Right-of-use land liabilities $ 650,000 $ 651,000 X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_LimitedLiabilityCompanyOrLimitedPartnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) - Equity Method Investments - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Schedule Of Equity Method Investments [Line Items] Â Â Mortgage Loan Balance [1] $ 15,280 $ 21,206 Grayson Properties II LP Â Â Schedule Of Equity Method Investments [Line Items] Â Â Mortgage Loan Balance [1],[2] $ 6,966 12,753 Maturity Date [2] 2026-03 Â Brunswick Associates Â Â Schedule Of Equity Method Investments [Line Items] Â Â Mortgage Loan Balance [1] $ 8,314 $ 8,453 Maturity Date 2030-12 Â [1] All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. [2] This construction loan required interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022. On January 1, 2023, monthly principal and interest payments on this loan commenced. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro-rate equity contributions from the partners, as discussed above. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated. X - DefinitionDebt instrument, maturity, month and year. + ReferencesNo definition available. + Details Name: uht_DebtInstrumentMaturityMonthAndYear Namespace Prefix: uht_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionEquity Method Investment Summarized Financial Information Mortgage Notes Payable + ReferencesNo definition available. + Details Name: uht_EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_GraysonPropertiesTwoLPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uht_BrunswickAssociatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Recent Accounting Pronouncements - Additional Information (Details) Jun. 30, 2024 ASU 2022-06 Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true ASU 2023-07 Â New Accounting Pronouncements or Change in Accounting Principle [Line Items] Â Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true X - DefinitionIndicates (true false) whether accounting standards update was adopted. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10

-Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -SubTopic 10 -Topic 326 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -SubTopic 10 -Topic 326 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -SubTopic 10 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4 + Details Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: instant X - DefinitionIndicates (true false) whether effect from applying amendment to accounting standards is immaterial. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -SubTopic 20 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3 + Details Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 43: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 44: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 45: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 46: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 47: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 48: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 50: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 51: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5Reference 52: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 53: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 54: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 55: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 56:

http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 57: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 58: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 59: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 60: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 61: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 62: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 63: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 64: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15Reference 65: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 66: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 67: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 68: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 69: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 70: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 71: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 72: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 73: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 74: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6Reference 75: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 76: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 77: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 78: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 79: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 80: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 81: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 82: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 83: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 84: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 85: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 86: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 87: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 88: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 89: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 90: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 91: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 92: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3 + Details Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=uht_AccountingStandardsUpdate202206Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=uht_AccountingStandardsUpdate202307Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Lease Accounting - Additional Information (Detail) 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Dec. 31, 2022 USD ($) Jun. 30, 2024 USD ($) Land Lease Jun. 30, 2023 USD ($) Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Mar. 31, 2022 USD ($) Dec. 31, 2021 USD ($) Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Lessee in connection with ground leases for land | Land Â Â Â 15 Â Â Â Â Â Right-of-use land assets $ 10,932,000 Â Â $ 10,932,000 Â Â $ 10,946,000 Â Â Ground lease liabilities 10,932,000 Â Â 10,932,000 Â Â 10,946,000 Â Â Specialty Hospital In Chicago, Illinois | Chicago, Illinois Â Â Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Lease Demolition Cost Â Â Â Â Â Â Â 1,500,000 Â Â Other operating expenses demolition costs Â Â $ 332,000 Â $ 1,100,000 Â Â Â Â Aiken Regional Medical Center and Canyon Creek Behavioral Health Â Â Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Monthly lease rent receivable 5,900,000 Â Â 5,900,000 Â Â Â $ 5,900,000 Â Lease payments expected 1,400,000 $ 1,400,000 Â Â Â Â Â Â Â Aiken Regional Medical Center and Canyon Creek Behavioral Health | Forecast Â Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Lease payments expected Â Â Â Â Â Â $ 5,400,000 Â Â Â Aiken Regional Medical Center Â Â Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Â Monthly lease rent receivable 4,100,000 Â Â 4,100,000 Â Â Â 4,100,000 Â Canyon Creek Behavioral Health Â Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Monthly lease rent receivable 1,800,000 Â Â 1,800,000 Â Â Â $ 1,800,000 Â Universal Health Services, Inc Â Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Financing receivable 83,000,000 Â Â 83,000,000 Â Â 83,300,000 Â Â Universal Health Services, Inc | Wellington Regional Medical Center | Palm Beach, Florida Â Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Â Monthly lease rent receivable Â Â Â Â Â Â Â Â $ 6,600,000 Universal Health Services, Inc | Subsidiary Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Financing receivable $ 83,000,000 Â Â $ 83,000,000 Â Â $ 83,300,000 Â Â Financing Arrangements Â Â Â Â Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Â Â Â Â Number of lease property | Lease Â Â Â 2 Â Â Â Â Â X - DefinitionFinancing receivable. + ReferencesNo definition available. + Details Name: uht_FinancingReceivable Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLease demolition cost. + ReferencesNo definition available. + Details Name: uht_LeaseDemolitionCost Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLeases Disclosure [Line Items] + ReferencesNo definition available. + Details Name: uht_LeasesDisclosureLineItems Namespace Prefix: uht_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMonthly lease rent receivable. + ReferencesNo definition available. + Details Name: uht_MonthlyLeaseRentReceivable Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of ground leases for land. + ReferencesNo definition available. + Details Name: uht_NumberOfGroundLeasesForLand Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of lease property. + ReferencesNo definition available. + Details Name: uht_NumberOfLeaseProperty Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionOperating lease payments expected. + ReferencesNo definition available. + Details Name: uht_OperatingLeasePaymentsExpected Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther operating expenses demolition costs. + ReferencesNo definition available. + Details Name: uht_OtherOperatingExpensesDemolitionCosts Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_MajorPropertyClassAxis=uht_SpecialtyHospitalInChicagoIllinoisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_ChicagoIllinoisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uht_AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uht_AikenRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uht_CanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uht_WellingtonRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uht_PalmBeachFloridaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uht_FinancingArrangementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Universal Health Services, Inc Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Lease revenue [1] $ 8,454 $ 8,236 $ 17,118 $ 16,023 Universal Health Services, Inc | Base Rents Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Lease revenue 6,888 6,506 13,860 12,780 Universal Health Services, Inc | Bonus Rents Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Lease revenue [2] 758 730 1,541 1,494 Universal Health Services, Inc | Tenant Reimbursements Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Lease revenue 808 1,000 1,717 1,749 Non-Related Parties Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Lease revenue 14,359 13,668 28,846 27,029 Non-Related Parties | Base Rents Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Lease revenue 10,872 10,480 22,044 20,714 Non-Related Parties | Tenant Reimbursements Â Â Â Â Leases Disclosure [Line Items] Â Â Â Â Lease revenue $ 3,487 $ 3,188 $ 6,802 $ 6,315 [1] Includes bonus rental on McAllen Medical Center, a UHS acute care hospital facility of $758 and $730 for the three-month periods ended June 30, 2024 and 2023, respectively, and $1,541 and $1,495 for the six-month periods ended June 30, 2024 and 2023, respectively. [2] Consists of bonus rental earned in connection with McAllen Medical Center. X - DefinitionLeases Disclosure [Line Items] + ReferencesNo definition available. + Details Name: uht_LeasesDisclosureLineItems Namespace Prefix: uht_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479016/842-30-45-3 + Details Name: us-gaap_OperatingLeaseLeaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uht_UniversalHealthServicesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=uht_BaseRentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=uht_BonusRentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=uht_TenantReimbursementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt and Financial Instruments - Additional Information (Detail) 1 Months Ended 3 Months Ended 6 Months Ended Apr. 10, 2024 USD ($) May 15, 2023 USD ($) Jul. 02, 2021 USD ($) Mar. 27, 2018 USD ($) Option Dec. 31, 2023 USD ($) Derivative Mar. 31, 2020 USD ($) Derivative Jan. 31, 2020 USD ($) Derivative Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Mar. 31, 2023 USD ($) Sep. 30, 2019 USD ($) Derivative Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Net borrowings on the line of credit Â Â Â Â Â Â Â Â Â Â Â $ 16,300,000 $ 13,300,000 Credit facility, Interest Rate Terms Â Â Â Â Â Â Â Â Â Â Â Borrowings under the Credit Agreement will bear interest at a rate equal to, at our option, at adjusted term SOFR for either one, three, or six months or the Base Rate, plus in either case, a specified margin depending on our total leverage ratio, as determined by the formula set forth in the Credit Agreement. The applicable margin after the first amendment ranges from 1.10% to 1.35% for adjusted term SOFR loans and 0.10% to 0.35% for Base Rate loans. Â Outstanding borrowings under revolving credit agreement Â Â Â Â $ 326,600,000 Â Â $ 342,900,000 Â Â Â $ 342,900,000 Â Letters Of Credit Outstanding Amount Â Â Â Â

3,100,000 Â Â Â Â Â Â Â Â Available borrowing capacity Â Â Â Â 45,300,000 Â Â 32,100,000 Â Â Â 32,100,000 Â Compensating Balance Amount Â Â Â Â Â Â Â Â 0 Â Â Â 0 Â Interest Rate Swap Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Notional amount Â Â Â Â $ 25,000,000 Â Â Â Â Â Â Â Â Derivative interest rate cap, payment received or accrued from counterparties Â Â Â Â Â Â Â 1,600,000 Â $ 1,400,000 Â 3,300,000 2,600,000 Interest Rate Swap | Cash Flow Hedge Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of interest rate cap agreements | Derivative Â Â Â Â 1 Â Â Â Â Â Â Â Â Derivative instruments, fixed rate Â Â Â Â 3.9495% Â Â Â Â Â Â Â Â Â Â Expiration date of interest rate Â Â Â Â Dec. 01, 2027 Â Â Â Â Â Â Â Â Interest Rate Swap Agreement One | Cash Flow Hedge Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of interest rate cap agreements | Derivative Â Â Â Â 1 Â Â Â Â Â Â Â Â Derivative instruments, fixed rate Â Â Â Â 0.565% Â Â Â Â Â Â Â Â Notional amount Â Â Â Â $ 55,000,000 Â Â Â Â Â Â Â Â Expiration date of interest rate Â Â Â Â Mar. 25, 2027 Â Â Â Â Â Â Â Â Interest Rate Swap Agreement Two | Cash Flow Hedge Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of interest rate cap agreements | Derivative Â Â Â Â Â 1 Â Â Â Â Â Â Derivative instruments, fixed rate Â Â Â Â Â 1.4975% Â Â Â Â Â Â Notional amount Â Â Â Â Â $ 35,000,000 Â Â Â Â Â Â Expiration date of interest rate Â Â Â Â Â Â Sep. 16, 2024 Â Â Â Â Â Â Interest Rate Swap Agreement Three | Cash Flow Hedge Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of interest rate cap agreements | Derivative Â Â Â Â Â Â Â Â Â 1 Â Â Derivative instruments, fixed rate Â Â Â Â Â Â Â Â Â Â Â Â 1.144% Â Â Notional amount Â Â Â Â Â Â Â Â Â Â Â Â $ 50,000,000 Â Â Expiration date of interest rate Â Â Â Â Â Â Â Â Â Â Â Â Sep. 16, 2024 Â Â Level 2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Mortgage debt Â Â Â Â $ 33,100,000 Â Â 20,100,000 Â Â Â 20,100,000 Â Mortgage loan fair value Â Â Â Â $ 31,200,000 Â Â 18,400,000 Â Â Â 18,400,000 Â Level 2 | Interest Rate Swap Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liability derivatives, fair value Â Â Â Â Â Â Â Â 6,400,000 Â Â Â 6,400,000 Â Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Repayment of mortgage loan $ 12,200,000 Â Â Â Â Â Â Â Â Â Â Â Â Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Margin points added to the reference rate Â 0.10% Â Â Â Â Â Â Â Â Â Â Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap | Cash Flow Hedge Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative instruments, fixed rate Â Â Â Â 3.9495% Â Â Â Â Â Â Â Â Â Â Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Agreement One | Cash Flow Hedge Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative instruments, fixed rate Â 0.505% Â Â Â Â Â Â Â Â Â Â Â Â Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Agreement Two | Cash Flow Hedge Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative instruments, fixed rate Â 1.41% Â Â Â Â Â Â Â Â Â Â Notional amount Â $ 35,000,000 Â Â Â Â Â Â Â Â Â Â Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Interest Rate Swap Agreement Three | Cash Flow Hedge Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Derivative instruments, fixed rate Â 1.065% Â Â Â Â Â Â Â Â Â Â Notional amount Â $ 50,000,000 Â Â Â Â Â Â Â Â Â Â Credit Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Outstanding borrowing Â Â $ 350,000,000 $ 375,000,000 Â Â Â 375,000,000 Â Â Â 375,000,000 Â Net borrowings on the line of credit Â Â 350,000,000 $ 50,000,000 Â Â Â Â Â Â Â Â Unsecured revolving amended credit agreement terminated date Â Â Â Jul. 02, 2025 Â Â Â Â Â Â Â Â Â Â Increase in borrowing capacity Â Â $ 375,000,000 Â Â Â Â Â Â Â Â Number of additional six month extension options | Option Â Â Â 2 Â Â Â Â Â Â Â Â Aggregate borrowings under Credit Agreement Â Â Â Â Â Â Â 25,200,000 $ 14,800,000 Â Â 47,000,000 34,500,000 Aggregate repayments Â Â Â Â Â Â Â Â $ 15,900,000 $ 11,800,000 Â Â $ 30,700,000 $ 21,200,000 Credit Agreement | Swingline/Short-Term Loans Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Outstanding borrowing Â Â Â $ 30,000,000 Â Â Â Â Â Â Â Â Credit Agreement | Letters of Credit Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Outstanding borrowing Â Â Â $ 40,000,000 Â Â Â Â Â Â Â Â Revolving A Facility | Minimum Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Facility fee payable on commitment Â Â Â 0.15% Â Â Â Â Â Â Â Â Revolving A Facility | Minimum | Base Rate Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Margin points added to the reference rate Â Â Â 0.10% Â Â Â Â Â Â Â Â Revolving A Facility | Minimum | Federal Funds Effective Rate Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Margin points added to the base rate Â Â Â 0.50% Â Â Â Â Â Â Â Â Revolving A Facility | Minimum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Margin points added to the reference rate Â Â Â 1.10% Â Â Â Â Â Â Â Â Margin points added to the base rate Â Â Â 1.00% Â Â Â Â Â Â Â Â Revolving A Facility | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Facility fee payable on commitment Â Â Â 0.35% Â Â Â Â Â Â Â Â Revolving A Facility | Maximum | Base Rate Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Margin points added to the reference rate Â Â Â 0.35% Â Â Â Â Â Â Â Â Revolving A Facility | Maximum | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Margin points added to the reference rate Â Â Â 1.35% Â Â Â Â Â Â Â Â Revolving B Facility | Base Rate Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Margin points added to the reference rate Â Â Â Â Â Â Â Â Â Â Â Â 0.20% Â Revolving B Facility | Federal Funds Effective Rate Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Facility fee payable on commitment Â Â Â Â Â Â Â Â Â Â 0.20% Â Revolving B Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Margin points added to the reference rate Â Â Â Â Â Â Â Â Â Â Â Â 1.20% Â X - DefinitionDerivative interest rate cap payment received or accrued from counter parties. + ReferencesNo definition available. + Details Name: uht_DerivativeInterestRateCapPaymentReceivedOrAccruedFromCounterParties Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine of credit facility expiration year and month. + ReferencesNo definition available. + Details Name: uht_LineOfCreditFacilityExpirationYearAndMonth Namespace Prefix: uht_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionLine of credit increase in borrowing capacity. + ReferencesNo definition available. + Details Name: uht_LineOfCreditIncreaseInBorrowingCapacity Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMargin on base rate. + ReferencesNo definition available. + Details Name: uht_MarginOnBaseRate Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMortgage debt. + ReferencesNo definition available. + Details Name: uht_MortgageDebt Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet proceeds from lines of credit. + ReferencesNo definition available. + Details Name: uht_NetProceedsFromLinesOfCredit Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of extension options. + ReferencesNo definition available. + Details Name: uht_NumberOfExtensionOptions Namespace Prefix: uht_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CompensatingBalanceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDescription of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (a),(c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFixed interest rate related to the interest rate derivative. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeFixedInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDate derivative contract ends, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column D)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column F)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column D)) -

Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B + Details Name: us-gaap_DerivativeMaturityDates Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionThe number of derivative instruments of a particular group held by the entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column C)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5AReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNumberOfInstrumentsHeld Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. + ReferencesNo definition available. + Details Name: us-gaap_LongTermDebtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=uht_InterestRateSwapAgreementOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=uht_InterestRateSwapAgreementTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=uht_InterestRateSwapAgreementThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RecourseStatusAxis=uht_SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=uht_RevolvingCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=uht_RevolvingAFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_BaseRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=uht_FederalFundsEffectiveRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=uht_RevolvingBFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â  Â  Covenant, Tangible net worth $ 125,000 Â  Tangible net worth $ 182,508 $ 191,824 Total leverage 44.00% 44.50% Secured leverage 2.50% 4.10% Unencumbered leverage 45.30% 44.20% Fixed charge coverage 3.20% 3.10% Maximum Â  Â  Debt Instrument [Line Items] Â  Â  Covenant, Total leverage 60.00% Â  Covenant, Secured leverage 30.00% Â  Covenant, Unencumbered leverage 60.00% Â  Minimum Â  Â  Debt Instrument [Line Items] Â  Â  Covenant, Fixed charge coverage 1.50% Â  X - DefinitionDebt instrument covenant compliance secured leverage ratio. + ReferencesNo definition available. + Details Name: uht_DebtInstrumentCovenantComplianceSecuredLeverageRatio Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDebt instrument covenant fixed charge coverage ratio. + ReferencesNo definition available. + Details Name: uht_DebtInstrumentCovenantFixedChargeCoverageRatio Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt instrument covenant leverage ratio. + ReferencesNo definition available. + Details Name: uht_DebtInstrumentCovenantLeverageRatio Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDebt instrument covenant tangible net worth. + ReferencesNo definition available. + Details Name: uht_DebtInstrumentCovenantTangibleNetWorth Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDebt instrument covenant unencumbered leverage ratio. + ReferencesNo definition available. + Details Name: uht_DebtInstrumentCovenantUnencumberedLeverageRatio Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFixed charge coverage ratio. + ReferencesNo definition available. + Details Name: uht_FixedChargeCoverageRatio Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLeverage ratio. + ReferencesNo definition available. + Details Name: uht_LeverageRatio Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionSecured leverage ratio. + ReferencesNo definition available. + Details Name: uht_SecuredLeverageRatio Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionTangible net worth. + ReferencesNo definition available. + Details Name: uht_TangibleNetWorth Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUnencumbered leverage ratio. + ReferencesNo definition available. + Details Name: uht_UnencumberedLeverageRatio Namespace Prefix: uht_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Total mortgages notes payable, non-recourse to us, net $ 19,970 $ 32,863 Nonrecourse Â Â Debt Instrument [Line Items] Â Â Outstanding Balance [1] 20,144 Â Less net financing fees [1] (174) Â Total mortgages notes payable, non-recourse to us, net [1] 19,970 Â Tuscan Professional Building Fixed Rate Mortgage Loan | Nonrecourse Â Â Debt Instrument [Line Items] Â Â Outstanding Balance [1],[2] $ 717 Â Interest Rate [2] 5.56% Â Maturity Date [2] 2025-06 Â Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan | Nonrecourse Â Â Debt Instrument [Line Items] Â Â Outstanding Balance [1] $ 7,789 Â Interest Rate 3.95% Â Maturity Date 2030-01 Â Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan | Nonrecourse Â Â Debt Instrument [Line Items] Â Â Outstanding Balance [1] $ 11,638 Â Interest Rate 4.42% Â Maturity Date 2033-09 Â [1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. [2] This loan is scheduled to mature within the next twelve months, at which time we will either refinance pursuant to a new mortgage loan or repay the mortgage balance in full utilizing borrowings under our Credit Agreement. X - DefinitionDebt instrument, maturity, month and year. + ReferencesNo definition available. + Details Name: uht_DebtInstrumentMaturityMonthAndYear Namespace Prefix: uht_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionFinancing fees net. + ReferencesNo definition available. + Details Name: uht_FinancingFeesNet Namespace Prefix: uht_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and many other borrowings secured by assets of the borrower. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_SecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_RecourseStatusAxis=us-gaap_NonrecourseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateLoanTypeAxis=uht_TuscanyProfessionalBuildingFixedRateMortgageLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateLoanTypeAxis=uht_PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateLoanTypeAxis=uht_RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Reporting - Additional Information (Detail) 6 Months Ended Jun. 30, 2024 Segment Segment Reporting [Abstract] Â Number of reportable segments 1 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

U=$U,J[<2_FGN?FXOIYA@X@7/-?&1 ;_/? 5+PIC"7#\U1N='=YI M%(^OGZW_U#H/SMQGB]]D\8=8Z]WU+)FA-=]D3:$_R\>?>>)0"S"7A6K_18^] M+)ZAO%%:EKTR("A%U?V??
>L7XDB!!!,*M%>@_U2!]0JL=;1#UKKU(=/9\]J6 MCZ@VTF#-7+1KTVJ#-Z(RVWBG:_A5@)Y>KF2UADWA:P172A9BG6FX>9\5695S M=&<,*W2.OMY]0& _?D!G2%3HRTXV*JO6ZFJA 8.QM,C[]
[WOWD(8AHXU%=^`]0\\!W72JK-3]05X?G"?'MRGK3TV8>\SSPKTH]+@-/18/7"E M(42UNG0YUED*W)9,NEVJ?9;SZQGDD^+U Y\M__TO$N&W+C=?R=B)T^S@-/-9
M7[YO1+$6U58AV$,DRGTM'WCK=_L@AT#0==.E&>PV_+P%$,[-[EX4M2\R%>-A M&84D8G\2V&B<+D(X.(B=^!$<_B\?KS+\Z9LBC9@UQP6*A>9 >T"VED* MCQ"OE7#QD]P5'FUJ6
MZ.O/=RZTB04C83A@([ N*1I/A&EZP)K^K^O:E@:7+RX74GO3"01B.O+!(49C M/%46"!XX#7O=.(8-!;P0I3 UHA#9O2B$?H(25^ZS2G"%WLQN;E9]H.3R;"% MCP2,CHN;0RPEF$XX<43,Q$M-
O^D=K]${I?@$'_7ZKT1(KV7MU-N!AXF7\9:K M3.TZ]C$7_*\&@JN8RN?>UDG@A'$\WA=;*J%D:E\&\B1^]KSAT#6V4&6[0T,F M*&]:]V:/X42)5<)=4B29*)=D8$KBI\H.]%$!.N_0.X':'!BG.!P#M:7 FV@" MZ,"3Q$^4'RN=55MA(&9MZ*,W%10EN8&&?V#[K)2U%G^W;&]^.R/D(H#VN"C: MT0#VYHS0B_#YR1P\5WO>3@S%DSO7;>Y,2#HNN@ZIE)"IW1D(EO@9MAV>SN7F MO(%-
*@S\SOR=CJ,#<1-_<1] _=Z N.1I%>")MZ<#0U,N)RT]0A+,9EO?1O\^>3.B; M9*C.(15D4T,Z:XF:Z>COWW 2UFEJ-=$.,>A#(C;AP="TZV==F*#]!O)85)K# M?KHAVC1*VMG]%*$M%:13*SQP+?
5S[3,^_FUO#BG445DIAKQPHK9YE& 2C%G, M)<;"R= 8^);Z^?8_M6P :M'2[A'4Z4"PZ=15T=UB4Q6=#K1+_;3[A4-CKU&? MTP 3YFFI1- VKY_KO;F!Q-]G8@VR$]T9M4F2X"0>-
_\N,8+9E"L#F5(_F785 M_>:%\+"9D:5A$EJ]YY0+V,1,2 <*I;&WK/\(':Y^ #(;J?L\KOA&Y@&UZ+CQS=':!"930&D'?W_"W9)QCC,W? MLV+6Z)VLQ=]_=946(Z$4D?D[+1,+!6YE##+N:)>C.XU0,
[%_/\-G:[CT 90 M_V2^DF4)K6VW%O9JI=[EI<3WMP M)]:9WPM"IR>70X?_!W"*ML+W08.D$+.51M0AX5P'E':]$]C'*;CTNJ68^D4 MY*%-8/XV8=6-+3![F.(/R'-9NI':+)^P*&+CP=8E1R,N^#O!.?
@]Q3&VX-ER%$._,'%TQH9& M@+W0"(S9LZT:'L"A=;3OG(]<6%9X>&P'X?2.A.>]OS >SPP2Y7\!4$L#!!0 ( M (F**%9-G-X:Y>.@, /(* 8 >&PO=V]R:W-H5UTSL4UL MK9;;;MLX$(9?A= 6BQ9(K9./65M
XZ!H%RA@U&A[L=@+6AI;!G22U)VVJ?? M(:6H4BH? B07,2G-_/S^X4CB_"C5=YT#&/)0<*$77F[,_M;W=9I#0?5 [D'@ MG:U4!34X53M?[Q70S"45W(^"8.P7E
DOF;MK*Y7,96DX$[!21)=%0=6/.^#R MN/!"[_'"9[;+C;W@)_,]W<$:S)?]2N',;U0R5H#03 JB8+OPWH6WR] EN(BO M#(ZZ-2;6RD;*[W;R,5MX@24"#JFQ$A1_#K
$SJT2H#8VL7BJY=O_)L8J=8!::B.+.AD) M"B:J7_I0%Z*5$ Y)1U0G1M0EPGQ,YH1>9LW5-#D[F21Z)L-*K9@:N-RT8W M3-AM7!N%=QGFF60I18:; AG!D9:
<9=3@Y(YR*E(@:RNLR>L552!,#H:EE+\A M;\F7]3UY_>H-><468()\8Y[@G>NX;1++"?EHO?U08GKHTN-%*:H1-=6(G%Y\0F]MT#TVJ2V8R2]XS@35@E).5U,PU MW3_O-MHH;+U_^ZQ6VL-
^;?L\WNH]36'AX0.G01W 2_[\(QP'?_49?R&Q3AGB M!@SQ.??DHS!4[-B& Z%:8P/XNX>VOYZ@:#!]@CK)9[A:\ 4 H1=8X-J^TN;D# EKEM9,( 7C4W M9$\5.5!>0AJ^M<:D118,@O
)_H6@#OZHP1^]#'Y]FY8FEXK]A*S/1K76]$4X M"MS?$R>7XSIFQHV9\--23EZ'&+Z+&AR1C8M>' M/KF(?BZB@SYMT*=GT9>R*/ 557%?:/'I-2U^(:@#.6L@9\^'!O*J19[]5:M;? MR5<$=J##X-
='G@.]NF6K77:#&$\'4X1Y EJ7V043V>S$[2M3WKX'+H+K5J+ M78/<&]F'[+<.)/8T^(FJ'1..:<-AB:C"H8(]#EC5Q,B].Z-LI,$3CQOF'>@% M90/P_E9*\SBQQ[FF)O\^U!+ P04 "
")@@A9=E\+;ZGJPK.N'#Z-1-5_FZZQZ7S[D&_6?NW*[SFKU<7L_ MJAZV>;;;85UJO1MSWX]$Z*S:#FZO]=Y^W-U?EKEX5F_SSUJMVZW6V_?-COBJ? MK@=L\/.++\7]LFZ^&-U?WWXO%6?1D?
*HECGFZHH-]XVO[L>_;H^ MR&C<5-B7^$^1/U4G[[WF4+Z5Y??PZ%O9Q5^[_>TZ&L/ #FNZHNUX?*]@7K8O/\FOTX=_,1)!1:A0(3(KG+,0'RK$1H4P/E-A?*BP] _[HN??WKIEE M=79SM2V?
O&U36M&:-WO_[FLKCQ2);A1OZZWZ;Z'JU3?3L?'2/W9% ;SKPWO[SU?FF^_7U9 M[JJILLZBN1K5J5(,>S0\-^/C< 'ZF ;^7=;8BJDW=U:;E>JTB6??/ #M1>W:A M=O90*+--T_,?\
[S:'^5#MO4>L]4N)WCI!=YNO5MES:#R-FKZ*#;SKLJK>ZOB1BIYC M"/%C"/&]O?",O8_9*MO,,)]= MC1Y/?6\78\%$+S,C4'$2CKE>++6+39@?QX9%81<;3N* 38QRDF@9]UE;2NO! MX-
B#09<>?.?=+K.M&F==>M));$Y@'ZJ';)Y?#Y3GJWS[F ]N_OXW%OO_H,;: M,RS2^]L/CiY'FDR1,(&$21!,BX3P& GAGAZ^+:%FJ4^; M.E??UA^H. B1<8*$S9"P% D32)@$P;1PB8[A$CDGCD]5M0,
F":7Z,CWZ,N_K1>Z,N2JK]-/"6\]D3U'>\Q _:\ MGQB3(M)>BH0))$R"8)KWQT?OCYW> Z+F]FTQ;Z[7]M>SP^;>:K& .E.7;-G^ MEBW_T;RGKBD_CBTG!N/8&.,:!O0=YAT,IDB#
@F3()CFZX\FMLMRL$3J[^'+)EPW_"QTW1?'R-A*1(FNO6&!-G4W)P< MW9PXK^*FQ/T6>?&6("=S)&R&A*5(F$#") BF10GS6^W%=TX'_W9I!1\/E;7+ MJ20P+^#<)OJZ'4I+.QV!@-
J4*)KNTA,YC3E=^G6SS;-5\3]U_FXNYNZS8G-0 M6CQU%I]GU=*[6RGH,E_G(,.0B8%BY.$&X&0$N4F+(]EL=G= M=KGA9!+XILHJB8+,3\;)F9YL-2SFU#PH.?-RCT)UK /-$#0Y-WL>*E%!:0)*
MDRB:'A&M3,7<.M7)V/HMVQZ%;3H2;!6)<\[&YNW.H=R%L47 XB1.)N;8LLM- M6,3,NPI!E!M.QH$?F;+*=2B@-(DBJ;[LY6)N1>F5J01N"S9L8CASZFY"WV'?Q60*-2F@-(FBZ1YO!2?N
M%IQ>EE+@A J2))&U#@FM>L;=ZMD+4@O5T+VVB$:V* MQ=TJUIF]!W0DV (3]_TD",VQ->DRM@C8V ^LQ )1;L)CW]Y_0"QK2GR>F PH M)5%P'+ SV4_>RD?<+1]=V()
=RA41^*$CJ2&EIE7@!I-H30!I4D43=^2TDI) M@0 .*P1(764*IE,ZC%%$H34)I$T?0H.-FD MZ):3ON0/N^U\V2042,\3RXZ8N6K1;:+WP.Y@,H6:%%":1-%TC[9J4N!6DTX\ M>G%
<0]=G!,9.,F3FN(:J1E":@-(DBJ9*02LO!6YYZ94YPX"2FLQ%K.XF]![W M'4RF4),"2I,HFN[Q5I$*W(K4RW*& 2'_<)]9*]/=QGO[&KJ.#$H3'7M$HJSJ M[FYEL\"J0JQSUC" :F50V@Q*2Z$T
:5)%$V/EE92"]R2FCMK&-CR$_,C*VWH MMM';]]#=B-T.04"-2A1-=VHK[P5N>>_U>&D[&947(WH[??H5H?E":@ M-'FI=_6'B;0:7NA>#O:"S&%HK\=*QKZ9?W+;[>MG*"TECH :WU"CDC#J<&"K
MIH5N->U,[C D/6?+T"SQQ];#E0[EW/D- L95&"3FW351;A+$L;ER5Q#EA@D/ MF"G#2=Q:'(;G.K*5L,).#ZDZESJD.Q2J986VEJ6Z/32?MP$UFD)I DJ3*)H> M:$:V<%?;>[W>Z@X:.!&*G7!*'D;DT-
NRRWX^ J:$51J$YM(C]?@$+K-0A46Z8 M),Z8N4A)%!Q')_M-]8X\>6256T6ZL"6)[E"HG!3:B0.W:3>,X"]3LL^'4 5)2A-0&D21=.C MH%640K>B="%Q&%)=/#)%9;>)WN.Z@\D4:E)
:1)%TSW:RDFA6T[JD3ATDWJ/ M:T(G,1.'4(LIE":@-(FBZ<\>;=6ZT_=;!C9D@EGYOG4ED)IHF./2)15W=VM:!:MAM&4*4, M2IM!:2F4)J TB:+T=(*:M%KMAM&MO@4<2MOZ#;1V_70[8:=CD!
;4H437=I M*^U%;FGO]6G#B%KIY((J $.E=P(FRX'MEI:]*)-AZ08'Q&;"=:G$(57.RFX0AC$(5'P?.(P:B6LZ%5[#N0.A6I9$;GGT$H<0HVF4)J TB2*]AP1 MHY,?SVI^?
>VW;'M?;"IOE=\IO/]^K#I^^_R#9L\?ZO)A_WM:W\JZ+M?[M\L\ M6^3;IH#Z_UU9UC_-#_1=?Q9N9O_ U!+ P04 " ")@@A9YAA+V+@" % M" & 'AL+W=O^K],<"JI[L@2!)VNI"FI05!M?EPIHYD
%]\,@ M./<+RH27C-S>0B4C61L:"P4T5514'4_2YW8Z_O[3>NV28W=L-/1B7=P!+, MCW*R4J);EHP5(#23@BA8C[W+_G >6WVG\)/!3A^LB8UD)>6-%;YE8R^P#@&'
MU%@&BKM3(%$2XN1NW#:<7FO2 @_7> 8O+G:,944Ü3"7_Q3*3C[V/'LE@32MN MKN7N*S3Q#"Q?*KEV7[)K= ./I)4VLFC Z$'!1/VG=TT>#@#(TPT(&T#X&! _ M 8@:0/1<"W$#B)]K8=
7.A^';M+W(P:FHR4W!%EM9'-+ESV'1KSQ82MDZ51 M>,H09Y*I%!G>.F0$5UIREE&#PM+@#\O\:"+79)I3L0%-F"#SVXJ9>_)N016> MYF!82OE[\H&\)C[1.>[JD6_0,4OOIXT3D]J)\
DG(G(ED4R3.3J>=!GI_'G M)_^)J3-2KC/RB0\2?B$CT2!6=[/;/CC4)4UA[&CC MTZ"VX"5O7O7/@\]=B7)LME+DLU?B.SHBN+VBN)3[,F,;1D^XTP3*C*2=:( MO)XMY?89GY$25/U
N^ZHIK]P]':T;).@=X'%LSW,?:=2>*PTJY4^'2CU>_%@ M<*PU[]2*'K3J+/@'?:T M7$#19-45L+4]=ONMC/KTK7J1_N3_G#:[]B?X8RK M1]#?3T@KZC:.*$)AS6:PCBQ[:IZZ-2"D:7KJBMIL$>
[98YS&I15P/.UE&8O M6 /MY$_^ E!+ P04 " ")@@A9V*U?.V,' !O( & 'AL+W=O=,\^U0O;^1!%Z+BGVJD#F7)ZJ=WO)"/MS,\>W[P66QWVCR8+V_V:,L?N/YC M_ZF&NWFO)1\;X\&8-5-
\)8L_1:YWM[-D MAG*^88="?Y:// /.H-#HRV2AFI_HL9,-9B@[*"W+;C$@*$75_F9?NXTX60!Z M[ M(MX",%RP<'VBW@#:&ML@:L^Z99LN;6CZBVDB#-G/1[$VS&J]P1E7'C@ZJA
MKP+6Z>5*5CDXA><(KI0L1,XTW#QH^ 7>T@K)#5HQM4/OP>,*7:$ '.'N[1#] ] MB+Y#HD* [^1!L2I7-W,-(:S.>=:]^5W[9N)X*?1O0)"?KY^#%;TI MY-F4=\2K\#^'ZBVBP1M$ K*PX%F]?
#GUP*']SM)&'W7MK-FT3;-IFUJ6"#*O M9EI4VS9TA19<7=NVK56[L*LU:7VM]BSCMS/(6\7K(Y\MO_\7CH*?;#9?2-G9 M#BSZ'5CXM"] A2HDJDR6W&9FNS9JUIIBO.>@-
!.LK;I5CE@I:RW^USRP6=ZJ"T\=2R,;D!4'ESOM80?[P4A)(&TZOMM5&63.TQA=1F3]K;D[[2G@VO M:W#*1E0,D@[R*)-*6^DCG<"A"1VYP"*S<,00#@9*#+R@'[3,OER9YB '="5T
M3*HU@\UU]9JUJD\1;+ 8[06(7I2\<[AGC X]A/-CE5;K@P=,Z4X%#63I85@ M:U&XZU.G]$*A#P MT= +8"_1+N^RK#Y .'41U+I(ZAVO3QUEA4VG@# -QK7()A;AQ(%[8'#LI_#?
M.:2I1IW/H%SF?"^5Z&*LSV9S X[=,Y&#;&7/Y^Y5YY:$\=@0BQ198(9W*DY?'=+%&-]4Z(JZ]GG@6.PG61/ ?3%$9A^M *>D>15' M$X06J2AP%'(\4"OV<^MO)EJ=?
(FG9(B#DWWIH$VE"$D<[1P>2!/[6?/7EW9J M5N13VB,TB2:%P2)&*"$.[ -!XO158X*H(,]>TF!B+ _.^NH!?2-OYY#90+O%3 M[H?&ZK8E!Q([^%E]169$NA5F*1DY"N;&+@TM?
N'*#$Q+O#0&@\,1FA:HWB7+ MFQ%![T2=7^U9K9^0^5GQVHX;6TH?&6>'_^W_KP\&$B5^$FTB,1=*UV)],/U. M%Y%.9TRI,DHF-DV%J-,1 YV2;!IZXB.\4T[V0&UXKSH0$VF1$O#P-$@D(%H
MB9]H[_)3*2L0) /,+YT]:#)#&?Q)1;.7% Z+F$VL21.7-X8N)7XN?6^ M[0E0,W,-R-MFU(KWHL,QL3 R=GIDH&3BI^2>5 ZJZ1NLE=EJG85_TR@:-SHV
ML21Q>F/@:1*_BE"&2>L;&;A$\ /]JKUQ(V_DN#"T!^79+T,)8UK /+E0E-:%^0 MD3)C: 9-J["GTI3F<41/HJFSSB)&J3/HAFZ ^.?ES]#/_7?77YQ40"WS*QY'KT7(]1F"GGSN]G/RI%[:"H\5LFW"
MC1(Z_GIBE<-&XAB^Z,"JU,_^]/QS* A,\1_GHFJO#/[&&#/9-A?\[X,XLL(U MW%+,V!I-*-@BAI.%*_T&!J9^!EZYH+Z!X-F*JC)>@$B"D4A(>^A/230A>-Q8 M6Z3B"#M&2SI0+?53K0<^-])O,"G-
!J&\9AL+5+I(G1P+1VXEOJ'N&PWQ?- M.1GD)K3.62'5H!)X!RJI@Z#ED_0F'*,V'A;\ MTVI".CF52H-)KDR%U+1'\;^P&DJ 0@7?@,K@;0R;6K>GV^V-EOOF@'@MM99E<[GC,.'6 M1@#^OI'0?
G0WY@7]_Q@L_P%02P,$% @ B8((60'W:Z] @ O < !D M !X;"]W;W)K&ULK55M3]LP$/XK5H8F)FTXKV7K MTDBTZ32F,54PML\FN386B9W93@O_?K:39J6$"C&^)+[S/<_C.UMW\8:+6UD
M*'17E4Q.G$*1>HRQS JHB#SA-3"]L^2B(DJ;8H5E+8#D%E25V'?=$:X(94X2 M6]]")#%O5$D9+ 223541<3^%DF\FCN=L'9=T52CCP$EDD#W%UOV;_8W'4N-T3"C)>_::Z*B?/103DL25.J2[[Y"ET^
MD>'+>"GM%VW:V'AR4-9(Q:L.K$]04=;^R5U7AQV ]Q3 [P#^/B!\ A!T@."Y M"F$'")^K$'4 FSIN<[>%2XDB22SX!@D3K=G,PE;?RG61*#/OY$H)O4LU3B4+
MA@_.H#'.N<^<7^;^-0_2/BM82R/T\5.G7)$M?DVS^2F0/[B3L[R0\Q)[\T$/BG&6\ G3\G4OY;N@> M6HJ1I3 C89U$_NDHQNO=^CX."L+]H/1QD.=&^U'SQU&GGX*H#VH3Q3OMJ *Q MLG-
HHPW3+5OLO?VH^;,=M@]_]0;S[P!?ZI'4SM)_M&W<^V"B!5E$I6PU%+N MR:GNEJ*=%:VA>&V;X0U7NK7:9:'"*P@3H/>7G*NM803Z@9W\!5!+ P04 M" ")@@A9A8=FKF<" "\!P &0
'AL+W=OR;FV$;%X %NVG_P G+ MIH2H?8FYG8_OQ B8;85\4A6 1B\UXVH>55HWUW&L\@IJK*Y$ ]S,%$+66)NN M+&/52,#$!=4L3I-D%->8\BB;N;&5S&:BU8QR6$FDVKK&\G4)3&SG42_:#ZQI
M66D[$&>S!I?P /I'LY*F%WL*H35P105'8YIMY.A=+Z=VO5OPD\)6';21S60C MQ)/MW)%YE%@A8)!K2\#F\PPWP)@%&8W?.V;DM[2!A^T]_=;E;G+98 4W@OVB M1%?S:!(A @5NF5Z+[5?
8Y3.TO%PPY7[1MEO;GT8H;Y46]2[8&-24=U_\LJO# M08#A' ](=P&I\^XVF MO 0D>I284%ZBA928EV#*KM4LUF8'NR[.=[1E1TM/T/KH7G!=*?2%$R# _QL?& MS.NE>
[UE&@1^:_D5ZB<7*$W208#7]^GV':]_@G45WG-!G2EK,CF7= M00?'H?;<7*L&YS"/S,%0()\ARCY^Z(V23P'E@5<>A.C9NF6 >LEF>-D[U$8+ M(AK]?
Y${W3"PP$Q!0&SHQ89!SG?!+]\A%X:>DQMYN=&[JO8(TIPB?,(MS#SG M-09NXW<7+NP7YI[SFWB_R5MJ9\XTH04%@FX9+H]IA7'GM*9>:WJN;.C-:F'D M2;7XX$:M09;NW5
H%RW7W>7J1_W3M.ANY+_+NW?M'LN2&ULE5=M M: .!\']'3#_+=VB?028>DBW%_?9_5O3AI M'=-^B>\D[>ZSS[.[IQROG?\:"N9(WTMCP\F@B+%Z,AZ'K.!2A9&KV&)GZ7RI
M(E[]:APJSRI/1J493R>31^-2:3LX/4YK%_[TV-71:,L7GD)=ELIOSMBX]5U?C*8"" VG$?D#!SQ>=LC#@"C&^MST$?4@RO/W?>7Z3< MD#R@G>J-O[_B-I\C\94S%=7IL7=K\G(:WN0AI9JL
4Y;$>4R>NQJ MV,73EVS9*W,\CG F2^.L-3QK#*>W&#ZB=[&(M!SFW-^TWX,$#V2:8?D;+K7 MX9O:CF@V&=)T,CWI?/G+H8: (>[ 4@[/0F5ROAD4$DL M?\6#TWMW#AY-GNY)[[!/[W"?]WW"
[37<#>O^P0-J/=+'0@=Z7RL?V9L-?>#* M^4@@2=J #B8/WQ,.8!Y0+)B^-0>)I0P((G(OXHA>6YS9X6U()^X\GDXG3]<\ M3$\'3[N5.OQSQ=6^6Q'=)&B[\)&C0;H]=#-@1$>?
+/K%VO#>R'R8(V"S(']ZOV-8<.BBYXT#61=(V,W7. MR: [)+4F[S7=@=#4)YMZ^/0\X3^M"9P6MF0IUQ70%8*X69_8ACD?O#/1<$?^K M-5+2%C X( ^O[$HVEMZ5-)O176'BYR.Z.Z)Y"GE#F6$3
!38*Y@WM8[@2W!- M7QS91U2:- MB%ZWR^?G[=92/BVDC($\^$"8=E($BE4_J7NTDVJ#H5B(4MS$>6PZ8;^'9BZ) MZD&>/",58>BZ.G"0:0XW^D J92" I,T<;"EYL?*=23WQ94T&-&NK_SXVE4-
L%?I0AHH,=#< MVOK5_LX[;ZYZV^/-A?F=\ACY@0PO83H9_70T(-]<0IN7Z*IT\5NXB&MD>BQ0 M8>SE /9E2'0O$]#_3^#T;U!+ P04 " ")@@A9E.*DLS07 "L2@ &0 M
'AL+W=OAM3XR['2WW],/&/H! 4:PV"+!QB.+\>OTRLZI0 $%1GIG8W=@76R*! MJKSSRZPLO=H4Y==]J76M'E997KT^6M;U^L79694L2JN1L5:Y_AF492KN,.O MY=U9M2YUG/)+J^QL.AY?
GJUBDQ^]><6??2[?O"]:.C.Y_ERJJEFMXG+[5F?% MYO71Y,A]\(NY6];TP=F;5^OX3M_J^M?UYQ*_G?E54K/2>66*7)5Z\?KH9O+B M[3D]SP_\W>A-%?RBJ)-Y47RE7SZFKX_&1)#.=%+3"C'^N]?
O=);10B#C#[OF MD=^27@Q_=JO_P+R#EWEI%W&3U+\7F1VXMm:#UDB*K M^%^UL<^.CU325'6QLB^#@I7)Y?_XPJN^E'%>Q2SMZM59#>IH MC[/$4O)6*)GNH>12?
2KR>EFI#WFJT^[!9^#*LS9UK+V=/KK@7YM\I&;C2$W' MT_-'UIMY4Z)/G]L]?]1_3Y.R?'T1/6I44\@Y\]_NIY.QR]!%/\T M>7F(-/4W#3>M7JC?M$J*%2)(@N<0QDK96YE<39Y?
7ZKY5JV:,EG&E@^BFYR3*-_R&*!$2^PTNZ5*'G<"L+S?,B;RI>4VV6!O2;2M;]HX$" M=0DASIG^9DVQFA2W;FI6&/B,:_X@)B&&7)-%3*Y>5HB4):]M5\-&]SIO-$F# MUL*7%=9-24?
N$9/S4LSK5L>E<.96%A8K<9D!@4;R#:V@'Q*]9D*M3KQTWF6D M[;=Z&=^;HFQ-_$>WR;&7A9@GJ6'+^C(DA-\+ Y[_2=U #;QAG*LF+ZWMUTM3 MIA C/.!$M-
GD";%)U,099'H'9F.HIV%V83(J>3,JBJDYM_L+7O'J1D\T58*(, M%4T*),:$GT6)T8I5WEPWFKB*7LS@JEX5O&2,D'G*G>\:0D*9JT[20O!*$]*FA-C=498;3V<1!18;[ 5:_=?
MW;PR#]^^]0BJ5'$JMN>"'JU$ AL0,1P(HH]A3 4&!KX])=L+8B>1:*J:/!9$ MKR2^G!6+!7*#FC<^_?P6 M>8ZCRP;QD31=PY@->P[%FTS3 FE3NMB^,&75!AG017)@@=#>6*]=+4[^:$S9 M?
5W\M?6Y.YJSU*>W/Q.F5+F'JR18(D_Q[O<'X^.B'#^\K1S/9KC;DJPBI M!=$, 7'(R"#-32X^WU3RM(@)-.@IK4D\M : Q8NWA??W97Z#C:TU_WPZ*D/ M1G9A$EQIR'NZAG@^.61_5E)A>K/>#/G
E$[9*)%%2U.DC]NF&JF?<_5>)WHU MAWQF$_Y>3=CJ.$?A54BJD! :5Q6J'PL%[&YQ1OQC\Q6G+ 9.-GHZH 2#65( MV%5&.(!,FH7*ZE\)>0>,9QK1OE4#R3F?
D3RK\WFQ%S!P1$ZK8:M6K[&MBTB. M>*N7!K0(Z(#A:U@5=,A<5DZP'_,>/D[;%UO$961;?F[6Q1NRPU>L0&:(^3M MMJKU2F5%P@H#[[_!80I4<1%>S0P"1V[BB.
(B2601FQ(U2OD54KV/,Z1A+/Q, M73T??:*$R3($B)=@"WS5FV(/9T&TK0G;+7192D!^G+<;\Q5PY!=]QQFPCTL< MF.2G'R,0L;XFTC$ -Y*6&D>^SPM/E2QT;09QDCL8= MHEB5T.7&
L7^"^>CB7N>MD[B:DEJY"AS U%2%@$$L=JVB*[UQD^%7F@16P6 M&COG#-3>%Y$82MW6!@19@E1-F9HH ..9MD[/JS-P)PB&9\LT1@%A0\ (1/_ ' MSX45$/E )/2CY@SGS?:G4H\8^[C>:8)T-
O@3[$+P@UES4Y_ M/6O-A7?@CV:M!74QQ T5#L5NY,:_PRI6QS&A-0A55[#Q;FA'$*K([=MBRB"] MHBAIX#-6#F#TBX*!$8@EOO"TFP0B'0GX.O!91X2DQ:IX6<.L7K2'WNY3I/S+(\;V0CBL# )DJ[-
=BJ;5G@G;-UV"BL1+=DSY)>I)*QJ:Y4,A$'CGYX M'CWWEGWJ8FH^NA1T+MV<)G792[%26HE( G@*YROLFZV8%5G!E] M@,2CQ4I'MJ.PH*8H(31:@SRFJNT3Q'SKZDX_C&AZ[$&YYZ9?E?
B&\J7W8KE MV;1->SLK?QL,9&$B;D)6>1'T(& I!%,!VF&+V!T%J=._1=2R7>5,=-=T]_HE ME[W,%>B\XR 2@,;!5H(HS <#*BBY0344D2?JF!'TF?Z3;"P=KS;5BV'?%2C& M@YS)&PYW;"+UFX; \[NZ>
0]R8*2X6C51U3BW3R@=%VJO3DF^':@%5BU+)J,(#E8 C:BM1$B:X!Z MM\V7LH$DBP3BB;"/Q[(MVJP-@J+$&C(H$HA9F#8?6I7:WR@3UF)&7):Y%FA' M@[*W*3GV2D0I%@MR!>E!F+IA_3E
<198*/;1#Y8=BHW$^S'^7Q6E/FFEVY1= M$][3A/%]=46CE=B&FF6JR5U0+#D$4]6S6Q+;!!MZ44%O>U9T"ER7MDW)UG?8 MZE@>DNJ1F!HZ":@+,8NG&Z/-^-
Q(*5B07D].=XM:ESNF90VOBDG))504N2\H M9KM6*I-()&L@-G%-NN(K*O-&<]+W]A4'Z M.UV[Z"'P50VW^7Q'00>X:??BY*864GT;?O6IP?ZUI8,]A7; .:ZB]NRC:HUR M3QN=DCOHF8S'ZE0"YV![-
VQ7!R4P+QHI[CG3I@1QVIX?M_36VN)>HMHG&,XN MX\A7@-T3@_#$:;>,&?>.3[AF"@FL2P,*5([ 2>N3D\2YKSI8Z8R#;2W!HB78 M#2DH@=XN2DI.JJ01QN[[UQA(&:]<
!H20BN:NR66.A\#YF.O=4'12)2?[;=7 M8V46 1H79,<>2^*;(=WY=[D@RX3R@04(CBV*8)M[11F3QLPY!%-QKLVXR9R&MLQU# M2I..4$Z\^JF%%?OHUNI!WARD
<$QK@>2I'V%'$$=TS;AGLCV)WL*J!U+$GEW M3X^ZG 7O#\.5?A1S92)'E^`D%R2%)Z"6Z=4_#UN^['#U!!#3C[H!;N'V[2'4 MTBD(^L!EB.$#K'X#R FR"Y,RD_5F%SN^?]'/^L$7V$8#@H+X*O>Z\
(/O)C%IH8A\U M8Q8!T:E&S955]I36GB9UTG]PONY<=-\)NTM+OD8(*OB])^S=4ZR=L\GV]/ZQ M4TK_U(OO_,GQ3Y3S;R2 ?1"+^D48^6[/F?PS=1&=7U]$8^3+3BZ[5!?( "?? M/:$"?
*8NH\O9\SUKS$^^>[34.[M12O"E/MMV^$"EYX8_J&\[2?EGTS=_2F%Z.2/">1>D;#C)9/2U#SLZ#Y2^OU2 K]/@0/].GPHU#?,UF M([8&VCH\$=T-=X_#V=*.MIH$8 A8S,Z+0CI<=0C=]!:
-K%-1EE, (W3]Q Y M5-030_S_1T#ZZ]K6>[O].OVP-F6\V\[%[T\(N>&A*[5I\?9"D$+\HO4#QEJ MKS1^0MWF6=]S0-L/,2XOZC0@6&K3"PMPN1BA(>&TR20+,J-ZJ.Z!XW] 9I)!+?
WO[];95STUZ9*CVE-E.9@Q:FX:>;4N@C4\[=C$8 M!\=/C1O']>'N\U"'"$[RB2IL =4)Z"EJ8!\R#!J?TQ:Q^~83EX&'6Y8B/CX> M&HBV@RD*.G@T"D<.M]K!#BDF_+&!#!'.E';:?.X\RN+
[CXN0*W)98KS[-EYQ M18$G43#BHV1ND (8T#(Y]BP(YK,P1(P@?&Y"%*4;A"HJ';:8H.$\@H:Y# _B MW6#PC-%D&+#HU!!OWP-
8M(8*Z"A!PG'@#A9("9T]\N/\>$W:JA$Z[2R9\MT!&O;,7'I3I>US^=VMM,*$<*FK:A7UBV. M@\.;]P=FL-@^_!$AGS!8$/V^2& 2?ZG\.0DT2'->05BVC]II"ALEO4ZXJS@T M2''5QJE(M4-
LX0EZ4E2U&Q!V8VO+G:.XJ^?1!1 J2X?D7!%S,%UMFTBV1_9] MYY2*A>J8=(@7VO[;Z//A=&(K+>Y5G5*OJG/.;JP#M8?>JMJ7*&Z:.ZI"[?'W MA1KMH6FTV[_8:55P0A+7)4A I9=&J46>
+]LDY:5J&NJV6CO9YZ'CGHOD::H M"NA8TN P8-3.'O+8QR-SA?CZ5AE=HB)R.?]S%O\):[^Q:'2 M*R+UD[Z/*?EW:.LNPZ=>73/>0;=CV*2T==$:M5R9^((Q^^ZDH*4+F=DMUVZ7:
MN\; ].70F)0[OA;KLJU6/_U\R/C"*;O!AJT]"[B!YV5N:D"Y>>+*9US+.# 5 M"RNUQQ9]U<,HVVFG_G?M:(L_6MSPF3K'IG2H)\#!?GL\^#/\4(='Y^;) B*YT],2%\NQ[
M)_O!6!7HA3HL;=M[A1]6S4]\DZ>*)NT$D?5?;+#,J*M'N>04QA2K:DE+VU6I M+4\(V$INJO&CI5030"CJ=PUC%W1&O9?-Y!#PVJI=>UPKI?D$UQ?D'X3!Q^7 M5-M6E@_+*VDP#4PN M"QTRG,
(S*4&=<6W'7O* K;K66C8;8TR4K>:HC >NQ)\T79SK.W(8" 1T;9W M4&GSS'LI[<4/B)7%5M/-*!H/+/QWW$?/E';?2^/X0$?)#&1 R<33T#@AC_>G M5/D
XI'ZTG8'096>@A1X;;NF7))M'01T.JKJ(OEZ*LY%X1[>*E@UWL1EZ@_> MZ7JJ@$ND'I/( !3>Y'#+YQ94=9D2)1LE8[Y?1K*5QR:=I:<4_NPX$K'J<4. MG+P+=\8O*U/7;8?F;0%2Z!?NJ>_RMXJWTF-
WO,%73KEG[RG[=LY<0<(#M5Q< M4E2Y2>]-54!--RZ8OY!3^^6HQ6UNYB7=V.$=FWV@&BPTF8+RIR?\F^;&L< MJG]+-FU'29M6]HP(66]H9P"E_< #;#Z'ADV#R?,AZ@.>'2.[!V:[ST;AYPQ+
MYIFYA08(D.38AM-X>UH7IRE9\()];+(Q!(LZO' YUP#[ M2#-V";*W%<%Z!Z?NV\DMYR%D7_;&FK] D;9#):%Z/\(FUF088,^)WBH8[HT(
M34Y"P8]4X)D24WR*ULE!D:PS\P^J"]KM0/L"V50B;>4OIK9)KXV[$2+Q'36I MZOA!T"@W%=J72-L*$7OV5FJSFL-,*;,#5"54T?((N>2J7=J9W'E[:.K&P?GX M,*X001B%5.8!1L
'D)N2XE7N3&QE0+WHR&;O9@+UJEY;CWR2TQWEN9? ]ANZ M^1=9PY7V$A_$;66N*,10J0Z/>ZUA#&DY$D 14.DGO*S.&<,16IV3_5'\K!8Q M5>S;O?P00'.9F3J#=]'; M2+T-
K^*6^I[^NH+;.F2LM7.Y&&:OP'2#C(/8.ST=CJDI5(W5UIH6 4):VQYL MN$UX&5CPHV98RD?;@19[Z_?4PL#/"F[@\I#@JG#7.$L:N:].[9QU09A4[\AU M"#?/:VJ]JKY-OA+S^=[-P &(HITE2D<:
3\Q,32%^1$S^45_4 ]S/LXHXP2 M^6$3?S$CHK%]N3(%*95WTK^DK11E9^;82B1D.6BM^WO97=-?'VJLIH%1DN^? M4C,'D"4A=9AK4Q'/G2!B,89+14G_G!]9>^][ #[ M[B"ZF[.?=0;
(O>]]P^AXJV:*0!3N<(;7U ^[H;WZ=CWMD7AU<;GW#LR_63[A M:+UL/@V.2()+D_]KTKF:[4AGO$\ZMUS5_PQ86M)?D7A!=\B>=I5)YDX%T%Y M)CZ:%DWM+]YRTX!G7:
;^3];H[$MC]PSO0P[3F3!:=2:,25-\=@">M?-3"Y_IL=)LOWC"@.O WDJM@"8 M-12S.!H?O E<]\Z^;>/\ ]\AUX_B^0_S$PV.M1 =YGH+K16I;-')DG /?D16G M 9@G2M8-<'E"-^[O8Y,)G#=TEBN)Y-!?-?
$R@^8]IMEHT%7+'%/5KN?Z.A"1 M'.]0OW#Y*5[Z>6E @TXR3\;_+1T%^5.0O^@A!?/:>_D\3G M/'DM?TS(?^K_%-._ 6BJG'Y.TZ?D&Y,3J/E"[P*W')Q)&->[I>Z6//?(YH7 M=5VL^,>EC@%5Z
%\ORB*VOU"&_@_4/7FOP%02P,$% @ B8((6;:3$5/G M! W@L !D !X;"]W;W)K&ULG5;;;N,V$/V5 M@5H46<"Q'=G9I&EB(-D+=@ML$>RVW8>B#[0TLHA0HI:D[

S1CW0T':>H;F/0J".R#DOCD]F4&L;Y40)I1'GK=+VB4#)YSBR'Y_)QC?7M826AK>.!HV7E6V1/CEHY<04I4N[9M)U M9MJ<<7QFKN5=V:%4@3;LN(N'8Z/$+-
CH:LT^B%LX0)T%IR,FSK/L9CR4T6[A MC&A3ZJPD1)^"BCACFMA98SI] CCHB \E[R85V/DB J>I.I-UR$>GQ M(5HC?!N$DI91$0JW;7!O[ @1O*=BGNF5,WK[;R4KK$'02+"ADHW$;J7E1(I7
ME@^(*&[ 0'B12XB^',[HX#TLZ#>+\W V.TQ/3M$IK^A W"3;3+8"A["#J(NN_]Z.HR!OO!8JR>4JW[_H,P>&ECU)\< M1ZBJX3PO?8L#S[!\W\)9\%Q>U5MJHI392GZTM-#8@II(O MH]$#N7S:BM?
^Y8+.N>G.3BDW:3')"^;-.A]AO'$W&$>E8[28=3M?#HJ<%=; M21:,Y$K=,-4H(<3=Q=:3,G*Y%,ZFY.Y U$6,4VSLF"' W3THPW0&^[F.:=]U M/MF9N2IVJSA9>I!&LW3CU[
Z#*^7WQNN!_16M+OMP[ /BLW$VLF23Y*;=+]^I&2G M29=F&W!:$EL6'SXD'U&<;HS]Y$I$#]M*:3=+2N_KR7#H\A(KX0:F1DU?5L96 MPM.K70]=;5$4P:A2PU&:7@PK(74RGX:U.SN?
FL8KJ?'.@FNJ2MBG*U1F,TO. MDF[A7JY+SPO#^;06:WQ _[&^L_0VW*$4LD+MI-%@<35+%F>3JS'O#QM^E;AQ M>_ D2R-^<0O-\4L29D0*LP](PCZ>\1K5(J!B,;G%C/9N63#_>< .:<0.\6R M%
ZOC?I-%KZ<)9<)%+@2C?+W9O,.VWC.&2\WRH5?V,2)69 WCAOJM:8&%12 MQW^Q;?.P9W"9OF(P:@U&@7=T%%B^%5[,I]9LP/)N0N.'$&]P)G)2O*6O MDNS\?)% ;J23G'$'0A?PEI+DO/2-
13<=>G+!&X=Y"W<5X4:OP&5P:[0O'?RH M"RP.[8=$;<=OU/&[&IT$O1SV -E9#T;I:'P"+]O%FP6\[!6\]\;1BG-P;:JE MU"(&_OMBZ;PEA?QQ+.2(.#Z.R*=FXFJ1XRRA8^'0/F(R_^:KLXOTAQ-\QSN^
MXU/H_[\^)^&.D_UV_!V<] ,/' M7#16ZC7X$F$EK?/@"+F*R&85T 8'KE^B%?NT_A/:2>[9!#Y0Y[@F;MXVH5%, MX$;#>Z$;ZE&\9=0CYX#:$X,"I/84$JRM:2A)"JDAA'11IZ0-L%*X[;>K:XM(
M[]2F1Z$^BD)$ M>$E9I-P1BJ@)1 M7"ZJN@EIY[.(2NAR=!RQBN20AZ+T8JKUZJ+63)O#LH+[:6@ M0/>B( OJ@GD9!0B$2B(D MP*/N/Z&P]& KX(F@:!2';@"WM21=F-
:T[=%9!ASL(UKW0E<7E_!UIXYCXNJ^ ML;H$ZYY82P-D@HU6EPK6N*9F4L![4BO1'+ONDK@&N9.06 ME$/EO72"@"<5BDM0Y!P$S1?H6F6?S&HHT)^458Z>6D%;8AX)"FCJ]AC@%O-F
M3TZVZ$>%!#QRM"B*T LCYU:6>]GO!9B#_L):#!7?IFU6^8 MLW,8&T%.'T6YI/ V* MX;&DR1PM;Z#O*V-\]\(.=K'_&]02P,$% @ B8((60AF+H-U#@ !R@ M !D
!X;"]W;W)K&ULS5K9;ALY%GW75Q!N]XP- ME+5O=A; 27I)$'>,.-T]P& >]"I*8E*+FJSRDJ^?/F<{UV:E\^+JDQUKBZ-L%6627/W2J7%S8N#P4&X
M\5&OUB7=Z+U\OI$K=:7*WS>7!E>)6DJB,Y5;7>3"J.6+@_/!V:LQO<\O_*'5 MC6U\%N3)HBB^T,7;Y,5!GPQ2J8I+DB#Q[UJ]5FE*@F#&7U[F0:V2%C8_!^D_ ML^_P92&M>EVD?
^JD7+\XF!^(1"UEE98?BYM?E?=G0O+B(K7\5]RX=R?3 Q%7 MMBPROQ@69#IW_^6MCT-CP;S_P-[^A5?!DNYTBMO*.+.7+YZ:X$8;>AC3ZP*[B
M:ABGP/QX_(&]5Q&+&\T0/RO(\7JEP7"0)PK6R)VBNMD'DBWA4Z+\4? MN*Z,LN*?YPM;&A34O_9%PBD:[U=$379F-S)6+P[015:9:W7P\F_#*;]9X^X M,:[=&#\F_;^7SL?
5'$V.Q7^D"B^@$>/")%B@4.OE6OS>O>J*7\[/+SG4JTJ[ M9T:ED).O1%GPDBKG*\@7^EYZ@$:IP!UH$-<^29&X46$=+RHJ(ZH\+G);I%!1 MPNZF')V+]^]?V]
[[2RMNUCI>T_JD$'E1"BPJ#5JSLFS/6@GE',M&@(2ZO)CU$J:Q%(,M+45 M F@KF";AWJ[JV;A49YJ<*8LS<:2/1:))N*8@D&$; P"'%<_P$$]EGI.J196L M@/AR@\?
7,HTHC/P&7EFZ;,*2N,@@F^UDK]JF1SY.1G$APSDQ&HD?R=;3"?[G M17[B(Y>2M.(F1Q36>@,AI<(2B$-99H*@O.A2U11>B=DR?F*"UMRAFVUL @2 MU-+#Y#. $>^'M.9PQ6?$Q9CO:"0[4Y&
(I5V[%&K$#)5)X62/$2O;N+LT11;Q M\H:777%9&5M)5!$-\5)>FE8L#J;86XRG ./ ()%."MD?PV]9)#):83*%=E&U8L M=ZQHN+5'G'O[OKCS4F"\J7\,91Q9NZW5.W25FDA3+-OR=TE] M'F&#: ?5F?
Q<&#++*51@\JS62(@[<21@KT%7>4']4KITI(SRIJ+N ]K2J7 .^ MJ)^(L'G1>YK3MTA0UA4.2;C2'WBYCD1E2*B#+FX<#? M ,@OBO?,RR74'/WMA_EPV_V@:[(Q@M6SW<'SX[K&/'0OH*4VBN)(G18S MDB?
*%88[8]FG*$C[9 !:)/"2U@9QF,G&?[^^J8"'"=.;X)'^>9/BE%]DT/@RL M:YE2O[2^&A9M(]UV?Y\F.KZ9]OG[^KY(, KHHTN12\SW.7-?O#>S;4TC5)QV M.EA]6++/[P.2ORL <5KPKS<"[(57LHH\B&-
T,_$;5&L[/)Y]L :U*1GT?8GL MB6AWWR]X>HT?9V*K/@G:#2#P!G<[[3JN_6OW,[=CNVK[N?R&'$KC0@-E5+ M+.UW9Y,#U]#AHBPV_%.O15&61<8?UTJ"X= +>+XL !G^@A34O_U[^6]02P,$
M% @ B8((64LZ9F?K!0 O0T !D !X;"]W;W)K&ULG5?;;MLX$/T50@6Z">#:CIVF02X&G*1%L]AN@[C=/BSV@99&%A&) M5$G*3OY^SY"2JFR3%-B7Q)1FSMS.#$=G.V/O7$'DQ7U5:G>>%-
(7)Y.)2PNJ MI!N;FC3>Y,96TN-H-Q-76Y)94*K*R6PZ/9I44NED<1:>W=C%F6E\J33=6.&: MJI+VX8)*LSM/#I+NP:W:%)X?3!9GM=S0BOS7^L;B-.E1,E61=LIH82D_3Y8'
M)Q>'+!\$_E*T!PO'T&859JS +?D=#P7BS\J=L"P--/X1 M0@W:<$YI+LK*6[Q5T/,+6TI)>[%,4]-HK_1&W%BC\3LEI-Z[LXF'%9:=I"WB M142Z/'8CX=B=ET=O@"WKP/
M>1[PYL_@#6,UI4H5.?'W2K@B'?X-!ZWS8FK94KG"?K"D=U2LGC] MZN!H>Q)"MX>]MXT+WZ%*E:TC%1\0K(T- M=:_&FV5*W)AE+, M1\(7)#XL5Q=".==0)I:KK^'-F^F[T<\
((_'%U"H5LV/4,KFN:LMPP9HWK9A< ME]1K7BF7EL8U2*K82P;@R;[8%2HMQ$ZZSC8@5(0,;F4#7;G&-!).U,T:Y1: M5O[A-X>9TIMTT21D=29DED&-WW]OR.%A;DTEE-
[B8"R.QK*,XK$BRY&HC(5! M\E*5<$3I."K#S F6Y1.68)[N,5D=N;'X HA05 M I:E,V+=!POC;%/#!4]653RN5!L22 ;PCY)C4?5,.+71*E>IA)7.6N=@0/B/
M:95Q&O.'D&SD$Y&Q5&U<2[P>7B3%HIR@2O$RA1/1JD*\[R2=V11U#@6WY K([01,;C4!^3>+N(J)$Q*N,<@, =.82IP7DUC16JTP\C( M\#:#0UKJE(4 X".3Q^!Q#GOH(W&+AWP$&
[AY/DD+QL+-Z<^-(_EZZENQ]R'EP&M(KX6$66:XT7$"6 MFY1#X;! 7BUJGH'*L\S9R520Y?S;'MRRO(U!62I#(L+-BK(S,PKINYQEM/8C M41+N3#?"R:JMY(I&/AFN2[#,1MLFV#3(+9N!,QPF
F0RF#]V6E"LY -S/MSK MS/@M8#SV!"'=,WX._#-IVH '%[116G.N0R:87-9Y\;V1%G5G\L8Z[7[8X7:K MZS(2OJ!L0\.2#?+5904*&$=KN58EQDUPG5514>)PKO/&H\G$ M']<7GV_?*)3]'F"I=
(7(L4'%O@=K*HK)9LP@A6*"I7$NMAC!39BU4CL9MB"' M]:(L.7^\RG R/=8\-T Q,2&IL>AT(&:Q;?OBC<42:0!)!FWN:)B [A*,J.$$ M>G7B0QYP.V'0\:S9*5^(6J((0X70L<%C)HK2#7'XM)5EP_4-7K<-
&N=-3Z". M*;%FD6S=*NB8*C)&P2.93_TXQ\B2>D.N8P96U3OLQBUQT,?]U %%9L_>@;,W MTZ,19,%'"]#6O56#>8J+C9W'H[Z+Q5[;Q0/MMG6?ONHR!H[#*T)F+>33XV>O
MM[1_(C[(E"DY+*!X'VCHGD> S9_&[7@8[..AK:H*=( ^DA^NRU!^E]K0*&\! M7H' M!D,6O;G,L@^< X.WIT&IF1\%V6_'L']A>$+2Y$(3MWCD@Y+:;PYL%)2 MOU*.G]K2)H.5NB*["1\.[
<:/F[7_=/^VV095_(?XO'#!H,?T\9A$N90G8[? MO4V$C1\+\>!-'1;TM?%8]\/ M)79%D [W-C?'=@_T7V^)?4$L#!!0 ( M (F"'%GH.!O=X@H * < 9 >&PO=V]R:W-H965T@G*R4IXJ6M=G6;*[R.-
ND,LG4C),\W+H/$ E)N"8!!@ E M*U]_3S=(BI)H9_)@F0O0Z.7TZ0;X=F/=@U\I%<1CD1O_[G050OGZXL*G*U5( M/["E,GBSL*Z0 ;=N>>%+IV3&DXK\8CP<7ET44IO3F[?\[).[>6NKD&NC/CGA
MJZ*0;OM>Y7;S[G[1TVCSXK)>K0 \N;MZ6CEZ_G])X'O"'5AO?N1PDR=S:![$YJ+T['9)*E=I( D2_];J3N4Y"8( M?]4R3]LE:6+WNI^ ]L.6^;2JSN;_ZFSL'IW.CL5F5K(*@^?[>8G5=MS2?)2
MFWO^%9LX=H3!:>6#+>K)T*#0)OZ7C[4?.A-FPR#O'GK M[$8X&@UI=,&F\FPHIPT%Y4MP>*LQ+]S\HF"2N$U36YF@S?+M18!4>G>1UA+> M1PGC)R1G]^%F!/U=F(";#1(R'X^DS\B:M
MB1.6-WG.1" ^ OE=NK4YOOOUF=#5\ M\XR"TU;!Z7/2ORH&STKHU^_L^J4X%"UN/9YY;]UK\:<2.;\NK _+H2MG$'V M.\DC2T?70<-UP=905,Z+"F%V0BZ=4DC.@+5H +N8W
)MR5AG"UZJC73K-XQ4&XGZE?=_2<5%H61TO MV#IGW[][X1!GWWXS&X^;SC 83>44QCBR[V%;]B7YI4:/4VME*GA_M(5)D-K B4H ,,9-B Q"
(@O3_DZ?',]&A9'HSB#R26D:>ZD0YZ(+MQ]M2!@PU M'">@S"\ =$]C UPHZ(&.O59%6L% +PL@FJ:1M!8"=3C_JF2N%]L^K@'"CHB$ M]"26-#V^8_T(.N9RJJB<"A1#U19#'H*+R4#\UL-
T2=01IJ$E:5*%42G*RJ6K!M1> MP@0.CXRMT4:'E?C]IR]10!%7SBI';B09"^T\>]DAN"08JXTC475)AI=B^XC/ M-RN+;#ZW&T/F5W.O,RT=E1,,P&(1<@U*B(*0%B?-%NK=P3L/ MH"4KDQ(]
1!$T[^%25$C$52P[1>_M]4#EKD*%1SF3,_^GU'# M2BS460GJ4J?2:R(_R.H\HMU 6_-#U?N16]K45+\1L,ABB-.4YO\-:_&C2/">) M]V6L=_EV(#X!H17!E46K%O; .)RB9^*Y#@:4W%*
<&;4L]ET&VE>IG]5FB*V MZQ$Z3(Y"RHP?P\E5DB$-2N?ZF+35!"-0(9QU&BO80U,O1R\:HT_>R&F@U%[ MV_'A#B(OQ&@PZQMR@)U[*@W6L<-C9GAUd6/B92S80A;:D+K 1:%^5S9&>:AC$
MQH>*,:(5FGS'VCMX-Q&"QXC^TUKON>KQR;2UL!O+"IINE6SB.!T<\!";0G6& MS"E0&$,L*[O61#4]8I7IL -4\&&E\B[,T9&=6EBS3%V:]M>GAZ/1&T[VA4QU MKDE$7:G86\}.^Q6UMU$'=;([-
Y4E1=(_QZ!U, (\D3);@%1:\-F\HU2 M3]8MI^IBUZJW63'S\NAH#L#-6Z.*&S [S_6R00$@ N'UW*@[U%K#>$YRN,G( M4#DU.+GG&'0W@^(+@M%]<-)&H;DXX7!P*-JKDWW O#
[I./^%N$IFLQG_OQQ> M4?Y/DMG5D"[&R?5L>-+URID%W^FIZ M:G[OJ,=R _$=RG9NL?' ^I\["%UWH3]97VJ2 ,,NZ.(/F9+E7T"-6N;8"M4O MMXSU7_#S6MRAYLBE3<0'L*.Q
.9Y_>:^Y3BN67BS:*:#;;EX]6T6H:HJ+*G0 MU@E*8O3?8M4HN0&S$P/F*NR*:^S*[O?]:+83M=O]%'5CTE/[1H/+797'KK&B H]+:E41NH9K-U'&=9SX$R>!??)]72LF25T])Y,Q _YI22A^B.Q!RS
0WZ_1 MP:RA!PK?!X/6SD@X_SA:?:'P[:BCH+3N'+U*VFU".PHM+/@9 %M'<* =3U6] M$=%%W!2EVF'/SP,CGY0<9-R!)4HOL^_9,/.:S:[!F('RIBN\X^H[-W.RB=
M'3F=KB)ZX&&48"=7Q,^E/%]C_*MK&B]@XDXZ58?=E6#Q"L?7'.9+4E1!TMW)( M59V(>_4HD3P?=MA.ZGAC'X0&)HL1:/QW%(A!R31T^TG?72QQ 8?]M5UD8IE3O9*ZJ(7@>)<'W_L-
5_=;N0W.AOAFFD7 MYQ6U="P@[@1VE<\VPV)36IMTM)V,1;;9%,1'.>I<0_7[ NLR2=8PU!Z.NBHX M@#:,NSUYM'0@/G=5;O8MC2?VEN2\[#0*54FM0F;+AJ'N;:E3,9N. ^7 Z:UKT
M1M&US"L^##E0K?>,"O&N E;FC@06HG5EWB&N3QW7'O#?W#IG-[S#P;NF\2=6 M1*/#323;TW\9,#;F+74.?<+D@'QL\0.PVT%LRYE>AT%.LM22&E:25"T&P[N M(J5>49$%@#(EG6-
X98K,T*9)J7_R >\-X\'A[DB/R8261B;L0RONI(_#M.4D MH3Z[$R<&-NV!9<%;=])IYV!/"KCH?A;._P12OG9-L=? M[6_&F.CKK4+?5XJ+SE5IM**Y";;D;U!S&X(M^'*E)/B"!N#]PMK0W- "[4?)F_\#4$L#
M!!0 ( (F"'%DCXZ6[NA$ 'HZ 9 >&PO=V]R:W-H965T)7D:Y4LCVN<&H]=MC-YV-H'$&B2 MG8!HIAL0K?SZ_H";Y;6;9(2(MJJWS&^=3C*>M,G/J]/1^=DF,<7) MBV?\[+U[\WXR/JD??
#"K=4D/SEX\VR8K_5&7 M/VS?._PZ:U;)S$87WMA".;U\?G(U?O)R1N-YP+^-WOGH;T6<+*S]F7Z\9Z? MC(@@G>NTI!42_.]&7^L\IX5 QB]AS9-F2YH8_UVO_IIY!R^+Q.MKF_]HLG+]
M_.3R1&5ZF51Y^<'N_J$#/W-:+[6YYW_53L9.L6-:^=)NPF3\WIA"_I]\#G*( M)ER.CDR8A D3IEIV8BI?)67RXIFS.^5H-%:C/YA5G@WB3$%*^5@ZO#685[YX
MI1>E2HI,O39%4J0FR+6;PI>N@N!+_^RLQ!XT\BP-Z[V4]29'UCM7;VU1KKWZ M>Y'IK#O_#+0U!$YJ E].[ESP^ZH8JNEHH":CR>R.]:8-PU<>;WH7PZ^,3W/K M*Z?5?UXMP"[
\5]]S,I:L_ZUR&">^&V2ZN?'=W\;GHZ=W4#IK M*)W=M?KO4,V=Z_53>WKY4-V]$;]^HMXF!8R4GB@'X\;:^:W:V,*4UGF>C0'Y M[:_;JW*MU2<'[^[WM\O)^.*I5VFR-
266I473DL1N8)"%TDNXE5*55I'_*/$? M3RX3M]*ESF!O.0C2*L%&JV85$&\KEV(G4Z1YE1FVHVFYOM&YLDNUL ZRQF.O MMI7S55+P'IB$N30WN7;F"4. % M($"O4S &FF]Y)7C(7&T=O*):_QX-
ZHB?F6#V^2MQ-/.P,)/*A@U*9IM04AMSQJV6 '"*P(,4=\-U9 M3.4V*1Z5]M%-DE=:,:?'INP!*BP _YC^C+$FU6'E XPX$ALI!D2!TM*D9IL0 M_4F*%]Z0=$4=-%]_W@IW]4)0^D*KE2Y($:+>>)$,,
<67AC!=ZZ/6 PBR@/%: M._CT&W4.-+413@0!6 -T>RRK(@,)3K?:PFZRGNZ1TPINA>E? +]VJ\9S#PU3M"+@$ M8X:SY9E+XP#J!%QFS&EP!/R 4 "Y$.Q9FW<(^_3D6AY=U8]."JL,@2)X>\K
M.,0)$S(.#JLAG(:(+K2K'4W!%KI-R#T02#0((V)^1(;BU6NX0*M>)L7/ _6O MX=60E :)(0,P%*XHE0%QH() IR/VG-[F\/&9^N>;E^\^"/(@D8WZ^.[U![7- M*Z^&XY'Z%@PEV4^@C61=OP=+M
U\1^DK+6'\$06)9A+0K')>2* >'-+4N8_4+"^L.(<(D;PI'<6,\ M&S'V)AHP/ 22?0H9,,&B!@>0(>;[H" +(VE@?$PWA3!<;8RF,7 1G:(K:^ M4=/Y"/E;GI/M[X-+E!OM*KA"Z.50'LT5%<,*MYV]!4J!
(:H1* MWG95)0[13,NJ*>(MI6!@&(*)((RE#A.#9$7-EL.XNARQQY17B2N&-JSCM[R M&]&O!!Y>-)V!?91]A)@DS]O$*![TL;[L#Z&[M>'[L,R/-Y\YFR M9ZJ4K!#R$LI5'[#)0+PTN
Q34[5!#G5(Q0YP@BN.V*C-&>3SD3D%-:2EB4TKI M*/QSJL'.)=-$E"G:_)12M"I/[N,S.C9L:HG=$(I[:U?@<4N=&:S2YM ZK8(0:O"#"3 MT=-F8?X]2!EIGR5B30A:#
[#1YR,^NNN'WBL)O@SN@>L,2AZI.%)SAJ2G=J],; M%#N:>Q )5;R^&Q".XR_9=9/TX>$$P%&GY1DCOI6^)?4@O&:Y-XBEX#%*2#4 M849^&[F3QB"76K-
Z^"'I!]*>=Z1]V@'5H7WU0>QA/52""N=$C6,^CJD#TQ,N MXJ@@YD6[(I:6.B3I%&('B7Q17AB; M!2P)J&&,X*M'\H,(@76IT!$J>;H%N^=J>X&0_[>W[/O(0K-9)1B%Q-AD^;J(BEVDELA[!
MRI%ZN1,,22C=U.(0 07O-!F.XV'3O.HH*'R!#R4MZP^)PHH+!<:B!T)9UUU M&16**FYG,(NO-D)+'!00U'4O6#*4Y,1^>?YG- 0WMDAD/[,LD(G,A/[L_9& MD$25H\V-9(6<:$IGAA9/_%HM<[OSS
(28VJHM$\/&B '(JJ0HBG M2;,.XGOO_!U)_QLUF0\G#6/"ZW@VO&P>9;##4!(%#P6/R)ZZ@S>>*AI!Z-V* MP\RI9J7$+$IGX>Q$"&'_\3P"9]A__-7V_JUBF5T,1WMD36?#>1]9C6?ZNH*9
MCH87>Q1,QI&N_B@%1WPY,$O)I ]-[,0A-BT1C3>A=L5:!9%,/U(X+93ZI8_S M=LZY$W' 5#.%Y-04U%##0&6(XAG.B.#ALY4B99 IJSK T!AR$*0\@IYRN.47A M3@B0GQF_M?'TS%
(XIY$LUA&D=\L*AYU5P!K.*?Y*=1+>LZ+BYEOOK*KHGP=4 M%&E%#I2['}$B)"Y*DC;51I649Y!G(^>RHQ23${2=IGPEQD5H)&';<)EPQ^'C MP.G0!Y/:DLHFR'2UHBC-
70*=1QTUR3HXQB[OAXOC]4/TKP +8H>.2F;3I0 M]1$RF%9_1])DJ@#V(B<)@XWPODL?R99HZ8.()703WA8:5G"CI8Q$#-C9*J>. MQ$;,)=[:+ !G*U%XE529Y=JN\C[A4I):%M
M0!;6M3F&:I7'=;K$LT[O(73&,C&J)>HWB8,EQT7Q"-0QKT\.:*:7F'$(6,! M.Z\,)[Z2<]>92"OI8*/<].F7^6D&.A+70(K'V7]-?C\>!R,GOPJ9LQ?I=CQG-U3HG;;#8, M_T.2_N!C,,ONT"F-F- -4-
F\NV#'V([[8Z512D9X44G&/VZUZ/A?*0^ M(]^9\+]C_'M%(LF0LY8MFO94%Y(J0/,&%3ADUS2FR?.* 8A92_(6=;"IU]Q$ M
]D@$)PRYY5'J5$=9XGQ]AU.S8.7:='U/BZSH/_A="@WD4>HQV%R<.'2,5" M,^!M*#X>?*I\"A_TWMDE8I%4%R\KD_-T<="'I=41MBL6_4Q?A"S8?S
MV(/W:ZL+\UE=K[$,7%\3&/Z>8.=_0V;Z5EV3M*ZY:1EOC!!^MU 12LFH7_PZNWFK27J_=Y\FMRG-[Q>' ^O02@ M9L"(^JBW):.<5YX*8@>HS>JH37CG8+&% S*( A+H2]4>#J#D\)@]&,]F#_X)
MR?6]/E7CBYEZ&"RB@0U 0GUDI#B"KS[,T&ID4H/'%R-1W56\>=YEJ#H6DTD:I MW'84F_2I7#M;K=9ML^TYB0B6U\'C[DU,.9-9',KI3!23L MQ[M:MDXR1PD S?%1L"OLSUY<$H SV*/;[S[
M")>O70X* F&]'$C5P'V'=!+$-2;WYLT;#B>B'&'+^=Y/T"F-5^O%[\DF?C M^'^G:S/W=VVA5=%8PUM[P??8F0].@HA\G'U@W)J*_MPC,$57.(_]\:T# MED-"07C!$35-G+NEP7*2VG9%IM]-D
T71I _3&*"F?IN#>SEXEQQV>.+X>S M[BG$773VJ.TWTS]=_EY:IU&5%5*;SGC2.KO*'3(;SF$JT7C31?JE8G<'Z&C4 M$)ET[-J#=M08=/(<"I(?=7/"3$H7I"$["XU.N6NZ%C R-'<]1?RI][-
)QL%D6X<,5Y+C-HVMLD0X0@:0]3 M%U]N\CA8 CQD3.0N9MMDDI*OR<_>HUTML*8$GJEX!&TUI-\QZ&1F5$1CZN MZ8L,^^^Z/*&.2X.:QM IUJKXA+![5\+ODFUT4LP-
%2F4$*XD+XC/]29M]2^E M0."YNRB&(I;/.)K7F3VR8+,JZC/GI&5'(6ZLM("LA[:%3BF]:1O0-N(RF(;< M 3EZ=+4C;)#%B4DG&A$2EU$57+!V+EVOYP9VZ[O253X)/7WB/B M/P2 ^7T!,$*"^&?I/S
8CI> H/W.8-+]WL4+DK[Q=TN%0O/&9G* A=7#&?[^ MR3[-9#\G]Q>H1S?#W1-K:\&YR$7^Y\$'K>D[@(?9#>^% ;N6*G%7[W:'X>?K'03D(!YPJUEI]>Z1G6 ' OS06=_1=:W&F31=,U#3<8P%-]
*N?[ M1=T*S'H2-FHZ_Y<78KZ_$G/F1J9%]1@#CSP%5\WD*8PPTW]X7[RVK$G*K@7 M2X=#[.'.\J]O2@8=T$R#7-Q30LZ/GN3HZ_FT"*E8CD!L,M^7OT32*[C5- MZ7KT8 ]-H7W0=HAN! ]-
[UM\YSU==_ FYU MJNH6WKT@@231Q+L$"Q7 MF.(+8_1K=,_C+2>Z5\?1+,I[]KY/Q%TB>_.6PN.Y&=VD!DCW0GK+)@GJ? M='FZX:UCLQR9^EQ!;5T'ARFMDP_63)=U"?
7N^DUPD@_K+KB'9]!KF]/5^7 V M$JZ\OUH/N&1KPC2G#YRX'R^-4.KU8(-&S47:6K?*A?"B+]P-8R?LJ"1E2#2 M^B1\2LA)$R23N(+:JNSZ,_HZJ P?D$!:MVK%MP#HFK'UONUP]7E,B1 =LNG*
M6UA2'3T &*J^#\W.HN!-QJ^])J *6"4R*>!S=/FP\HK^9ZP'2Y?9;X-]^)R MO<34T?!B?]*+^TB)?A!VW0?&[ZXK\! M4$L#!!0 ( (F"'%FYRWA@AP0 #D* 9 >&PO=V]R:W-
H965T595.M2:R6PZO9RT2MMB.4]SMWXY=WTTVO*M MI]"WK?*/-VS<=E&<%;N).UTW428FRWFG:K[G^*&[]1A-1I1*MVR#=I8\KQ?% M]=G5S87L3QO^UKP-
!]\DGJR<>Y#!NVI13(40&RZC("C\;/@-&R- H/%YP"Q& MDW+P\'N' EOR';ZL5. WSGS456P6Q@,W*:[3C=S)X$_+VWIW0^/:'9=';Q!-[YZ.-YPCM_KH_T MS_4J1(^,^/>8NQQMXCB:5,E5Z%3)BP)E$-
AON%A^_]W9Y?3U$UPO1JX73Z$_M+QY/0_SPZD?ZO\M_]IXZKZ7R:-4'G F!-/LAD/:H5$CMB+#*LBP865B4RK/ M:,KI6V5)W-4ETUJ5VNBH.5!LO.OKABKM46GDM19]:'1'SH]KGYP&F0T8]9#L
MA+:-+AM2=>VY5I%A.CI2)'8-H]:%M%KA,V0_3NDC#P5L'I'^%OV"G'B$C6MG MM".W?C9C66S5(ZV]:RFBQ1"LI]]6/3!JNM320CH^=
M+I6!AY[S8:XD*A:]K6*X[CI!"Z*L*C_M8"F=;=1SR[1BH[$3302TA596R2AK M@>5%:YCTC#B@QMY%R0#9@0 (S]BH2&#P;"F3G16GJ%?":^") ;0ZE*#K?>>" M"""9Z+'-]AG<@J6VI8/^8]JF))
2UW-\()>(K5(3!_E,=X^[RX ,O$\(>&9< MF8"&-,2=E. ^6"VS]Q&+$*]!=#?L3T2_RJ6 5CJ5!!1NQ*D:Q[MD>&0"V5 N M(.MJX[I&XB:W XR*WSMGA2_D%!J2'\A]@)2<(MBBSGJ?LBDGEK(EIT2'.'*=
M#;:P051::XL-&F8J]/EDA16"/J3B8^)CH4RE-[KJ=W1>B\>XZ)SG[" #2'0_ M@!^*C-0N%T:(?9XC68Y-4Z,VDG5L]]5! H5AOE
M=_D4&Q(87TGUK1R&$C*KI',D(;ATUK6Z3.+*VCX=3PA9K*1"9.,8]\P8L@?9 M B^W4M0J'-0JO/#24_8J?Q64/]P151Y3@87$P3/*T7,N3\MB2QJMN, $PD%7 MB
*4D>K=VJP&H,$=NS(F!]=YR[Y.CY8 F-[&?+./L^.[Z#H_! ;;Z/JO?*U M1K(:7N/H]/3G%P7Y_%#)@^BZ]#B TGAJI$_4/LC*!JROG8N[@1@87XO+_P!0 M2P,$% @ B8((67-Y,O.9! F@L !D
!X;"]W;W)K&ULE5;;:422*NMAQ;,W(3C).IFX\MM,\=/H MD2L1-0@H "A9?]]=D&(46U;=%XD7[-ESSBZ6.%L9^^!R1 ^/A=+N/,J]7YQV MNR[-L1"N8Q:HZ-1MQ!21^.S\.S&CL],Z974
M>&/!E44A[/H"E5F=1[UH\^!6SG//#[KCLX68XQWZKXL;2W?=!B63!6HGC0:+ ML -HTCN]&/#ZL.!/B2NW=0VL9&K, ]]RLZCF FAPM0S@J"_)5ZB4@Q$-+[7 MF%&3D@.WKS?H'X-VTC(5#B^-
^B8SGY')Q%D.!.E\K=F=86UGB'CI4:Y\ KN M>FT<05HZ;XHZF!@44E?_XK'VX34!21V0!-Y5HL#RO?!B?&;-"BRO)C2^"%)# M-)&3HFMRYRV]E13GQ[>H!-OCS!ZS>>]0->?Y]G
MNU7_-9DZ;^GN[UVZ*]C!;EC>?]=N(5(\CVA_.7(=H_%OO_1&\;L]I <-Z<$^ M]/&'1^F\U'/X':F)X1YMX>H::EQ1M;\L*@FTT>',P,Z!*PY5Q"^EIP4>1 M2B6]1+=+V_[]SF"YX: *<\!VC=>2.7
TW/<,%.!F6^8V9J9V6*&-3,.S#?, M0B"#"0 "(@56!?(F*!".(Z@+L.F"-J2$6.<-9>KWH4>ITM;!I=!KPK@D MSQYV(!U"KWTRZ.T#4#2"=D0V'A]"TCX^?N[8((9A#$=9BVT+M<^Y^%3XX9LU
M"ONDI8#ZY4GW66H<&EY4>%/.+LF(D=4"L%K"!@]Z6 MCN,86O4@HC6">:S,:S)O%^IIB8ZW,[R-N41?]MM)V^N(62R,)^ND4&K],TDY MVV45V]1^D2U/6WQ$FT]'6:L= /ZSXX]?VR&=79_.
[M9YJ4 [#Z=*1[&E]M71 MJ7G:'#PGU7GKQ_+JU'HM[%R2"H4S"HV)6 2V.@E6-]XLPNEK:CR=Y<(E?3PR MM+R WL\,F5G?><(+F.#[^%U!+ P04 " ")@@A9%L7D]"L* !.' &0 M
'AL+W=OO(+R9G010;%UL MR.F@\5B7VSKPG/] MSL=SZ-.UD%]4SI@FCV51];-^KO7J9#A4:S-Y?BIJ7?'*S211=5E2^73)"K$^ZP?]YL8GOLPU MWAB>GZ[HDMTQ_7DUDW
U;*5DO&25XJ(BDBW.^A?!R66"[YL7_N!LK3J_"7HR M%^(+7KS/SOH^&L0*EFJ40.'K@;UA18&"P(RO3F:_58D+N[\;Z6^-[^#+G"KV M1A1 \DSG9_U)GV1L0>M"?
Q+K=\SY,T9YJ2B4^21KJZ[?)VFMM"C=8K"@Y)7] MIH\N#]]9$+H%H;';*C)67E%-ST^E6!.);X,T_&%<-:O!.%YA4NZTA*<1&5#I7Y+Q)R!!&U2L(:?4,Q=%VKC LIFUHW29H\JA"\@A+4(.>E]I"7#VV
! M&$!N0:=4.5^166/UK3%C_N1>Z=W5\UK.:=6\@3&,(O(+N=,#64& 4?+^?>]2UI5:\0+N5!*I*YRZ.#H<#XX(LD(!-SP#)"P;-W0JVX MAN4WMY>]M ?_Q&\RRX%O0!0Y3&%=
PK@(HJ]K2M['=)GY38,!'79:"--6OO MV:,HZ=9:8Q.YS[E"APGHA!3HG,OL>$5-%IDL22&H(8,#,AE$P$20&5%Y+G>P M%',F&61%@LE:D%IY!#8!I2%GF,,=N1@0$XD_(9V04DP?<(IB#"A0YXT-Q-J

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`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}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}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§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|?)2_2VFL M3FGW6/CZ@3K I<7$_%.6K25;LYS-%853,^=C/*_1KC>H[[#6__67L!W\7B:U M(K(MX-/'WO^D+(\A6:\KD,K2[YP_\%&,1W0KCS6.5:H-@E60TLJ3:,M2 MLARGG8WCRMI=/^SU.L%9_6Y3Z^->#=9M-_)>6R):N8B65\1')==!ED7F!?_L M9%5$MJ6SG>ML5[I*VU4*KXAL2W@G%[Q3O!F#;S@,9?CLHF^\)-\#4N3M 2U M-E8D"\)FJF?J+Z;J^]Z_^ QKA=!U,A2;I+PA2QK(I?^(GV9*#[* /' M86@]_\4J0O_.'ORTWN4G[+*Ÿ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§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

XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 284 278 1 true 82 0 false 19 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Statements of Income Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical Condensed Consolidated Statements of Income (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Changes in Equity Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity Condensed Consolidated Statements of Changes in Equity Statements 7 false false R8.htm 100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical Condensed Consolidated Statements of Changes in Equity (Parenthetical) Statements 8 false false R9.htm 100080 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash

Flows Statements 9 false false R10.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 10 false false R11.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 11 false false R12.htm 995455 - Disclosure - General Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneral General Notes 12 false false R13.htm 995465 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Notes 13 false false R14.htm 995475 - Disclosure - Dividends and Equity Issuance Program Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram Dividends and Equity Issuance Program Notes 14 false false R15.htm 995485 - Disclosure - Acquisitions and Divestitures Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestitures Acquisitions and Divestitures Notes 15 false false R16.htm 995495 - Disclosure - Summarized Financial Information of Equity Affiliates Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliates Summarized Financial Information of Equity Affiliates Notes 16 false false R17.htm 995505 - Disclosure - Recent Accounting Pronouncements Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 17 false false R18.htm 995515 - Disclosure - Lease Accounting Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccounting Lease Accounting Notes 18 false false R19.htm 995525 - Disclosure - Debt and Financial Instruments Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstruments Debt and Financial Instruments Notes 19 false false R20.htm 995535 - Disclosure - Segment Reporting Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSegmentReporting Segment Reporting Notes 20 false false R21.htm 995545 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Tables http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions 21 false false R22.htm 995555 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables Summarized Financial Information of Equity Affiliates (Tables) Tables http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliates 22 false false R23.htm 995565 - Disclosure - Lease Accounting (Tables) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingTables Lease Accounting (Tables) Tables http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccounting 23 false false R24.htm 995575 - Disclosure - Debt and Financial Instruments (Tables) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsTables Debt and Financial Instruments (Tables) Tables http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstruments 24 false false R25.htm 995585 - Disclosure - General - Additional Information (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail General - Additional Information (Detail) Details 25 false false R26.htm 995595 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformat Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Details http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables 26 false false R27.htm 995605 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail 1) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationDe Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail 1) Details http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables 27 false false R28.htm 995615 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Details 28 false false R29.htm 995625 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Details 29 false false R30.htm 995635 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail Dividends and Equity Issuance Program - Additional Information (Detail) Details 30 false false R31.htm 995645 - Disclosure - Acquisitions and Divestitures - Additional Information (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail Acquisitions and Divestitures - Additional Information (Detail) Details 31 false false R32.htm 995655 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Details 32 false false R33.htm 995665 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail Limited Liability Companies Accounted for Under Equity Method (Detail) Details 33 false false R34.htm 995675 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Details 34 false false R35.htm 995685 - Disclosure - Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail) Details 35 false false R36.htm 995695 - Disclosure - Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail) Details 36 false false R37.htm 995705 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) Details 37 false false R38.htm 995715 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) Notes http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEqu Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) Details 38 false false R39.htm 995735 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails Recent Accounting Pronouncements - Additional Information (Details) Details 39 false false R40.htm 995745 - Disclosure - Lease Accounting - Additional Information (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail Lease Accounting - Additional Information (Detail) Details 40 false false R41.htm 995755 - Disclosure - Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesC Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) Details 41 false false R42.htm 995765 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail Debt and Financial Instruments - Additional Information (Detail) Details 42 false false R43.htm 995775 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Details 43 false false R44.htm 995785 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Details 44 false false R45.htm 995795 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 45 false false All Reports Book All Reports uht-20240630.htm uht-20240630.xsd http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 false false JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "uht-20240630.htm": { "nsprefix": "uht", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "dts": { "inline": { "local": [ "uht-20240630.htm" ] }, "schema": { "local": [ "uht-20240630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "keyStandard": 177, "keyCustom": 101, "axisStandard": 29, "axisCustom": 0, "memberStandard": 23, "memberCustom": 57, "hidden": { "total": 11, "http://xbrl.sec.gov/dei/2023": 4, "http://fasb.org/us-gaap/2023": 6, "http://www.universalhealthrealtyincometrust.com/20240630": 1 }, "contextCount": 284, "entityCount": 1, "segmentCount": 82, "elementCount": 607, "unitCount": 19, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 531, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 4, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome", "longName": "100010 - Statement - Condensed Consolidated Statements of Income", "shortName": "Condensed Consolidated Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R3": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical", "longName": "100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical)", "shortName": "Condensed Consolidated Statements of Income (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_21ce9bac-f2eb-4b7c-94e8-23be52f46ffb", "name": "uht:BonusRentalIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "link:footnote", "p", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_21ce9bac-f2eb-4b7c-94e8-23be52f46ffb", "name": "uht:BonusRentalIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "link:footnote", "p", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "longName": "100030 - Statement - Condensed Consolidated Statements of Comprehensive Income", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "us-

gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R5": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100040 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity", "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Equity", "shortName": "Condensed Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_849b6f24-4245-46ea-bcd7-3f4fb0744d5f", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f4665629-0b0a-4198-a75d-fe034a521dd3", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R8": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical", "longName": "100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "uht:DividendsPerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "uht:DividendsPerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneral", "longName": "995455 - Disclosure - General", "shortName": "General", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions", "longName": "995465 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram", "longName": "995475 - Disclosure - Dividends and Equity Issuance Program", "shortName": "Dividends and Equity Issuance Program", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestitures", "longName": "995485 - Disclosure - Acquisitions and Divestitures", "shortName": "Acquisitions and Divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_a6e037d5-edb5-4983-ba42-60d3ce7b1d45", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a6e037d5-edb5-4983-ba42-60d3ce7b1d45", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliates", "longName": "995495 - Disclosure - Summarized Financial Information of Equity Affiliates", "shortName": "Summarized Financial Information of Equity Affiliates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRecentAccountingPronouncements", "longName": "995505 - Disclosure - Recent Accounting Pronouncements", "shortName": "Recent Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccounting", "longName": "995515 - Disclosure - Lease Accounting", "shortName": "Lease Accounting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:DisclosuresOfLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:DisclosuresOfLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstruments", "longName": "995525 - Disclosure - Debt and Financial Instruments", "shortName": "Debt and Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSegmentReporting", "longName": "995535 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables", "longName": "995545 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions (Tables)", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables", "longName": "995555 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables)", "shortName": "Summarized Financial Information of Equity Affiliates (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingTables", "longName": "995565 - Disclosure - Lease Accounting (Tables)", "shortName": "Lease Accounting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "uht:DisclosuresOfLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "uht:DisclosuresOfLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R24": { "role":

"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsTables", "longName": "995575 - Disclosure - Debt and Financial Instruments (Tables)", "shortName": "Debt and Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:ScheduleOfFinancialCovenantsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:ScheduleOfFinancialCovenantsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail", "longName": "995585 - Disclosure - General - Additional Information (Detail)", "shortName": "General - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_9620ba0a-0383-4ecd-b800-f7d08213ca66", "name": "uht:NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction", "unitRef": "U_Property", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9620ba0a-0383-4ecd-b800-f7d08213ca66", "name": "uht:NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction", "unitRef": "U_Property", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma "longName": "995595 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions - Additional Information (Detail)", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:NumberOfBedFacility", "unitRef": "U_Bed", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:NumberOfBedFacility", "unitRef": "U_Bed", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD "longName": "995605 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions - Additional Information (Detail 1)", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions - Additional Information (Detail 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_1b6bda06-8983-4202-b8c8-7f0aca2d4d4d", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1b6bda06-8983-4202-b8c8-7f0aca2d4d4d", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "longName": "995615 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)", "shortName": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_bd5385f4-f142-4b5e-9109-3e97c145d65e", "name": "uht:OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bd5385f4-f142-4b5e-9109-3e97c145d65e", "name": "uht:OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "longName": "995625 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail)", "shortName": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_6bc51aeb-3a09-49a5-9ff9-a0ec95878534", "name": "uht:OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates", "unitRef": "U_Renewaloptions", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "div", "div", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6bc51aeb-3a09-49a5-9ff9-a0ec95878534", "name": "uht:OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates", "unitRef": "U_Renewaloptions", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "link:footnote", "div", "div", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail", "longName": "995635 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail)", "shortName": "Dividends and Equity Issuance Program - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "us-gaap:PaymentsOfDividends", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R31": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "longName": "995645 - Disclosure - Acquisitions and Divestitures - Additional Information (Detail)", "shortName": "Acquisitions and Divestitures - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:NumberOfBusinessesAcquired", "unitRef": "U_Acquisition", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:NumberOfBusinessesAcquired", "unitRef": "U_Acquisition", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "longName": "995655 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail)", "shortName": "Summarized Financial Information of Equity Affiliates - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_15db8ee4-acba-40b4-b499-93062353a124", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "U_Property", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_15db8ee4-acba-40b4-b499-93062353a124", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "U_Property", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "longName": "995665 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail)", "shortName": "Limited Liability Companies Accounted for Under Equity Method (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_6098dd0b-8793-4f35-973f-1ad635f3fa1b", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6098dd0b-8793-4f35-973f-1ad635f3fa1b", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "longName": "995675 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)", "shortName": "Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_361d92dd-807e-497f-aa3e-33660d871c33", "name": "us-gaap:LongTermLoansPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "link:footnote", "div", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_361d92dd-807e-497f-aa3e-33660d871c33", "name": "us-gaap:LongTermLoansPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "link:footnote", "div", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslspsAccountedUnderEquityMethodDetail", "longName": "995685 - Disclosure - Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail)", "shortName": "Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_3b13fa74-d0eb-41ec-8394-6cfbe0bee973", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_571dd15c-b90b-430d-b6cb-9dfd46c845d2", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "uht:EquityMethodInvestmentsSummarizedIncomeStatementInformationTableTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R36": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslspsAccountedUnderEquityMethodDetail", "longName": "995695 - Disclosure - Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail)", "shortName": "Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "us-gaap:Assets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_46ef10c0-7c0d-4dfe-b109-e7c62feed267", "name": "uht:EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "uht:EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R37": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail "longName": "995705 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "shortName": "Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9620ba0a-0383-4ecd-b800-f7d08213ca66", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "link:footnote", "div", "div", "uht:EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R38": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq "longName": "995715 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail)", "shortName": "Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_2ac233f8-0cc2-4e9e-b571-357908090159", "name": "uht:EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2ac233f8-0cc2-4e9e-b571-357908090159", "name":

"uht:EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails", "longName": "995735 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details)", "shortName": "Recent Accounting Pronouncements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_0609389e-e090-41d0-8536-c85becf7ae66", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0609389e-e090-41d0-8536-c85becf7ae66", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "longName": "995745 - Disclosure - Lease Accounting - Additional Information (Detail)", "shortName": "Lease Accounting - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:NumberOfGroundLeasesForLand", "unitRef": "U_Land", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "uht:DisclosuresOfLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "uht:NumberOfGroundLeasesForLand", "unitRef": "U_Land", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "uht:DisclosuresOfLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties "longName": "995755 - Disclosure - Lease Accounting - Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions (Detail)", "shortName": "Lease Accounting - Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_752e5797-7a81-45e7-9aa2-bc4e8fe64bdf", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c7ffbcb9-dc92-4146-9e55-0664368a8259", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "div", "uht:DisclosuresOfLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R42": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "longName": "995765 - Disclosure - Debt and Financial Instruments - Additional Information (Detail)", "shortName": "Debt and Financial Instruments - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:ProceedsFromLinesOfCredit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:DebtInstrumentInterestRateTerms", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R43": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail", "longName": "995775 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)", "shortName": "Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "uht:DebtInstrumentCovenantTangibleNetWorth", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "uht:ScheduleOfFinancialCovenantsTableTextBlock", "div", "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "uht:DebtInstrumentCovenantTangibleNetWorth", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "uht:ScheduleOfFinancialCovenantsTableTextBlock", "div", "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "longName": "995785 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail)", "shortName": "Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_9ad82ef1-458a-4248-8d66-ed38e70053ad", "name": "us-gaap:SecuredDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4e525504-be71-4baa-b4c7-07142052bdb1", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "unique": true } }, "R45": { "role": "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSegmentReportingAdditionalInformationDetail", "longName": "995795 - Disclosure - Segment Reporting - Additional Information (Detail)", "shortName": "Segment Reporting - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b86efefe-135e-4868-b4be-ad510dd08439", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "uht-20240630.htm", "first": true, "unique": true } }, "tag": { "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "uht_AccountingStandardsUpdate202206Member": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AccountingStandardsUpdate202206Member", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2022-06.", "label": "Accounting Standards Update 2022-06 [Member]", "terseLabel": "ASU 2022-06" } } }, "auth_ref": [] }, "uht_AccountingStandardsUpdate202307Member": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AccountingStandardsUpdate202307Member", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2023-07", "label": "Accounting Standards Update 2023-07 [Member]", "documentation": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r78", "r143", "r545", "r571", "r575" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income/(loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r24", "r410", "r413", "r474", "r566", "r567", "r860", "r861", "r862", "r874", "r875", "r876" ] }, "uht_AcuteCareHospitalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AcuteCareHospitalsMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Acute Care Hospitals", "label": "Acute Care Hospitals [Member]", "documentation": "Acute Care Hospitals." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r800" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r72" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r382", "r383", "r384", "r589", "r874", "r875", "r876", "r903", "r929" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r806" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r806" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r806" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r806" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r132", "r133", "r134", "r135", "r136", "r178", "r179", "r180", "r182", "r192", "r231", "r232", "r272", "r273", "r274", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r295", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r394", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r415", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r436", "r437", "r440", "r441", "r442", "r443", "r453", "r454", "r457", "r458", "r459", "r460", "r470", "r471", "r472", "r473", "r474", "r517", "r518", "r519", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",

"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities
[Abstract]" } } }, "auth_ref": [] }, "uht_AggregateInitialOfferingPriceOfThresholdAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AggregateInitialOfferingPriceOfThresholdAmount", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Aggregate initial offering price of threshold amount", "label": "Aggregate Initial Offering Price of Threshold Amount", "documentation": "Aggregate initial offering price of
threshold amount." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous
Compensation Amount" } } }, "auth_ref": [ "r771", "r782", "r792", "r817" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r774", "r785",
"r795", "r820" ] }, "uht_AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Aiken Regional Medical Center and Canyon Creek Behavioral Health", "label": "Aiken Regional Medical Center And Canyon Creek Behavioral
Health [Member]", "documentation": "Aiken Regional Medical Center and Canyon Creek Behavioral Health." } } }, "auth_ref": [] },
"uht_AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services", "label": "Aiken Regional Medical Center Aurora Pavilion Behavioral Health
Services [Member]", "documentation": "Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services." } } }, "auth_ref": [] }, "uht_AikenRegionalMedicalCenterMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AikenRegionalMedicalCenterMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Aiken Regional Medical Center", "label": "Aiken Regional Medical Center [Member]", "documentation": "Aiken Regional Medical Center." } } },
"auth_ref": [] }, "uht_AikenSouthCarolinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"AikenSouthCarolinaMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Aiken, South Carolina", "label": "Aiken South Carolina [Member]", "documentation": "Aiken, South Carolina." } } }, "auth_ref": [] },
"ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } },
"auth_ref": [ "r806" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } },
"auth_ref": [ "r813" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r778", "r786", "r796",
"r813", "r821", "r825", "r833" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements
[Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r831" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "AmendmentFlag", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": {
"en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted
submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfAboveAndBelowMarketLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AmortizationOfAboveAndBelowMarketLeases", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Amortization related to above/below market leases, net", "label": "Amortization of above and below Market Leases", "documentation": "Amount of non-cash amortization of intangible asset
(liability) for above and below market leases." } } }, "auth_ref": [ "r867" ] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Amortization of debt premium", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount
and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r6", "r60",
"r85", "r325" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr":
"debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": {
"role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt
issuance costs." } } }, "auth_ref": [ "r81", "r325", "r455", "r867" ] }, "uht_AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets": { "xbrltype": "percentItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Annual advisory fee as percentage of average invested real estate assets", "label": "Annual Advisory Fees As Percentage Of Average Invested
Real Estate Assets", "documentation": "Annual advisory fees as percentage of average invested real estate assets." } } }, "auth_ref": [] }, "us-
gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than
Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref":
[ "r396" ] }, "uht_AssetPurchaseAndSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"AssetPurchaseAndSaleAgreementMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Asset Purchase and Sale Agreement", "label": "Asset Purchase And Sale Agreement [Member]", "documentation": "Asset purchase and sale
agreement." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlclspAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total
Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits
obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r100", "r141", "r166", "r208", "r217", "r222", "r269", "r301", "r302", "r303", "r304",
"r305", "r306", "r307", "r308", "r309", "r398", "r402", "r438", "r542", "r623", "r747", "r762", "r891", "r892", "r913" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:",
"label": "Assets [Abstract]" } } }, "auth_ref": [] }, "uht_AtMarketATMProgramsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "AtMarketATMProgramsMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "At-The-Market Equity Issuance Program (ATM)", "label": "At Market A T M Programs [Member]", "documentation": "Shelf registration." } } }, "auth_ref": [] },
"uht_AverageInvestedRealEstateAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"AverageInvestedRealEstateAssets", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Average invested real estate assets", "label": "Average Invested Real Estate Assets", "documentation": "Average invested real estate assets." }
} }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r828" ] },
"ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [
"r829" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": {
"label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r824" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r824" ] },
"ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [
"r824" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } },
"auth_ref": [ "r824" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing
MNPI Disclosure" } } }, "auth_ref": [ "r824" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]",
"terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r824" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type",
"documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365",
"r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype":
"decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": {
"en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r827" ] }, "ecd_AwardsCloseToMnpiDiscIndName": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } },
"auth_ref": [ "r826" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards
Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r825" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time
to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r825" ] },
"uht_BRBMedicalOfficeBuildingFixedRateMortgageLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":

"BRBMedicalOfficeBuildingFixedRateMortgageLoanMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "BRB Medical Office Building Fixed Rate Mortgage Loan", "label": "B R B Medical Office Building Fixed Rate Mortgage Loan [Member]", "documentation": "BRB
medical office building fixed rate mortgage loan." } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"BaseRateMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "uht_BaseRentsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "BaseRentsMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties
], "lang": { "en-us": { "role": { "terseLabel": "Base Rents", "label": "Base Rents [Member]", "documentation": "Base rents." } } }, "auth_ref": [] }, "uht_BonusRentalIncome": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "BonusRentalIncome", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Bonus rental", "label": "Bonus Rental Income", "documentation": "Bonus rental income." } } }, "auth_ref": [] }, "uht_BonusRentsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "BonusRentsMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties
], "lang": { "en-us": { "role": { "terseLabel": "Bonus Rents", "label": "Bonus Rents [Member]", "documentation": "Bonus rents." } } }, "auth_ref": [] }, "uht_BrunswickAssociatesMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "BrunswickAssociatesMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Brunswick Associates", "label": "Brunswick Associates [Member]", "documentation": "Property Owned by Limited Liability Company in which we have a
majority, non-controlling equity interest" } } }, "auth_ref": [] }, "uht_BusinessAcquisitionsAndDispositionsLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "BusinessAcquisitionsAndDispositionsLineItems", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Business Acquisitions And Dispositions [Line Items]", "label": "Business Acquisitions And Dispositions [Line Items]", "documentation": "Business acquisitions and
dispositions." } } }, "auth_ref": [] }, "uht_BusinessAcquisitionsAndDispositionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "BusinessAcquisitionsAndDispositionsTable", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Business Acquisitions And Dispositions [Table]", "label": "Business Acquisitions And Dispositions [Table]", "documentation": "Business acquisitions and dispositions." } } },
"auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": {
"en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "uht_CanyonCreekBehavioralHealthMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CanyonCreekBehavioralHealthMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Canyon Creek Behavioral Health", "label": "Canyon Creek Behavioral Health [Member]", "documentation": "Canyon Creek Behavioral Health."
} } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and
Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on
hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term,
highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes
in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r31", "r139", "r721" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role":
{ "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "periodStartLabel": "Cash and
cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents,
Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage;
including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and
other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to
known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r31", "r89", "r164" ] },
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role":
{ "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "(Decrease)/increase in
cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect
from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of
demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their
maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r89" ] },
"uht_CashDistributionsInExcessOfIncomeFromLimitedLiabilityCompanies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "CashDistributionsInExcessOfIncomeFromLimitedLiabilityCompanies", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Cash distributions from LLCs", "label": "Cash Distributions In Excess Of Income From Limited Liability Companies", "documentation": "Equity investment distribution." } } }, "auth_ref": []
}, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Cash Flow Hedge", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a
forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r50" ] }, "uht_CatholicHealthInitiativesIowaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CatholicHealthInitiativesIowaMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Catholic Health Initiatives Iowa", "label": "Catholic Health Initiatives Iowa [Member]", "documentation": "Catholic Health Initiatives-Iowa." } }
}, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation": "Indicates (true false) whether accounting standards update was adopted."
} } }, "auth_ref": [ "r111", "r112", "r113", "r132", "r133", "r176", "r231", "r232", "r271", "r272", "r273", "r280", "r281", "r295", "r385", "r392", "r393", "r404", "r405", "r406", "r419", "r420",
"r431", "r436", "r437", "r439", "r440", "r441", "r453", "r457", "r458", "r459", "r470", "r517", "r518", "r564", "r565" ] }, "us-
gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "documentation": "Indicates (true false) whether effect from applying amendment to
accounting standards is immaterial." } } }, "auth_ref": [ "r109", "r178", "r191", "r276", "r391" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed
Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r804" ] }, "uht_ChicagoIllinoisMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "ChicagoIllinoisMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Chicago, Illinois", "label": "Chicago Illinois [Member]", "documentation": "Chicago, Illinois." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code",
"label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "uht_CliveBehavioralHealthHospitalMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CliveBehavioralHealthHospitalMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Clive Behavioral Health Hospital", "label": "Clive Behavioral Health Hospital [Member]", "documentation": "Clive Behavioral Health Hospital." }
} }, "auth_ref": [] }, "uht_CliveBehavioralHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"CliveBehavioralHealthMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Clive Behavioral Health", "label": "Clive Behavioral Health [Member]", "documentation": "Clive behavioral health." } } }, "auth_ref": [] },
"uht_CliveIowaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CliveIowaMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Clive, Iowa", "label": "Clive Iowa [Member]", "documentation": "Clive, Iowa." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r805" ] }, "ecd_CoSelectedMeasureName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r805" ] }, "us-
gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareCashPaid",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends and dividend equivalents, per share", "verboseLabel": "Declared and paid dividends, per
share", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r96" ] }, "us-gaap_CommonStockMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": {
"terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r750", "r751", "r752",
"r754", "r755", "r756", "r759", "r874", "r875", "r903", "r926", "r929" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Common shares, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } },
"auth_ref": [ "r71" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": {
"role": { "terseLabel": "Common shares, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be

issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r71", "r611" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r71" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common shares, outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r71", "r611", "r629", "r929", "r930" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2024 - 13,848,950; 2023 - 13,823,899", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r71", "r544", "r747" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r810" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r809" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r811" ] },
"ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r808" ] }, "us-gaap_CompensatingBalanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensatingBalanceAmount", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Compensating Balance Amount", "label": "Compensating Balance, Amount", "documentation": "The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability." } } }, "auth_ref": [ "r139" ] },
"uht_ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions", "label": "Components Of Lessor Lease Revenue With U H S Facilities And Non Related Parties Table [Text Block]", "documentation": "Components of lessor lease revenue with UHS facilities and non-related parties." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r25", "r149", "r151", "r157", "r536", "r554" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Subtotal - comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r47", "r99", "r149", "r151", "r156", "r535", "r553" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income:", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r36", "r38", "r58", "r59", "r230", "r705" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r36", "r38", "r58", "r59", "r230", "r576", "r705" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r36", "r38", "r58", "r59", "r230", "r705", "r842" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "verboseLabel": "Percentage of revenues generated from leases and tenants", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r36", "r38", "r58", "r59", "r230" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." }
} }, "auth_ref": [ "r36", "r38", "r58", "r59", "r230", "r705" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } },
"auth_ref": [ "r120", "r171", "r398", "r399", "r402", "r403", "r484", "r715", "r854", "r855", "r856", "r890", "r893", "r894" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r120", "r171", "r398", "r399", "r402", "r403", "r484", "r715", "r854", "r855", "r856", "r890", "r893", "r894" ] }, "us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Invoices accrued for construction and improvements", "label": "Construction in Progress Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for construction in progress expenditures that have occurred." } } }, "auth_ref": [ "r32", "r33", "r34" ] }, "us-gaap_ConstructionLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionLoan", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLC
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Construction loan", "label": "Construction Loan", "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans." } } }, "auth_ref": [ "r69" ] }, "uht_ConstructionLoanOutstandingBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "ConstructionLoanOutstandingBalance", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Construction loan outstanding balance", "label": "Construction Loan Outstanding Balance", "documentation": "Construction loan outstanding balance." } }
}, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "lang": { "en-us": { "role": {
"label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r872" ] }, "uht_ConversionOfLoanToEquityMethodInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "ConversionOfLoanToEquityMethodInvestment", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Loan balance converted to equity invesment", "label": "Conversion of Loan to Equity Method Investment", "documentation": "Conversion of loan to equity method investment.", "verboseLabel": "Conversion of Loan to Equity Method Investment" } } }, "auth_ref": [] }, "uht_CorpusChristiCorpusChristiTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CorpusChristiCorpusChristiTexasMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Corpus Christi Corpus Christi Texas", "label": "Corpus Christi Corpus Christi Texas [Member]", "documentation": "Corpus Christi Corpus Christi, Texas." } } }, "auth_ref": [] },
"uht_CorpusChristiTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CorpusChristiTexasMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Corpus Christi, Texas.", "label": "Corpus Christi, Texas [Member]", "terseLabel": "Corpus Christi, Texas" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Advisory fee", "totalLabel": "Cost of Goods and Services Sold, Total", "terseLabel": "Advisory fees to UHS", "documentation": "The aggregate costs related to goods produced and sold and services

rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r83", "r516" ] }, "uht_CostOfMedicalOfficeBuilding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CostOfMedicalOfficeBuilding", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Cost of medical office building", "label": "Cost Of Medical Office Building", "documentation": "Cost of medical office building." } } }, "auth_ref": [] }, "uht_CostOfMedicalOfficeBuildingIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CostOfMedicalOfficeBuildingIncurred", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "label": "Cost Of Medical Office Building Incurred", "documentation": "Cost of medical office building incurred.", "terseLabel": "Cost of medical office building incurred" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Costs and Expenses, Total", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r82" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r131", "r169", "r170", "r313", "r331", "r482", "r722", "r724" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CumulativeDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CumulativeDividends", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Cumulative dividends", "label": "Cumulative Dividends", "documentation": "Amount of cumulative cash dividends distributed to shareholders." } } }, "auth_ref": [] }, "uht_CumulativeDividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "CumulativeDividendsMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative dividends", "label": "Cumulative Dividends [Member]", "documentation": "Cumulative dividends." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r37", "r230" ] }, "uht_DearbornMichiganMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DearbornMichiganMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Dearborn Michigan", "label": "Dearborn Michigan [Member]", "documentation": "Dearborn michigan." } } }, "auth_ref": [] }, "uht_DebtAndFinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DebtAndFinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Debt and Financial Instruments", "label": "Debt And Financial Instruments Disclosure [Text Block]", "documentation": "Debt and financial instruments disclosure." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Margin points added to the reference rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding Balance", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r14", "r101", "r327" ] }, "uht_DebtInstrumentCovenantComplianceSecuredLeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant, Secured leverage", "label": "Debt Instrument Covenant Compliance Secured Leverage Ratio", "documentation": "Debt instrument covenant compliance secured leverage ratio." } } }, "auth_ref": [] }, "uht_DebtInstrumentCovenantFixedChargeCoverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DebtInstrumentCovenantFixedChargeCoverageRatio", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant, Fixed charge coverage", "label": "Debt Instrument Covenant Fixed Charge Coverage Ratio", "documentation": "Debt instrument covenant fixed charge coverage ratio." } } }, "auth_ref": [] }, "uht_DebtInstrumentCovenantLeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DebtInstrumentCovenantLeverageRatio", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant, Total leverage", "label": "Debt Instrument Covenant Leverage Ratio", "documentation": "Debt instrument covenant leverage ratio." } } }, "auth_ref": [] }, "uht_DebtInstrumentCovenantTangibleNetWorth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DebtInstrumentCovenantTangibleNetWorth", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant, Tangible net worth", "label": "Debt Instrument Covenant Tangible Net Worth", "documentation": "Debt instrument covenant tangible net worth." } } }, "auth_ref": [] }, "uht_DebtInstrumentCovenantUnencumberedLeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DebtInstrumentCovenantUnencumberedLeverageRatio", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant, Unencumbered leverage", "label": "Debt Instrument Covenant Unencumbered Leverage Ratio", "documentation": "Debt instrument covenant unencumbered leverage ratio." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Base rate description", "label": "Debt Instrument, Description of Variable Rate Basis", "documentation": "Description of reference rate used for variable rate of debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest Rate", "terseLabel": "Debt Instrument Interest Rate Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r19", "r311" ] }, "us-gaap_DebtInstrumentInterestRateTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateTerms", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility, Interest Rate Terms", "label": "Debt Instrument, Interest Rate Terms", "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets." } } }, "auth_ref": [ "r19" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r171", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r456", "r732", "r733", "r734", "r735", "r736", "r868" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r114", "r732", "r904" ] }, "uht_DebtInstrumentMaturityMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DebtInstrumentMaturityMonthAndYear", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Maturity Date", "terseLabel": "Debt Instrument Maturity Date", "label": "Debt Instrument Maturity Month And Year", "documentation": "Debt instrument, maturity, month and year." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r42", "r43", "r60", "r61", "r62", "r66", "r94", "r95", "r171", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r456", "r732", "r733", "r734", "r735", "r736", "r868" ] }, "us-gaap_DebtInstrumentUnamortizedPremium": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedPremium", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": {
"role": { "totalLabel": "Debt Instrument, Unamortized Premium, Total", "verboseLabel": "Plus net debt premium", "label": "Debt Instrument, Unamortized Premium", "documentation":
"Amount, after accumulated amortization, of debt premium." } } }, "auth_ref": [ "r60", "r62", "r896" ] }, "uht_DeferredChargesNotesReceivableAndOtherAssetsNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DeferredChargesNotesReceivableAndOtherAssetsNet", "crdr": "debit",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"documentation": "Deferred charges, notes receivable and other assets, net.", "label": "Deferred Charges, Notes Receivable and Other Assets, Net", "terseLabel": "Deferred charges, notes
receivable and other assets, net" } } }, "auth_ref": [] }, "uht_DenisonTexasMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DenisonTexasMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Denison Texas", "label": "Denison Texas [Member]", "documentation": "Denison, Texas." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel":
"Depreciation, Depletion and Amortization, Nonproduction, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction",
"documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize
the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the
period of an asset that is not used in production." } } }, "auth_ref": [ "r6", "r41" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel":
"Depreciation, Depletion and Amortization, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate
expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [
"r6", "r211" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Derivative Contract", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount
or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r599", "r602", "r616", "r617", "r618", "r619",
"r620", "r621", "r622", "r624", "r625", "r626", "r627", "r641", "r642", "r643", "r644", "r647", "r648", "r649", "r650", "r677", "r680", "r684", "r686", "r750", "r752" ] }, "us-
gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr":
"credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang":
{ "en-us": { "role": { "terseLabel": "Liability derivatives, fair value", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value,
before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net
settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [
"r13", "r52", "r77", "r144", "r724" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"DerivativeFixedInterestRate", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative instruments, fixed rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": []
}, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative Instrument", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r51", "r53", "r54", "r55",
"r599", "r602", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r624", "r625", "r626", "r627", "r641", "r642", "r643", "r644", "r647", "r648", "r649", "r650", "r677", "r680", "r684",
"r686", "r724", "r750", "r752" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Hedging Relationship", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r10", "r51", "r54" ] },
"uht_DerivativeInterestRateCapNetPaymentReceivedOrAccruedFromCounterParties": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DerivativeInterestRateCapNetPaymentReceivedOrAccruedFromCounterParties", "crdr": "debit",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Derivative interest rate cap, net payment received or accrued from counterparties", "label": "Derivative Interest Rate Cap Net Payment Received Or Accrued From
Counter Parties", "documentation": "Derivative interest rate cap, net payment received or accrued from counter parties." } } }, "auth_ref": [] },
"uht_DerivativeInterestRateCapPaymentOffsetDueToCounterParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "DerivativeInterestRateCapPaymentOffsetDueToCounterParties", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivative interest rate cap, offset due to counterparties", "label": "Derivative Interest Rate Cap Payment Offset Due To Counter Parties", "documentation": "Derivative
interest rate cap payment offset due to counter parties." } } }, "auth_ref": [] }, "uht_DerivativeInterestRateCapPaymentReceivedOrAccruedFromCounterParties": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DerivativeInterestRateCapPaymentReceivedOrAccruedFromCounterParties",
"crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Derivative interest rate cap, payment received or accrued from counterparties", "label": "Derivative Interest Rate Cap Payment Received Or
Accrued From Counter Parties", "documentation": "Derivative interest rate cap payment received or accrued from counter parties." } } }, "auth_ref": [] }, "us-
gaap_DerivativeMaturityDates": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeMaturityDates", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Expiration date of interest rate", "label": "Derivative, Contract End Date", "documentation": "Date derivative contract ends, in YYYY-MM-DD format." } } }, "auth_ref": [
"r601", "r602", "r677", "r679", "r682", "r683", "r685", "r752" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "DerivativeNotionalAmount", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r900",
"r901" ] }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNumberOfInstrumentsHeld",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "totalLabel": "Derivative, Number of Instruments Held, Total", "terseLabel": "Number of interest rate cap agreements", "label": "Derivative, Number of Instruments Held",
"documentation": "The number of derivative instruments of a particular group held by the entity." } } }, "auth_ref": [ "r48", "r49", "r601", "r677", "r678", "r681", "r752" ] },
"uht_DesertValleyMedicalCenterFixedRateMortgageLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"DesertValleyMedicalCenterFixedRateMortgageLoanMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Desert Valley Medical Center Fixed Rate Mortgage Loan", "label": "Desert Valley Medical Center Fixed Rate Mortgage Loan [Member]", "documentation": "Desert
valley medical center fixed rate mortgage loan." } } }, "auth_ref": [] }, "us-gaap_DirectFinancingLeaseInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "DirectFinancingLeaseInterestIncome", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "verboseLabel":
"Interest income on financing leases - UHS facilities", "terseLabel": "Interest income on financing leases", "label": "Direct Financing Lease, Interest Income", "documentation": "Amount of
interest income from net investment in direct financing lease." } } }, "auth_ref": [ "r202", "r469" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": {
"label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "uht_DisclosuresOfLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DisclosuresOfLeasesTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccounting" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Accounting", "label":
"Disclosures Of Leases [Text Block]", "documentation": "Disclosures of leases." } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": {
"negatedLabel": "Dividends and dividend equivalents", "totalLabel": "Dividends, Total", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind
(PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r3", "r96" ] }, "uht_DividendsAndEquityIssuanceLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DividendsAndEquityIssuanceLineItems", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Dividends and Equity Issuance [Line Items]", "label": "Dividends And Equity Issuance [Line Items]", "documentation": "Dividends and equity issuance." } } }, "auth_ref": [] },
"uht_DividendsAndEquityIssuanceTable": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"DividendsAndEquityIssuanceTable", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Dividends And Equity Issuance [Table]", "label": "Dividends And Equity Issuance [Table]", "documentation": "Dividends and equity issuance." } } }, "auth_ref": [] },
"uht_DividendsPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "DividendsPerShare", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": {
"role": { "documentation": "Dividends, per share.", "terseLabel": "Dividends and dividend equivalents, per share", "label": "Dividend Per Share" } } }, "auth_ref": [] },
"dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal
Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1,
Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal
Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide
financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype":
"dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period
End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the
EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } },
"auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document
Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r766" ] },
"dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document
Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r799" ] },
"dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type",
"label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting
SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"EarningsPerShareBasic", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ],
"lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "terseLabel": "Basic earnings per share", "label": "Earnings Per Share, Basic", "documentation": "The amount

of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r158", "r183", "r184", "r185", "r186", "r187", "r194", "r196", "r198", "r199", "r200", "r201", "r429", "r430", "r537", "r555", "r725" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "terseLabel": "Diluted earnings per share", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r158", "r183", "r184", "r185", "r186", "r187", "r196", "r198", "r199", "r200", "r201", "r429", "r430", "r537", "r555", "r725" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r764" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r764" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r764" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r838" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r764" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r764" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r764" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r764" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r134", "r152", "r153", "r154", "r172", "r173", "r174", "r179", "r188", "r190", "r203", "r275", "r283", "r343", "r382", "r383", "r384", "r387", "r388", "r408", "r410", "r411", "r412", "r413", "r416", "r428", "r447", "r448", "r449", "r450", "r451", "r452", "r474", "r566", "r567", "r568", "r589", "r653" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlclspsAccountedUnderEq
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlclspsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlclspsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r265", "r266", "r268" ] }, "uht_EquityMethodInvestmentGroupOfInvesteesNameMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentGroupOfInvesteesNameMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlclspsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlclspsAccountedUnderEquityMethodDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees", "label": "Equity Method Investment Group Of Investees Name [Member]", "documentation": "Equity method investment, group of investees name." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlclspsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlclspsAccountedUnderEquityMethodDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r138", "r166", "r269", "r438" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlclspsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlclspsAccountedUnderEquityMethodDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r138", "r166", "r269", "r438" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlclspsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlclspsAccountedUnderEquityMethodDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees", "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]", "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity." }
} }, "auth_ref": [ "r857", "r869", "r884", "r905" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Ownership", "terseLabel": "Non-controlling equity interest, ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r265" ] },
"uht_EquityMethodInvestmentSummarizedFinancialInformationAdvancePaymentToLoansToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentSummarizedFinancialInformationAdvancePaymentToLoansToRelatedParty", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlclspsAccountedUnderEquityMethodDetail" ],

```
"lang": { "en-us": { "role": { "terseLabel": "Advances payable to us", "label": "Equity Method Investment Summarized Financial Information Advance Payment To Loans To Related Party",
"documentation": "Equity method investment summarized financial information advance payment to loans to related party." } } }, "auth_ref": [] },
"uht_EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet", "crdr":
"debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Net property, including construction in progress", "label": "Equity Method Investment Summarized Financial Information Assets Property Plant
And Equipment Net", "documentation": "Equity method investment summarized financial information assets property plant and equipment net." } } }, "auth_ref": [] },
"uht_EquityMethodInvestmentSummarizedFinancialInformationDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentSummarizedFinancialInformationDepreciationAndAmortization", "crdr": "debit",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Equity Method Investment Summarized Financial Information Depreciation And Amortization",
"documentation": "Equity method investment summarized financial information depreciation and amortization." } } }, "auth_ref": [] },
"uht_EquityMethodInvestmentSummarizedFinancialInformationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "EquityMethodInvestmentSummarizedFinancialInformationInterestExpense", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Interest, net", "label": "Equity Method Investment Summarized Financial Information Interest Expense", "documentation": "Equity method
investment summarized financial information interest expense." } } }, "auth_ref": [] }, "uht_EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail" ],
"lang": { "en-us": { "role": { "verboseLabel": "Mortgage notes payable, non-recourse to us", "terseLabel": "Mortgage Loan Balance", "label": "Equity Method Investment Summarized
Financial Information Mortgage Notes Payable", "documentation": "Equity Method Investment Summarized Financial Information Mortgage Notes Payable" } } }, "auth_ref": [] },
"uht_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses", "crdr": "debit", "presentation":
[
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Equity Method Investment Summarized Financial Information Operating Expenses", "documentation": "Equity
method investment, summarized financial information, operating expenses." } } }, "auth_ref": [] }, "uht_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"EquityMethodInvestmentSummarizedFinancialInformationOtherAssets", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Equity Method Investment Summarized Financial Information Other Assets", "documentation": "Equity method
investment summarized financial information other assets." } } }, "auth_ref": [] }, "uht_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities",
"crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Equity Method Investment Summarized Financial Information Other Liabilities", "documentation": "Equity Method
Investment Summarized Financial Information Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail" ],
"lang": { "en-us": { "role": { "totalLabel": "Our share of equity in LLCs, net", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the
entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the
entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r213",
"r263", "r858", "r883" ] }, "uht_EquityMethodInvestmentsAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentsAccruedExpensesAndOtherLiabilities", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail" ],
"lang": { "en-us": { "role": { "negatedLabel": "Amounts included in accrued expenses and other liabilities", "label": "Equity Method Investments Accrued Expenses And Other Liabilities",
"documentation": "Equity method investments accrued expenses and other liabilities." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "label": "Equity Method
Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliates" ], "lang": { "en-us": { "role": {
"terseLabel": "Summarized Financial Information of Equity Affiliates", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire
disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the
operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual
benefit of the members of the group." } } }, "auth_ref": [ "r116", "r267", "r270", "r839" ] }, "us-gaap_EquityMethodInvestmentsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq
], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments", "label": "Equity Method Investments [Member]", "documentation": "Investment in the stock of an investee which
is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition." } } }, "auth_ref": [] },
"uht_EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method", "label": "Equity Method Investments Summarized Combined Balance
Sheet Information Table [Text Block]", "documentation": "Equity Method Investments Summarized Combined Balance Sheet Information." } } }, "auth_ref": [] },
"uht_EquityMethodInvestmentsSummarizedIncomeStatementInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EquityMethodInvestmentsSummarizedIncomeStatementInformationTableTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method", "label": "Equity Method Investments Summarized Income
Statement Information Table [Text Block]", "documentation": "Equity Method Investments Summarized Income Statement Information." } } }, "auth_ref": [] }, "us-
gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Limited Liability Companies Accounted for Under Equity Method", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity
method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the
value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r264" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation
Assumption Difference, Footnote" } } }, "auth_ref": [ "r807" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]",
"terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r771", "r782", "r792", "r817" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r768", "r779", "r789", "r814" ] },
"uht_EvansvilleIndianaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EvansvilleIndianaMember",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Evansville indiana.", "label": "Evansville Indiana[Member]", "terseLabel": "Evansville, Indiana" } } }, "auth_ref": [] },
"uht_EvansvilleRehabilitationHospitalEvansvilleIndianaAndCorpusChristiFacilityCorpusChristiTexasMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "EvansvilleRehabilitationHospitalEvansvilleIndianaAndCorpusChristiFacilityCorpusChristiTexasMember",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Evansville Rehabilitation Hospital Evansville Indiana and Corpus Christi Facility Corpus Christi Texas.", "label": "Evansville Rehabilitation Hospital Evansville Indiana
And Corpus Christi Facility Corpus Christi Texas [Member]", "terseLabel": "Evansville Rehabilitation Hospital Evansville, Indiana and Corpus Christi Facility Corpus Christi, Texas" } } },
"auth_ref": [] }, "uht_EvansvilleRehabilitationHospitalEvansvilleIndianaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "EvansvilleRehabilitationHospitalEvansvilleIndianaMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Evansville Rehabilitation Hospital Evansville, Indiana", "label": "Evansville Rehabilitation Hospital Evansville Indiana [Member]", "documentation": "Evansville Rehabilitation Hospital
Evansville, Indiana." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [
"r813" ] }, "uht_FTXMobPhaseTwoLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"FTXMobPhaseTwoLPMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "FTX MOB Phase II limited partnership", "label": "F T X Mob Phase Two L P [Member]", "documentation": "Property Owned by Limited Liability Company
in which we have a majority, non-controlling equity interest" } } }, "auth_ref": [] }, "uht_FairMarketValueOfRealEstateAssetSold": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FairMarketValueOfRealEstateAssetSold", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Fair market value of real estate asset sold", "label": "Fair Market Value Of Real Estate Asset Sold", "documentation": "Fair market value of real
estate asset sold." } } }, "auth_ref": [] }, "uht_FairMarketValueOfRealEstateAssetsReceived": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FairMarketValueOfRealEstateAssetsReceived", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Fair market value of real estate assets received", "label": "Fair Market Value Of Real Estate Assets Received", "documentation": "Fair market
value of real estate assets received." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq
], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r11" ] }, "us-
gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq
```

], "lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r56", "r57" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r318", "r347", "r348", "r349", "r350", "r351", "r352", "r435", "r488", "r489", "r490", "r733", "r734", "r741", "r742", "r743" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r318", "r347", "r352", "r435", "r489", "r733", "r734", "r741", "r742", "r743" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r318", "r347", "r348", "r349", "r350", "r351", "r352", "r488", "r489", "r490", "r733", "r734", "r741", "r742", "r743" ] }, "uht_FederalFundsEffectiveRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FederalFundsEffectiveRateMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Federal Funds Effective Rate", "label": "Federal Funds Effective Rate [Member]", "documentation": "Federal funds effective rate." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r326", "r341", "r417", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r552", "r731", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r879", "r880", "r881", "r882" ] }, "uht_FinancingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FinancingArrangementsMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangements.", "label": "Financing Arrangements [Member]", "terseLabel": "Financing Arrangements" } } }, "auth_ref": [] }, "uht_FinancingFeesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FinancingFeesNet", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less net financing fees", "label": "Financing Fees Net", "documentation": "Financing fees net." } } }, "auth_ref": [] }, "uht_FinancingReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FinancingReceivable", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Financing receivable", "label": "Financing Receivable", "documentation": "Financing receivable." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r140", "r293" ] }, "uht_FireMesaOfficeBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FireMesaOfficeBuildingMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Fire Mesa Office Building [Member]", "label": "Fire Mesa Office Building [Member]", "documentation": "Fire Mesa office building located in Las Vegas." } } }, "auth_ref": [] }, "uht_FirstThreeYearRenewalOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FirstThreeYearRenewalOptionsMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "First Three Year Renewal Options", "label": "First Three Year Renewal Options [Member]", "documentation": "First three year renewal options." } } }, "auth_ref": [] }, "uht_FixedChargeCoverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FixedChargeCoverageRatio", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Fixed charge coverage", "label": "Fixed Charge Coverage Ratio", "documentation": "Fixed charge coverage ratio." } } }, "auth_ref": [] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r775", "r786", "r796", "r821" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r775", "r786", "r796", "r821" ] },
"ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r775", "r786", "r796", "r821" ] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r775", "r786", "r796", "r821" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r775", "r786", "r796", "r821" ] }, "uht_FourZeroFiveEightWMelroseFacilityChicagoIllinoisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FourZeroFiveEightWMelroseFacilityChicagoIllinoisMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "4058 W. Melrose Specialty Facility, Chicago, Illinois", "label": "Four Zero Five Eight W Melrose Facility Chicago Illinois [Member]", "documentation": "Four Zero Five Eight W. Melrose Facility Chicago, Illinois." } } }, "auth_ref": [] }, "uht_FrederickMarylandMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "FrederickMarylandMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Frederick, Maryland", "label": "Frederick Maryland [Member]", "documentation": "Frederick, Maryland." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfRealEstateDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfRealEstateDiscontinuedOperations", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of real estate assets", "label": "Gain (Loss) on Disposition of Real Estate, Discontinued Operations", "documentation": "Amount of difference between the carrying amount and the sales price of real estate properties sold as part of discontinued operations." } } }, "auth_ref": [] }, "uht_GraysonPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "GraysonPropertiesMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Grayson Properties", "label": "Grayson Properties [Member]", "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest" } } }, "auth_ref": [] }, "uht_GraysonPropertiesTwoLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "GraysonPropertiesTwoLPMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLC
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Grayson Properties II LP", "terseLabel": "Grayson Properties Two L P", "label": "Grayson Properties Two L P [Member]", "documentation": "Grayson properties two LP." } } }, "auth_ref": [] }, "uht_GroundLeaseAndMasterFlexLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "GroundLeaseAndMasterFlexLeaseAgreementMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Ground Lease and Master Flex-lease Agreement", "label": "Ground Lease And Master Flex Lease Agreement [Member]", "documentation": "Ground lease and master flex-lease agreement." } } }, "auth_ref": [] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Our share of net income", "terseLabel": "Equity in income of unconsolidated LLCs", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r6", "r79", "r104", "r212", "r263", "r549" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r294", "r296", "r638" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r296", "r638" ] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued interest", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":

"Accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r866" ] }, "uht_IncreaseDecreaseInLeasingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "IncreaseDecreaseInLeasingCosts", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Leasing costs paid", "label": "Increase Decrease In Leasing Costs", "documentation": "Increase decrease in leasing costs." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInLeasingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInLeasingReceivables", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Lease receivable", "label": "Increase (Decrease) in Leasing Receivables", "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements." } } }, "auth_ref": [ "r5" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total", "negatedLabel": "Other, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r5" ] }, "uht_IncreaseDecreaseInTenantReservesDepositsDeferredAndPrepaidRents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "IncreaseDecreaseInTenantReservesDepositsDeferredAndPrepaidRents", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant reserves, deposits and deferred and prepaid rents", "label": "Increase Decrease In Tenant Reserves Deposits Deferred And Prepaid Rents", "documentation": "Increase (decrease) in tenant reserves, deposits, deferred and prepaid rents." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r778", "r786", "r796", "r813", "r821", "r825", "r833" ] }, "uht_InitialRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "InitialRent", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Initial rent", "label": "Initial Rent", "documentation": "Initial Rent." } } }, "auth_ref": [] }, "uht_InlandValleyCampusOfSouthwestHealthcareSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "InlandValleyCampusOfSouthwestHealthcareSystemMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Inland Valley Campus of Southwest Healthcare System", "label": "Inland Valley Campus Of Southwest Healthcare System [Member]", "documentation": "Inland Valley Campus of Southwest Healthcare System." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r831" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r767", "r837" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r767", "r837" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r767", "r837" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets (net of accumulated amortization of $11.4 million and $12.5 million, respectively)", "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r39", "r40" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Income (Expense), Net, Total", "terseLabel": "Interest expense, net", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r106" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r159", "r162", "r163" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r65", "r922" ] }, "uht_InterestRateSwapAgreementOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "InterestRateSwapAgreementOneMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Agreement One [Member]", "label": "Interest Rate Swap Agreement One [Member]", "terseLabel": "Interest Rate Swap Agreement One" } } }, "auth_ref": [] }, "uht_InterestRateSwapAgreementThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "InterestRateSwapAgreementThreeMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Interest rate swap agreement three.", "label": "Interest Rate Swap Agreement Three [Member]", "terseLabel": "Interest Rate Swap Agreement Three" } } }, "auth_ref": [] }, "uht_InterestRateSwapAgreementTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "InterestRateSwapAgreementTwoMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Interest rate swap agreement two.", "label": "Interest Rate Swap Agreement Two [Member]", "terseLabel": "Interest Rate Swap Agreement Two" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r718", "r757", "r758" ] }, "uht_InvestmentCommitments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "InvestmentCommitments", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment to investment", "label": "Investment Commitments", "documentation": "Commitments to invest." } } }, "auth_ref": [] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in limited liability companies (\"LLCs\")", "periodStartLabel": "Investment Owned, Fair Value, Beginning Balance", "periodEndLabel": "Investment Owned, Fair Value, Ending Balance", "label": "Investment Owned, Fair Value", "verboseLabel": "Investments in and advances to LLCs before amounts included in accrued expenses and other liabilities", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": [ "r580", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r600", "r603", "r604", "r614", "r615", "r661", "r664", "r665", "r666", "r672", "r673", "r674", "r675", "r676", "r689", "r690", "r692", "r693", "r694", "r752", "r762", "r927" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r592", "r594", "r595", "r597", "r600", "r661", "r664", "r668", "r673", "r674", "r687", "r688", "r693", "r695", "r696", "r697", "r698", "r752" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r592", "r594", "r595", "r597", "r600", "r661", "r664", "r668", "r673", "r674", "r687", "r688", "r693", "r695", "r696", "r697", "r698", "r752" ] }, "us-gaap_InvestmentTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeExtensibleEnumeration", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment, Type [Extensible Enumeration]", "documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company." } } }, "auth_ref": [ "r592", "r597", "r662", "r664", "r667", "r668", "r669", "r674", "r691", "r693" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Net Real Estate Investments and Financing receivable", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r541" ] }, "uht_KindredChicagoCentralHospitalCentralChicagoIllinoisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "KindredChicagoCentralHospitalCentralChicagoIllinoisMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Kindred Chicago Central Hospital Central Chicago, Illinois", "label": "Kindred Chicago Central Hospital Central Chicago Illinois [Member]", "documentation": "Kindred Chicago Central Hospital Central Chicago, Illinois." } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r859" ] }, "uht_LastTwoYearRenewalOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LastTwoYearRenewalOptionsMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Last Two Year Renewal Options", "label": "Last Two Year Renewal Options [Member]", "documentation": "Last two year renewal options." } } }, "auth_ref": [] }, "uht_LeaseAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LeaseAndOtherReceivables", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Lease and other receivables from UHS", "label": "Lease And Other Receivables", "documentation": "Lease and other receivables." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD

"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties
], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement."
} } }, "auth_ref": [ "r843" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LeaseContractualTermDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties
], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } },
"auth_ref": [ "r843" ] }, "uht_LeaseDemolitionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"LeaseDemolitionCost", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lease
Demolition Cost", "documentation": "Lease demolition cost." } } }, "auth_ref": [] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LeaseExpirationDate1", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Lease expiration date", "label": "Lease Expiration Date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-
DD format." } } }, "auth_ref": [] }, "uht_LeaseExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "LeaseExpirationMonthAndYear", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "End of Lease Term", "verboseLabel": "End of Lease Term", "label": "Lease Expiration Month And Year", "documentation": "Lease expiration, month and year."
} } }, "auth_ref": [] }, "uht_LeasePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LeasePercentage",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Lease percentage", "label": "Lease Percentage", "documentation": "Lease percentage." } } }, "auth_ref": [] }, "uht_LeaseReceivableOther": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LeaseReceivableOther", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Lease
receivable - other", "label": "Lease Receivable Other", "documentation": "Lease receivable, other." } } }, "auth_ref": [] }, "uht_LeaseRenewalNoticePeriod": { "xbrltype":
"durationItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LeaseRenewalNoticePeriod", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Option to renew lease, notice period prior to termination date of current term", "label": "Lease Renewal Notice Period", "documentation":
"Lease renewal, notice period." } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract",
"lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "uht_LeasesDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LeasesDisclosureLineItems", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties
], "lang": { "en-us": { "role": { "terseLabel": "Leases Disclosure [Line Items]", "label": "Leases Disclosure [Line Items]", "documentation": "Leases Disclosure [Line Items]" } } }, "auth_ref":
[] }, "uht_LeasesDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LeasesDisclosureTable",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties
], "lang": { "en-us": { "role": { "terseLabel": "Leases Disclosure [Table]", "label": "Leases Disclosure [Table]", "documentation": "Leases Disclosure [Table]" } } }, "auth_ref": [] }, "us-
gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Lessee operating lease, existence of option to extend", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
"documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r465" ] },
"uht_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Aggregate lease payments for thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Lessee
operating lease liability payments due after year four." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "Aggregate lease payments for 2025", "documentation": "Amount of
lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods
are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "Aggregate lease payments for 2028", "documentation": "Amount of
lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "Aggregate lease payments for 2027", "documentation": "Amount of
lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods
are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "Aggregate lease payments for 2026", "documentation": "Amount of
lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r466" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "verboseLabel": "Aggregate lease payments for 2024", "documentation":
"Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal
year." } } }, "auth_ref": [ "r907" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseRenewalTerm", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Operating lease renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal,
in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r906" ] }, "us-
gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "verboseLabel": "Lease contract term", "terseLabel": "Lease renewal term", "documentation": "Term of
lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r906" ] }, "us-
gaap_LessorOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseRenewalTerm", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Renewal Term (years)", "label": "Lessor, Operating Lease, Renewal Term", "documentation": "Term of lessor's operating lease renewal, in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r909" ] }, "us-
gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseTermOfContract",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Term of lease", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r909" ] }, "us-
gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Letters of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a
beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of
the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Letters Of Credit Outstanding Amount", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of
credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "uht_LettersOfCreditTerminatedAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LettersOfCreditTerminatedAmount", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit terminated as of the reporting date.", "label": "Letters of Credit Terminated
Amount" } } }, "auth_ref": [] }, "uht_LeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LeverageRatio",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Total leverage", "label": "Leverage Ratio", "documentation": "Leverage ratio." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total
Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of
economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r18", "r166", "r269", "r301", "r302",
"r303", "r304", "r305", "r306", "r307", "r308", "r309", "r399", "r402", "r403", "r438", "r610", "r726", "r762", "r891", "r913", "r914" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel":
"Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [

"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r76", "r103", "r548", "r747", "r869", "r884", "r905" ] }, "uht_LimitedLiabilityCompanyOrLimitedPartnerMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LimitedLiabilityCompanyOrLimitedPartnerMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Limited Liability Companies", "label": "Limited Liability Company Or Limited Partner [Member]", "documentation": "Limited liability company or limited partner." } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Line of Credit, Total", "verboseLabel": "Outstanding borrowings under revolving credit agreement", "terseLabel": "Line of credit borrowings", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r14", "r101", "r923" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Facility fee payable on commitment", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "uht_LineOfCreditFacilityExpirationYearAndMonth": { "xbrltype":
"dateItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LineOfCreditFacilityExpirationYearAndMonth", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"verboseLabel": "Maturity date", "terseLabel": "Unsecured revolving amended credit agreement terminated date", "label": "Line Of Credit Facility Expiration Year And Month",
"documentation": "Line of credit facility expiration year and month." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Outstanding borrowing", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r16" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r16" ] }, "uht_LineOfCreditIncreaseInBorrowingCapacity": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LineOfCreditIncreaseInBorrowingCapacity", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Increase in borrowing capacity", "label": "Line Of Credit Increase In Borrowing Capacity", "documentation": "Line of credit increase in borrowing capacity." } } }, "auth_ref":
[] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "uht_LondonInterbankOfferedRatesLiborMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "LondonInterbankOfferedRatesLiborMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "London interbank offered rates libor.", "label": "London Interbank Offered Rates (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } },
"auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Mortgage loan fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_LongTermLoansPayable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermLoansPayable", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "totalLabel": "Loans Payable, Noncurrent, Total", "terseLabel": "Third-party term loan", "label": "Loans Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r20" ] },
"srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r230", "r740", "r897", "r924", "r925" ] }, "us-gaap_MajorPropertyClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "MajorPropertyClassAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Major Property Class", "label": "Major Property Class [Axis]", "documentation": "Amount of property owned but leased or available for lease to third parties, by major property class." } } }, "auth_ref": [ "r107" ] }, "us-gaap_MajorPropertyClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"MajorPropertyClassDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Major Property Class", "label": "Major Property Class [Domain]", "documentation": "The major classes of assets leased or available for lease to third parties under operating lease agreements as of the balance sheet date." } } }, "auth_ref": [ "r107" ] }, "us-gaap_ManagementServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ManagementServiceMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel":
"Management Service", "label": "Management Service [Member]", "documentation": "Contractually stipulated right to receive compensation for operating and managing business." } } },
"auth_ref": [ "r898" ] }, "uht_MarginOnBaseRate": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"MarginOnBaseRate", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Margin points added to the base rate", "label": "Margin On Base Rate", "documentation": "Margin on base rate." } } }, "auth_ref": [] },
"uht_MasterFlexLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"MasterFlexLeaseAgreementMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "documentation": "Master flex lease agreement.", "label": "Master Flex Lease Agreement [member]", "terseLabel": "Master Flex Lease Agreement" } } },
"auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r354", "r515", "r563", "r601", "r602", "r663", "r667", "r670", "r671", "r691", "r716", "r717", "r728", "r737", "r744", "r749", "r895", "r915", "r916", "r917", "r918", "r919", "r920" ] },
"uht_McAllenMedicalCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"McAllenMedicalCenterMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": {
"verboseLabel": "McAllen Doctor's Center", "terseLabel": "McAllen Medical Center", "label": "Mc Allen Medical Center [Member]", "documentation": "McAllen medical center." } } },
"auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r805" ] }, "ecd_MeasureName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r805" ] }, "uht_MedicalOfficeBuildingsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "MedicalOfficeBuildingsMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Medical office buildings", "terseLabel": "Medical Office Buildings", "label": "Medical Office Buildings [Member]", "documentation": "Medical office buildings." } } }, "auth_ref": [] }, "uht_MemberLoanUsedToRepayMortgageLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "MemberLoanUsedToRepayMortgageLoan", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Member loan used to repay mortgage loan", "label": "Member Loan Used To Repay Mortgage Loan", "documentation": "Member loan used to repay mortgage loan." } } }, "auth_ref": [] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [

"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestitures" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions and Divestitures", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r68", "r97" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r354", "r515", "r563", "r601", "r602", "r663", "r667", "r670", "r671", "r691", "r716", "r717", "r728", "r737", "r744", "r749", "r895", "r915", "r916", "r917", "r918", "r919", "r920" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "terseLabel": "Minority ownership interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r22", "r102", "r166", "r269", "r301", "r303", "r304", "r305", "r308", "r309", "r438", "r547", "r613" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minority ownership interest held by a third-party", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage upon completion of the minority ownership purchase", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r824" ] }, "uht_MonthlyLeaseRentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "MonthlyLeaseRentReceivable", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Monthly lease rent receivable", "label": "Monthly Lease Rent Receivable", "documentation": "Monthly lease rent receivable." } } }, "auth_ref": [] }, "uht_MortgageDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "MortgageDebt", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage debt", "label": "Mortgage Debt", "documentation": "Mortgage debt." } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate, Type of Property", "label": "Real Estate, Type of Property [Axis]", "documentation": "Information by type of real estate property." } } }, "auth_ref": [ "r119", "r130", "r704", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714" ] }, "srt_MortgageLoansOnRealEstateLoanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateLoanTypeAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type [Axis]", "documentation": "Information by type of loan for investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r129", "r703" ] }, "srt_MortgageLoansOnRealEstateLoanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateLoanTypeDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type [Domain]", "documentation": "Type of loan within investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate", "label": "Real Estate [Domain]", "documentation": "Land and any structures permanently fixed to it." } } }, "auth_ref": [ "r119", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r832" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r230", "r740", "r897", "r924", "r925" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r806" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r161" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r161" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r89", "r90", "r91" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net income", "totalLabel": "Net income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r80", "r91", "r105", "r138", "r147", "r150", "r154", "r166", "r178", "r183", "r184", "r185", "r186", "r189", "r190", "r197", "r208", "r216", "r221", "r224", "r269", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r430", "r438", "r551", "r631", "r651", "r652", "r727", "r760", "r891" ] }, "uht_NetProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NetProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Net proceeds from lines of credit.", "label": "Net Proceeds from Lines of Credit", "terseLabel": "Aggregate borrowings under Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_NetRentableArea": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetRentableArea", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Rentable square feet", "label": "Net Rentable Area", "documentation": "Net rentable area for properties owned." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r109", "r110", "r115", "r137", "r176", "r177", "r180", "r181", "r192", "r193", "r276", "r277", "r389", "r390", "r391", "r414", "r426", "r432", "r433", "r434", "r444", "r445", "r446", "r461", "r462", "r475", "r520", "r521", "r522", "r570", "r571", "r572", "r573", "r575" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype":

"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts
are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": [ "r132", "r133", "r134", "r135", "r136", "r175",
"r178", "r179", "r180", "r182", "r185", "r192", "r201", "r231", "r232", "r272", "r273", "r274", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r295", "r382", "r383", "r384", "r385",
"r386", "r387", "r388", "r392", "r393", "r394", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r415", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425",
"r427", "r428", "r429", "r430", "r431", "r436", "r437", "r440", "r441", "r442", "r443", "r453", "r454", "r457", "r458", "r459", "r460", "r470", "r471", "r472", "r473", "r474", "r517", "r518",
"r519", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r579" ] }, "us-
gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Summarization of the changes in an accounting principle or a new accounting
pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items." } } }, "auth_ref": [ "r35", "r132", "r133", "r134",
"r135", "r136", "r175", "r178", "r179", "r180", "r182", "r185", "r192", "r201", "r231", "r232", "r272", "r273", "r274", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r295", "r382",
"r383", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r394", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r415", "r416", "r419", "r420", "r421", "r422",
"r423", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r436", "r437", "r440", "r441", "r442", "r443", "r453", "r454", "r457", "r458", "r459", "r460", "r470", "r471", "r472", "r473",
"r474", "r517", "r518", "r519", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r579" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r805" ] },
"ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r775", "r786", "r796", "r813",
"r821" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO
NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r803" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO
NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r802" ] }, "ecd_NonPeoNeoMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r813" ] }, "uht_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NonRule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "documentation": "Non rule 10b51 arr modified flag", "label": "Non Rule 10b5-1 Arr Modified Flag" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag":
{ "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1
Arrangement Adopted" } } }, "auth_ref": [ "r832" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement
Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r832" ] }, "us-gaap_NonrecourseMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "NonrecourseMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Nonrecourse", "label": "Nonrecourse [Member]", "documentation": "Liability for which creditor does not have recourse to debtor but rather has recourse only to
property used for collateral in transaction or other specific property." } } }, "auth_ref": [ "r399", "r403" ] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label":
"Nonrelated Party [Member]", "terseLabel": "Non-Related Parties", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r870", "r871" ] }, "us-
gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableGross", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Financing
Receivable, before Allowance for Credit Loss, Total", "terseLabel": "Financing receivable from UHS", "label": "Financing Receivable, before Allowance for Credit Loss", "documentation":
"Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } },
"auth_ref": [ "r108", "r117", "r118", "r142", "r286", "r289", "r729", "r730", "r852", "r885" ] }, "uht_NumberOfAcuteCareAndBehavioralHealthCareHospitalFacilities": { "xbrltype":
"integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfAcuteCareAndBehavioralHealthCareHospitalFacilities", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of hospital facilities leased", "label": "Number Of Acute Care And Behavioral Health Care Hospital Facilities", "documentation":
"Number of acute care and behavioral health care hospital facilities." } } }, "auth_ref": [] }, "uht_NumberOfAcuteCareHospitalLeased": { "xbrltype": "integerItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfAcuteCareHospitalLeased", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of acute care hospital leased", "label": "Number Of Acute Care Hospital Leased", "documentation": "Number of acute care hospital
leased." } } }, "auth_ref": [] }, "uht_NumberOfBedFacility": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"NumberOfBedFacility", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of bed facility", "label": "Number Of Bed Facility", "documentation": "Number of bed facility." } } }, "auth_ref": [] },
"uht_NumberOfBehavioralHealthCareHospitalLeased": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"NumberOfBehavioralHealthCareHospitalLeased", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of behavioral health care hospital leased", "label": "Number Of Behavioral Health Care Hospital Leased", "documentation": "Number
of behavioral health care hospital leased." } } }, "auth_ref": [] }, "us-gaap_NumberOfBusinessesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "NumberOfBusinessesAcquired", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Number of acquisitions", "label": "Number of Businesses Acquired", "documentation": "The number of businesses acquired by the entity during the period." } } }, "auth_ref":
[] }, "uht_NumberOfBusinessesDisposed": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"NumberOfBusinessesDisposed", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"verboseLabel": "Number of dispositions", "label": "Number Of Businesses Disposed", "documentation": "Number of businesses disposed." } } }, "auth_ref": [] },
"uht_NumberOfExtensionOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfExtensionOptions",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Number of additional six month extension options", "label": "Number Of Extension Options", "documentation": "Number of extension options." } } }, "auth_ref": []
}, "uht_NumberOfGroundLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfGroundLeases",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of ground leases", "label": "Number Of Ground Leases", "documentation": "Number of ground leases." } } }, "auth_ref": [] },
"uht_NumberOfGroundLeasesForLand": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"NumberOfGroundLeasesForLand", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Lessee in connection with ground leases for land", "label": "Number Of Ground Leases For Land", "documentation": "Number of ground leases for land." } } }, "auth_ref": [] },
"uht_NumberOfHospitalsOperatingLeaseTermsOfExistingAndRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "NumberOfHospitalsOperatingLeaseTermsOfExistingAndRenewalOptions", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of hospitals operating lease terms of existing and renewal options", "label": "Number Of Hospitals Operating Lease Terms Of Existing
And Renewal Options", "documentation": "Number of hospitals operating lease terms of existing and renewal options." } } }, "auth_ref": [] }, "uht_NumberOfLeaseProperty": { "xbrltype":
"integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfLeaseProperty", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Number of lease property", "label": "Number Of Lease Property", "documentation": "Number of lease property." } } }, "auth_ref": [] }, "uht_NumberOfLeaseRenewalOptionExercised": {
"xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfLeaseRenewalOptionExercised", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of lease renewal option exercised", "label": "Number Of Lease Renewal Option Exercised", "documentation": "Number of lease
renewal option exercised." } } }, "auth_ref": [] }, "uht_NumberOfLeasedPropertiesForMedicalOfficeBuildingsAndFreeStandingEmergencyDepartments": { "xbrltype": "integerItemType",
"nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfLeasedPropertiesForMedicalOfficeBuildingsAndFreeStandingEmergencyDepartments",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of medical office buildings and free standing emergency departments", "label": "Number Of Leased Properties For Medical Office
Buildings And Free Standing Emergency Departments", "documentation": "Number of leased properties for medical office buildings and free standing emergency departments." } } },
"auth_ref": [] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfRealEstateProperties",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Number of real estate investments", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the
balance sheet date." } } }, "auth_ref": [] }, "uht_NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction": { "xbrltype": "integerItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of
real estate investments", "label": "Number Of Real Estate Properties Including Property Under Construction", "documentation": "Number of real estate properties including property under
construction." } } }, "auth_ref": [] }, "uht_NumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"NumberOfRenewalOptions", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Number of term renewal options", "label": "Number Of Renewal Options", "documentation": "Number of renewal options." } } }, "auth_ref": []
}, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSegmentReportingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an
entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r878" ] },
"uht_NumberOfTradingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfTradingPeriod",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member", "label": "Number Of Trading

Period", "documentation": "Number of trading period." } } }, "auth_ref": [] }, "uht_NumberOfWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "NumberOfWhollyOwnedSubsidiaries", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Number of wholly-owned subsidiaries", "label": "Number Of Wholly Owned Subsidiaries", "documentation": "Number of wholly-owned subsidiaries." } } }, "auth_ref": [] }, "uht_OperatingExpensesDemolitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingExpensesDemolitionCosts", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Operating expenses demolition costs.", "label": "Operating Expenses Demolition Costs", "terseLabel": "Operating expenses demolition costs" } } }, "auth_ref": [] }, "uht_OperatingExpensesExcludingDemolition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingExpensesExcludingDemolition", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses excluding demolition", "label": "Operating Expenses Excluding Demolition", "documentation": "Operating expenses excluding demolition." } } }, "auth_ref": [] }, "uht_OperatingExpensesExcludingDepreciationAndAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingExpensesExcludingDepreciationAndAmortizationExpense", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Operating expenses (excluding depreciation and amortization expense.", "label": "Operating Expenses Excluding Depreciation And Amortization Expense", "terseLabel": "Operating expenses excluding depreciation and amortization expense" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Income before equity in income of unconsolidated limited liability companies (\"LLCs\") and interest expense", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r208", "r216", "r221", "r224", "r727" ] }, "uht_OperatingLeaseAdditionalNumberOfRenewalOptionsAtFairMarketValueLeaseRates": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeaseAdditionalNumberOfRenewalOptionsAtFairMarketValueLeaseRates", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "label": "Operating Lease Additional Number Of Renewal Options At Fair Market Value Lease Rates", "documentation": "Operating Lease Additional Number Of Renewal Options At Fair Market Value Lease Rates" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Lease Income, Total", "terseLabel": "Lease revenue", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r202", "r467", "r468" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Ground lease liabilities", "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Right-of-use land liabilities", "terseLabel": "Ground lease liabilities, net", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r464" ] }, "uht_OperatingLeasePaymentsExpected": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasePaymentsExpected", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "verboseLabel": "Lease payments expected", "terseLabel": "Lease payments expected", "label": "Operating Lease Payments Expected", "documentation": "Operating lease payments expected." } } }, "auth_ref": [] }, "uht_OperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease terms on ground leases", "label": "Operating Lease Remaining Lease Term", "documentation": "Operating lease remaining lease term." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Right-of-use land assets", "terseLabel": "Right-of-use land assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r463" ] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasedAssetsLineItems", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leased Assets [Line Items]", "label": "Operating Leased Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "uht_OperatingLeasesAnnualFutureMinimumPaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Annual Minimum Rent", "label": "Operating Leases Annual Future Minimum Payments Receivable", "documentation": "Operating leases, annual future minimum payments receivable." } } }, "auth_ref": [] }, "uht_OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates": { "xbrltype": "positiveIntegerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of renewal option at existing lease rates", "terseLabel": "Number of renewal options at existing lease rates", "label": "Operating Leases Number Of Renewal Options At Existing Lease Rates", "documentation": "Operating leases, number of renewal options at existing lease rates." } } }, "auth_ref": [] }, "uht_OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates": { "xbrltype": "positiveIntegerItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of renewal options at fair market value lease rates", "label": "Operating Leases Number Of Renewal Options At Fair Market Value Lease Rates", "documentation": "Operating leases, number of renewal options at fair market value lease rates." } } }, "auth_ref": [] }, "uht_OperatingLeasesRenewalOptionsAtExistingLeaseRatesExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasesRenewalOptionsAtExistingLeaseRatesExpirationYear", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal option at existing lease rates expiration year", "documentation": "Operating leases, renewal options at existing lease rates, expiration year.", "label": "Operating Leases Renewal Options At Existing Lease Rates Expiration Year" } } }, "auth_ref": [] }, "uht_OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Renewal options at fair market value lease rates expiration year", "label": "Operating Leases Renewal Options At Fair Market Value Lease Rates Expiration Year", "documentation": "Operating leases, renewal options at fair market value lease rates, expiration year." } } }, "auth_ref": [] }, "uht_OperatingLeasesRenewalOptionsAtLeaseRatesStipulatedInLeaseExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasesRenewalOptionsAtLeaseRatesStipulatedInLeaseExpirationYear", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Renewal options at lease rate stipulated in lease expiration year", "label": "Operating Leases Renewal Options At Lease Rates Stipulated In Lease Expiration Year", "documentation": "Operating leases renewal options at lease rates stipulated in lease expiration year." } } }, "auth_ref": [] }, "uht_OperatingLeasesRenewalOptionsTermAtExistingLeaseRates": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasesRenewalOptionsTermAtExistingLeaseRates", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options term at existing lease rates.", "label": "Operating Leases Renewal Options Term At Existing Lease Rates", "terseLabel": "Renewal option term at existing lease rates" } } }, "auth_ref": [] }, "uht_OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Renewal options term at fair market value lease rates", "label": "Operating Leases Renewal Options Term At Fair Market Value Lease Rates", "documentation": "Operating leases, renewal options term at fair market value lease rates." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneral" ], "lang": { "en-us": { "role": { "terseLabel": "General", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r67", "r98", "r577", "r578" ] }, "uht_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "documentation": "Organization consolidation and presentation of financial statements." } } }, "auth_ref": [] }, "uht_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "documentation": "Organization consolidation and presentation of financial statements." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets:", "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":

"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized derivative (loss)/gain on cash flow hedges", "label": "Unrealized net gain/(loss) on cash flow hedges", "verboseLabel": "Unrealized (loss)/gain on cash flow
hedges", "totalLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Total", "documentation": "Amount, after tax and reclassification,
of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r145", "r146" ] }, "us-
gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": {
"totalLabel": "Total other comprehensive (loss)/gain:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of
other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r4", "r7", "r99", "r148", "r151" ] }, "us-
gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": {
"label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive gain/(loss):" } } }, "auth_ref": [] }, "us-
gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCostAndExpenseOperating", "crdr": "debit",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": {
"terseLabel": "Other operating expenses", "label": "Other Cost and Expense, Operating", "documentation": "The total amount of other operating cost and expense items that are associated
with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r84", "r556" ] }, "us-gaap_OtherExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "OtherExpenseMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Other Expenses", "label": "Other Expense [Member]", "documentation": "Primary financial statement caption encompassing other expense." } } }, "auth_ref": [ "r12" ] },
"uht_OtherOperatingExpensesDemolitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"OtherOperatingExpensesDemolitionCosts", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Other operating expenses demolition costs", "label": "Other Operating Expenses Demolition Costs", "documentation": "Other operating expenses demolition costs." } } }, "auth_ref": [] },
"ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } },
"auth_ref": [ "r805" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel":
"Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r773", "r784", "r794", "r819" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r776", "r787", "r797", "r822" ] }, "ecd_OutstandingRecoveryIndName": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r776", "r787", "r797", "r822" ] }, "srt_OwnershipAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Ownership", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method
investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname":
"OwnershipDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Ownership", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and
named security investment." } } }, "auth_ref": [] }, "uht_PalmBeachFloridaMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "PalmBeachFloridaMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Palm Beach, Florida", "label": "Palm Beach Florida [Member]", "documentation": "Palm Beach, Florida." } } }, "auth_ref": [] },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-
us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r801" ] },
"uht_PaymentsForDepositOnRealEstateAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"PaymentsForDepositOnRealEstateAssets", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"negatedLabel": "Deposit on real estate assets", "label": "Payments For Deposit On Real Estate Assets", "documentation": "Payments for deposit on real estate assets." } } }, "auth_ref": [] },
"us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel":
"Payments of Dividends, Total", "terseLabel": "Dividends declared and paid", "label": "Payments of Dividends", "negatedLabel": "Dividends and dividend equivalents", "negatedTerseLabel":
"Dividends paid", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } },
"auth_ref": [ "r29" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr":
"credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us":
{ "role": { "totalLabel": "Payments of Financing Costs, Total", "negatedLabel": "Financing costs paid", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan
and debt issuance costs." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Payment to acquire business", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the
acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r26", "r395" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel":
"Payments to Acquire Investments, Total", "negatedLabel": "Investments in LLCs", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the
purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r87" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel":
"Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Cash paid for acquisition of properties", "label": "Payments to Acquire Property, Plant, and Equipment",
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not
intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r88" ] }, "uht_PaymentsToAssetExchangeTransaction": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "PaymentsToAssetExchangeTransaction", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Net cash paid as part of asset exchange transaction", "label": "Payments To Asset Exchange Transaction", "documentation": "Payments to asset exchange transaction." } } }, "auth_ref": []
}, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PaymentsToFundLongtermLoansToRelatedParties", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"Payments to Fund Long-Term Loans to Related Parties", "negatedLabel": "Advances made to third-party partners", "documentation": "The cash outflow associated with extending a long-
term loan to a related party. Alternate caption: Payments for Advances to Affiliates." } } }, "auth_ref": [ "r864", "r910" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us":
{ "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r804" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r804" ] },
"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } }
}, "auth_ref": [ "r803" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r813" ] }, "ecd_PeoName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r806" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel":
"PEO Total Compensation Amount" } } }, "auth_ref": [ "r802" ] }, "uht_PercentageOfAnnualRentalIncrease": { "xbrltype": "percentItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "PercentageOfAnnualRentalIncrease", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "verboseLabel": "Percentage of annual rental increase", "terseLabel": "Percentage of annual rental increase on cumulative and compound basis", "label":
"Percentage Of Annual Rental Increase", "documentation": "Percentage of annual rental increase." } } }, "auth_ref": [] },
"uht_PercentageOfAnnualRentalIncreaseOnCumulativeAndCompoundBasis": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "PercentageOfAnnualRentalIncreaseOnCumulativeAndCompoundBasis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ],
"lang": { "en-us": { "role": { "verboseLabel": "Percentage of annual rental increase", "documentation": "Percentage of annual rental increase on cumulative and compound basis.", "label":
"Percentage Of Annual Rental Increase On Cumulative And Compound Basis", "terseLabel": "Percentage of annual rental increase on cumulative and compound basis" } } }, "auth_ref": [] },
"uht_PercentageOfLease": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "PercentageOfLease", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Percentage of lease", "label": "Percentage Of Lease", "documentation": "Percentage of lease." } } }, "auth_ref": [] },
"uht_PercentageOfLeaseGuaranteed": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"PercentageOfLeaseGuaranteed", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Percentage of lease guaranteed", "label": "Percentage Of Lease Guaranteed", "documentation": "Percentage Of Lease Guaranteed." } } },
"auth_ref": [] }, "uht_PercentageOfOwnershipInterestRelatedParties": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"PercentageOfOwnershipInterestRelatedParties", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Percentage ownership of outstanding shares", "label": "Percentage Of Ownership Interest Related Parties", "documentation": "Percentage of
ownership interest related parties." } } }, "auth_ref": [] }, "uht_PercentageOfRentableSquareFeet": { "xbrltype": "percentItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "PercentageOfRentableSquareFeet", "presentation": [

"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Percentage of rentable square feet", "label": "Percentage Of Rentable Square Feet", "documentation": "Percentage of rentable square feet." } }
}, "auth_ref": [] }, "uht_PeriodToPurchaseRespectiveLeasedFacilitiesAfterLeaseTerms": { "xbrltype": "durationItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "PeriodToPurchaseRespectiveLeasedFacilitiesAfterLeaseTerms", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Period to purchase respective leased facilities at same price after lease terms", "label": "Period To Purchase Respective Leased Facilities After Lease Terms", "documentation": "Period to purchase respective leased facilities after lease terms." } } }, "auth_ref": [] },
"uht_PeriodToPurchaseRespectiveLeasedFacilitiesPriorToEndOfLeaseTermOrRenewalTerms": { "xbrltype": "durationItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "PeriodToPurchaseRespectiveLeasedFacilitiesPriorToEndOfLeaseTermOrRenewalTerms", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Period to purchase respective leased facilities prior to end of lease term or renewal terms", "label": "Period To Purchase Respective Leased Facilities Prior To End Of Lease Term Or Renewal Terms", "documentation": "Period to purchase respective leased facilities prior to end of lease term or renewal terms." } } }, "auth_ref":
[] }, "uht_PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan", "label": "Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan [Member]",
"documentation": "Phoenix children's east valley care center fixed rate mortgage loan." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Preferred shares of beneficial interest, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r70", "r329" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Preferred shares of beneficial interest, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r70", "r611" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "Preferred shares of beneficial interest, issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r70", "r329" ] }, "us-
gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": {
"periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred shares of beneficial interest, outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r70", "r611", "r629", "r929", "r930"
] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r70", "r543",
"r747" ] }, "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ProceedsFromCollectionOfLongtermLoansToRelatedParties", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel":
"Advance received from LLC", "negatedLabel": "Advance received from LLC", "label": "Proceeds from Collection of Long-Term Loans to Related Parties", "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates." } } }, "auth_ref": [ "r863", "r910" ] }, "us-
gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr":
"debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "lang":
{ "en-us": { "role": { "terseLabel": "Net cash proceeds from stock issued", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel":
"Proceeds from Issuance or Sale of Equity, Total", "terseLabel": "Issuance of shares of beneficial interest, net", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r581" ] }, "us-
gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel":
"Proceeds from Lines of Credit, Total", "terseLabel": "Net borrowings on the line of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r27", "r868" ] }, "us-
gaap_ProceedsFromSaleOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfRealEstate", "crdr": "debit",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Cash received for sale of real estate asset", "label": "Proceeds from Sale of Real Estate", "documentation": "Cash received for the sale of real estate that is not part of an investing activity during the current period." } } }, "auth_ref": [ "r86" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel":
"Other", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r898" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel":
"Product and Service", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [
"r226", "r516", "r557", "r558", "r559", "r560", "r561", "r562", "r719", "r738", "r748", "r844", "r888", "r889", "r897", "r924" ] }, "srt_ProductsAndServicesDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel":
"Product and Service", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r226", "r516",
"r557", "r558", "r559", "r560", "r561", "r562", "r719", "r738", "r748", "r844", "r888", "r889", "r897", "r924" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel":
"Net income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r138", "r147", "r150", "r160", "r166", "r178", "r189", "r190", "r208",
"r216", "r221", "r224", "r269", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r397", "r400", "r401", "r430", "r438", "r538", "r550", "r588", "r631", "r651", "r652",
"r727", "r745", "r746", "r761", "r862", "r891" ] }, "uht_PropertyOwnedByLimitedLiabilityOrLimitedPartnerCompany": { "xbrltype": "stringItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "PropertyOwnedByLimitedLiabilityOrLimitedPartnerCompany", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Property Owned by LLC/LP", "label": "Property Owned By Limited Liability Or Limited Partner Company", "documentation": "Property owned by limited liability or limited partner company." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref":
[ "r801" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } },
"auth_ref": [ "r801" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r346", "r354", "r378", "r379", "r380", "r491",
"r515", "r563", "r601", "r602", "r663", "r667", "r670", "r671", "r691", "r716", "r717", "r728", "r737", "r744", "r749", "r752", "r887", "r895", "r916", "r917", "r918", "r919", "r920" ] },
"srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r346", "r354", "r378", "r379", "r380", "r491", "r515",
"r563", "r601", "r602", "r663", "r667", "r670", "r671", "r691", "r716", "r717", "r728", "r737", "r744", "r749", "r752", "r887", "r895", "r916", "r917", "r918", "r919", "r920" ] }, "us-
gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"RealEstateInvestmentPropertyAccumulatedDepreciation", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel":
"Accumulated depreciation", "label": "Real Estate Investment Property, Accumulated Depreciation", "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes." } } }, "auth_ref": [ "r539" ] }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "RealEstateInvestmentPropertyAtCost", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Real Estate

Investment Property, at Cost, Total", "terseLabel": "Buildings and improvements and construction in progress", "label": "Real Estate Investment Property, at Cost", "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r540" ] }, "us-gaap_RealEstateInvestmentPropertyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyNet", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Real Estate Investment Property, Net, Total", "label": "Real Estate Investment Property, Net", "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r921" ] }, "us-gaap_RealEstateInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestments", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Net Real Estate Investments", "label": "Real Estate Investments, Net", "documentation": "Amount of real estate investments, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; (7) other real estate investments; (8) real estate joint ventures; and (9) unconsolidated real estate and other joint ventures not separately presented." } } }, "auth_ref": [ "r540", "r928" ] }, "us-gaap_RealEstateInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentsAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Investments:", "label": "Real Estate Investments, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RealEstatePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePeriodIncreaseDecrease", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Period Increase (Decrease), Total", "terseLabel": "Additions to real estate investments, net", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) before accumulated depreciation of real estate investments for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r931" ] }, "us-gaap_RealEstatePropertiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLC "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Property Ownership", "label": "Real Estate Property Ownership [Axis]", "documentation": "Information by ownership of the property." } } }, "auth_ref": [] }, "us-gaap_RealEstatePropertiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLC "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties", "label": "Real Estate Properties [Domain]", "documentation": "Represents categories of ownership of real estate properties." } } }, "auth_ref": [] }, "us-gaap_RecourseStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RecourseStatusAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Recourse Status", "label": "Recourse Status [Axis]", "documentation": "Information by recourse or nonrecourse status of liability." } } }, "auth_ref": [ "r399", "r403" ] }, "us-gaap_RecourseStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RecourseStatusDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Recourse Status", "label": "Recourse Status [Domain]", "documentation": "Recourse or nonrecourse status of liability." } } }, "auth_ref": [ "r399", "r403" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.org/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r768", "r779", "r789", "r814" ] }, "us-gaap_RelatedAndNonrelatedPartyStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedAndNonrelatedPartyStatusAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Party Status [Axis]", "documentation": "Information by related and nonrelated party status." } } }, "auth_ref": [ "r167", "r168", "r479", "r480", "r481", "r482", "r605", "r606", "r607", "r608", "r609", "r628", "r630", "r753" ] }, "us-gaap_RelatedAndNonrelatedPartyStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedAndNonrelatedPartyStatusDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Party Status [Domain]", "documentation": "Related and nonrelated party status." } } }, "auth_ref": [ "r167", "r168", "r479", "r480", "r481", "r482", "r605", "r606", "r607", "r608", "r609", "r628", "r630", "r753" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r353", "r479", "r480", "r605", "r606", "r607", "r608", "r609", "r628", "r630", "r660" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r167", "r168", "r479", "r480", "r481", "r482", "r605", "r606", "r607", "r608", "r609", "r628", "r630", "r660" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r634", "r635", "r638" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r353", "r479", "r480", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r605", "r606", "r607", "r608", "r609", "r628", "r630", "r660", "r912" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r476", "r477", "r478", "r480", "r483", "r584", "r585", "r586", "r636", "r637", "r638", "r657", "r659" ] }, "uht_RenewalOptionTermsMaximumAdditionalPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RenewalOptionTermsMaximumAdditionalPeriod", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Renewal period of respective leased facilities at same price after lease terms", "label": "Renewal Option Terms Maximum Additional Period", "documentation": "Renewal option terms maximum additional period." } } }, "auth_ref": [] }, "uht_RenewalOptionsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RenewalOptionsTerm", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Renewal option term", "label": "Renewal Options Term", "documentation": "Renewal options term." } } }, "auth_ref": [] }, "uht_RenoNevadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RenoNevadaMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Reno, Nevada", "label": "Reno Nevada [Member]", "documentation": "Reno, Nevada." } } }, "auth_ref": [] }, "uht_RepaymentOfLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RepaymentOfLoan", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of loan", "label": "Repayment Of Loan", "documentation": "Repayment of loan." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {

"terseLabel": "Repayment of mortgage loan", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r865" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Repayments of Lines of Credit", "terseLabel": "Aggregate repayments", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r30", "r868" ] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of mortgage notes payable", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r30" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r169", "r170", "r313", "r331", "r482", "r723", "r724" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r769", "r780", "r790", "r815" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r770", "r781", "r791", "r816" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r777", "r788", "r798", "r823" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "terseLabel": "Cumulative net income", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r73", "r96", "r546", "r570", "r575", "r583", "r612", "r747" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative net income", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r134", "r172", "r173", "r174", "r179", "r188", "r190", "r275", "r283", "r382", "r383", "r384", "r387", "r388", "r408", "r411", "r412", "r416", "r428", "r566", "r568", "r589", "r929" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r209", "r210", "r215", "r219", "r220", "r226", "r228", "r230", "r344", "r345", "r516" ] }, "uht_RevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RevenueMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue [Member]", "documentation": "Revenue." } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Revenues, Total", "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r155", "r166", "r209", "r210", "r215", "r219", "r220", "r226", "r228", "r230", "r269", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r438", "r538", "r891" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "uht_RevolvingAFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RevolvingAFacilityMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving A Facility", "label": "Revolving A Facility [Member]", "documentation": "Revolving A facility." } } }, "auth_ref": [] }, "uht_RevolvingBFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RevolvingBFacilityMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving B Facility", "label": "Revolving B Facility [Member]", "documentation": "Revolving B facility." } } }, "auth_ref": [] }, "uht_RevolvingCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RevolvingCreditAgreementMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Agreement", "label": "Revolving Credit Agreement [Member]", "documentation": "Revolving credit agreement." } } }, "auth_ref": [] }, "uht_RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan", "label": "Rosenberg Children Medical Plaza Fixed Rate Mortgage Loan [Member]", "documentation": "Rosenberg children's medical plaza fixed rate mortgage loan." } } }, "auth_ref": [] }, "uht_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "Rule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Rule 10b51 arr modified flag.", "label": "Rule 10b5-1 Arr Modified Flag" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r832" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r832" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r355", "r853", "r877" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Scenario", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r192", "r355", "r840", "r877" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Mortgages, Excluding Net Debt Premium", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r20", "r42", "r43", "r60", "r61", "r62", "r66", "r94", "r95", "r733", "r735", "r873" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r265", "r266", "r268" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLC "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r166", "r265", "r266", "r268", "r269", "r438" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcslpsAccountedUnderEq "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedStatementsOfIncomeUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLC "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r138", "r166", "r265", "r266", "r268", "r269", "r438" ] }, "uht_ScheduleOfFinancialCovenantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "ScheduleOfFinancialCovenantsTableTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement", "label": "Schedule Of Financial Covenants Table [Text Block]", "documentation": "Schedule of Financial Covenants." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfOperatingLeasedAssetsTable", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule Of Operating Leased Assets [Table]", "label": "Schedule of Operating Leased Assets [Table]", "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } },
"auth_ref": [] }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities", "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block]", "documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease." } } },
"auth_ref": [ "r107", "r886", "r908" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]",
"documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r63", "r64", "r634", "r635", "r638" ] },
"us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebt", "crdr": "credit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total mortgages notes payable, non-recourse to us, net", "terseLabel": "Mortgage notes payable, non-recourse to us, net", "label": "Secured Debt", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r14", "r101", "r923" ] },
"uht_SecuredLeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "SecuredLeverageRatio",
"presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Secured leverage", "label": "Secured Leverage Ratio", "documentation": "Secured leverage ratio." } } }, "auth_ref": [] }, "us-
gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate",
"documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r902" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname":
"Security12bTitle", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r763" ] },
"dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r765" ] },
"srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r119", "r121", "r122", "r123",
"r124", "r125", "r126", "r127", "r128", "r228", "r229", "r593", "r596", "r598", "r664", "r668", "r674", "r693", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r720",
"r739", "r752", "r897", "r924" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract",
"lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label":
"Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r204", "r205", "r206", "r207", "r208", "r214", "r218", "r222", "r223", "r224", "r225", "r226", "r227", "r230" ] }, "us-
gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel":
"Share-Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense",
"documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r5" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373",
"r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381" ] }, "uht_SharesOfBeneficialInterestAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "SharesOfBeneficialInterestAbstract", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": {
"terseLabel": "Shares of Beneficial Interest:", "label": "Shares Of Beneficial Interest [Abstract]", "documentation": "Shares of beneficial interest." } } }, "auth_ref": [] }, "us-
gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": {
"periodStartLabel": "Balance, Shares", "periodEndLabel": "Balance, Shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShortTermDebtMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Swingline/Short-Term Loans", "label": "Short-Term Debt [Member]", "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis",
"presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Short-Term Debt, Type", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Short-Term Debt, Type", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r15" ] }, "uht_SierraMedicalPlazaIMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "SierraMedicalPlazaIMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Sierra Medical Plaza I", "label": "Sierra Medical Plaza I [Member]", "documentation": "Sierra medical plaza I." } } }, "auth_ref": [] },
"uht_SouthwestHealthcareSystemInlandValleyCampusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"SouthwestHealthcareSystemInlandValleyCampusMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Southwest Healthcare System Inland Valley Campus.", "label": "Southwest Healthcare System Inland Valley Campus [Member]", "terseLabel": "Southwest Healthcare System Inland Valley Campus" } } }, "auth_ref": [] }, "uht_SpecialtyFacilityEvansvilleIndianaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630",
"localname": "SpecialtyFacilityEvansvilleIndianaMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Specialty facility evansville indiana.", "label": "Specialty Facility Evansville Indiana[Member]", "terseLabel": "Specialty Facility Evansville Indiana" } } }, "auth_ref": [] },
"uht_SpecialtyFacilityInCorpusChristiTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"SpecialtyFacilityInCorpusChristiTexasMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Specialty Facility In Corpus Christi Texas [Member]", "label": "Specialty Facility In Corpus Christi Texas [Member]", "terseLabel": "Specialty Facility In Corpus Christi Texas" } } },
"auth_ref": [] }, "uht_SpecialtyHospitalInChicagoIllinoisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"SpecialtyHospitalInChicagoIllinoisMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Specialty Hospital In Chicago, Illinois", "label": "Specialty Hospital In Chicago, Illinois [Member]", "documentation": "Specialty hospital in chicago, illinois." } } }, "auth_ref": [] }, "us-
gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": {
"terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r21", "r134", "r152", "r153",
"r154", "r172", "r173", "r174", "r179", "r188", "r190", "r203", "r275", "r283", "r343", "r382", "r383", "r384", "r387", "r388", "r408", "r410", "r411", "r412", "r413", "r416", "r428", "r447",
"r448", "r449", "r450", "r451", "r452", "r474", "r566", "r567", "r568", "r589", "r653" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023",
"localname": "StatementGeographicalAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r119", "r130",
"r228", "r229", "r593", "r596", "r598", "r664", "r668", "r674", "r693", "r704", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r720", "r739", "r752", "r897", "r924" ] },
"us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome",

```
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r172", "r173", "r174", "r203", "r516", "r580", "r590", "r603", "r605", "r606", "r607", "r608", "r609", "r611", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r624", "r625", "r626", "r627", "r628", "r630", "r632", "r633", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r653", "r753" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Scenario", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r192", "r355", "r840", "r841", "r877" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r172", "r173", "r174", "r203", "r516", "r580", "r590", "r603", "r605", "r606", "r607", "r608", "r609", "r611", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r624", "r625", "r626", "r627", "r628", "r630", "r632", "r633", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r653", "r753" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r772", "r783", "r793", "r818" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issued, net (in shares)", "verboseLabel": "Share issued", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r70", "r71", "r96", "r581", "r653", "r699" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issued, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r70", "r71", "r96", "r589", "r653", "r699", "r761" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchased (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r9", "r70", "r71", "r96", "r582", "r653", "r700" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r9", "r70", "r71", "r96", "r589", "r653", "r700", "r761" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance", "totalLabel": "Total Equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r71", "r74", "r75", "r92", "r613", "r629", "r654", "r655", "r747", "r762", "r869", "r884", "r905", "r929" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsUnauditedForLlcslpsAccountedUnderEquityMethodDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r44", "r45", "r46", "r134", "r135", "r153", "r172", "r173", "r174", "r179", "r188", "r275", "r283", "r343", "r382", "r383", "r384", "r387", "r388", "r408", "r410", "r411", "r412", "r413", "r416", "r428", "r447", "r448", "r452", "r474", "r567", "r568", "r587", "r613", "r629", "r654", "r655", "r701", "r761", "r869", "r884", "r905", "r929" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends and Equity Issuance Program", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r93", "r165", "r328", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r342", "r343", "r418", "r656", "r658", "r702" ] }, "srt_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SubsidiariesMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary", "label": "Subsidiaries [Member]", "documentation": "Entity in which controlling financial interest is held. Includes, but is not limited to, variable interest entity (VIE) consolidated by primary beneficiary. Excludes entity in which broker-dealer holds controlling financial interest but control is likely to be temporary." } } }, "auth_ref": [ "r899", "r910", "r911", "r912" ] }, "uht_SuburbanPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "SuburbanPropertiesMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Suburban Properties", "label": "Suburban Properties [Member]", "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest" } } }, "auth_ref": [] }, "uht_SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan", "label": "Summerlin Hospital Medical Office Building Three Fixed Rate Mortgage Loan [Member]", "documentation": "Summerlin hospital medical office building three fixed rate mortgage loan." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2023", "localname": "TX", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "label": "TEXAS" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r812" ] }, "uht_TangibleNetWorth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "TangibleNetWorth", "crdr": "debit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Tangible net worth", "label": "Tangible Net Worth", "documentation": "Tangible net worth." } } }, "auth_ref": [] }, "uht_TempleTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "TempleTexasMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma ], "lang": { "en-us": { "role": { "terseLabel": "Temple, Texas", "label": "Temple Texas [Member]", "documentation": "Temple, Texas." } } }, "auth_ref": [] }, "uht_TenantReimbursementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "TenantReimbursementsMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties ], "lang": { "en-us": { "role": { "terseLabel": "Tenant Reimbursements", "label": "Tenant Reimbursements [Member]", "documentation": "Tenant reimbursements." } } }, "auth_ref": [] }, "uht_TenantReservesDepositsAndDeferredAndPrepaidRents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "TenantReservesDepositsAndDeferredAndPrepaidRents", "crdr": "credit", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant reserves, deposits and deferred and prepaid rents", "label": "Tenant Reserves Deposits And Deferred And Prepaid Rents", "documentation": "Amount at the balance sheet date that has been received by the entity that represents collections of cash or other assets related to real estate operations revenue for which revenue has not yet been recognized and money paid in advance to protect the provider of a product or services, such as a lessor, against damage or non-payment by the tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property and other contractual breaches." } } }, "auth_ref": [] }, "uht_TenantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "TenantsMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD ], "lang": { "en-us": { "role": { "terseLabel": "Tenants", "label": "Tenants [Member]", "documentation": "Tenants." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r804" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r811" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r831" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [
```

"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r833" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r326", "r341", "r417", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r552", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r879", "r880", "r881", "r882" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r834" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r835" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r833" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r833" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r836" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r834" ] }, "uht_TripleNetLeaseAgreementPeriod": { "xbrltype": "durationItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "TripleNetLeaseAgreementPeriod", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Initial lease term on property", "label": "Triple Net Lease Agreement Period", "documentation": "Triple net lease agreement period." } } }, "auth_ref": [] }, "uht_TuscanyProfessionalBuildingFixedRateMortgageLoanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "TuscanyProfessionalBuildingFixedRateMortgageLoanMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Tuscan Professional Building Fixed Rate Mortgage Loan", "label": "Tuscany Professional Building Fixed Rate Mortgage Loan [Member]", "documentation": "Debt Instrument 100% consolidated" } } }, "auth_ref": [] }, "uht_TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "2704 North Tenaya Way Fixed Rate Mortgage Loan", "label": "Two Seven Zero Four North Tenaya Way Fixed Rate Mortgage Loan [Member]", "documentation": "Two seven zero four north Tenaya way fixed rate mortgage loan." } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r132", "r133", "r134", "r135", "r136", "r178", "r179", "r180", "r182", "r192", "r231", "r232", "r272", "r273", "r274", "r275", "r278", "r279", "r280", "r281", "r282", "r283", "r295", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r394", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r415", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r428", "r429", "r430", "r431", "r436", "r437", "r440", "r441", "r442", "r443", "r453", "r454", "r457", "r458", "r459", "r460", "r470", "r471", "r472", "r473", "r474", "r517", "r518", "r519", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r396" ] }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfCostGoodOrServiceExtensibleList", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Cost, Product and Service [Extensible List]", "label": "Cost, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of cost from product sold and service rendered." } } }, "auth_ref": [ "r898" ] }, "uht_UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthrealtyincometrust.com/20240630", "localname": "UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "4 Unconsolidated Limited Liability Companies / Limited Partner", "label": "Unconsolidated Limited Liabilities Or Limited Partner [Member]", "documentation": "Unconsolidated limited liabilities or limited partner." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r830" ] }, "uht_UnencumberedLeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname": "UnencumberedLeverageRatio", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Unencumbered leverage", "label": "Unencumbered Leverage Ratio", "documentation": "Unencumbered leverage ratio." } } }, "auth_ref": [] },
"uht_UniversalHealthServicesHospitalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"UniversalHealthServicesHospitalIncMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "lang": { "en-us": { "role": {
"terseLabel": "UHS Hospital Facilities", "label": "Universal Health Services Hospital Inc [Member]", "documentation": "Universal health services hospital Inc." } } }, "auth_ref": [] },
"uht_UniversalHealthServicesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"UniversalHealthServicesIncMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUhsAndRelatedPartyTransactionsAdditionalInformationD
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedParties
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Universal Health Services, Inc", "verboseLabel": "UHS Facilities", "label": "Universal Health Services Inc [Member]", "documentation": "Related-party principal tenant." } } }, "auth_ref": [] }, "uht_UniversalHealthServicesOfDelawareIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"UniversalHealthServicesOfDelawareIncMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Universal Health Services of Delaware Inc", "label": "Universal Health Services Of Delaware Inc [Member]", "documentation": "Wholly-owned subsidiary of Universal Health Services, Inc.; Advisor to UHT" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Variable Rate", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Variable Rate", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } }
}, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel":
"Weighted Average Number of Shares Outstanding, Diluted, Total", "terseLabel": "Weighted average number of shares outstanding - Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r195", "r200" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "totalLabel":
"Weighted Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted average number of shares outstanding - Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r194", "r200" ]
}, "uht_WellingtonRegionalMedicalCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"WellingtonRegionalMedicalCenterMember", "presentation": [
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Wellington Regional Medical Center", "label": "Wellington Regional Medical Center [Member]", "documentation": "Wellington regional medical center." } } }, "auth_ref": [] }, "uht_WildomarCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthrealtyincometrust.com/20240630", "localname":
"WildomarCaliforniaMember", "presentation": [ "http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthrealtyincometrust.com/20240630/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInforma
], "lang": { "en-us": { "role": { "terseLabel": "Wildomar, California", "label": "Wildomar California [Member]", "documentation": "Wildomar, California." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX

210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-4" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org//323/tableOfContent" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "4", "Publisher": "SEC" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "3", "Publisher": "SEC" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":

"1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting

Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-

1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX

210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-

S99-5" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic":

"210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, r839": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "323", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2" }, r840": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, r841": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "(a)", "Publisher": "SEC" }, r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X

(SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-13" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting

Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 61 0000950170-22-094044-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-094044-xbrl.zip M4$L#!!0 ( (J""%F75?//HA " (VU' 0 =6AT+3(P,C0P-C,P+FAT M;>RJ:W>;.8XN^GU^A7;FS.[J=1H)[Y=4=>^5E?'T[9__\.#UUI,G?_@_?_F7G_X7P.CAXR?/1_I_>A!?H[? MTR/HR? 3R7A*H[___.KIZ.$L[^W0=#F"T?9RN7O_WKWW M[]_?+74\7TM^U^)NGNW<&P$<=KXU)VR?CQ[BDD;WE5 &1 #AWXAXW[K[ M,MZURH7_5XC[0ISXVFQW?SY^N[T<_9#_.&K? XG=/IS29[(\>CZ'B=<'#?_\+OVI^;7GAXU'7_X5+^R#:-1O!^]/ET M-GW.A)^_E?*\OYO>7^+MWCAC ]:'D\JL7XO#'Q#.2]OS][^CIOTP["V:DO MEKOSTVNZH'SW[>S=O?:$OZWT4=.]!;Q%W#UN77&1AE<S7YPFL]+WVK.]R<#H(._*CZN\!![VJ5<=3>/C(M];SG&Z MJ+/YSM!!HX%M>^3CJRD76.RE\]? C\.&I62[FR]\O!W5\T\R5[S'3_7 MC,;GOYH?G5IWAY3XAY]6>)T/&RQ@8F)??)2IWHF9BIUWAY3XAY]6-)T/&RQ@8F)??)2IWHF9BIU

RE$GI(*D M#(@$6V9'.?K-'S/'@??3)IR[. M7FEH+ A^_P D .13SD1HP5-R2+7GZI*CR$KL\S^$*1HYT8D^M?'JM@"2##!, MHT/?&X"$SJN]Z+SZ.Y2'@!D$,[C:$1S%HT[9R=$S>(\5!0CQ2CISB 3'CI56*:Y]6:K57"?TO5N/#=_S__8>= MO)M\F_II#/]KA[/X1YQ)*(MTW2G.+\OG\Z>:=^GE29QD36Q(0EA&0WBR3)DO4J(:F(5)C:2L'2*]NF2V:YZ-M\W(V/1Y/,KJ$:^R.*_)-GMP?H-UUJ"O2()E%5I@L7T1ZE,//K'99&#%7V.'0 MR5UQ]TS2S1W,4 -=$7KA9#WL31770YPX,2B2%<+ 77S&0CD322D1') MDO$\Z'6IXCKI$C'S13J# C,"
<4L$*TB9;0).8"RE(+_Z>)VNZ'HWFS93.PKU MZ/-ZB(M1!T(218)E>\Y3)M.H+&Z^KA/>R_/TZT47+4/T'-=VQ;R%,I$$PARBT5+$'8Y(D\RE[ 8.FJ1BRG42WU]AY8;R,%2*]&-*I:([ M/ZJS CGC& I*9Y*UH*D\9;="VCEE9@>S;+<'OB\]BBFOT&82Q$[Z[*APAAPO.M;1:)R!*HLRR*(*CEGFK5S9SX)=ZNE))ZJ,3RP&2(TB%F>8[$E C(&-:V/!!<
MI9@T[R3MO435ZCF;6[OE0'LW,+=69JY79.]$TBR:,%.B2;WRPI<.H*3,VLBP MFJUD!:S4BIGC=7Y:RJD3&CT=#U4=2V: M-/_?W'9X\ E%=!"][UWTM9?1^]HP"^-
DC_^GS<%LU)VFK0(%!E!'7/1IVQN M.S8\K1/?68,V?>#=*P'9#IV5/46F')GRZ!Q!7IGL.0CKD,6E=D)SH;2-_K&E M\2)?@<@TJX>L3W@*<]K:=M:6$5O_G8M"6'%RDF,!F]UC$P&=PBEE!"4
M[429+&<"LHYZE*.433U1)+NZG31-#Z$NM[7#/VP=WHS.5?"*)>G(B%"%!\) M$TG J\-F94_Q*F&FL+,:"14$XLQD=S4*B91.3AO)!!=/:T2S#;QB!AQ?V_-? MA.,[.YD-
[,3^$DN'].S_^O$)^+O]5BVP']?\74R,$U8@PTE"/$B%G,V^JR>8 M"^\#V_#J MT%G94[R2TC'"HD?"!H>XQA19GE\)1K656BEN61?^[N;PBLH!EK?5D1V2D$.B M=]/^,JB_U/FY S0]
[+=F'.KY>+Z9>BWB4Q#,(V52**ZP0E8+A[0@^2?/_V.- M:!$IFZ5-Q?%GK;R?TQE T(([>_?)W-=W'T1T"^/>(I(-]N(5_VMHFUD2%L.,U. M-4_(,4.12%AI(PARBT5+$'8Y(D\RE[ 8.FJ1BRG42EQL%)MQ?]0#].!4?
T:)OP$Y(.4\Z8&U2\"R?/Y}'\\ MDK]U'$=-*$1{^//]' 9*?8>8:FS03%2(:,,90TPY$[1-W(FEO-"* MP^X7ZML.C'YU57G?M+K[^[AIWL,IN_31?NO(5,B!YVM,$?6F52] )$ D0.1= MYZX%)
<%2AC(DEM(V%I&Q+@-?.>_(=':"72>MX[8#D6K R!JKW'H#D9!IWX&I HI^M1?)0_VYV#'P(Z!'7M,YD&$[[3EY?B^O]Q)B[0)$@4CF9)>644ZV#@%C!3@(. @X^,:)+$=1FWYTAP6+VS1W!R-
GD4,RO M+. 82VV[\.?7AH,4XX%A\" 0RL'WP6GO=-1HVP$) H N]9L>T:+-@83QS[A- MT_>P3,B_K,T&WKX0/,6"43F2HK?()D:S>Q\)TIQQ%"7#WE//G2,=CR!].0IK MLXE"RX$0&XL-,HC*?EE%
$D 20#)AX"D\1X+%64&/%]&.DB%;/ $R>"#$B%2 M;99 \HEC2M4<*DD8.F+RM#QN Y%VA0_Y\^.W+]?YU)=]\UT O''W>V_X4+H? M2!
[]WOT>2^!#!Z4^C=P/,5,6EX(A.SJK1Y^KT7B:OS@=5]/CV,2BP3G8:F(9 MR#AJ{]VVSBC5(SMJA\LF=;I;'&7]JLHCD+&EF^%Q-+U]@)FOCT02\B>RJVXADQYN<_
M+:,PYOLAHM*R9IRELRL_ZP@Z_VK/FYV<_73#QXI-S%K12>?OZ/V69]U/0+Y<4 M\/W)Y+6.TU40_11;#^;3!8*NJ$A7)V5WL$!_CNKLPC09VG^+=C@]KMZ7'V?5
MO,ZB^CC),+2%Y=L&R+RZ,'ZOKAJ_#QW5L1Y_SY>K1CPI M/D+UH?Y6_3/_];BI?LW+%:I_S$:Q8GC0=F__D,5X,D_&LR(060JFQ^_98T>A M^?%0B)^_["R441?,IWBC9J.-?
VL;][" SZ7@1\!5C*3Y*?OCR<92]OO$L>_U_MMQA^GM^*8'R$?U0A!P9!\MF+ MQ?=0V029WXZ:(ZY_,'>"!,GF?K/B>6O6:1WC5QY%'0L)=M~TU'3XQ/7THY&:)*>_\J9<!=C_IJQ;I
MK'=Q5HE:OC,L,3YY8S7Y6+U@8PLRU&L%>:HZT.^HP[X3*L3M*W$@HD#TX<9'(@DP/V"\#A0(D#$07B=IRXG1;13V=%S/M#I/1O29NIZ48N C$@8@"<1!C[:YWL-3E=<\EH-?
BW4=A!BY"-G&GH/_R-UI M<.C2TKV=G3@P;[M,W&'(.*#7P9';1S'N$IKC-Q^;C^(.PQ/N4NYOC:[:L^YWVO1!D&^7Y#;!JT'QV/(@$)0O74; MV/^3L>,$IV)!.4 Y;M\];WOQ@&;LMV:
'CQ5#T[MI/IBA[.5PRA0A3TG#E3A M8J5&.>9&XJ?GPW%SK7\G*,@> M*@BHPU/5X6'SQ Y2#S:0Z=Z-S/:&Q-@_UD;0=V>SJ>*AA=8BL[#%I.RREP,%# M)PV$$TC;6=) .(&TG24-A!-
(VUG20#B!M)TE#81SCTGK-B]WRPREA\^'WJNL MSC_L:&8C9Q59&MRVGO'H>R!*=]%[[Z3GS5.[L3GWMZ;6-5[+_/JB=C[9G!A* MA=8*>?
UN^]FTV9J1V7V[+51YDW{[M49YF_>OO[.$'/"!KHH[KIFF/=8L@&B M-FF7[B+S+X!5C\.JP 7!U&F$4\QH8WC*N*,<,B(9+H-4(?%.L&HZ]O\^'@]#
MG#3S+>$W(S^<%=3Z8SPI#_1R.I#W,M:.N/PX?CL>E9M.QL-A.LB/LORQF5X# MN#__)*=Z\RV?!MV%>><0^R[,:< XP+B=8R1@W%HPCNJ@><:..;JS/Y:"0$YK
M@0PUA'FLHX]X">.LHR0:B[PV/-B,,@8$1##A%!)<3!}[C3&484'S #._<[M M'B,!Y]:"+I=FDMQ@5 MTS0$1'C2B#*D=$RH1 XC3DJCLFHFR@JJ/>.A(B\(ME;=$IG%-46.4\(SF$Q MLR6*WBZ*-
IE=^=5WX-1@.C!*] E.'Z:%WSVJ ;BZ,]0>*JZNVW_T@AC%#*M M+QB31U:)F)$OB92BP$2YF\C')*:BA,C:%>23F"._ X2"PC*RP'. O77DNQ?P MU( 1VB>X ^\14 Y0[FZ4\\9D/.,P3&N*0C2O
M,ZC&J?I;',54^]H.JX6 OCBPXC H[P/2=ILT$$X@;6=) ^$$TG:6-!!.(&UG M20/A! >)VEC003B!M9TD#X=QCTM9]&*^EHAZ%_!SSO/:*.R#GJU-68GZ=JQ?&.M-
^L==B_)|Z9I9C$,JE'\;M_S_=LCNGK]+N9E]"HM#IM%=V\686F82MZC:*U"_MG+N,*3AP)%/PC
B7;&)+6^(J6.\)1I!+C'C*KRR+%EFB+=5,>R7CK9M%5Z=]JWGR^3XJ#WL':+]1##!K4YC5%;&K5D?>O2*:$@JL M!IW=.K4[I[-0TGRG%Z.(}SPF@3SV#G&MLD?"<79JDC2"N?
Q'EFYZ,8EI;+++ M@PP3MG@<^!!EN.2**83CJ2!WHQG_ULFR-SNQ'10L4RQZI-3 ]7*@)3@W0"K-M06[ M%O]]/U->32QOW+#>!+ W46\9NB8?P8(=S!A.VC" @[6DV"12M3Z"[/>32QOW+#>! <# #2]!O#=A]3-
LY608'X4X' MP3I"\(\44>(EXE@P9 P-B'/L(E%&*MG=3OD=#D(;Z';5Z;I7K6W .P#O +P# M\ Y T #0 - T #0 ,@0H0(<9,18L0X*N(%2B0EQ*T0R 9IVH:G$EOG$XV= M[8)"A+C#^YYPT'C%?
<]F.JG]-).5R3*.7!'OK#$GIW'4V%,5XK?R.O;/A,&^ M:$\=-"C' T<4=!9T%EB]?=) 9WL2B+2@.<;#6=\# ML8E*W<4&X,OPKUDS/)[Z,??QZU5^XH6.2$]2E:! P$ M# 2_!5B]NZP&->XO;T&-
#X;5H,,]Y2VH,7C0H+.01;AVSL@;*9PRR&B3%$<^ M(,>2038Z0KG45G*>Q28Q9!'V4G76?<3VR;C:F?*MN'?\L/*7^HO=8BCT%1V M%*IP_EM5I/A+%NL%-7SOVRC1,0%+0/%* 5)$.>)
((-90I(+S9.'*>E.;/ MTOXL)Q>T9R5M-?RZ;N:71,/M-#;OTLN3K,C>_C(>#NVD.?_T8]H&DR,N[AX) MOA;>_M2>B>QA*3]4 $ < '' OFLQZ"SH+ .@LZ.Q.4 LZ"SH+.@N,!)T%5F^= MU:#&/4Z;
[_7)+9L,DTEC%%.@B-O\BK+D/8R*9BH$3<3,MIZX/GFJ/R"<1- M4,AZG[8?"">QD0Y0F4OTC-=90NIWA &)S2 FC<+R;O'#2"A[/WK(:HI">, M!'2FR>Z,\-Q*G5T3J8U'7"6-=&
(&B1"E%IA*%9ZVRPCNS+X=.K]5JI;+ W9S MW1ZE$6491*/XZBIO\2J'OGQ27RQUY/1.]L7?O"T^YWPF]9@7X':G1%J$&$0 M81!A8.J!4@LBW$.F'A:U!R+"^TUF/TF#
<8";R6B^ MC=/S/&;_]LO@S OL>L.N[YK,>@LZ"SH+.CL3E +.@LZ"SH+C-SAZK(UUW]Y M,:(GTB"CE$ <8X%T,@HY(QPQ@<3 ECK5*B(P44(B1;%#7&B,'-$:82YBQ/F-
M!LN,]5\Y,'W3QJ6 CYNN:L ('@@E^U0#!B %( 6.!;!Z1T@#G06=!9T%G05& M'D8PP(AA0EN&L/($<64#,A83)+P7."9L@^AD*B$$ SO2$1*&#ZZD/7^.\BH_ M\P.&:A2GÜ6=;CZJL1-
XVQU4:CK]6QS%\CDW_[,C6MF!=%L@XN7CX(W$ZK9KQ ML [5@H'[H)\K,O_[Q(-'^> 5FT,>9GT6F!U!"\ &P ; AAT3&, &P ; !L & MP ; !L & P ; !L &P (:.8@,T9;MS\\Y*ZHA-
KF@!>+!8.2I-$A1 M8Q71,7FM;N[#!<=B%,(CYZ)'G B&K+$A_VJ<\Y'+J.+ -?,AWT^,XN=8$ZW); M[I5MCE\/QU]_*UL9?[?UJ/SQ9';^,UF6GY MU7?V\[0BZJO,VT\\WGQ#6P!N &X
[BX++*SUG%%DC'&(>X7G$SL5DU(%[G' MK(L""@##NO@#WS@_QW-$2C \S-QU/[:!"69V6NWCVST9V5CIQ2Q^_N4&UNQF MK+Y(%R@%R[0KF@5ZM*L"
GH$>@1Z!'H$>@39D,/,AJPY7R%3](E(CP*. 7'J M&++<1&1QD(+&$SHY/3W+:F*MW'Z+GVTW_)OPUFH1Y__&$_:I,1TJG=;&K= M,'XNB5[
MO4D3O#:&X>ST&*,0Q],/1YX1;,P+/#L]F'2QN[XUIP?V:6"#' ;,L'LK(66P MS@G! DJ>\1P>>HJQ!;Z,(:49*"P.#59WKU'!3B/T$U3N
M'[-1K!@>5!13#F:]$RVB1[2H41C/,CP*!("(620UPRAESB##*NLGVCRB2UE/W\<&RSB7DW MFS93.RIVZ9JQ:=IWKUJ9-VJ??R]SR0:,FTW9F1LBLE>6!@!Q;P'Q8=':7P 9 MU] 5F G.I"
((!Y&1D=N$++4:44&ILPG{)&PGR#@=^W^?CX=YU9M?_S.KIV?;_MW YB&A 5$!40%*1U>T1-@2<<)4,2EUWSQ 6R7F)D"5'<9">4L"5$##EPZT- M0E"%.*4!F8@3HE(XYZDB"ON=1E2J\$
8"J@*J JH"JC:/.H:E,U4K3DRC.L< MP=.,JD11Y)1U3)L)*KN=?D%U8(FGPP2Q"7$@XC(>>^0%IY0KPC7<6F#T$A*.342 M.2PPXI%H9%TP"#NEL!'4<\ZVC=D/J[HPE T(/D#PAMH+0'%
\0WBK,L F;A/ M*&\)*$ _*(&,X0X[$(*7+>!J7>A%@*$"+VBB.2W&5_VAN&=(H:I<@CS7\C.O%M MX^R]\"H'G&^LK+UWP!4\8\!4P-3U8RHVD4N6!+)>)>2B 36*D?%DE'P1,/
M;LEWM4'3F$@Y*F7S=[A&.@,P*I,UH\)8,!MV&E.)P0.% 54?4=>6?Q;&M"_7 MJ0.7FO9=R+QQJWMO^%"Z@3P@[['D/31W\75>#NHR"'9!_9^C.H-/8X25,]$. MI\?
5^_+CK)I7#E#4N@[:.&*K\JJT>MMA\RX=I_G&2/])4 MXU2].K:CS_ERJ:B:&Z #69S7XTDU/8[5A_I;]<_\U^.F^C4O5ZBNEMZR UF, MY_9D/"L"D:5@>CR>-784FA\/A?
C9R&:,*ZO&]BG>}$U!H79<+'VC^J.VH/CN; MCA?.6GF6[&J6AR\?1T-[+V3%FP7)$N(\YPL&^M%OH4) @=!,VL^-_U]NZ)'}YB,B^0@ M-1N VZ[R&U!*
<(PEDCH$'+>2PC2E!A4:GV9P5S(<=EE;M/<.)DH1YQR6+4LH MAIP/"K'$D\.*\R#2H+F-4C,A^_#}[@:E+U6YS% M5/O:3JLS&WW2.Q_7OOB,N_,B[8N<(_M^R@;V";(.63:P3Y!MR+*!?8)L0Y8-
M[!-D&[)L8)\@VY!E_O<:JGN?2U=]?8]"_E!5G>)Y73(>GC*4*SN<_[&ZY$=_M=.WO5=LN8Y4AL_C=_1)(.TE,4P(ZYBXC^ZC]N[+\\R!SP?M.74!40%1_>=_:$HH*!MP.P1Q_;=W## 2
M5Y)XF0.,2!&GBB/-3$21!8$Q==Y9M]6,HJQ5T6,DI+"()V&0CBJ@1#WW#L=_M_5]=]L!QG^7@UJNCB]NWWJB!$09P%8'KXO68U7<1.$LT083XACG-6,XWVB%O'@U"$8J.V%@]3+HR,& 4:
M!>)&!90S>8XH%=30G. ,02"K'\]:$IA_OA94[^ +)]/@DSEK,3Z/A6RSF>AK^M6P7Q_E1V@_-TQ#J\@QV^M,6X=7LF3VI%W,;.+1W_ MK43&S\X%QE]CYZYU{(]9O6C?Q7\OZS8+_S[.3VL?
5SUD[Z)O/LZZ_?40,;4 M// ,B"^0U?EWA,?!"S[IFR \BU"U ^(&4#E,>L78 R1. VX/"[=5EA!2P MP8Q99#'GB&LID4XF(:*L6I!1R^WSF*[S>HQ*'/L)UKN?2'L 3L GT#GA[T6 L
M(,0V/82)NAV.'X(@+SRX)?NXCMF_3T.,/5V^?_=&KG[?KJ']I:\C% QMU0{6DL?^DVO1SC$:TPK0_Q <3U8T RX!9P"[@%W Y'7, MX!9P"ZH$W(*R MAZ)L@/*8M7L'*# .:2?
DMR2E%%;;R^7WZA327N/ M41*4(VX<1EHYAIB-3'O!H^);G7J;$EQ/Q6]B)IKB4=6_+^KV.C7V6?,,!D: M 8$!(9B!) 14.1+<[B9RL8%)'A"5JD2?5XE?:U?:_D!'[H=04=I0YO$HSMKZ-%;US#?'\
MBA7ON9PCE0T.P=I5N?-U7*S+FR.<+X/E+C"#!C/?8T RX!9P"[@%W Y'7, M MX!9P"ZH<+VZOV3;&FX 3T2@HIA%7PB'C>$+!6"%H],,*K:ILV M;2D5G D7==8AP727"D!:.6$"VU8I?
GX)BWAHM\)9$F(,Z,0CKF_S="2&'8Z M.FK-Y3FX XNC.+^P)],7*,EGMCUZ.6T^_;U,8OS-UK/RYM.4=?8N^JEMVSIE M"R@/_706/MC/-Y_":[-B\JOO,?DVP8S>WUS>0(EY]_O9 D,#0P-
#_RA#'HS=N"\W2+9J%G58H8VI[ M"\\1NL/>6BRNV#)CA [CGD.*VX_2AJ]@G(8#++H#28$T$H 10 B@!E 1*4 &! M"DB/%0LJ=11&4<2BQ(@G9Y")Q"/"@HF<%]*1@X 21"-CI({!S\<8:CBUQ"
(,64#<YDQ?[#H M!J9D8-(<2!!(>17@WVEWV4-)DSV9]A:YQ+*'DDXAYX)5N+H MM \L>Z_+'NK]DYO7[YO4B=333=6.A^R2CV MR\$ "^XQ"]XL_L+T&$OBW#++$4_F
T*#X5MUC4#1*I9D8NK."!U I-M4"E0Z>BI-"DI<-P$>8XS6<I"D28F(B45)4ECYK=WDU5"!!EM0C9BBSC.F;TC MTJ+(DU8D6JNT'#259@\P$48"E0*5 14"E0ZT94*[R"+F'#%3XE0B(W)>)^2T
MU4.%*).-6RT3S#K!9+G<8<2MRR2MF$786.>BY#QLMTSLFIIOUBFA-9M@3 Z0 MHZ%, L@:R/J>R96YH!*."EG&$^).**2E82B_YV5PWN87E\E5"**M3_D[UDK$ M@TG(,,J0D"P*+
;WI>PPX+B7X(E1Y@ 1%<)>8%)@TOMA4AE%8H4+O:$AQYU8 M(8>]1E)'AQFWPJ6M"D(B@A)-",(:YEBU;*)EN"8H.BI^P$$GH@;-I)3(B=S=
M@J6]IM*S_K/\;9,]W(0)'GIM[_Y5&H0#X:X6[BOG_R_=]R#L^Q@KZ\O_M/;V);-A-6L6^8N+IEH0GU:=3MU_;^?3NS'B&9-B&??R<]5/CZ3?AH_HU#/8^<'GF2U+H]G
MOX:Z/9G.:T_*I[^>V%"_$C=7KE306>75XW^78=Y/0 \ZI,.EOT\K%;D<_O4Q!G_,ZAQVM9G8 M_A[M='%4O2O_?*E6:QNJ#_,,P@-Q#<\VU/_L//6_WQ!^U:3JV9&=?BJ%JM[_W1Y
MV=)IW=:NGF8">G+V .:O6(W4_1\UC^==U#'#%Q^2GK6M_VMH\IO?6O\MM^ M%7YUP+]]'M-6#GWW.SBW25RN#\&/CYM9M5K#=CO[N/UBY0>PH5$#I+\=KL8I* BW MK*!B8)P
Q<.3!2$V]](&(P6A!NF<&"B>RX<5:'*@D@/^"\CA0(4#P7A!B[< MH$VTUVJW/:G+28'U[# 5/6KA!FW%H$40#DP4A(,<:[C1P5/OE\)+:=>#VI2S MM??< D9MWF,T9M B5!,'1?
T')NZ@R:%/3_=Z>>S O0U9N,.P:6"O@Q-WC&;< M)S7'SSZV9>';8>IYU,(=C!$_6^71]6D\3$6/6CBPX@-1]'X(=QB1!XU\9VR18%0O@ '!,<8# MR-AO9 .[HJ#$SNO3NUT>7[ M*'7?K;3=/48?
X[BCTY5&*=L=Y[ON5P39!NR,&"?(-N090/[! F&++!O8YU[+]JUR';ZR7.=3PLE?4ZZ[XG"EFQ^* M?!(^,NW_,;U0\@;G^2?4>55];<] \$]QA, M8(8D)+ #!B%/FD-
8F(9TP"]X$&KC>.L'=FL2%3D@QE;JC'$,:1X(2UU0RK /' M8NL$]ZZ5]\URT2[LK)S#>N$P]K;[]/PI[*]>O_S_>R$32]QU/8QVS,P$N[ M=4;7R?D7(*CO$I0.*02!$6.:9X(2&CG++?
*1:.*BBMK*7@AJT?@_CYIIB/V M-27\:N:GRT)5,YMY>:"GB\6\=LONC,L/S>MF5GYTWDRG^9)790,,L3Y$&[. M*\5BCK[H96*SFF,2)2F!&D.<,8DTM@09R:R-07AOU*')C2H\X8(#N0&Y#5&5
M0&Y]16W"4\ES!,8ETXC,F)"EF"#,%3,^N08"SH,FMPT(Q,F"9 ,D-L050GD]L/D]NAL,.Z5+#'A0GCID. A1X(\ M=*2-8"C11+Q7VE+*+Y-E9$H0(CUBRHA,ED)E@E44.2)-<,E@BA\$FRS2O*K
M[["F(71BS+CRW9M!{,N++X ^:!R0NT&=/="'>#L,P3CX)B'.6 T"/K0\C9+XLX MQ9SCJG"9[H+UPB=ND8Y<9HHD.>=E B/L"6;442RB?VBZ^R,+J8G ,%0FWBVA>?<==&O'V1$V3,3]G
/D&V(P39!NR;&"?>RW;O2^DZ\2H9R$_R.J.MYP.60]/&8K5?<[?>#VR@Z[O6K; M90R3:A:_NYGY'LX8G;]_'Z=@C*MB#E-YZ>.:.1'2&$1HX0BC@5&+AF)='0Q M"9>< -UL+\0BS_7C$0C!
(BZ41R9IB0CU2C+G+>;IRJFC%>R>+^=EPBC.ZR:L MBO!Y/+J/VCNOSH.5>?M-74!40%3_^1\Z#<(\1DZY3KALP1UBRBJ. HT.<1)\O QQ) MGUS$+D:C&-0:E4WZ'D]#,RA7SO\[^+)?
DS\%X>V+^)O/Q__0X*#&P8O]=2;N M'6 _<$ MTC"CL(A(AEBRNYP,;JH%DM$I+"/QW&[U/]]Z'A,RPD%/7<+RW]M.7;;+>>T7 ML0Q-G/DBH5GT!R?Q%EK.[3%$^5U'*&O@JE-\%[0/3<&) -N
;> 6\#M<,0% MW YQ=6OBG 9F$=>4Y^PN!*2)4@EGC#!5'FWO1W'+>;[GH9_+=O%<7Z4]D/S M-(2Z/(.=OK5U>#5[9D_JA9UV+4"_EL78 R1.- VX/"
[34KB#SVG#F&!+4<<6<,TN5,A"NN_JF*YI]D4,Q"1W_922,(E8I&KC%2 MF&6\4L'+TO:(#.$A"1$V4'?#>#.&C;09BAV.+R[UPPSMA8O8ODE/CS- M3*=VWJZO_I&}>Q^KZT^J[6DD?^G6,
(ZQ'Q\F]2$Z@*^A^#$@&W )N ;> V^&( M"[@%W )N096 6U#V4)0-4!ZS=H>_"HM2JR+G*+FH$.<4(VL30T)119CG6)"M M^3F22]8K85%(NA3EE4,VZ(
PC<3Y)*YIO#P:VVPA."S:BJW[O?@V,8 M& $&! :$8 :2$%#E2'"[F\@E,$V$YQHG2CBGB1DHB (,\8,8PRTTMK $0N M>[16 $[[VI{5'^C( 1 J2A*/![%65N?QJJ> ^>8X/MGOD\9[F_N\}?
GQP^#: M> _"D(.Z {!JL&*P8K!BL^)#%!2L>I5H/3%RPXE&J]<#$!2L>I5H/3 Q+}-] MEW.DLL'Y?+LJ=+Z.BW5Y V^&^("[@%W )N M097CQ>W5G6&)8$\X4T@P'1$W22&G=$)2:(NT"0
MT<0AKD*T6I,86;C<&983TU==7OI[T_;5'28F5,E1-8G0BHQ+4D,;$84P[JD']{Y,P "2EC],8%GD(?2T0@$1C* M[HYPD.#M\/'+ _3-#]AJ&9Q47VT]:S*,/*V/:K2M/E4'<7P,,8C!IX/-@'K
MLDG&^>,A'XN31=4VTSI49QK<"XS>4OW?EW[O?5+?L>0WAFS6H+9J$UF*(P! M_#\ /PP/),!2@!^ 'X ?@!^ 'X ?@!^ 'X ?@!^ 'YXJ&W:HK24 M:,.61Q)8@+J
#VG"%F.:IR"#E_[R'!R-FG,I+;):"\0Q=LA%E?) 4MFLUD:/MR>4YN#>+HSB_L"2URFY9[8]>CEM/OV]3&+\S=:S\N;3E'7V+OJI;=LZ90LH M#_UT%C[8SS>?PFNS8O*K[VWY-L&2WM]??
[V0)# T,#0 \H0V/OM%0V M(IRH11P8CVQ*!-G I/5$:AU)'UT2P- C8F@X>/.V(`R_=(MF8:<5RIC:WL)S MA.ZPMQ:+*[;,&*'#N.>0XO:CM*$J&*?A@ N@-%@3 2@!E !* "6 $E1 H +2 MY]$?
B1L,L$26N["X]1H9:3&*4M 8O"]%BSX6>%]1K'@=%V_2!_LY_S5=AGKV M\6TS[\H2B\6\=LN%==/XH7G=$,JOSYOI-%_RJHQ\,!?[L3)DH+4*H%"(1H;B
M92$:.0@H030R1NH8_'P,B8QPZ03"U#/$D]/(,IM0U-HYA:E)7OL0"T8C[E%-&Q@2*420J4\CTN46JMYGD'F;*R">4 M\\/CT@%N.#!L7KX#ZOYK.8L5PY.*8LK!_.6#)/J8%BB%9IDIX@#]T]7RC]1#
M9>?$-+<>85.*FM$2I(U.R!!&/,ILHOD]GFC\3:/8 M+P<#++C'+'BSW.PO0(=]T*'6EADI+!+.,,2#]\A$C%&*/D2=N"&&]T*'B\,_ M>=1,\SBW+_Z]K!=?'C!.)TP#C0*-.HT"C?
9$H\,%&'((B41,%/&4"55[B1'S MQ FAN?)*7:,1dB.0T-0E"%.%A4&]"5 KG/%5$83]H&J4*3X396?$8J!2H M%*AT]%2]F*(NJHA\(C9'ETHC9UU".K]24EIAR!.5RL1CU"4B=4D@KC.+ZL-D
M"D1HHRP-F*5!4ZEF"0Z7QX,PDXI, 3UG&_[NV:FF_6*6$HFQ\B!P-MW1) UD#6]TRNG%,?I26("F%0V;4%F90,$H0ZEJ@/2FP=IX:M"#GBC4AR5]HM
M#$,Z18U2Y)'F]XA._*')]9N<*B>_^8,WE1O$NP?Q,L:\W>]]6K4UNDP3 M?4C_QZS.\&SMM/I[M-/%4?6N_/.E6K7 5A_FRW:Q-V-SMZ%XUI1SG]H8JORJ M:X.UB_S'^T7^YSA?TE9-JIX=V=G'?
+MZ5]TH^O &YV4SKQ9V2"-YC%6_\CO M'[75BSQ@H3K?0L.9#@>V>-F64PBV\BJ%FV=A,:GP]%^.7,YJ@D@^A)=ZI M5^B\'O%5U>#5[9D_JA9UV+4"_EL78 R1.- VX/"
<72Z:LX"F/$L.Q\K#E\O1U'YIEHM\^\\Q_+KZ*8+Q8_S7 MLR]DI4WM21N?M/'$SC/9G(U"%]VN[OW3Y>[VT[JM73W-!/3D[/M7M:UW/T?_M8_G77W_ZY9J/R2T_DX^UONUM'U-ZZU_EM_TJ_J
?]4\OJT=[D+4;RPPT3^^ M:^*5I+6=E5Q^J'\IR.@'8MT>3V0\%'$W.S_(G[XM<FV70-[OX-PF<;D^!#\^ M;F,5:JG#[>SC]FO:'L"&<1@V0_C9"&:>@(-R^"@]JWVI"X'2M6SPU3TJ(4,
MM!6#%D$X,%$0#G*LX48'3[U?'B^G70]J4XY@W7,+&+5YC]&808M031P4]1^8 MN(,FASX]W>OEL0/W-F3A#L.F@;T.3MPQFG&?U!P_^]B6A6^J>=1"W.?V5LDV!5+(
#P"U5'FW&0\@8[^1 3BX*PY.[+PZM=/E+=,H M@,*>"P=0V(S4+"ZJNMO#$+ 6#AL+(3ZM YQ%B!WV',H0.[0/SA63N*71].F M,;]]X @ 9-@
3C<%0Y;FQH##FY02:TIU+WW4K;W6/T,8X[.H5CE++<=;[K-M7N6\P]$8U4$J<\KR##=E008<&G]@GR#9DV< ^0;8ARP,V";(-63:P3Y!MR+*! M?>ZU,:\JU^$KRW4^)9S\
>6Z*PY7&O2AN7(RX9@899S4R//@D8J(Z;IWTRZG'V'*%L*$, M<2$C,C[_F8*FS&K.O,9,)_UVK,QOEHMV862E?.\+A_:VW:?G3^M]]?KE]X[K M91.-^?
V=UCMF8P9>VJTSVL5QY2,EJ,@DY4%%E+PUB">GD*6,(F6C-T)IKH+K MA. &=10YTT!L0&Q#5"406T $AK'20FB&M)$$<2]L?A4-2LR0{$UT,<;+Q&8P M210+B@BW#G%KV[BR^
/@.7^9[G3BT5O, M4{J.(GNVQ4]*$29BN VP:I2N"VGKC->FQY4A$Y MG4@IT&5:P\$CH[1+1E,L]-9TJE&!$A/LB M)\BVG[*!?8)L0Y8-[!-D&{)L8)\@VY!E_L$V88L&]@GR#9DV< ^]UJV>U])
MUXE1ST)^D 4=,SD=LAZ>,A2K^YR .\7ID!UW[>6VRQ@FU2Q^=S?S/9PQ.G__M/H[!&%?%*:.SD\=L>1X4 PC+!:_#/)175F(D+0D.$\6YPY>GCHA.)N+@4/[' M(IXT109S@CRU(6'#*?
=7MTRN8/=\.2\31C%>-V%5A,_CT7W4WGUY'C1Y[S5U M 5$!4?WG?VA*"@;<#L$<0&W=PLPN,H9"J,A^V@C>W:L, 9[ PL 8 0 IQ3C,&4H! M@%MP7H>"=G!> ( 8 0 @ !! &C,:
<[Y#&H,.2VP.FUWLP/M8E[[12Q# MT_@_D2L3!=F#'1 $66N[:,CXN;R.(Z166+T&9 LUHS$@&7 +N 7< FZ'(R[@ M]FYM7\9ZDK 4B(0H$%=,(*NB1MHR0:@C02[FV-AJ^S6*NI^%?
RW9QG!^E_=\M#:$NSV"G;VT=7LV>Y9-Z8:?=TO'?2F3\[%Q@_ #5V[EK'_IC5B_9=_/>R;K/P M[^/AM/9QU4/V+OKFXZR[7U:AS@+,65CH0KKOBIN:?9%#,0JD>;]7N%>-$ M9QQ3(9
@7",>DD_.:HZ8#%(:Z879WO?IAS">C6$C;89BA^.+",PO"W[M(K9O MTM/C#%=OGS?3J9VWZZM_9&O)QXI>"\N>1O*7;LO+,1[0"I/Z$'U 5#\&) -N M ;> 6\#M<,0%W )N ;>@2L
M*'LHR@4HHCUF[=X#RHYT4WY15@04?$4_$(JX3 M1H:D@*\1-'&7?/#FUN A?!113,Y* $QX0X MEPX93?.K1&GO0T0F8Q^= 1"XW&/@'O-%*\2O-.GM.?Z C]T.@*"TH\W@49VU]
M&JMZYIOC^&2_C\'M;>;WQH<;#X-J[\&1@K@#FLNP8K!BL&*PXD,6%ZQXE&H] M,''!BD>!U@,3%ZQXE&H],'$/Q8KW7,Z1R@8'8.VJT/DZ+M;ES1%.E\%B%YA M@XGO,2 9<
NX!=P";HFK[]\)/>F M[>U@\0E7SM",<(W@X_?\SR,$W$X9J%A?51UO/ MJ@PC,]NC*DV;3]51#*]C.T+O\6 3L"Z,9)QO'OZQ.%E4,3.M0W6FP,W Z"W5 M_WWI]XG]1U+?F/(5JTEF(W:9(,"&, /P
_#\,S&> 'X ?@!^ ' MX ?@!^ 'X ?@!^ 'X ?@AYO.F=D@":1H.3+7FHZ4.2L\2@IKZ(WCDJUM:L: MD2'$0 226%/$I,WNS.(KS"WM8?9U">V:,;HY?3YM/?
MRZ3#WVP]*\V^37F,WT4_M6U;IZRQ\M!/9^&#_=S3E)LBXOXFW(_]@3V!/B2B$UPYA17;JNW>9F'T%86)UW'Q)GVP MG_?TV6H9Q_?-
O.N!+%8S&NW7%@WC1^:U\VL_/]\F4[S):_*R,=VL1\K*D93 MHCA,"H5H!*'1H8S3GD,)HI$Q4D?_YW=);2V.Y>A0FZ.12 VR(GE$*1&!:"T\ MWEJ=>9N9YF%&(S!= @0*!
H$>B<"-2P(+Q%EPB-N,H&Z9#6*4A9Z=)&0U,=D M\S )#E>(N<=C%$=#=?> ^B'[8O'P'U/MYW2%)&\1,Y MQ''JGL6=XL%^W"SHH[NN!CVN[3\\EU>N7W_$N 4N+WXQ/N
<#+#@'K/@S8YN_@O081]TJ&6.RK$UR$87J92E3^3 M,:?R.8K-7\36(4>D19$GK4BT5NFMCJ!!46GV !-A=M8*!%0*5 I4.B(J?70V M8/?;K!FV\?!FH>FYC:K)+_Z'D=K-L%X9_[

uht:EquityMethodInvestmentGroupOfInvesteesNameMember 2023-01-01 2023-06-30 0000798783 uht:RevolvingBFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-06-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember us-gaap:NonrecourseMember 2024-01-01 2024-06-30 0000798783 uht:InterestRateSwapAgreementOneMember us-gaap:CashFlowHedgingMember 2020-03-31 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 2018-03-27 0000798783 2023-06-30 0000798783 uht:ChicagoIllinoisMember uht:SpecialtyHospitalInChicagoIllinoisMember 2022-10-01 2022-12-31 0000798783 us-gaap:NonrelatedPartyMember 2024-04-01 2024-06-30 0000798783 uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember 2023-04-01 2023-06-30 0000798783 uht:GraysonPropertiesTwoLPMember 2024-03-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0000798783 srt:MaximumMember 2024-01-01 2024-06-30 0000798783 us-gaap:CommonStockMember 2022-12-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2024-06-30 0000798783 uht:UniversalHealthServicesIncMember 2023-12-31 0000798783 uht:CliveIowaMember uht:CliveBehavioralHealthMember uht:UniversalHealthServicesIncMember 2024-06-30 0000798783 uht:TenantReimbursementsMember us-gaap:NonrelatedPartyMember 2024-04-01 2024-06-30 0000798783 uht:BaseRentsMember us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0000798783 us-gaap:CommonStockMember 2024-03-31 0000798783 uht:CumulativeDividendsMember 2024-04-01 2024-06-30 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 srt:MinimumMember uht:RenoNevadaMember uht:SierraMedicalPlazaIMember uht:UniversalHealthServicesIncMember uht:GroundLeaseAndMasterFlexLeaseAgreementMember 2023-01-01 2023-03-31 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000798783 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0000798783 uht:CanyonCreekBehavioralHealthMember uht:UniversalHealthServicesIncMember 2024-06-30 0000798783 uht:InterestRateSwapAgreementTwoMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-01-31 0000798783 us-gaap:ManagementServiceMember 2024-04-01 2024-06-30 0000798783 2023-01-01 2023-06-30 0000798783 uht:AccountingStandardsUpdate202206Member 2024-06-30 0000798783 uht:CanyonCreekBehavioralHealthMember 2022-03-31 0000798783 srt:MinimumMember uht:CliveIowaMember uht:CliveBehavioralHealthMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 srt:MaximumMember uht:RevolvingAFacilityMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2018-03-27 2018-03-27 0000798783 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000798783 uht:TenantReimbursementsMember us-gaap:NonrelatedPartyMember 2023-04-01 2023-06-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000798783 uht:ChicagoIllinoisMember uht:SpecialtyHospitalInChicagoIllinoisMember 2023-01-01 2023-06-30 0000798783 uht:CumulativeDividendsMember 2022-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2023-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000798783 uht:CliveBehavioralHealthHospitalMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000798783 uht:BaseRentsMember us-gaap:NonrelatedPartyMember 2024-04-01 2024-06-30 0000798783 us-gaap:OtherExpenseMember 2024-01-01 2024-06-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-12-31 0000798783 uht:MedicalOfficeBuildingsMember uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2024-06-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000798783 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000798783 uht:RenoNevadaMember uht:SierraMedicalPlazaIMember uht:UniversalHealthServicesIncMember uht:MasterFlexLeaseAgreementMember 2023-06-30 0000798783 srt:MaximumMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 srt:SubsidiariesMember uht:UniversalHealthServicesIncMember uht:AssetPurchaseAndSaleAgreementMember 2022-01-01 2022-03-31 0000798783 uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember uht:BonusRentsMember 2024-01-01 2024-06-30 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember uht:FederalFundsEffectiveRateMember 2018-03-27 2018-03-27 0000798783 uht:GraysonPropertiesTwoLPMember 2024-06-30 0000798783 uht:GraysonPropertiesTwoLPMember 2024-01-01 2024-06-30 0000798783 uht:RevolvingBFacilityMember uht:FederalFundsEffectiveRateMember 2024-01-01 2024-06-30 0000798783 uht:CumulativeDividendsMember 2023-04-01 2023-06-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2023-07-01 2023-09-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesHospitalIncMember 2024-04-01 2024-06-30 0000798783 uht:FTXMobPhaseTwoLPMember 2024-01-01 2024-06-30 0000798783 us-gaap:ManagementServiceMember 2023-01-01 2023-06-30 0000798783 uht:RenoNevadaMember uht:SierraMedicalPlazaIMember uht:UniversalHealthServicesIncMember uht:GroundLeaseAndMasterFlexLeaseAgreementMember 2023-01-01 2023-06-30 0000798783 2024-04-30 2024-06-30 0000798783 uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember 2021-01-01 2021-12-31 0000798783 uht:TenantsMember uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2023-04-01 2023-06-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-04-01 2023-06-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2024-01-01 2024-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2023-04-01 2023-06-30 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2023-04-01 2023-06-30 0000798783 us-gaap:EquityMethodInvestmentsMember 2024-06-30 0000798783 uht:CumulativeDividendsMember 2023-01-01 2023-06-30 0000798783 us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 uht:InterestRateSwapAgreementTwoMember us-gaap:CashFlowHedgingMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-05-15 0000798783 uht:BrunswickAssociatesMember 2024-01-01 2024-06-30 0000798783 srt:MaximumMember uht:GraysonPropertiesTwoLPMember uht:DenisonTexasMember 2024-06-30 0000798783 uht:CumulativeDividendsMember 2023-06-30 0000798783 uht:RenoNevadaMember uht:SierraMedicalPlazaIMember uht:UniversalHealthServicesIncMember uht:GroundLeaseAndMasterFlexLeaseAgreementMember 2023-01-01 2023-03-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000798783 uht:BrunswickAssociatesMember 2024-06-30 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2023-01-01 2023-06-30 0000798783 uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember 2021-12-31 0000798783 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000798783 uht:RevolvingCreditAgreementMember 2021-07-02 0000798783 us-gaap:RetainedEarningsMember 2022-12-31 0000798783 2024-04-01 2024-06-30 0000798783 uht:RevolvingCreditAgreementMember 2021-07-02 2021-07-02 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember us-gaap:NonrecourseMember 2024-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2024-04-01 2024-06-30 0000798783 us-gaap:CommonStockMember 2023-03-31 0000798783 uht:UniversalHealthServicesIncMember 2023-04-01 2023-06-30 0000798783 uht:CumulativeDividendsMember 2023-03-31 0000798783 uht:TenantReimbursementsMember us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0000798783 uht:RevolvingCreditAgreementMember us-gaap:ShortTermDebtMember 2018-03-27 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-06-30 0000798783 us-gaap:ProductAndServiceOtherMember us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0000798783 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-05-15 2023-05-15 0000798783 uht:CanyonCreekBehavioralHealthMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 us-gaap:NonrecourseMember 2024-06-30 0000798783 us-gaap:ManagementServiceMember 2023-04-01 2023-06-30 0000798783 uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember srt:ScenarioForecastMember 2024-01-01 2024-12-31 0000798783 uht:TenantReimbursementsMember uht:UniversalHealthServicesIncMember 2023-04-01 2023-06-30 0000798783 uht:TenantReimbursementsMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 uht:CumulativeDividendsMember 2023-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000798783 uht:UniversalHealthServicesIncMember 2024-03-31 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-04-01 2024-06-30 0000798783 uht:SuburbanPropertiesMember 2024-01-01 2024-06-30 0000798783 uht:FTXMobPhaseTwoLPMember 2024-06-30 0000798783 us-gaap:InterestRateSwapMember 2023-12-31 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2024-04-01 2024-06-30 0000798783 srt:SubsidiariesMember uht:UniversalHealthServicesIncMember 2023-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000798783 uht:TenantReimbursementsMember us-gaap:NonrelatedPartyMember 2024-01-01 2024-06-30 0000798783 uht:ChicagoIllinoisMember uht:SpecialtyHospitalInChicagoIllinoisMember 2023-01-01 2023-12-31 0000798783 uht:BaseRentsMember uht:UniversalHealthServicesIncMember 2023-04-01 2023-06-30 0000798783 us-gaap:CommonStockMember 2024-06-30 0000798783 srt:SubsidiariesMember uht:UniversalHealthServicesIncMember 2024-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2023-01-01 2023-06-30 0000798783 uht:SuburbanPropertiesMember 2024-06-30 0000798783 2024-03-31 0000798783 uht:EquityMethodInvestmentGroupOfInvesteesNameMember 2024-01-01 2024-06-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0000798783 uht:CatholicHealthInitiativesIowaMember 2024-01-01 2024-06-30 0000798783 srt:MinimumMember uht:LastTwoYearRenewalOptionsMember uht:CliveBehavioralHealthHospitalMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 srt:MinimumMember uht:FirstThreeYearRenewalOptionsMember uht:CliveBehavioralHealthHospitalMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 us-gaap:CommonStockMember 2023-06-30 0000798783 uht:UniversalHealthServicesIncMember 2024-06-30 0000798783 uht:RenoNevadaMember uht:SierraMedicalPlazaIMember uht:UniversalHealthServicesIncMember uht:GroundLeaseAndMasterFlexLeaseAgreementMember 2024-01-01 2024-06-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember us-gaap:NonrecourseMember 2024-06-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 us-gaap:CommonStockMember 2023-12-31 0000798783 uht:FirstThreeYearRenewalOptionsMember uht:CliveBehavioralHealthHospitalMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 uht:RenoNevadaMember uht:SierraMedicalPlazaIMember uht:UniversalHealthServicesIncMember uht:GroundLeaseAndMasterFlexLeaseAgreementMember 2023-03-31 0000798783 srt:MinimumMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 us-gaap:RetainedEarningsMember 2024-06-30 0000798783 us-gaap:ProductAndServiceOtherMember us-gaap:NonrelatedPartyMember 2023-04-01 2023-06-30 0000798783 uht:AikenRegionalMedicalCenterMember 2024-06-30 0000798783 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 uht:CanyonCreekBehavioralHealthMember 2024-06-30 0000798783 uht:UniversalHealthServicesIncMember 2024-04-01 2024-06-30 0000798783 us-gaap:RetainedEarningsMember 2023-06-30 0000798783 us-gaap:RetainedEarningsMember 2024-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2023-01-01 2023-06-30 0000798783 uht:AccountingStandardsUpdate202307Member 2024-06-30 0000798783 uht:InterestRateSwapAgreementThreeMember us-gaap:CashFlowHedgingMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-05-15 0000798783 srt:MaximumMember uht:LastTwoYearRenewalOptionsMember uht:CliveBehavioralHealthHospitalMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2023-12-31 0000798783 uht:AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember 2024-06-30 0000798783 us-gaap:ProductAndServiceOtherMember us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesHospitalIncMember 2023-01-01 2023-06-30 0000798783 srt:MaximumMember uht:FirstThreeYearRenewalOptionsMember uht:CliveBehavioralHealthHospitalMember uht:UniversalHealthServicesIncMember 2024-01-01 2024-06-30 uht:Hospital iso4217:USD shares uht:Lease pure uht:Disposition utr:sqft uht:Bed uht:Acquisition uht:Derivative uht:Option uht:Property uht:Land shares uht:Segment uht:Renewaloptions uht:Subsidiary uht:Time iso4217:USD uht:RenewalOption_02_-12-31 false 0000798783 0.005 1 1 1 1 10-Q true 2024-06-30 2024 false 1-9321 UNIVERSAL HEALTH REALTY INCOME TRUST MD 23-6858580 UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA PA 19406-0958 610 265-0688 Shares of beneficial interest, $0.01 par value UHT NYSE Yes Yes Large Accelerated Filer false false false 13848952 8454000 8236000 17118000 16023000 14359000 13668000 28846000 27029000 220000 245000 440000 476000 342000 292000 751000 773000 1359000 1365000 2720000 2731000 24734000 23806000 49875000 47032000 6806000 6849000 13615000 13467000 1369000 1323000 2707000 2625000 6975000 8250000 14506000 15771000 15150000 16422000 30828000 31863000 9584000 7384000 19047000 15169000 272000 260000 656000 639000 -4580000 -4176000 -9127000 -7873000 5276000 3476000 10576000 7935000 0.38 0.25 0.77 0.58 0.38 0.25 0.76 0.57 13798000 13784000 13795000 13781000 13832000 13809000 13828000 13806000 758000 730000 1541000 1495000 5276000 3476000 10576000 7935000 -1062000 715000 -871000 -1032000 -1062000 715000 -871000 -1032000 4214000 4191000 9705000 6903000 651638000 649374000 274622000 262449000 377016000 386925000 56870000 56870000 433806000 443795000 83043000 83279000 516929000 527074000 14328000 9102000 5577000 8212000 6816000 6180000 7905000 8166000 11400000 12500000 8193000 9110000 10932000 10946000 15071000 17579000 586551000 596369000 342900000 326600000 19970000 32863000 1024000 490000 10145000 13500000 10932000 10946000 10879000 11036000 395850000 395435000 0.01 0.01 5000000 5000000 0 0 0 0 0.01 0.01 95000000 95000000 13848950 13848950 13823899 13823899 138000 138000 270592000 270398000 836637000 826061000 923107000 902975000 6441000 7312000 190701000 200934000 586551000 596369000 13824 138000 270398000 826061000 -902975000 7312000 200934000 26 -207000 -207000 -1 12000 12000 413000 413000 1.455 20132000 20132000 10576000 10576000 -871000 -871000 10576000 -871000 9705000 13849 138000 270592000 836637000 -923107000 6441000 190701000 13803 138000 269472000 810661000 -863181000 12011000 229101000 19 75000 75000 376000 376000 1.435 19820000 19820000 7935000 7935000 -1032000 -1032000 7935000 -1032000 6903000 13822 138000 269923000 810596000 -883001000 10979000 216635000 13825 138000 270454000 831361000 -912998000 7503000 196450000 25 -61000 -61000 -1 12000 12000 211000 211000 0.73 10109000 10109000 5276000 5276000 -1062000 -1062000 5276000 -1062000 4214000 13849 138000 270592000 836637000 -923107000 6441000 190701000 13804 138000 269698000 815120000 -873050000 10264000 222170000 18 37000 37000 188000 188000 0.72 9951000 9951000 3476000 3476000 715000 715000 3476000 715000 4191000 13822 138000 269923000 810596000 -883001000 10979000 216635000 10576000 7935000 13615000 13467000 -89000 -73000 -24000 383000 347000 413000 376000 375000 490000 -1309000 -618000 -157000 -241000 -534000 38000 764000 604000 -1038000 -2285000 23865000 22322000 5892000 3869000 120000 688000 369000 3500000 -4335000 -8789000 100000 -9667000 -8889000 16300000 13300000 12918000 4995000 49000 132000 20156000 19837000 -10000 76000 -16833000 -11588000 -2635000 1845000 8212000 7614000 5577000 9459000 8211000 7736000 902000 1808000 (1) General This Quarterly Report on Form 10-Q is for the quarter ended June 30, 2024. In this Quarterly Report, "we," "us," "our" and the "Trust" refer to Universal Health Realty Income Trust and its subsidiaries. In this Quarterly Report on Form 10-Q, the term "revenues" does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%. As of June 30, 2024, we had investments in four jointly-owned LLCs/LPs. We currently account for our share of the income/loss from these investments by the equity method (see Note 5). The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2023. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.  0.33 0.95 4 (2) Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Leases: We commenced operations in 1986 by purchasing certain properties from subsidiaries of UHS and immediately leasing the properties back to the respective subsidiaries. The base rentals and lease and renewal terms for each of the hospitals leased to subsidiaries of UHS as of June 30, 2024, are provided below. The base rents are paid monthly. The lease on McAllen Medical Center also provides for bonus rent which is paid quarterly based upon a computation that compares the hospital's current quarter revenue to a corresponding quarter in the base year. The hospital leases with subsidiaries of UHS, with the exception of the lease on Clive Behavioral Health Hospital (which is operated by UHS in a joint venture with an unrelated third party), are unconditionally guaranteed by UHS and are cross-defaulted with one another. The lease for the Clive facility is guaranteed on a several basis by UHS (52%) and Catholic Health Initiatives-Iowa (48%).  The combined revenues generated from the leases on the three acute care and three behavioral health care hospital facilities leased to subsidiaries of UHS at June 30, 2024, accounted for approximately 24<span style="color:#000000;white-space:pre-

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and 25% of our consolidated revenues for the three months ended June 30, 2024 and 2023, respectively and approximately 24% and 25% of our consolidated revenues for the six months ended June 30, 2024 and 2023, respectively. In addition to the six UHS hospital facilities, we have twenty-one properties consisting of medical/office buildings, (including one newly constructed medical office building ("MOB") that was substantially completed during the first quarter of 2023 and one MOB that was acquired during the third quarter of 2023), and free-standing emergency departments ("FEDs") that are either wholly or jointly-owned by us that include tenants which are subsidiaries of UHS. The aggregate revenues generated from UHS-related tenants comprised approximately 41% of our consolidated revenues during each of the three and six-month periods ended June 30, 2024 and 2023. On December 31, 2021, we entered into an asset purchase and sale agreement with UHS and certain of its affiliates, which was amended during the first quarter of 2022, pursuant to the terms of which: (i) a wholly-owned subsidiary of UHS purchased from us, the real estate assets of the Inland Valley Campus of Southwest Healthcare System located in Wildomar, California, at its fair market value of $79.6 million; (ii) two wholly-owned subsidiaries of UHS transferred to us, the real estate assets of Aiken Regional Medical Center ("Aiken"), located in Aiken, South Carolina (which includes an acute care hospital and a behavioral health pavilion), at its fair-market value of approximately $57.7 million, and Canyon Creek Behavioral Health ("Canyon Creek"), located in Temple, Texas, at its fair-market value of approximately $26.0 million, and; (iii) we paid approximately $4.1 million in cash to UHS. As a result of UHS' purchase option within the lease agreements of Aiken and Canyon Creek, the transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP and the properties acquired by us in connection with the asset purchase and sale agreement with UHS, as amended, were accounted for as financing arrangements. Our consolidated balance sheets as of June 30, 2024 and December 31, 2023 include financing receivables related to this transaction of $83.0 million and $83.3 million, respectively.  Also on December 31, 2021, Aiken and Canyon Creek (as lessees), entered into a master lease and individual property leases as amended, (with us as lessor), for initial lease terms on each property of approximately twelve years, ending on December 31, 2033, subject to the terms of the master lease. Aiken and Canyon Creek have the right to renew their leases, at the then current fair market rent (as defined in the master lease), for seven, five-year optional renewal terms. Pursuant to the leases, as amended during the first quarter of 2022, the aggregate annual rental rate during 2024 on the acquired properties, which is payable to us on a monthly basis, is approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($4.1 million related to Aiken and $1.8 million related to Canyon Creek). The portion of the lease payments that is included in our consolidated statements of income, and reflected as interest income on financing leases, was approximately $1.4 million for each of the three months ended June 30, 2024 and 2023, and approximately $2.7 million for each of the six-month periods ended June 30, 2024 and 2023. There is no bonus rental component applicable to either of these leases. Pursuant to the terms of the master leases by and among us and certain subsidiaries of UHS, dated December 24, 1986 and December 31, 2021 (the "Master Leases"), which govern the leases of McAllen Medical Center, Wellington Regional Medical Center (governed by the Master Lease dated December 24, 1986), Aiken Regional Medical Center and Canyon Creek Behavioral Health (governed by the Master Lease dated December 31, 2021, as amended), all of which are hospital properties that are wholly-owned subsidiaries of UHS, UHS has the option, among other things, to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities from us at their appraised fair market value upon any of the following: (i) at the end of the lease terms or any renewal terms; (ii) upon one month's notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the leases in the event that UHS provides notice to us of their intent to offer a substitution property/properties in exchange for one (or more) of the four wholly-owned UHS hospital facilities leased from us, should we be unable to reach an agreement with UHS on the properties to be substituted. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for a specified period after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for a specified period after, the lease term at the same terms and conditions pursuant to any third-party offer. In addition, a wholly-owned subsidiary of UHS is the managing, majority member in a joint-venture with an unrelated third-party that operates, and leases from us, Clive Behavioral Health. This 100-bed behavioral health care facility is located in Clive, Iowa and was completed and opened in late December, 2020, and the hospital lease commenced on December 31, 2020. The lease on this facility is triple net and has an initial term of 20 years with five
10-year renewal options. On each January 1st through 2040 (and potentially through 2070 if the first three of five, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. The first three of the five 10-year renewal options will provide for annual rental as stipulated in the lease (2041 through 2070) and the two additional 10-year lease renewal options will be at fair market value lease rates (2071 through 2090). Pursuant to the lease on this facility, the joint venture has the option to, among other things, renew the lease at the terms specified in the lease agreement by providing notice to us at least 270 days prior to the termination of the then current term. The joint venture also has the right to purchase the leased facility from us at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days' notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the joint venture decline to exercise its purchase right). Additionally, the joint venture has rights of first offer to purchase the facility prior to any third-party sale. The table below details the existing lease terms and renewal options for each of the hospital leases that are related to UHS as of June 30, 2024, consisting of three acute care hospitals and three behavioral health hospitals:

<table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:51.86%;"></td><td style="width:1.38%;"></td><td style="width:1%;"></td><td style="width:10.6%;"></td><td style="width:1%;"></td><td style="width:1.4%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3.76%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> Hospital Name </td><td style="vertical-align:bottom;text-align:left;">
</td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Annual<br/>Minimum<br/>Rent </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">
</td><td style="vertical-align:bottom;text-align:left;">
</td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> End of<br/>Lease Term </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">
</td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Renewal<br/>Term<br/>(years) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">
</td><td style="vertical-align:bottom;">
</td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> McAllen Medical Center </td><td style="white-space:pre-wrap;vertical-align:bottom;">
</td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,485,000 </td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December, 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (a) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Wellington Regional Medical Center </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,639,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December, 2026</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(b)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,072,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December, 2033 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (c) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Canyon Creek Behavioral Health </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,041,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December, 2033</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(c)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clive Behavioral Health Hospital</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,775,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December, 2040 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (d) </td> </tr> </table> (a) UHS has one 5-year renewal option at existing lease rates (through 2031). (b) UHS has one 5-year renewal option at fair market value lease rates (through 2031; see additional disclosure below). The annual rental will increase by 2.5% on an annual compounded basis on each January 1st through 2026. (c) UHS has seven 5-year renewal options at fair market value lease rates (2034 through 2068). The annual rental rate will increase by 2.25% on a cumulative and compounded basis on each January 1st through 2033. (d) The UHS-related joint venture has five 10-year renewal options; the first three of the five 10-year renewal options will be at computed lease rates as stipulated in the lease (2041 through 2070) and the last two 10-year renewal options will be at fair market lease rates (2071 through 2090). On each January 1st through 2040 (and potentially through 2070 if the first three of five, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. Upon the December 31, 2021 expiration of the lease on Wellington Regional Medical Center located in West Palm Beach, Florida, a wholly-owned subsidiary of UHS exercised its fair market value renewal option and renewed the lease for a 5-year term scheduled to expire on December 31, 2026. Effective January 1, 2024, the annual lease rate for this hospital, which is payable to us monthly, is $6.6 million and on each January 1st<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;

Roman;min-width:fit-content;"> thereafter through 2026, the annual rent will increase by 2.50% on a cumulative and compounded basis (there is no bonus rental component of the lease payment). Management cannot predict whether the leases with wholly-owned subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases. During the third quarter of 2023, we acquired the McAllen Doctor's Center, an MOB located in McAllen, Texas for a purchase price of approximately $7.6 million, including transaction costs. The building has approximately 79,500 rentable square feet and is 100% master leased to McAllen Hospitals, L.P, a wholly-owned subsidiary of UHS. The triple-net master lease is for twelve years scheduled to expire on August 31, 2035. McAllen Hospitals, L.P. has the option to renew the lease term for three consecutive ten-year terms. The initial annual base rent is approximately $624,000. During the first quarter of 2023, construction was substantially completed on 5ierra Medical Plaza I, a multi-tenant MOB located in Reno, Nevada, consisting of approximately 86,000 rentable square feet. This MOB is located on the campus of the Northern Nevada Sierra Medical Center, a newly constructed acute care hospital that is owned and operated by a wholly-owned subsidiary of UHS, which was completed and opened during April of 2022. The cost of the MOB is estimated to be approximately $35 million, approximately $30 million of which was incurred as of June 30, 2024. In connection with this MOB, we entered into a ground lease and master flex-lease agreement with a wholly-owned subsidiary of UHS. The master flex-lease agreement has a ten-year term scheduled to expire on March 31, 2033, and covers approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually plus a pro-rata share of the common area maintenance expenses. The master flex-lease is subject to a reduction during the term based upon the execution of third-party leases. The ground lease and the master flex lease each commenced during March, 2023. We are the lessee on thirteen ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments), including one that commenced in March, 2023. The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 25 years to approximately 74 years. The annual aggregate lease payments on these properties are approximately $571,000 during each of the years ended 2024 through 2028, and an aggregate of $31.3 million thereafter. See Note 7 for additional lease accounting disclosure. Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of June 30, 2024 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses. Advisory Agreement: UHS of Delaware, Inc. (the "Advisor"), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the "Advisory Agreement"). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the "Independent Trustees"). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor's performance has been satisfactory. The Advisory Agreement was renewed for 2024 with the same terms as the Advisory Agreement in place during 2023 and 2022.  Our advisory fee for the three months ended June 30, 2024 and 2023, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets. Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2024 as compared to 2023 and 2022. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.4 million and $1.3 million for the three-month periods ended June 30, 2024 and 2023, respectively, and were based upon average invested real estate assets of $782 million and $756 million, respectively. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $2.7 million and $2.6 million for the six-month periods ended June 30, 2024 and 2023, respectively, and were based upon average invested real estate assets of $773 million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share Ownership:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of June 30, 2024 and December 31, 2023, UHS owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our outstanding shares of beneficial interest.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC reporting requirements of UHS:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s comprised approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our consolidated revenues during each of the three and six-month periods ended June 30, 2024 and 2023, and since a subsidiary of UHS is our Advi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC's website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.</span></p> 0.52 0.48 3 3 0.24 0.25 0.24 0.25 6 21 0.41 0.41 0.41 0.41 79600000 2 57700000 26000000 4100000 83000000 83300000 P12Y 2033-12-31 7 P5Y 5900000 4100000 1800000 1400000 1400000 0 P90D 100 P20Y 5 P10Y true 3 0.0275 2 P10Y 2071 2090 P270D P270D <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below details the existing lease terms and renewal options for each of the hospital leases that are related to UHS as of June 30, 2024, consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> acute care hospitals and three behavioral health hospitals:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:51.86%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:10.6%;"></td> <td style="width:1%;"></td> <td style="width:1.4%;"></td> <td style="width:15%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11%;"></td> <td style="width:1%;"></td> <td style="width:3.76%;"></td> </tr> <tr style="height:0pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Hospital Name</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Annual<br/>Minimum<br/>Rent</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">End of<br/>Lease Term</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Renewal<br/>Term<br/>(years)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">McAllen Medical Center</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,485,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December, 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (a) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Wellington Regional Medical Center </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,639,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December, 2026</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(b)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,072,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December, 2033 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (c) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Canyon Creek Behavioral Health </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,041,000</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December, 2033</span></span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</span></span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(c)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clive Behavioral Health Hospital</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,775,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> December, 2040 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> (d) </td> </tr> </table> (a) UHS has one 5-year renewal option at existing lease rates (through 2031). (b) UHS has one 5-year renewal option at fair market value lease rates (through 2031; see additional disclosure below). The annual rental will increase by 2.5% on an annual compounded basis on each January 1st through 2026. (c) UHS has seven 5-year renewal options at fair market value lease rates (2034 through 2060). The annual rental rate will increase by 2.25% on a cumulative and compounded basis on each January 1st through 2033. (d) The UHS-related joint venture has five10-year renewal options; the first three of the five 10-year renewal options will be at computed lease rates as stipulated in the lease (2041 through 2070) and the last two 10-year renewal options will be at fair market lease rates (2071 through 2090). On each January 1st through 2040 (and potentially through 2070 if the first three of five, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. 3 5485000 2026-12 P5Y 6639000 2026-12 P5Y 4072000 2033-12 P35Y 1841000 2033-12 P35Y 2775000 2040-12 P50Y 1 P5Y 2031 1 P5Y 2031 0.025 7 P5Y 2034 2068 0.0225 5 P10Y 2041 2070 2071 2090 0.0275 P5Y 6600000 0.025 7600000 79500 1 P12Y 2035-08-31 624000 86000 35000000 30000000 P10Y 0.68 1300000 13 P25Y P74Y 571000 571000 571000 571000 571000 31300000 0.007 0.007 1400000 1300000 702000000 756000000 2700000 2600000 773000000 750000000 0.057 0.057 0.41 (3) Dividends and Equity Issuance Program Dividends and dividend equivalents: We declared and paid dividends of approximately $10.2 million, or $.730 per share, during the second quarter of 2024 and approximately $10.0 million, or $<span

style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">.720 per share, during the second quarter of 2023. We declared and paid dividends of approximately $20.2 million, or $1.455 per share, during the six-month period ended June 30, 224, and approximately $19.8 million, or $1.435 per share, during the comparable period of 2023. Amounts reflected above include accrued dividends that were paid related to the vesting of restricted stock. Dividend equivalents, which are applicable to shares of unvested restricted stock, were accrued during the first six months of 2024 and 2023 and were or will be paid upon vesting of the restricted stock. Equity Issuance Program: During the second quarter of 2024, we filed a shelf registration statement on Form S-3 (File No. 333-270730) (the "Form S-3"), registering the offer and sale, from time-to-time, of an indeterminate amount of the common shares of beneficial interest, preferred shares and debt securities up to an aggregate initial offering price of $100 million to or through one or more underwriters, dealers or agents, or directly to purchasers. The Form S-3 became effective on April 30, 2024. No shares were issued under the Form S-3 since the effective date of April 30, 2024 through June 30, 2024. As of June 30, 2024, we have paid or incurred approximately $287,000 in various fees and expenses related to the Form S-3. The availability of the potential liquidity under this shelf registration statement depends on investor demand, market conditions and other factors. We make no assurance regarding when, or if, we will issue any securities under this registration statement.  10200000 0.73 10000000 0.72 20200000 1.455 19800000 1.435 100000000 0 287000 (4) Acquisitions and Divestitures  Six Months Ended June 30, 2024: Acquisitions: There were no acquisitions during the first six months of 2024. Divestitures: There were no divestitures during the first six months of 2024.  Six Months Ended June 30, 2023: New Construction: In January 2022, we entered into a ground lease and master flex-lease agreement with a wholly-owned subsidiary of UHS to develop, construct and own the real property of Sierra Medical Plaza I, an MOB located in Reno, Nevada, consisting of approximately 86,000 rentable square feet. This MOB is located on the campus of the Northern Nevada Sierra Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS, which was completed and opened during April of 2022. Construction of this MOB, for which we engaged a non-related third party to act as construction manager, commenced in January, 2022, and was substantially completed in March, 2023. The master flex lease agreement in connection with this building, which commenced in March, 2023 and has a ten-year term scheduled to expire on March 31, 2033, covers approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually, plus pro-rata share of the common area maintenance expenses. This master flex lease agreement is subject to reduction based upon the execution of third-party leases. Additionally, during March, 2023, the ground lease for this property commenced and a right-of-use asset and lease liability was recorded in connection with this lease. The cost of the MOB is estimated to be approximately $35 million, approximately $30 million of which was incurred as of June 30, 2024. Acquisitions: There were no acquisitions during the first six months of 2023. Divestitures: There were no divestitures during the first six months of 2023.  0 0 86000 P10Y 2033-03-31 0.68 1300000 35000000 30000000 0 0 (5) Summarized Financial Information of Equity Affiliates In accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting. The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied. Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities. Returns of investments are classified as cash flows from investing activities. At June 30, 2024, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of June 30, 2024 we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties. The following property table represents the four LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of June 30, 2024: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:41.408%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.302%;"></td> <td style="width:1%;"></td> <td style="width:1.4%;"></td> <td style="width:42.889%;"></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:0pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Name of LLC/LP </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Ownership </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Property Owned by LLC/LP </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Suburban Properties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> St. Matthews Medical Plaza II </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Brunswick Associates (a.)(b.) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 74 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">% </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> Mid Coast Hospital MOB </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> FTX MOB Phase II (c.) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> Texoma Medical Plaza II </td> </tr> </table> (a.) This LLC has a third-party term loan of $0.3 million, which is non-recourse to us, outstanding as of June 30, 2024. (b.) We are the lessee with a third party on a ground lease for land. (c.) During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. During the first quarter of 2023, the LP repaid $175,000 of the member loan and the remaining $3.3 million member loan balance was converted to an equity investment in the LP. (d.) This LP constructed, owns and operates the Texoma Medical Plaza II, on which construction substantially completed in December 2020. The MOB is located in Denison, Texas, on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS. We have committed to invest up to $10.2 million in equity and debt financing, of which $7.5 million, net, has been funded as of June 30, 2024. This LP entered into a third-party construction loan commitment, which is non-recourse to us, which had an outstanding balance of $7.0 million as of June 30, 2024. Monthly principal and interest payments on this loan commenced on January 1, 2023. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro rata equity contributions from the partners. The third-party partner's share of the pro rata equity contributions was partially funded with a six-month, $128,000 partner loan from us, which was repaid during July, 2024 with interest. Our share of the pro rata equity contributions, as well as the third-party partner loan, were funded utilizing borrowings from our revolving credit agreement. As a result of the repayment of a portion of the construction loan, an associated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million letter of credit was terminated.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(e.)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are the lessee with a UHS-related party for the land related to this property.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at June 30, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(amounts in thousands)</span></p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(amounts in thousands)</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,057 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,043</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,307 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,269 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 826 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 812 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,724 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,717 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> 472 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 461 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 946 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 916 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 142 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 198 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 301 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 439 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">617</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 572 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,336</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,197 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Our share of net income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 268 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">656</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 639 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs/LPs that were accounted for under the equity method as of June 30, 2024 and December 31, 2023:   <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> (amounts in thousands) </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net property, including construction in progress </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27,608 </td> <td style="white-space:nowrap;vertical-align:bottom;"> 

</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,408</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets (a.)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,679</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,667</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 32,367 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,155</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities (a.)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,272 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,074</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Mortgage notes payable, non-recourse to us</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,280</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,206</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Equity</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,015</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,875</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities and equity</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 32,367 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,155</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investments in and advances to LLCs before amounts included in</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">  accrued expenses and other liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,328 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,102 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">  Amounts included in accrued expenses and other liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,751 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,729 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Our share of equity in

LLCs, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,577</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,373 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> (a.) Other assets and other liabilities as of June 30, 2024 and December 31, 2023 include approximately $650,000 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">651,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UH5.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f June 30, 2024, and December 31, 2023, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:53.971%;"></td><td style="width:1.34%;"></td><td style="width:1%;"></td><td style="width:9.942%;"></td><td style="width:1%;"></td><td style="width:1.34%;"></td><td style="width:9.902000000000001%;"></td><td style="width:1%;"></td><td style="width:1.34%;"></td><td style="width:1%;"></td><td style="width:9.942%;"></td><td style="width:1%;"></td><td style="width:1.34%;"></td><td style="width:10.164%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mortgage Loan Balance (a.)</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Name of LLC/LP</span></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6/30/2024</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12/31/2023</span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity Date</span></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Brunswick Associates (2.80% fixed rate mortgage loan)</span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,314 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,453</span></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December, 2030</span></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grayson Properties II (3.70% fixed rate construction loan) (b.)</span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,966</span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,753</span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March, 2026</span></span></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,280 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 21,206 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:top;"> </td></tr></table> (a.) All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. (b.) This construction loan required interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022. On January 1, 2023, monthly principal and interest payments on this loan commenced. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro-rate equity contributions from the partners, as discussed above. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated. Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and the Trust, at any time, potentially subject to certain conditions, have the right to make an offer ("Offering Member") to the other member(s) ("Non-Offering Member") in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member ("Offer to Sell") at a price as determined by the Offering Member ("Transfer Price"), or; (ii) purchase the entire ownership interest of the Non-Offering Member ("Offer to Purchase") at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member. 0.33 0.95 4 The following property table represents the four LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of June 30, 2024: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:41.408%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11.302%;"></td><td style="width:1%;"></td><td style="width:1.4%;"></td><td style="width:42.889%;"></td></tr><tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> Name of LLC/LP </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Ownership </td><td style="vertical-

align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">  </td> <td style="vertical-align:bottom;">  </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Property Owned by LLC/LP </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Suburban Properties </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:top;"> 5t. Matthews Medical Plaza II </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Brunswick Associates (a.)(b.) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 74 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:top;"> Mid Coast Hospital MOB </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> FTX MOB Phase II (c.) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:top;"> Forney Medical Plaza II </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Grayson Properties II (d.)(e.) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:top;"> Texoma Medical Plaza II </td> </tr> </table> (a.) This LLC has a third-party term loan of $8.3 million, which is non-recourse to us, outstanding as of June 30, 2024. (b.) We are the lessee with a third party on a ground lease for land. (c.) During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. During the first quarter of 2023, the LP repaid $175,000 of the member loan and the remaining $3.3 million member loan balance was converted to an equity investment in the LP. (d.) This LP constructed, owns and operates the Texoma Medical Plaza II, on which construction substantially completed in December 2020. The MOB is located in Denison, Texas, on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS. We have committed to invest up to $10.2 million in equity and debt financing, of which $7.5 million, net, has been funded as of June 30, 2024. This LP entered into a third-party construction loan commitment, which is non-recourse to us, which had an outstanding balance of $7.0 million as of June 30, 2024. Monthly principal and interest payments on this loan commenced on January 1, 2023. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro rata equity contributions from the partners. The third-party partner's share of the pro rata equity contributions was partially funded with a six-month, $128,000 partner loan from us, which was repaid during July, 2024 with interest. Our share of the pro rata equity contributions, as well as the third-party partner loan, were funded utilizing borrowings from our revolving credit agreement. As a result of the repayment of a portion of the construction loan, an associated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million letter of credit was terminated.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(e.)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are the lessee with a UHS-related party for the land related to this property.</span></div></div> 0.33 St. Matthews Medical Plaza II 0.74 Mid Coast Hospital MOB 0.95 Forney Medical Plaza II 0.95 Texoma Medical Plaza II 8300000 4700000 3500000 175000 3300000 10200000 7500000 7000000 5700000 128000 3100000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Below are the condensed combined statements of income (unaudited) for the four LLCs/LPs accounted for under the equity method at June 30, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.38%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.22%;"></td> <td style="width:1%;"></td> <td style="width:9.184000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td colspan="8" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(amounts in thousands)</span></p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(amounts in thousands)</span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">  </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,057 </td> <td style="white-space:nowrap;vertical-align:bottom;">  </td> <td style="white-space:pre-wrap;vertical-align:bottom;">  </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,043</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,307 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,269</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">826</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">812</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,724</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,717</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">472</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">461</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">946</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">301</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">439</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 617 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,336 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,197</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Our share of net income</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 272 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">268</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 656 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 639 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2057000 2043000 4307000 4269000 826000 812000 1724000 1717000 472000 461000 946000 916000 142000 198000 301000 439000 617000 572000 1336000 1197000 272000 268000 656000 639000 Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs/LPs that were accounted for under the equity method as of June 30, 2024 and December 31, 2023:  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.993%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.62%;"></td> <td style="width:1%;"></td> <td style="width:12.883000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-

wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;"> (amounts in thousands) </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net property, including construction in progress </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,688</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other assets (a.) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,679 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,667 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,367</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,155 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other liabilities (a.) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,272</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,074 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Mortgage notes payable, non-recourse to us </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,280 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,206 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Equity </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 14,815 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,875 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total liabilities and equity </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,367</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,155 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Investments in and advances to LLCs before amounts included in </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">  accrued expenses and other liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">14,328 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,102</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  Amounts included in accrued expenses and other liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,751</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,729</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Our share of equity in LLCs, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,577 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,373 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (a.) Other assets and other liabilities as of June 30, 2024 and December 31, 2023 include approximately $650,000 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">651,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div> 27688000 28488000 4679000 4667000 32367000 33155000 2272000 2074000 15280000 21206000 14815000 9875000 32367000 33155000 14328000 9102000 1751000 1729000 12577000 7373000 650000 650000 651000 651000 <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f June 30, 2024, and December 31, 2023, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:53.971%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:9.902000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:9.942%;"></td> <td style="width:1%;"></td> <td style="width:1.34%;"></td> <td style="width:10.164%;"></td> </tr> <tr style="height:0pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mortgage Loan Balance (a.)</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:0pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-decoration:underline;min-width:fit-content;">Name of LLC/LP</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6/30/2024</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12/31/2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity Date</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Brunswick Associates (2.80% fixed rate mortgage loan)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,314 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,453</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December, 2030</span></span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grayson Properties II (3.70% fixed rate construction loan) (b.)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,966</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,753</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March, 2026</span></span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 15,280 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 21,206 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> </tr> </table> (a.) All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. (b.) This construction loan required interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022. On January 1, 2023, monthly principal and interest payments on this loan commenced. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro-rata equity contributions from the partners, as discussed above. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated.  8314000 8453000 2030-12 6966000 12753000 2026-03 15280000 21206000 5700000 3100000 P60D P90D (6) Recent Accounting Pronouncements Segment Reporting In November, 2023, the FASB issued ASU 2023-07, Segment Reporting, Topic 280, "Improvements to Reportable Segment Disclosures ("ASU 2023-07") which was issued to improve the disclosures about s public entity's reportable segments and

address requests from investors for additional, more detailed information about a reportable segment's expenses. The ASU requires existing annual segment disclosures to also be disclosed on an interim basis and also requires disclosures around significant segment expenses and disclosures to identify the title and position of the chief operating decision maker ("CODM"). The standard is effective for the fiscal year ended December 31, 2024 and interim periods thereafter. We do not expect the standard to have a material impact on our consolidated financial statements.

Reference Rate Reform

In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, "Reference Rate Reform." The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. Beginning in the first quarter of 2020, we elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. We will continue to evaluate the impact of the guidance and may apply other elections as applicable as additional changes in the market occur. In December 2022, the FASB issued ASU 2022-06, Deferral of the Sunset Date of Topic 848 ("ASU 2022-06") which was issued to defer the sunset date of Reference Rate Reform (Topic 848); Facilitation of the Effects of Reference Rate Reform to December 31, 2024. ASU 2022-06 is effective immediately for all companies. ASU 2022-06 has no impact on the Company's condensed consolidated financial statements for the three and six months ended June 30, 2024.

(7) Lease Accounting

As Lessor:

We lease most of our operating properties to customers under agreements that are typically classified as operating leases (as noted below, two of our leases are accounted for as financing arrangements effective on December 31, 2021). We recognize the total minimum lease payments provided for under the operating leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease. We have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers ("tenant reimbursements") from the associated rental revenue if certain criteria were met. We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and for the leases that qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three and six months ended June 30, 2024 and 2023.

On December 31, 2021, as a result of the asset purchase and sale transaction with UHS, as amended during the first quarter of 2022, the real estate assets of two wholly-owned subsidiaries of UHS were transferred to us (Aiken and Canyon Creek). As discussed in Note 2, these assets are accounted for as financing arrangements and our consolidated balance sheets at June 30, 2024 and December 31, 2023 reflect financing receivables related to this transaction amounting to $83.0 million and $83.3 million, respectively. Pursuant to the leases, as amended during the first quarter of 2022, the aggregate annual rental during 2024 on the acquired properties, which is payable to us on a monthly basis, amounts to approximately $5.9 million ($4.1 million related to Aiken and $1.8 million related to Canyon Creek). The portion of these lease payments that will be included in our consolidated statements of income, and reflected as interest income on financing leases, is expected to be approximately $5.4 million during the full year of 2024. Lease revenue will not be impacted by the lease payments received related to these two properties.

The components of the "Lease revenue – UHS facilities" and "Lease revenue – Non-related parties" captions for the three and six month periods ended June 30, 2024 and 2023 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the term of the lease. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.

| | Three Months Ended | | Six Months Ended | |
|---|---|---|---|---|
| | June 30, | | | |
| | 2024 | 2023 | 2024 | 2023 |
| UHS facilities: | | | | |
| Base rents | $ 6,888 | $ 6,506 | $ 13,860 | $ 12,780 |
| Bonus rents (a.) | — | — | — | 758 |

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 730 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,541 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Tenant reimbursements </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,717 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,749 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Lease revenue - UHS facilities </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,454</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,236 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,118</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,023 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Non-related parties: </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Base rents </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,872 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,480 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,044 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,714 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Tenant reimbursements </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,487 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,188 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,802 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,315</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease revenue - Non-related parties</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,359 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,668</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,846 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 27,029 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (a.) Consists of bonus rental earned in connection with McAllen Medical Center.   Disclosures Related to Certain Hospital Facilities: Vacant Specialty Facility and Land: Chicago, Illinois - Land: The lease on this facility expired on December 31, 2021. Demolition of the former hospital was completed during 2023. The aggregate demolition expenses amounted to approximately $1.5 million, of which approximately $1.1 million were incurred during the first and second quarters of 2023, and $332,000 were incurred during the fourth quarter of 2022. Evansville, Indiana - Specialty Facility:The lease on this specialty facility expired during 2019, and the facility has been vacant since that time. We continue to market the Chicago, Illinois, and Evansville, Indiana properties to third parties. Future operating expenses related to these properties will be incurred by us during the time they remain owned and unleased. Former facility - Corpus Christi, Texas: In December, 2023, we sold this vacant specialty facility. As lessee: We are the lessee with various third parties, including subsidiaries of UHS, in connection with ground leases for land at fifteen of our consolidated properties. Our right-of-use land assets represent our right to use the land for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities were recognized upon adoption of Topic 842 based on the present value of lease payments over the lease term. We utilized our estimated incremental borrowing rate, which was derived from information available as of January 1, 2019, or the commencement date of the ground lease, whichever is later, in determining the present value of lease payments for active leases on that date. A right-of-use asset and lease liability are not recognized for leases with an initial term of 12 months or less, as these short-term leases are accounted for similarly to previous guidance for operating leases. We do not currently have any ground leases with an initial term of 12 months or less. As of June 30, 2024, our condensed consolidated balance sheet includes right-of-use land assets of approximately $10.9 million and ground lease liabilities of approximately $10.9 million. During the first quarter of 2023, the ground lease for the newly constructed and substantially completed Sierra Medical Plaza I commenced and a right-of-use asset and lease liability was recorded in connection with this lease.  2 83000000 83300000 5900000 4100000 1800000 5400000 The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three and six month periods ended June 30, 2024 and 2023 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the term of the lease. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:33.773%;"></td> <td style="width:1%;"></td> <td style="width:12.737%;"></td> <td style="width:1%;"></td> <td style="width:12.24%;"></td> <td style="width:1%;"></td> <td style="width:12.737%;"></td> <td style="width:1%;"></td> <td style="width:2.519%;"></td> <td style="width:1%;"></td> <td style="width:12.737%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Six Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> UH5 facilities: </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Base rents </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,888</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,506 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,860</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,780 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Bonus rents (a.) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 750 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 730 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,541 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Tenant reimbursements </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,717 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,749 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Lease revenue - UH5 facilities </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,454</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,236 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,118</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,023 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-

align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Non-related parties: </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Base rents </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,872 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,480 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,044 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,714 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Tenant reimbursements </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,487 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,180 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,802 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,315 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Lease revenue - Non-related parties </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,359</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,668 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,846</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:right;">27,029 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (a.) Consists of bonus rental earned in connection with McAllen Medical Center.  6888000 6506000 13860000 12780000 758000 730000 1541000 1494000 808000 1000000 1717000 1749000 8454000 8236000 17118000 16023000 10872000 10480000 22044000 20714000 3487000 3188000 6802000 6315000 14359000 13668000 28846000 27029000 1500000 1100000 332000 15 10900000 10900000 (8) Debt and Financial Instruments Debt: Management routinely monitors and analyzes the Trust's capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of equity issuances. This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust's current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust's current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust's growth. On May 15, 2023 we entered into the first amendment to our amended and restated revolving credit agreement ("Credit Agreement") dated as of July 2, 2021 among the Trust as borrower, the lenders party thereto and Wells Fargo Bank, N.A., as administrative agent. The amendment replaced LIBOR with term SOFR plus .10% ("adjusted term SOFR") as an alternative benchmark rate under the Credit Agreement for settings of benchmark rates that occur on or after the closing date in accordance with the benchmark replacement provisions set forth in the Credit Agreement. On July 2, 2021, we entered into an amended and restated Credit Agreement to amend and restate the previously existing $350 million credit agreement, as amended and dated June 5, 2020. Among other things, under the Credit Agreement, our aggregate revolving credit commitment was increased to $375 million from $350 million. The Credit Agreement, which is scheduled to mature on July 2, 2025, provides for a revolving credit facility in an aggregate principal amount of $375 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans. Under the terms of the Credit Agreement, we may request that the revolving line of credit be increased by up to an additional $50 million. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in most of the Trust's wholly-owned subsidiaries. Borrowings under the Credit Agreement will bear interest at a rate equal to, at our option, at adjusted term SOFR for either one, three, or six months

or the Base Rate, plus in either case, a specified margin depending on our total leverage ratio, as determined by the formula set forth in the Credit Agreement. The applicable margin after the first amendment ranges from 1.10% to 1.35% for adjusted term SOFR loans and 0.10% to 0.35% for Base Rate loans. The Credit Agreement, as amended by the first amendment, defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month adjusted term SOFR plus 1%. The Trust will also pay a quarterly revolving facility fee ranging from 0.15% to 0.35% (depending on the Trust’s total leverage ratio) on the committed amount of the Credit Agreement. The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods. The margins over adjusted term SOFR, Base Rate and the facility fee are based upon our total leverage ratio. At June 30, 2024, the applicable margin over the adjusted term SOFR rate was 1.20%, the margin over the Base Rate was 0.20% and the facility fee was 0.20%. At June 30, 2024, we had $342.9 million of outstanding borrowings pursuant to the terms of our $375 million Credit Agreement and $32.1 million of available borrowing capacity. There are no compensating balance requirements. At December 31, 2023, we had $326.6 million of outstanding borrowings, $3.1 million of outstanding letters of credit and $45.3 million of available borrowing capacity. In our consolidated statements of cash flows, we report cash flows pursuant to our Credit Agreement on a net basis. Aggregate borrowings under our Credit Agreement were $25.2 million and $14.8 million during the quarters ended June 30, 2024 and 2023, respectively, and aggregate repayments were $15.9 million and $11.0 million during the quarters ended June 30, 2024 and 2023, respectively. Aggregate borrowings under our Credit Agreement were $47.0 million and $34.5 million during the six-months ended June 30, 2024 and 2023, respectively, and aggregate repayments were $30.7 million and $21.2 million during the six-months ended June 30, 2024 and 2023, respectively. The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts then outstanding under the Credit Agreement. We are in compliance with all of the covenants in the Credit Agreement at June 30, 2024, and were in compliance with all of the covenants of the Credit Agreement at December 31, 2023. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed. The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:61.652%;"></td><td style="width:1.5%;"></td><td style="width:13.703%;"></td><td style="width:1.5%;"></td><td style="width:1%;"></td><td style="width:8.942%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8.702%;"></td><td style="width:1%;"></td></tr><tr style="height:0pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Covenant </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30,<br/>2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> December 31,<br/>2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Tangible net worth </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> > $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000</span></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 182,508 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 191,824 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Total leverage </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> < =60% </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44.0 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44.5 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Secured leverage </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> < 30% </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.5 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.1 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Unencumbered leverage </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> < 60% </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 45.3 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44.2 </td><td style="white-space:nowrap;vertical-align:bottom;"> % </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">Fixed charge coverage </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> >1.50x </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 3.2x </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 3.1x </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> </table> As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of June 30, 2024 (amounts in thousands):  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.71%;"></td> <td style="width:1.4%;"></td> <td style="width:1%;"></td> <td style="width:12.502%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.382%;"></td> <td style="width:1%;"></td> <td style="width:1.4%;"></td> <td style="width:17.604%;"></td> </tr> <tr style="height:0pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Facility Name </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding<br/>Balance<br/>(in, thousands) (a.) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Interest<br/>Rate </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Maturity<br/>Date </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tuscan Professional Building fixed rate mortgage loan (b.) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">717</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.56</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June, 2025</span></span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Phoenix Children's East Valley Care Center fixed rate <br/>  mortgage loan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,789</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.95</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January, 2030</span></span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rosenberg Children's Medical Plaza fixed rate mortgage loan</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,630</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.42</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">September, 2033</span></span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total, excluding net debt premium and net financing fees</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,144</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  Less net financing fees</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">174</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total mortgages notes payable, non-recourse to us, net</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 19,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr></table> (a.) All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. (b.) This loan is scheduled to mature within the next twelve months, at which time we will either refinance pursuant to a new mortgage loan or repay the mortgage balance in full utilizing borrowings under our Credit Agreement. On April 10, 2024, the $12.2 million fixed rate mortgage loan on Summerlin Hospital Medical Office Building III was fully repaid utilizing borrowings under our Credit Agreement. <span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024 and December 31, 2023, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of June 30, 2024, had a combined carrying value of approximately $20.1 million and a combined fair value of approximately $18.4 million. The mortgages outstanding as of December 31, 2023, had a combined carrying value of approximately $33.1 million and a combined fair value of approximately $31.2 million. The fair value of our debt was computed based upon quotes received from financial institutions. We consider these to be "level 2" in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow. Financial Instruments: In December 2023, we entered into an interest rate swap agreement on a total notional amount of $25 million with a fixed interest rate of 3.9495% that we designated as a cash flow hedge. The interest rate swap became effective on December 1, 2023 and is scheduled to mature on December 1, 2027. If one-month term SOFR is above 3.9495%, the counterparty pays us, and if one-month term SOFR is less than 3.9495%, we pay the counterparty, the difference between the fixed rate of 3.9495% and one-month term SOFR. In March 2020, we entered into an interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge. The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. On May 15, 2023, this interest rate swap agreement was modified to replace the benchmark rate from LIBOR to term SOFR. If one-month term SOFR is above 0.505%, the counterparty pays us, and if one-month term SOFR is less than 0.505%, we pay the counterparty, the difference between the fixed rate of 0.505% and one-month term SOFR. In January 2020, we entered into an interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge. The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. On May 15, 2023, this interest rate swap agreement was modified to replace the benchmark rate from LIBOR to term SOFR. If the one-month term SOFR is above 1.41%, the counterparty pays us, and if the one-month term SOFR is less than 1.41%, we pay the counterparty, the difference between the fixed rate of 1.41% and one-month term SOFR. Although we can provide no assurance we will ultimately do so, at a future date in 2024, we are considering replacing this interest rate swap agreement with either an interest rate swap or interest rate cap agreement on a total notional amount of approximately $35 million. During the third quarter of 2019, we entered into an interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. On May 15, 2023, this interest rate swap agreement was modified to replace the benchmark rate from LIBOR to term SOFR. If one-month term SOFR is above 1.065%, the counterparty pays us, and if one-month term SOFR is less than 1.065%, we pay the counterparty, the difference between the fixed rate of 1.065% and one-month term SOFR. Although we can provide no assurance we will ultimately do so, at a future date in 2024, we are considering replacing this interest rate swap agreement with either an interest rate swap or interest rate cap agreement on a total notional amount of approximately $50 million. We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties. We consider those inputs to be "level 2" in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At June 30, 2024, the fair value of our interest rate swaps was a net asset of $6.4 million which is included in deferred charges and other assets on the accompanying condensed consolidated balance sheet. During the second quarter of 2024, we received approximately $1.6 million from the counterparty, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the first six months of 2024, we received approximately $3.3 million from the counterparty, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the second quarter of 2023, we received approximately $1.4 million from the counterparty, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the first six months of 2023, we received approximately $2.6 million from the counterparty, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other comprehensive income ("AOCI") within shareholders' equity. Amounts are reclassified from AOCI to the income statement in the period or periods the hedged transaction affects earnings. We do not expect any gains or losses on our interest rate swaps to be reclassified to earnings in the next twelve months.  0.001 350000000 375000000 350000000 2025-07-02 375000000 40000000 300000000 50000000 Borrowings under the Credit Agreement will bear interest at a rate equal to, at our option, at adjusted term SOFR for either one, three, or six months or the Base Rate, plus in either case, a specified margin depending on our total leverage ratio, as determined by the formula set forth in the Credit Agreement. The applicable margin after the first amendment ranges from 1.10% to 1.35% for adjusted term SOFR loans and 0.10% to 0.35% for Base Rate loans. 0.011 0.0135 0.001 0.0035 0.01 0.0015 0.0035 2 0.012 0.002 0.002 342900000 375000000 32100000 0 326600000 3100000 45300000 25200000 14800000 15900000 11800000 47000000 34500000 30700000 21200000 The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:61.652%;"></td> <td style="width:1.5%;"></td> <td style="width:13.703%;"></td> <td style="width:1.5%;"></td> <td style="width:1%;"></td> <td style="width:0.942%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:0.702%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:0pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Covenant </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> June 30,<br/>2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> December 31,<br/>2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tangible net worth </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> > $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 182,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 191,824 </td> <td style="white-space:nowrap;vertical-align:bottom;"> 

</td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total leverage </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> < =60% </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44.0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Secured leverage </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> < 30% </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.1 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unencumbered leverage </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> < 60% </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 45.3 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44.2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Fixed charge coverage </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> >1.50x </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 3.2x </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> 3.1x </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> </table>  125000000 102500000 191824000 0.60 0.44 0.445 0.30 0.025 0.041 0.60 0.453 0.442 0.015 0.032 0.031 As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of June 30, 2024 (amounts in thousands):  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.71%;"></td> <td style="width:1.4%;"></td> <td style="width:1%;"></td> <td style="width:12.502%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.382%;"></td> <td style="width:1%;"></td> <td style="width:1.4%;"></td> <td style="width:17.604%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> Facility Name </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Outstanding<br/>Balance<br/>(in,thousands) (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Interest<br/>Rate </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Maturity<br/>Date </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Tuscan Professional Building fixed rate mortgage loan (b,) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 717 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.56 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> June, 2025 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Phoenix Children's East Valley Care Center fixed rate <br/> mortgage loan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,789 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.95 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> January, 2030 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Rosenberg Children's Medical Plaza fixed rate mortgage loan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.42 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> September, 2033 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total, excluding net debt premium and net financing fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,144 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;">  Less net financing fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (174 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> ) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total mortgages notes payable, non-recourse to us, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 19,970 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr></table> (a.) All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. (b.) This loan is scheduled to mature within the next twelve months, at which time we will either refinance pursuant to a new mortgage loan or repay the mortgage balance in full utilizing borrowings under our Credit Agreement. 717000 0.0556 2025-06 7789000 0.0395 2030-01 11638000 0.0442 2033-09 20144000 174000 19970000 12200000 20100000 18400000 33100000 31200000 25000000 0.039495 2027-12-01 0.039495 0.039495 0.039495 55000000 0.00565 2027-03-25 0.00505 0.00505 0.00505 35000000 0.014975 2024-09-16 0.0141 0.0141 0.0141 35000000 50000000 0.01144 2024-09-16 0.01065 0.01065 0.01065 50000000 6400000 1600000 3300000 1400000 2600000 (9) Segment Reporting Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio. Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance. No individual property meets the requirements necessary to be considered its own segment. 1 false false false false false Includes bonus rental on McAllen Medical Center, a UHS acute care hospital facility of $750 and $730 for the three-month periods ended June 30, 2024 and 2023, respectively, and $1,541 and $1,495 for the six-month periods ended June 30, 2024 and 2023, respectively. UHS has one 5-year renewal option at existing lease rates (through 2031). UHS has one 5-year renewal option at fair market value lease rates (through 2031; see additional disclosure below). The annual rental will increase by 2.5% on an annual compounded basis on each January 1st through 2026. UHS has seven 5-year renewal options at fair market value lease rates (2034 through 2068). The annual rental rate will increase by 2.25% on a cumulative and compounded basis on each January 1st through 2033. The UHS-related joint venture has five 10-year renewal options; the first three of the five 10-year renewal options will be at computed lease rates as stipulated in the lease (2041 through 2070) and the last two 10-year renewal options will be at fair market lease rates (2071 through 2090). On each January 1st through 2040 (and potentially through 2070 if the first three of five, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. This LLC has a third-party term loan of $8.3 million, which is non-recourse to us, outstanding as of June 30, 2024. We are the lessee with a third party on a ground lease for land. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. During the first quarter of 2023, the LP repaid $175,000 of the member loan and the remaining $3.3 million member loan balance was converted to an equity investment in the LP. This LP constructed, owns and operates the Texoma Medical Plaza II, on which construction substantially completed in December 2020. The MOB is located in Denison, Texas, on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS. We have committed to invest up to $10.2 million in equity and debt financing, of which $7.5 million, net, has been funded as of June 30, 2024. This LP entered into a third-party construction loan commitment, which is non-recourse to us, which had an outstanding balance of $7.0 million as of June 30, 2024. Monthly principal and interest payments on this loan commenced on January 1, 2023. During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro rata equity contributions from the partners. The third-party partner's share of the pro rata equity contributions was partially funded with a six-month, $128,000 partner loan from us, which was repaid during July, 2024 with interest. Our share of the pro rata equity contributions, as well as the third-party partner loan, were funded utilizing borrowings from our revolving credit agreement. As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated.  We are the lessee with a UHS-related party for the land related to this property.  Other assets and other liabilities as of June 30, 2024 and December 31, 2023 include approximately $650,000 and $651,000, respectively, of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.  All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.  This construction loan required interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  On January 1, 2023, monthly principal and interest payments on this loan commenced.  During the first quarter of 2024, $5.7 million of the third-party construction loan was repaid utilizing pro-rate equity contributions from the partners, as discussed above.  As a result of the repayment of a portion of the construction loan, an associated $3.1 million letter of credit was terminated.  Consists of bonus rental earned in connection with McAllen Medical Center.  All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.  This loan is scheduled to mature within the next twelve months, at which time we will either refinance pursuant to a new mortgage loan or repay the mortgage balance in full utilizing borrowings under our Credit Agreement.

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{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{$;+$COG M.,P? V;;POU]'GB>;C'R54)ZO0A>WE76_7@AQ'//;BYA]70Z=NGLL.G>Z^7Y9 MF+()P,^>G[K[L3@IS3XY=+Q04:^*\W?E'*5YM[')RB-.NY.55H'H+'[*4"AU MYE7$'FV.5- =9PU'3GM3=M[IOA%4D>\507541*@']R?IPLQ+7-I\N/U;I]^\\K3DAZRR)@H39H;B2)- 7&G {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{6)]&._Q:J1^:;JAJMS96$VJ M1_59_VI7S)_%3SFBV>P>EMEL_=7JTE>K1S_]X\UO/_V\FFSY9%?+/O*8+^IN M(]%,OTQCN4%8SL_FV%(]; [_.N>3G*L38,63Y[7R_KW>SONLNN?#UU?3%I:^7 MB8S2:)95CMJUSJMXIO2LTXW6\R._?/&\/7OFDMW&NDQ=5)^.FO+,F=_O=K9V M77JKJS<+,N+,;AKINGM3F=4FP MAQUFB@Q;I:5!7GI?UEE$Y%CR*(7\-U:!,;(59E)N*;9"Y>#29<((N+RB.6JQ M@3/*2/+N0?+5,P+I+)E10B G2\U)6X$,L2ZG6!QE-\B!W'9_3FO'>9:0&I7I M3.? L,G/.AF2DGM"0Y<,#DC 0&[DIC?!4Y%0A&E?.$$YE@L*HI+TU=BMV=)GG M+0^QC$K^CLW"64LWTY[L5 M5DEZX?<&,32GPY*Z:?/?TZ7EBNFZOG M.2TJS;8EMNC$W*P*>#6;%F'^.P=A\4OUS!Z?++O/WC?+Q=&G%Q-&V_7+;C_DZ.[/-3S2?!JM,YL-*OMI)3TRY"410%5_O#//*RG=KKL M5O/\96AQBF/H8LIL.V3_)E- F;F)RT$A5%IO$8F+C,^#:Q&*A,B/BRU)#G M1,;@F% H3MM0'FW"YY.2EWDD_M$-Q'^7<3B_,NQI4Q8!=T|GE5L"S7MWN MJK-NWQ2)GXKWV7XX+Z-/9%@${|OOZ0WHVWV MI31NYHCBSRL:\^,^?QE5]KTAUC*)9^[V?;[K4)1JL\+4UN1I0$V"B.LD.V MR"0"F(^'LM+IMN=\0K,(J(]YR"[;&F1Y=L0)"V6T2IXX_I F2.5C/%03[!QQ M]L2?UGW7 S>/0#61)&9R6#<1,^(=6;+01,GI0^A-$\F70X, MB4A+63R[=IXJHYS8RL?2SAL?8VA?YK#Y?5,Y>1OIR2KXX^M/1GHXH^C6_)6S M3_G7BR;.\L%STQG6>V=Vl6TMRQ>KES9KCS09,YXKWF^+WJ@"] M6L4YBY<6XMX\OYU47U/7DBK/X_;SK]=:.EO7B\|{GT'H@WJZ<[E@X^RTDZ,] MBB6BZU:*/*#=;U> MI8%;ZKW7X6<=QZB;#Q=5IFL*_#-:A.G\VH>8H:KA)8J M6(PPIB)';,:@G,/$[#@E)8D1%N+6KD@B&L5,27)D#@^YLSDHM)H@0026&JN< M.,4++O9LI- YM!]HGVM1LD,ZTLYS!]5HRY;EE&F4/:++K8Q*9;"1*,N"4. U6 M;_4Z"Y=]+&<"*1]R4>!\N7;8(FJI,5Q93]C>F;]'M,O5U[CI0BO& !8>P)]' M>XL+RLK"9KM8G?] [M:>O'MG2X9Q]:VQSCG:QJ%P=V|84*;ZNMJQGH3ZM0|FT M8NW OYPMGSCO<_]_!MZTN8TD.QOI*XB^[FLI@LG)?5'/.Q'JS6Y'=TLQTH3O**

[U?FSH%5#8PHZY]| '-I96LZY>=CG{!MF'US\^8M|-T MPT-5<9$GA2R S8)>MI;??BN!$,9TW,;>Z<6*T??306L<$AS'F86TO!R(XPT1 MU->V8G#[_5XWP:J;.@VYVGYF6\=*1?H]-BX[4*7/-U4:S9WOF!?5&)#GO!V85' M_^M/H.*$^?A?3Q8P' TT9Q*8L@@BE:'8/U$1)KC1.F$HI>-R M.:(K_'!@O#JONA_R, +TN]_:&^(B-M]OL@O%AEAK9<95[J5]
;QA$^#^,%%W M0GRQOF/G0K@R;>+&]262G4!JO\< ^.47L;M^STX%Y7=]R*F\Y@K)3ZUU>Q?] M]2_+^:%E"C[^1\DA)BT!E_K?#ZA2-@D"+YHT ?S@,%D?7M8/R "!R,:GICE+
ME^0%V(=."!A%K'>9QJGI 17@M|4"Y,JI:I(UFD[Y\M1U<:-'OQX:83WN#B' M$W(>=/>O6)+F5%'6Q[2UM*TS\2OS'879++)>$F;%(;S^/]EO>D.l1')@R,U,C" MBZI,@=]5+X5>LW?
+Z&KUXCZ*H)?TM)=XD!>FA:%W8-UO8Q8!';>,; M-Z'6FRS&E2?TX7/,]WY$=Q\[G?5KRL>=W35;>I AW.>,:_+?$:G^DN"BM;9@ M<)&SB.T<>"
V^4@,9)-55,Q083HEV,JHI*R@)$H+QSG*2)Q(EAC#6"S%I,CX'B1+]WE4 MQ>/'S[\W,,3?UW +K^;M)Z_]? E']2=, 9M^/](H7IZ. O#+Y?O\<7$1Z "W M:[!\CJ,5P:K0$@>MZ&_SE?
3Q<=Q_:?HY6(QB[468?3,GSY_%DZ?#_K1s$Q0E M@WYTA/3lH 05Q1$AKR&2\T0$K$4H.8?*80[T4F M0FA-DS4L"Q$P^I&1@WXTZ$=?J7ZD!7.B"$&L,)3(7 (0T3L2@W)>>,,T%
[Y@N M@@DEM *M2.+1A*N(4RX0+Q18-%1CLD>?]!*,_QFGTT\POE]-_7V/O_O'JQP=1 MC 9W4,L'O[!]_RI$WVML80IJZ>A9'!2B)RD]!H7H[@J1#-H*'@51(D1$?D04 M(-
!P1*,T2*%[*( *:.UD'!1+%@+IS0#ANLL$=Y)K,K7'1P:,!'(;JB:NVI M$O6@$ T*40L1+7-(B7G"&$M$!J9(4!8TG(#-$;"?0K?:E',3G=(&CF; >QPE M7BE!DJ%.J$*SRJ9/"M&OL_DT?
QY<18^J$?W;W']>S';C9U4M2J?/G^5!-7J2 M4F10C8[01]{X'Z)(1#@P0Z5-GE@E*-&YF"!8U])T,-19BJDPA'KP'&$"@B%! M*+C;4,Z+XL"<'RB6-JA&@VKTU:I&7-(L
F@XR@I+1.06M*(L22Z@\10F37;= M%]\L%9N8X$1JJ8@L21 ,C",I4I^"S-HIU2?5Z&W^! MU3-4(?L?*ESU831C0 M&9F,%TN2)
[5HK@X*)KY)?IS#T+Q0VG00+'.QA!7YH6XEP<F'3 MMW.7ITJ8IQ^Q^JD=P'JVXRD.F-1)7S'+[_Z&(;7UXN_4OFI*BBX^LA4W939; M3F?+W!#TGV__RR=!J9&.4(=&-=-
THD%PJ36-BIJG*3?C3Z=35Y,_/3=__DN M3\D_WCQ29=AX44\'FC9*NW6KM8\.%C/VLLN%HY1;EST1*E(B!?SP7L$/6KP3 MQD6MQ3&"/[_/IN^P%=/O6-
7YVG_&0W>DEA>VERTOUH!A!XN33T:SU1*;]I6. MV'OAT'?.Q3I;L@5%$#%AW8%,"KNN3)DX[1@+J.2C37*F M^>SJ/!>P!I/;,OW=Y'.WAR!"/'1;G,#0TT"=#TF=\3C4F53RPC$@3
7VFW3 MZ9V0C"3E0#EDCGG!^T&=/U^$OL5^4@B\U>#>LI.F!<[OKX%0QXA(62JZ1.]D M:Y9<9ALL"E/4R+,@3K%"2!'6Q22LH1U4FVRXC9870HTVP$-L(CXZO!'4>!5U
MT'JOS?K?\[G_7&WC@J+U2")5GIH>BM31V6R^Q,ZGC3I5H,[.$.8+3(^3T6H) M-LC_MH7YH]I=JJV3W\>J;I XD/.U:!KGC;%2@;L^YLED5%6XWE&33%0Q45$2
MD9JT420$(C@*7+.2J6.F8]!9Q!*5/"%,.O8CDZBIY4*8$$1/U4V:/O_JC0 M&TA(_UCD!'96J>N/=M6/2%_BM$_0BEOZVB*/7,!^06:S;62#8":(-;>AN#", MSRLH0!KO;34?
S?.'V>1#!;N9@[VZW&(*X_K'34:YYFQ-MFA$1,E C6&0$[(! L@5V520M2G=BI)8;JI.G)%?0$AO:XMG5-\Z6K?(A+LTA\ ?32=%A+E! NG=OGNA89=8(DHH,,F%!/E4 M$'5-"BY$/V!
(W,CVUS\IT^]5>TGO\YQ^9@@)BD#:9>VWIR#>U;+YJ.%^B#@?AC6;+(!3\0!C5/%_(.[__'O;TY' M_]F"_C70FNUY;$XAJ*;X1^^8=W;<)@<\V 2/*J0TQ.5LB&:^<)>89[K#O(6P
M7(O("/41$=3!LCCC'DO:4.LO4?DO;-1_Z;8LY>]SFMO24]Y%5CS=]<>Y#$0 &8T &DX8S]&:6V:2Y$ZF3GIQ,#FK%!@&BD")"T43 M"S8K;)*/)FLFP=)X*'HPO30C3A Y^J1&
BKR=VLM'/+RCM8LM*8(5-Z%0GTO M?K#'&*LVL 7SO<;)W'SYWB-[V_,XK_6)/D8D-.66RLQ(B$X1R3TC3C!'(C<@ M_RA3T72Q@&^38M!HF)LU10WSU79M?
FR6YF@4VBN;8!..^Q M_@'7OO=Q>PZF M:1R?@VA$;K9!)6QML44C3*N\;6FQZ7$-'_^'GZY01+*F2?;I=6:N/.D?^5%6 M0I2@?
DF#;M(0,P&69XGFVNH$EDK.G0S#++\EPN4B'1R(XU4_/76OL7LW7FL;G MU=]Q:V?>VHEWVFE(!{SKXO]9O-7/Q>'4A&6JP+:)
MA,#GAK#HP'A@*B,>>B1::A=#++:H3D'U;9GG%S@);^&HX;9OCIJ6@/;<@B<[ MWL'69-N&??^QFGQ>8Z@CO6SAOU\A3O*-2?!DUQU|\>SL#NFDP8J]QB?Y>.MW MO3?T)?
K;88U6D^5Z:>9KUU!CK+5]6M;?=E@'=I^!=6IKNGOH+LT^)65+)*9B M+PL-2K;/GE M0G(^%;XZ[M+;GLO?.UBA\\6K\E-=8,.R&\X\2%@/D4\"-P"<*.
M&FJLTT&%T@]/V*7Y%/_X]S=['1L^KWMIU#R*T?JK&F0:+S:0XC<@UX,M5X_: M;S5Y'83WH '_/ E#YE8Q@IP+D6C-%9;VP$&N!7{/#"M2P#FMVU%?ZM-E]ZL
MFT#MM!9]BSED3[45Z]WH[<>,O2;6) >?ISS%[E>P5*%V[=AOFM4VKG]VFOI5 MPICW\PT9[L/4WO-]P_D(;I&HGHL'WXA$%09O-N\W56&QOT3'1WH.^*K MMI>?
SE)>W_?=/F- 7IW&\UR%-P+TK\ZF/^Q)M'7G^2U Y;'F\P>%0)ZF.W6E MO\N9O!N,Y=TVAHD#3>]IK>IW?M^DH[_?%.?5G6L]IFJKP1=^\M%_7F O@=T=
M7&]/I>'#>W.7+7B@NHV[K?>!"H[.:C^%UA>*GHIK.U^<\KOVK7"GS$JZ_>_. MS32&(3V%(?40+[X/R,8#EO67 <#K 0"^DP,Q\VNOADX6HU_0!???,/_+W];Z M\0 +/QREX2C=
[":Bl&7\;#M)1*&%@;K&MJ^W".K0]_7P)&&\S*1G.RR!?@MQL!"_'HYDK^%(?=C;8_*;9IZFU'V;4LO9:N&-K0]_7#6O5_?1Z.$P\XO5 :<*0M#HR8/8-1;&:+H<^'<[!P-
IZ,N6!M1T! M =4"8RO2DL!+;5@MB4.GHZ94TI@\L#!V)W]CSU@;.S&8[CPPMX&Y#5OZM3.W M(-@+G("' D8E5*:,"X8 0:FLK'<\@.8X[?Q3_;/N;$A'G,7Q^:0Z[CNBY?A
M$D0XK1#>TS3RV!!M_+_U@T&@?#/':! H>]%YJT1,D1$>.0@42A/Q1@H2E)>! M&UF$ZFC+#^'CW#VM+Z<(PKLY]\>*F9G!)3 PN6%+OP$F%PL/'C1DDHL&AN6-
M(|:Z2'2)H$%3KT%W?@QOYP,P7TYWOAP(@8FUY,I#TSN[DQ.R,)$28+$ZL,T M7!"K4R!@XJ<<&.*-/XK?\,Z9G)-#W'I@KB@\W.P MOG#3;P68]#4)
(QF5UHEIXJUA(%@DR"%N)6$BI22]Y;1TB@4>PG>Z/N%M+.Y8 MH3AYS_[2FP!)?>UG:6"@ P/|=ABHD::((@MQC@$#%<$1+X0#+IJ#T5S2 ]56 M#^&7O2<&ZNS 0
<&.C#0@8$>30-EA0D6*!'64R)#R01444MRTD4I016EG<:X M#^'SO1\&*N@!|L&!CHPT(&!?DL,U#B,'>>,Y.Q! \U%$5^<(TDH1QG3(<@. MDM)#^)/OAX%*<<\@ 5\5
QWR;>]TX/[,RI9U\B"ACGNN^"G'@Y5F*VS,^H@R MZG&@9VZR&%^IN!(J.:ID)#R@PX2Z0 *3CC@3I2D1I)5QT I?3V?P?!^GRV. M5<>A[!N*XTJB>']R9V"- VL<6..MD+L,J-
\W61"E"$9$HL3B-_ 04^/E'B34^2,V5PZ MWMW?ZKE%4?3K?'9V.#QP(\M)XO@W=C4. 'KCEPS?M+X8A%VA0$R31@%880Q$MM
M2=$VB,1!C7>\PS6S5(%Y3D3V%C$B&?'!:0)\EVHAD@->^ZA<4S]HJO# -0>N M.7#-;XIK\B@BIU02[4!EE#1;XIUB)#IGDXJ6"5\NBE3"8_)-;4:G,4#UQRXY\
U!XMK:@4V=32>;"LHD59[XD+,1 ?)-M=&!<6--Q%F'!C53)$45+(%(B,GD2F01!6=:.&,BHZD:0'Y9H/FQ3\Y+GFKA<69-M?OCR\G<8?_O97=:')E*Z;Q8;XVJ>UM.>5*58Y27A4AD@%
M9 =F#U"A8L5EXX/4'1"[8$%@P_\(§RHCO0+MR9")3XK1E*B5PEV?JK[8%YJK_M-#L+XVE./_J)G\;\YGW.RYVT];>X&F_A_3I.9O&?WXTR4.0Y/'LY7^6;;3#C MUZS.\?
W=M]B:RRCFQSR9?1RA:WSY/N,>),S:3_!;LURCT*S7:($+MA@]6TW] M*L%8TG;\G/6N,EO-1S[./F2"BPZK"??]_OM/B[__GH!5_CEZ&.&-_@89RMX M<:IWKN!5S?
VY[MWH##9O3;H/OQ"S-/(+C_\QVJ:1X*>C#CELL(M_YQC/@LP M6,'JI^+%XPVS/;S; ]X+A>8($^NPKC6CJGQJ_?:6(^/KQ]-W.%K\EDS\Y[EJ M"4_\E-./S=,9I:?T^S4+A\V9^/-%?
K'(YW[NEWDG_K433_LP7HS#> +4^&>] MQV6!LOH2K4^=$]__\:UKKB(G6I^W277?<]/+ ML|PN-1\:X&W,!7NDP[75+A_ 7OAZ)PB4@=_^G^_X=U=/]DMK(>]W.6XJ-3XV
MQR+,)NG2U5I+KK^&^5_^AM+KRRGCR\OAGA;U#,?CVSD>NVK<^HB(X8A\>=K1 M(^,'}G0\]2O84)/G<4\\V=HX2Y&XRE8MK/5 LS'Q?-O=O.'.O0[UZ&?SV?G M,
(_/)YBS.%DE;&\/5RR6\U7KWIWB->_F>3&TNW^*2,*/$PGY2J,<2D>ON2K$ MT=X,QSTHR4MGFA[SQDX3R;>\:3/QL *!U9X MIS09IJA311#X.3'HYDF(09%(N?5<2A&
[S:2]\"EX81:6WL4*.)IUB11%8R3 MC$KOGPXKM"=R8(5VKT2 ]}U =`R?9Z/?"7=T3-_>B.3;E"U!^C" ;KP4^QP MHI4,-A%N.6KIS!/KDB<\[\)4D/( =.%#:.GUE#?
RZ5BPA2?:#,"%@\8^<-2! MH]XG1Y4RNP#_3S)CBD@N!"9I&J(2#4Y&%2/OU%\^A+) ,+QQ5/RAVP!/GJ(,+ M_D[']>ULZ2>MXC_H_$,QPE",DYG?CC-Y^ M\,,'W=YARE_)E
_,$2Q.W2_2[D3(\OBL3MB6P[)W MXGRJ*N(-0AP<)'$_?5O9G4#! A0)$40!,FV9V@2Z*YKYI.7RLIT1#I0D#W&
M;@9)>=0TT2SC0RC5"],!]3GWUY9Q=U6N1!UQ2WL)_BYH<>\)V|#+N[!5*]EJ:880"4V&7\& )SEX7GS+|M<1K<8^nVL>]HI,Ei&;)*|R.@8"5)3 M8KB0PMA4N-
P(X7&:T^"I)U18 =(H)A(LI:281"UG(GJM+TN6=\!T?@8P]%,& MAOD-I>:[\LZGM7",;;E1>?,)@6%S!)N[14Y>(3@? &Z1Y ^.E!,H-(J&0IR/0,I,"N*U
MBH1&D5.QA2:YD94@&6FX%XI@J!]8F-02ZS@GA7-&91"ZK*/;]"ZQ,V%FXX M/ ?FLK3%$^L3:'WB>BIA8;Z9\<$>I1[^&LCRX7CYDF)VM%TS@X_?)AD MV,+GW!U<-7H.\-
!E0W;=P@RN5O!B&)V!CST#0.*P\5L"5LEX#O;,X'-. MKY86RS'8+-T+,/RA/YOFE],,: L[N7+LM7*,]G$P';32_>7BC:O.QVHG2APL MP[YY]>
(O7WB(*0MYW2/??.^.:>7TXI]KN|S+D"3?PS#L,=/K#UUS!FKW>9-X MTWN]8)XM#&IWQ)\7GLX]^*YO<[*YJPGN|5]PON;&Y*T"6QYL]V^*SY|:)@GC
M8;J^7M%/8^C@>S_$>^8WKO[Y]>$8A["./1?=R\?;H"?!RAW]D] 7X,SM-_$0RY1O1 M3L=QX-'Y^BT_MO2;ICKS&O3577AGAV"0[OH"TS,,TGYP(NF3%MSIY#OXP+GT MB9CB-
9'26.(L#Z1PEC(WW"N[<0)6I!7%1$FRQ$0'7!8"K1@BK#(R:A:EH0=< M.=(>"=:78W\"S-!C7X]]=\$^RR7W627BBI5$"HO7(XL&*#1"@5XE 0=B"&P/4Q'QVAH
M885D(1.1T4;BK8A$&9MHXKK4R+1U1N6.,\ I3GW!@MA@Y+"A29:6,VYLD6S MM,JH/^0P>SN:SB9S9-"%Q?8SM'GR>I0P4F>=M3"&@YSBU|&@.8<'2![MM#K(6
MP2<8>2+H:JC66DS4+FW)/FM1M_;_9^+/IR F?IV,SW N,(RW;YMOQ;%9-R8Q MG_<(I4IU:!LO@TW.I\\H#3Y\!X[CDPK@C%+B;@[5R"@9D8N>R(Q:1ZQL4B
M)9-.^\WP>V<2]4X1S;@'I4Q'$HSV!$">4L88I?*0#5)]Y+1^EBDL>J.UA]8> M6O=6>Q/:L8)*HB/C1!9*2> &L#([1@M8O2%O)%*PH&&;* L163/,\U9(D$42 MY>$_3G&I#MK>9?
S(W+?!VV/K4]51#\2BV6X4]\R243Z26!QPLX0?/L5"N,X! M=!Y-5=PPBH.E0BAK2)8"C.)D#+.$F]"*VZ(,%*K0S:*?_:3>%+O8NB]6,1/ MZW3U 3GF2<-$GX>ES\-R?
18K*X332A#%%6:'UYE8'@0)R=!D&2_1;UPQYCX" M)!=+:(P \=EE$I1A1"CCJ*6.,N4.6?E21]QNN*I+_9Z-NK78?!,#[4]U!X" MU%H:A1?^ZIK^VE#EVUZHA_XE)EDUCFO0-
*5YP%1@EG)FI?>@/C-!9 J% M>%HRH9JK8+03/J3#2 7V>CA*8XV&9"*P)?C@<@X#;>+.9GV'.B>ZMXV;5+7*1TV4UK4I/^WNC M_;"C-'C,IX!F8,",QM*X0+SDD@@9$Y?1*%?
$8=#^]R>99FF_?>^&8^QX#QD M)5!O04O##"V84&4\G\$VC6INI NF"MT%|=FX"1E8;)#P>;]D7"#/YGYRWBQSOFQR?MAF'BL,M@ J_\$SJ M_%::YNm9N
2JI7(7;$ZD)*,0^>T( Y@FNC$N1;6"R;E M1E@Y5SE()4C!\R9I/24V94-4"(P6&76*&[7PWJSL*88N%*=UFQJM+I&G5;'M5V?J?@"ZAJ>'N+:PWT@$-=47:5-]:9+\)X\"I]+N?
#88#OZG)?$QJ2%+72(A M;'PR"'-\;=]4R?BTMHQMCC)F#H-& )SB?#H%YO%A_#$#(;Z> B\ T9\LE.&YNH,)LSPQWSZG1 M]JR K"_?K_/)=.Z!RT R5?&UR+N(LN0OX\F2NPY)BA\
[QSK9"+8FWZ \@VD<46CH:;$ M?\PMN*"[")\Z!7]F!(\Q*=#-M_ZORWG]-4[_ O^'/MOG[*7GVW7*.:@K<= MVK?3[Y.O_0(SO.K5Y=(-8>9!F]075Q-(=/RR^7;P70..ZI!-
R0:SP>HO&^NS M6/1++?2R&M:7[]1GA@^^AE^6@X@ULUO*+;< >G99(:]J?<)&!_8X*_X MJ]*YHV8\>053@;F9SHX'_VC6Y.OA% KN/@&) PB"+.C&! FE] MD,?-]U?T!
(TV=Q065R2!5$IX0&XP+46(F&5:DA!R(48F'07+\ '?.$B/Q;.B M&5$Y)Q 3@1,?5"$QJ: 4I3EJNPKYT"-,XEV!V:+*^2MT/TYK $ZF.;Y,\TGR MYP^"./JZ&/,'D!E
3_>SY86&DG*BQ/BH6V^U3:1+%6)E%/AV<9A7!"%^ XD MT2R@AY@++$DH$@DDRB*@B%Y9]W99C-,'T:\(D=K&<CC9 <=.#W/L6@%O8O1U4
M70:/#H36L68%"""NH#T!>7MURA]Y'M*PK>(O#\;2*UDZ=7SQR.L<9Q BR&E/Z M@BS2%/OM]FCQO(\QG\VJG=H)@"UX>;SF#]VF+_TOT+16?$%G_D,FHW'*BTUX
ML9YK%QT;"=:F*I*8TG)^.EKW!2V*15P$P@W;_>UB;-H/MGI,\BB!"N//2#.8 MBW-YTO#YAL[GN^AU=TO_<#+NN4\8)7>=R9$HJ&9%2%(+AIU % 90HP) MY
F[103A6\)P+MY\NB%CP,&\KI-"XQB9#(>P:^QU>]?C|*;$S_ZD*=O1ZO/ M5$?3,$\?91[!U8PJ.R"';_5WS6\9N;RY6*)F?1UOF0[YL#-LMX]BRR\',^@T M7KDT[_.'ZKKY+5>)-?
]PQW5X4'/Z[0ADYL?E_4KTT](<_?'U^^^,P?0Z!]OJ M]?L_ZC>$FJ-F8Z&.FM_'9X $W-*CYL7;4Q#Z'SN3&P1V^UA--KU\X?!%,7^ M?()9:5ZL-
/[BNX4Q#@9.US@IJUY,T\&N:RX7M#5-AW4X[<_T19^\>;=#S^_^*Y;@WJ\X"<) MJS7=!-H_UV=0 MD6NUCL.S=I -V_,=]/4V&#@/O TFZD81 GEQ>@1,<5:MREH.!-1#U V!^OX.
M3'1?EK,VFC).P51FA6+.# ?D!I2D"Q4I^A2CV"@GN"^:>WN*L(F S_\6]WI M@R*^T?C@J*X%Q=A:L$X0D^ETHWTM:J[X'D-3P M1%OKI+
[S^OV,3KVRTAXUG8MYZ^H=W[F*G$!0$:I57T&W5GZO )#Q2,\93BK M!V&(L$CY;5"?1>R=+!NOIZ23VOBR)A.^]++$MTS0[\;,%/Z0<9D==F:8C^&LR M^.A1O*Q6 *Q"?
#PM'7[?)@#WV W,!B<)DP0]0.0E57_JB^>^G/4@_(06!.U MH(_H68=M:.K![K9QKHRONH^.F^\$4,D(UWHPNC)P /;ITT4_[(*=G0U:)>@-D MIPlY=WW[_[ MK18Y.E**UT
2!Q/L'S7N T!6=F\X^8U+ ,0R8KJ-\VK"P!\,\V3 MCUVK]2\@K\7CJW2 4 G*+^J?M4C7F<> CY47CE%8UQ&O'L3ECWXXQ_VMH^[ MM]5!EP2TH)1VSUIBJUM9%P%
(Q;>S0#T= _UKJ^*#&5H !@(C( 4?[,LP7A !\O M-0Z,;;G2, *M4Q .!LT"/$VBT&||.>C81LYKG%#]:41T3;[)^72 ME3Z:MDVFKLFM,-!\N^SINY?-CSXB2:YN8--J!-.K6X ^-
U2MX]7)W\>7ZA4 MDO%"K,1K/H(EXG+&HF2:6B%R,9O%^JBF#I2O3#)UH(>Q1(E50I-H5<@1#(^\ M67'RR>GQP!NGP)2U/NK!:5>M:5TY&SAX-*C(LD).lW>@Z6E4G/M"*,-
JEDD[ M8E.2Q(K I2BIZ,VC>"&-O*BV=(W0R\ZH*F(1NC72]5KZT M,6#<_0MH=$@9&J4^.2$NQI`)Q&GN24R&&Y\" M+9S>R:6.=|HO?
#_O2BU;^G!N\CNJ[+OVE)OOFKH@*X[R)V:^W-R8>SV%M< R MJK>ME7CH2W#5A/^>9>7:1"P_#MF"D8^#<:6>WK82<5:4= MJU#.SL_0U
+M=,7,PRKHRS:[^K??PH<8Y)= ;0<+X.BN8G'G0:$>\V";X G\ M$HGT@1&O?")%:1%M8<7E#5A*F:K$G2->)P]"V"5BC3(D&A]XD"H*OC5"J#)@
MEWAPO3!T_68U!/3M+S]NQL,YJ?+>)+9I_$AA8!V--7M^F:Y4RQ;V@HN/"P MLP*TBY:F+C2^\6A#36?252L*"Z%^&,$(6R$W!O9N8"B#T_EI1C+2'L\6AFD
MC2*K&X198_^G8%W6RLUX1:,[A6AM\L%QV! WG'S?\#$G2]'ZVTB5]-UV=^ MU)E:_SVN%WVZIR9H$@Z7QO2KM9OQ+@ .99+1)X>N7URDC/6G\8TJXIN9_]PY
M'@8C&$ZMC3AIEP5&BY/%DY_JP%LP[W+=)FE9Q7:2!ZW.G1:!&KKWW:EL!&S &*:15*+&:-WIR!M-M7;>=HC-KL\/EZJPO\-I^+*WSNL-SBTV-
H05?!]BD%NGUSWB6*7!5HA7BAL?WMVJY+,+7D;2K ?KGBE-0LF& M""%"Y#(;*<-E-5J[8$H&O5DZ*L&ZMY' LY&P;).GSE&!J=\OU.@?%VOVVW+) M=G2?
RHKCJW,9/>"%*J2A@]MJQRGLCN?$A(+9]Y,B(2=)@A*1ET!SX!NA*45F M$72(Q"0-6^T=)T[ "SC-7A+1.9.K8WK;ZZIRA#[?5J/!/SUI#:'A^W%R^%+;0 MAFXM?_P',-
_5.G3AFAU"E/W=H6JS@!8W>A^L(?L*+BG[5);3HAM'EU^FAI M9K2GC9/QY\%I=+=\?'@DK"817,&H%)7{J#!1KK#$%YE,<(X[CB878(5V0/9 M1U_ Z%
MM*>%:T=D8($XY2@!69-8]DFSM'$CR##IA!*"& ET(9F0Q/G@B8M:9&4! !7; MZV[+P[SRNZ*Q7*BE!TZ4 =FP/G (NFR,8%,.>-6":+_OKJ@-@$=`W 0SYTB26]<([90FR4 M@H
^C2E&?2*Q>"=%#(!'&TDW%#5&) [$JS-@F*@J#%-B7 Z)FEN-U&L4O"[ MA>^E]5-W._2W;IUV)K6NKL_X@%2\]DS-AUV4;I>#Y?B2?ZA2*SH PR*"Y^*^
M]B7];HV[Z]9:L>R0#= #<*%GK9W';C\V99>F^&]OP-P.D\& '4W!2"33/!F4 M]\Y>0XB)\60(EQ;)@110O\'FRC8DYUP!H-LHO'+;L] =8NRZ^^KL+0B)97'=@NHZC2Z]E-Y_0/=K-S
MWL?JY*HW3B\\VYU'JW.TKQ-M#2M@KZIGJ2QW81%BB2CZQ=?P&NJ"AL_:W5]\ M"WO4I9JYVAVZ#&;_DE=T#^ZJJQ82O4%L%T:2!UQ9?-M/1H9SX'%TA1$VO?M MVBQ3
>8$Q;07LZ6K?FD'77$4M>KY7ISBU;.M=(-#J2WG*-^/1_/I8E!7 MNK\GN?.9+X?WZ.3Z%^O3[?06 :WS>I(S#D#@#RVA0#$=<.*&Z2-EI\Q$F7XU"
M6*81YJG+MXT/WSWG[>_J*2!M_EP5EK_VMZT?^K:UNN*V=54VEMNTOLRB>B- MJF+W%[%O=!%[;,47F5F[%6:2J?#&(=>)RP8SP<0+,,)YW48.OEFD5 MC^DWBQ>
KH;^;)I?+HYA%TM3,PNU;;_85A;DXV Z:./:7R[:N*K>1^U6B&/0 MHJ_I;N1?\1"[GM^:(2Y8R/\F,O#&(=B]AD/Y!Y*L&[ET^U4>:OQ!L.5+ M)HN=DEO#0N*WU>3\XF)L&?A]
N_=!-]JI.?5BCZJU#^WD05_0QWZ)EG #WAQ M[BGO^9/-Z_Y\2?\]V) ]X>^I$G@OAG;)B[>]1OHTN'7AV?EZ+KU)R MA/5LT[--+P"?
+J/RGE$O+O\>6/1,NEO9IB1GW#/1%YE(]$54,U'/1+TDZIFH M9Z)>$CT>DNIMKIT3X7I(ULO=,/-3H[MG"M[/;\8]A?W"FX"56M-CT:'_(B7#7??!GM M-*_9[:W4?H]3KP'&.R2 [3?
:^M/9,>2=(2(ICF6U/'!.*V!PY+#AL/+LGF7C(6]JCUP[1*SAF/7>4N$ 9D<$Y$KPV)\O*4>BD MO$P;]Y53<,8S3SBS&1"/,^)E;2*ZG'Q(WJOHY>BND>O'KT.?4M[]-JE[@6:
MEJ4ID51J9K*44?<*1/!H+$_%4;F1,2:%9)(%B'/%8R)AH8FGT1,ABB_.A92% MW3=Z,7%D]=69S1XKK??PU<-7#U]?@*_DBC"Q$ ?6'Y$%X,M2*HAR7.K$O:!2
M7X8OGP[GEAHB<@"%+6)Z,VQ_;8H.P9JGD]9.T@%6#,U@8>2.2F M@'ZF"P&-+!"2*!>)LVST1DE!{GQ)W!H2=!9$2A%)8)P3SWFB/H&QR_=_^,&!$ MK]KUD-5OZ3.
K"R3=-98DCEJ61(PR$L#/Y35)1:E(M_(7@]?F^QT)%F!>B:% M%<1%5;!$@!$V&N9TV+M!>]3DU6F8>PKO0>M IMUM!R\0DC966Q)03F'F: MDU"B)3Y+79SVA=H-
+YHPC)N8,\D65"R904$+*BF2G!$B:%5$IOL'+>FNSKG\ MO"B\CU:[*Z_\OBV[!$Z)Z?IK:(^&W+Z2(FYU$>\I02ZWD1?M"A$Q9LSIK8BU
MD1&5C$TTLQAHWHAY4\6KP!EA&G!7"FJ)$TP1+F6RQDE7XMX/+BR]9V_<36X> M/G4N>8:,9 ^-SQ8:M?2>":QOP#G G-*'6.8<5J-RPF8FO=N 1D5M$H)F4#^3
M@W>)2Z'#4(2$YQ*5@!6]Z^-PH+TX-B#8P^./3CN"AP'+]9F74BF]D32 > ML ]#7X0)V@6PUS? D2OFDZ:@-^(IKA6%.)TUX3$Z'JRCT-3^P=$PTX-C#XX]
M.;@N"MP!%2SB2M0%1D31')E22B4$["+I532!^8VBIT(G&G;20B4"Q_F2+Q M!E$U,,X4?AD?0',T\NJ*ISTX]@&#N_9UKI=(Y=]H]TCY?%CCJ27QG.LG/.
M"/TP8=DW68PG"M9*HJ,S.F)-*$1F)8D3P1 OF3(JQN+3EDJU/"OC##$8BBA5 M-L1AH>H09;8E:QE2V;L'] A$RS[!^A*5/#ZX?CR(>EBZ;(^5SQ4K!1 .6)LKX?K/5CV8-
F#'Y,,"RTB33@EP MTBB!WL^B2#!,$<I9$(J+R*W? $M-E>21DE"$;HWP$!F'WZ*!?UCO?.P=+/!1 MS6_>@^6=G;:W# I[C'G-'RP)Z!.8:S^_QSV_GE;[^3V6^?6TVL_OLYU]-S/^-
G,,.>PI_-C/NB]C<-I*]W:2H_2_C$9GDH9_EU)SY MR0XKVS\]X=G/[W'/KZ?5?GZ/97X]K?;S>RSSZVGU2$[S.1 M[^#R7F+6,RY(T=

(2&8PFP5).L,BRMB[I9#;*D3)1HK(BD."3@G>T(|[H0"R3 MAF;I4W%I[_=1Z)$UO$]%_LAP[*&OY3WU+7VBJ!6D4M$K1PSUG$BI.9;)4\1F M8YV)-/-"+Z.62U*X)#*!KPN1-";B%(\D2NM$]3JM_0Y MH%8N03A0JD@4+@)J8>9#%CG1CAL/R!23*ANEJCP3DMM(`)XTO&,E(!VU)#NK M,E="F;1W78OS(RK[LB\]:O5;^@Q0*]&@K)>!Z"@,D9PJXCG"$."/,UR6J-5& MQ@*6DU2)$Y,EH%8!D`O",H`[6ZR5-D6L$K]GU*)'AO6H=1M?]8JX`\[8O.M`KDWW1@1X<=Z>0&LJECY)P52OY245CW-[<.S!L0?'YP2.5/GD`PLD*4N)] RKF:A\',/I(,-6#8Q\TN#=OY^5R55NNX/3I`MLOMTV3M';%8LSUH(PE0)8.MG0[S7&J`P"V43BS;9#4]QIH(X^$VFN%P4>?+OOQX.IA:,0]6#Y7L)1%2!Y*(5R)`F")M$8[!*V*L<#1;SL)F++>7DN=D"Z%6@THL>2366T."2,ZD6'2,>S^I9^)(Z[X0`M2P^6/5CV8'EO8*EC\(Z#/FD=@*5*DGCC%"DL))H"MX5O5*WB2:$RRDGP01)9MG"/>40>*IK1>V\BYH'L/:|)'5O8E_GJP[,&R!\O[`DMC]}.*4Z(2WOCS4A-G`M'"6FZ,(3U6AQ7P;+) W8YS$37I0%S3)*8C-3) <*9KSW*8:]ET/EYHCRW@S_`M6M\I_.YA&@_-\%=G#[H8R1<[OV(AFK4U:&GDE_EIG@PB_)T&'_C`M\2RW__E]W]$L$&55Q(LS92)=,X3FX(@U'N8DX@TAO2B^7PZ?#GTHP__\2*/`MR!_O'X8.WHQ'T\%T-FW&I0GCT7Q:[\Of89/]9)13,Q@AUHUR"Y&?!K.3YN?X M>CC,H^;GG! 2FC<5_8^7%+6R(@\RI5[0Y"P]K! MS#9!]5 Q+/3MO_"@U^&/A]BZ+X%>\YAV:]>4^N8$9-&'\5'S=C@<MC,:#:4/:36H>#O)_/\G-L)XF@^BSP03 ;[X(<=\&O*D$>RH`MX92SXP<<\@_Y=(S !.,"A6 &$T C`P9WLH"N3WX*&L'IV3`CN*7Y!$P8'+8X`M;G"^_L.'2?X`P >VRK(IF&T>36$_G0\'W6@Z,_.)N//8*S,\O"\^9=M<[[% MA'9N!Q:>>62@P\64P0[4JA`O1"!"1RM]IL4:OAE=J!U7V9'$4R(2'B1!2DX* M%SX5S1F+=FD' O=7J^]BR=^,I[,KK3^]9OVIZ\X5CJ\.FGD E0R>'L(0CI"H MH)-X-9B8%(=)X" MG60B8@BN** E'E9W_QVPUV3!OA;QR/KY##=&3VP`Z2'YE.>@-4TBO/)Y ), M*NH,)M-9E;33#.^EY!]S/P$KH]HIB#9'}DGZ>&@'=',)^;(V=)9.3YLUX<@:,]^9D,H"1'C6_Y\]^^K)Y0!/M`M[87)>-2I0!\R!JRG%M$6>+0!;,?/=EM?3YN?\G2:\\LGM@1?@$8_J1`#X@XG`MWGKN/_K)8`S4O`9S1PA4PWE"<)K.PW0`P#A!'-=ZH__?'^T[0B@O3W0BM(I`M*I/-$,$+9-^A*>1;"@J,._A`F5`MB;0:%'(9,0%),9H2M5*X507\ESDRX{0R?^JJ5*-^"DB"[JH5F?96Q%+V/:3KZAT, MJX0{D'$A%DUD3\7K9SY\YHM!]AQ,$4.*Y/QZ440L&"_K0ZY M&ZU?\-9:E]4&FHY_&$$"P6JPAETY]/X;.&N^WU\-HB-E;P)J$*T.BZJ)NU`M/_HA:$KPW*6AC3_FRQ,_;@!!YC/H&3O"&69`L].ZVX`6DYH"R(.6,YY,QI]P`M7J`@@5;5^G;019CR9/`1GJ[S'8Q:*L=Q^H]^,,2C=9@L#N;_^A'8;N=-=7ZB`MIMWM0AR?0B>Q]M0@G2TKW.0Y4@M]#C>940H_%LE2"K'&A7`MKTH)&#0LP`QFVG(3+#0CS2GT=3)MZK-3U.RGG0H]/1E/9J0^V;6"??@8.Y\Q`M-C\=P&S\9'B.? ;S_ECEV8I)A25N9BT!R%61! MXP?N)*6!619$(3L`M-6&<4MCN'$"5HHQ8JQ)5UAGG-ZXAWYU$?EJ@U-,FCN/FA\L>\W4_*)B&ER7F`M4LL9Y4] ,(A0L\D\SCKW`QH ,S`? ?0JMXMS00>#/)GX9I1^'(Q`U`(-0ZW4`M756\B]"PL6^=9^U^!*5=Y;WR"